{"status": "ok", "message-type": "work-list", "message-version": "1.0.0", "message": {"facets": {}, "total-results": 494, "items": [{"indexed": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T20:59:50Z", "timestamp": 1574283590144}, "reference-count": 0, "publisher": "Springer Science and Business Media LLC", "issue": "4", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Clinical Pharmacokinetics"], "published-print": {"date-parts": [[1985]]}, "DOI": "10.2165/00003088-198510040-00003", "type": "journal-article", "created": {"date-parts": [[2009, 3, 4]], "date-time": "2009-03-04T22:21:17Z", "timestamp": 1236205277000}, "page": "315-333", "source": "Crossref", "is-referenced-by-count": 80, "title": ["Clinical Pharmacokinetics of the Depot Antipsychotics"], "prefix": "10.1007", "volume": "10", "author": [{"given": "Michael W.", "family": "Jann", "sequence": "first", "affiliation": []}, {"given": "Larry", "family": "Ereshefsky", "sequence": "additional", "affiliation": []}, {"given": "Stephen R.", "family": "Saklad", "sequence": "additional", "affiliation": []}], "member": "297", "container-title": ["Clinical Pharmacokinetics"], "language": "en", "deposited": {"date-parts": [[2013, 1, 20]], "date-time": "2013-01-20T14:41:44Z", "timestamp": 1358692904000}, "score": 47.430424, "subtitle": [""], "issued": {"date-parts": [[1985]]}, "references-count": 0, "journal-issue": {"issue": "4"}, "URL": "http://dx.doi.org/10.2165/00003088-198510040-00003", "ISSN": ["0312-5963"], "issn-type": [{"value": "0312-5963", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T12:21:24Z", "timestamp": 1574770884105}, "publisher-location": "Cham", "reference-count": 196, "publisher": "Springer International Publishing", "isbn-type": [{"value": "9783319278810", "type": "print"}, {"value": "9783319278834", "type": "electronic"}], "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2016, 1, 1]], "date-time": "2016-01-01T00:00:00Z", "timestamp": 1451606400000}, "delay-in-days": 0, "content-version": "unspecified"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2016]]}, "DOI": "10.1007/978-3-319-27883-4_7", "type": "book-chapter", "created": {"date-parts": [[2016, 3, 2]], "date-time": "2016-03-02T13:04:48Z", "timestamp": 1456923888000}, "page": "139-175", "source": "Crossref", "is-referenced-by-count": 1, "title": ["Antipsychotics"], "prefix": "10.1007", "author": [{"given": "Michael W.", "family": "Jann", "sequence": "first", "affiliation": []}, {"given": "W. Klugh", "family": "Kennedy", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2016, 3, 3]]}, "reference": [{"key": "7_CR1", "unstructured": "Perel JM, Jann MW (2006) Antipsychotics. In: Burton ME, Shaw LM, Schentag JJ, Evans WE (eds). Applied pharmacokinetics and pharmacodynamics \u2013 principles of therapeutic drug monitoring, 4th ed. Philadelphia, Lippincott Williams and Wilkins. pp 813\u2013838"}, {"key": "7_CR2", "author": "A Jorgensen", "first-page": "111", "year": "1986", "unstructured": "Jorgensen A (1986) Metabolism and pharmacokinetics of antipsychotics. In: Bridges JW, Chasseaud LF (eds) Progress in drug metabolism, vol 9. Taylor, and Francis, London, pp 111\u2013174", "volume-title": "Progress in drug metabolism"}, {"key": "7_CR3", "doi-asserted-by": "publisher", "first-page": "1193", "DOI": "10.2217/pgs.11.55", "volume": "12", "author": "T Moons", "year": "2011", "unstructured": "Moons T, de Roo M, Clees S, Dom G (2011) Relationship between P-glycoprotein and second generation antipsychotics. Pharmacogenomics 12:1193\u20131211", "journal-title": "Pharmacogenomics"}, {"key": "7_CR4", "doi-asserted-by": "publisher", "first-page": "359", "DOI": "10.2165/00003088-200746050-00001", "volume": "46", "author": "MC Mauri", "year": "2007", "unstructured": "Mauri MC, Volonteri LS, Colasanti A, Fiorentino A, De Gaspari IF, Bareggi SR (2007) Clinical pharmacokinetics of atypical antipsychotics. Clin Pharmacokinet 46:359\u2013388", "journal-title": "Clin Pharmacokinet"}, {"key": "7_CR5", "doi-asserted-by": "publisher", "first-page": "516", "DOI": "10.2174/138920010791636202", "volume": "11", "author": "JJ Sheehan", "year": "2010", "unstructured": "Sheehan JJ, Sliwa JK, Amatniek JC, Grinspan A, Canuso CM (2010) Atypical antipsychotic metabolism and excretion. Curr Drug Metab 11:516\u2013525", "journal-title": "Curr Drug Metab"}, {"key": "7_CR6", "doi-asserted-by": "publisher", "first-page": "1110", "DOI": "10.1208/s12249-012-9839-7", "volume": "13", "author": "JA Bartlett", "year": "2012", "unstructured": "Bartlett JA, Maarschalk KV (2012) Understanding the oral mucosal absorption and resulting clinical pharmacokinetics of asenapine. AAPS PharmSciTech 13:1110\u20131115", "journal-title": "AAPS PharmSciTech"}, {"key": "7_CR7", "doi-asserted-by": "publisher", "first-page": "781", "DOI": "10.2165/11200860-000000000-00000", "volume": "23", "author": "J Weber", "year": "2009", "unstructured": "Weber J, McCormack PL (2009) Asenapine. CNS Drugs 23:781\u2013792", "journal-title": "CNS Drugs"}, {"key": "7_CR8", "doi-asserted-by": "publisher", "first-page": "199", "DOI": "10.1016/j.pnpbp.2008.09.026", "volume": "33", "author": "C Figueroa", "year": "2009", "unstructured": "Figueroa C, Brecher M, Hamer-Maansson JE, Winter H (2009) Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release. Prog Neuropsychopharmacol Biol Psychiatry 33:199\u2013204", "journal-title": "Prog Neuropsychopharmacol Biol Psychiatry"}, {"key": "7_CR9", "doi-asserted-by": "publisher", "first-page": "417", "DOI": "10.2165/00023210-200721050-00005", "volume": "21", "author": "LP Yang", "year": "2007", "unstructured": "Yang LP, Polsker GL (2007) Paliperidone extended release. CNS Drugs 21:417\u2013425", "journal-title": "CNS Drugs"}, {"key": "7_CR10", "doi-asserted-by": "publisher", "first-page": "739", "DOI": "10.1007/s12325-009-0055-0", "volume": "26", "author": "L Citrome", "year": "2009", "unstructured": "Citrome L (2009) Using oral ziprasidone effectively: the food effect and dose\u2013response. Adv Ther 26:739\u2013748", "journal-title": "Adv Ther"}, {"key": "7_CR11", "doi-asserted-by": "publisher", "first-page": "509", "DOI": "10.2165/00003088-200140070-00003", "volume": "40", "author": "CL DeVane", "year": "2001", "unstructured": "DeVane CL, Nemeroff CB (2001) Clinical pharmacokinetics of quetiapine. Clin Pharmacokinet 40:509\u2013522", "journal-title": "Clin Pharmacokinet"}, {"key": "7_CR12", "doi-asserted-by": "publisher", "first-page": "495", "DOI": "10.1002/hup.2338", "volume": "28", "author": "S Preskorn", "year": "2013", "unstructured": "Preskorn S, Ereshefsky L, Chiu YY, Poola N, Loebel A (2013) Effect of food on the pharmacokinetics of lurasidone: results of two randomized, open-label, crossover studies. Hum Psychopharmacol Clin Exp 28:495\u2013505", "journal-title": "Hum Psychopharmacol Clin Exp"}, {"key": "7_CR13", "first-page": "253", "volume": "14", "author": "LJ Cohen", "year": "1994", "unstructured": "Cohen LJ (1994) Risperidone. Pharmacotherapy 14:253\u2013265", "journal-title": "Pharmacotherapy"}, {"key": "7_CR14", "doi-asserted-by": "publisher", "first-page": "169", "DOI": "10.1177/0091270009347866", "volume": "50", "author": "DA Spyker", "year": "2010", "unstructured": "Spyker DA, Munzar P, Cassella JV (2010) Pharmacokinetics of loxapine following inhalation of a thermally generated aerosol in healthy volunteers. J Clin Pharmacol 50:169\u2013179", "journal-title": "J Clin Pharmacol"}, {"key": "7_CR15", "doi-asserted-by": "publisher", "first-page": "225", "DOI": "10.1007/BF00431855", "volume": "56", "author": "GM Simpson", "year": "1978", "unstructured": "Simpson GM, Cooper TM, Lee JH, Young M (1978) Clinical and plasma level characteristics of intramuscular and oral loxapine. Psychopharmacol 56:225\u2013227", "journal-title": "Psychopharmacol"}, {"key": "7_CR16", "doi-asserted-by": "publisher", "first-page": "494", "DOI": "10.2165/00003088-199528060-00007", "volume": "28", "author": "GV Milton", "year": "1995", "unstructured": "Milton GV, Jann MW (1995) Emergency treatment of psychotic symptoms. Clin Pharmacokinet 28:494\u2013504", "journal-title": "Clin Pharmacokinet"}, {"key": "7_CR17", "first-page": "319", "volume": "20", "author": "A Forsman", "year": "1976", "unstructured": "Forsman A, Ohman R (1976) Pharmacokinetics of haloperidol in man. Curr Ther Res 20:319\u2013336", "journal-title": "Curr Ther Res"}, {"key": "7_CR18", "first-page": "220", "volume": "46", "author": "JR Magliozzi", "year": "1985", "unstructured": "Magliozzi JR, Hollister LF (1985) Elimination half-life and bioavailability of haloperidol in schizophrenic patients. J Clin Psychiatry 46:220\u2013221", "journal-title": "J Clin Psychiatry"}, {"key": "7_CR19", "doi-asserted-by": "publisher", "first-page": "396", "DOI": "10.2165/00003088-198917060-00004", "volume": "17", "author": "JS Froemming", "year": "1989", "unstructured": "Froemming JS, Lam YWF, Jann MW et al (1989) Pharmacokinetics of haloperidol. Clin Pharmacokinet 17:396\u2013423", "journal-title": "Clin Pharmacokinet"}, {"key": "7_CR20", "doi-asserted-by": "publisher", "first-page": "1117", "DOI": "10.2165/00003088-200544110-00002", "volume": "44", "author": "SH Preskorn", "year": "2005", "unstructured": "Preskorn SH (2005) Pharmacokinetics and therapeutics of acute intramuscular ziprasidone. Clin Pharmacokinet 44:1117\u20131133", "journal-title": "Clin Pharmacokinet"}, {"key": "7_CR21", "doi-asserted-by": "publisher", "first-page": "305", "DOI": "10.1016/S0920-9964(99)90040-3", "volume": "36", "author": "R Bergstrom", "year": "1999", "unstructured": "Bergstrom R, Mitchell M, Jewell H et al (1999) Examination of the safety, tolerability, and pharmacokinetics of intramuscular (IM) olanzapine compared to oral olanzapine in healthy subjects. Schziophr Res 36:305\u2013306", "journal-title": "Schziophr Res"}, {"key": "7_CR22", "doi-asserted-by": "publisher", "first-page": "475", "DOI": "10.2165/00003088-200847070-00004", "volume": "47", "author": "DW Boulton", "year": "2008", "unstructured": "Boulton DW, Kolia G, Mallikaarjun S et al (2008) Pharmacokinetics and tolerability of intramuscular, oral, and intravenous aripiprazole in healthy subjects and in patients with schizophrenia. Br J Clin Pharmacol 47:475\u2013485", "journal-title": "Br J Clin Pharmacol"}, {"key": "7_CR23", "doi-asserted-by": "publisher", "first-page": "315", "DOI": "10.2165/00003088-198510040-00003", "volume": "10", "author": "MW Jann", "year": "1985", "unstructured": "Jann MW, Ereshefsky L, Saklad SR (1985) Clinical pharmacokinetics of the depot antipsychotics. Clin Pharmacokinet 10:315\u2013333", "journal-title": "Clin Pharmacokinet"}, {"key": "7_CR24", "doi-asserted-by": "publisher", "first-page": "58", "DOI": "10.1017/S1092852913000783", "volume": "18", "author": "JM Meyer", "year": "2013", "unstructured": "Meyer JM (2013) Understanding depot antipsychotics: an illustrated guide to kinetics. CNS Spectr 18:58\u201368", "journal-title": "CNS Spectr"}, {"key": "7_CR25", "doi-asserted-by": "publisher", "first-page": "91", "DOI": "10.1016/j.schres.2003.11.001", "volume": "70", "author": "M Eerdekens", "year": "2004", "unstructured": "Eerdekens M, Van Hove I, Remmerie B, Mannaert M (2004) Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr Res 70:91\u2013100", "journal-title": "Schizophr Res"}, {"key": "7_CR26", "doi-asserted-by": "publisher", "first-page": "281", "DOI": "10.1016/j.schres.2013.06.041", "volume": "150", "author": "S Mallikaarjun", "year": "2013", "unstructured": "Mallikaarjun S, Kane JM, Bricmont P et al (2013) Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study. Schizophr Res 150:281\u2013288", "journal-title": "Schizophr Res"}, {"key": "7_CR27", "first-page": "1", "volume": "8", "author": "S Spanarello", "year": "2013", "unstructured": "Spanarello S, La Ferla T (2013) The pharmacokinetics of long-acting antipsychotic medications. Curr Clin Pharmacol 8:1\u20138", "journal-title": "Curr Clin Pharmacol"}, {"key": "7_CR28", "doi-asserted-by": "publisher", "first-page": "356", "DOI": "10.1111/j.1600-0447.1980.tb00621.x", "volume": "62", "author": "R Deberdt", "year": "1980", "unstructured": "Deberdt R, Elens P, Berghmans W et al (1980) Intramuscular haloperidol decanoate for neuroleptic maintenance therapy, efficacy, dosage schedule, and plasma levels. Acta Psychiatrica Scand 62:356\u2013363", "journal-title": "Acta Psychiatrica Scand"}, {"key": "7_CR29", "first-page": "298", "volume": "57", "author": "FC Wei", "year": "1996", "unstructured": "Wei FC, Jann MW, Lin HN, Paio-Chien C, Chang WH (1996) A practical loading dose method for converting schizophrenia patients from oral to depot haloperidol therapy. J Clin Psychiatry 57:298\u2013302", "journal-title": "J Clin Psychiatry"}, {"key": "7_CR30", "first-page": "1155", "volume": "44", "author": "L Ereshefsky", "year": "1993", "unstructured": "Ereshefsky L, Toney G, Saklad SR, Anderson C, Seidel D (1993) A loading-dose strategy for converting from oral to depot haloperidol. Hosp Community Psychiatry 44:1155\u20131161", "journal-title": "Hosp Community Psychiatry"}, {"key": "7_CR31", "doi-asserted-by": "publisher", "first-page": "1022", "DOI": "10.1016/j.pnpbp.2009.05.014", "volume": "33", "author": "D Hough", "year": "2009", "unstructured": "Hough D, Lindenmayer JP, Gopal S et al (2009) Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 33:1022\u20131031", "journal-title": "Prog Neuropsychopharmacol Biol Psychiatry"}, {"key": "7_CR32", "doi-asserted-by": "publisher", "first-page": "177", "DOI": "10.2165/00003088-199937030-00001", "volume": "37", "author": "JT Callaghan", "year": "1999", "unstructured": "Callaghan JT, Bergstrom R, Ptak LR et al (1999) Olanzapine. Clin Pharmacokinet 37:177\u2013193", "journal-title": "Clin Pharmacokinet"}, {"key": "7_CR33", "doi-asserted-by": "publisher", "first-page": "432", "DOI": "10.1111/j.1365-2125.1980.tb01074.x", "volume": "9", "author": "FJ Rowell", "year": "1980", "unstructured": "Rowell FJ, Hui SM, Fairburn AF et al (1980) The effect of age and thioridazine on the in-vitro binding of fluphenazine to normal human serum. Br J Clin Pharmacol 9:432\u2013434", "journal-title": "Br J Clin Pharmacol"}, {"key": "7_CR34", "doi-asserted-by": "publisher", "first-page": "377", "DOI": "10.1111/j.1365-2125.1981.tb01135.x", "volume": "11", "author": "FJ Rowell", "year": "1981", "unstructured": "Rowell FJ, Hui SM, Fairburn AF et al (1981) Total and free serum haloperidol levels in schizophrenic patients and the effect of age, thioridazine and fatty acid on haloperidol serum protein binding in vitro. Br J Clin Pharmacol 11:377\u2013382", "journal-title": "Br J Clin Pharmacol"}, {"key": "7_CR35", "first-page": "5", "volume": "36", "author": "CL DeVane", "year": "2002", "unstructured": "DeVane CL (2002) Clinical significance of drug binding, protein binding, and binding displacement of interactions. Psychopharm Bull 36:5\u201321", "journal-title": "Psychopharm Bull"}, {"key": "7_CR36", "doi-asserted-by": "publisher", "first-page": "115", "DOI": "10.1067/mcp.2002.121829", "volume": "71", "author": "LZ Benet", "year": "2002", "unstructured": "Benet LZ, Hooper BA (2002) Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 71:115\u2013121", "journal-title": "Clin Pharmacol Ther"}, {"key": "7_CR37", "doi-asserted-by": "publisher", "first-page": "445", "DOI": "10.1007/BF01046700", "volume": "34", "author": "YF Cheng", "year": "1988", "unstructured": "Cheng YF, Lundberg T, Bondesson U et al (1988) Clinical pharmacokinetics of clozapine in schizophrenic patients. Eur J Clin Pharmacol 34:445\u2013449", "journal-title": "Eur J Clin Pharmacol"}, {"key": "7_CR38", "doi-asserted-by": "publisher", "first-page": "163", "DOI": "10.1016/S0024-3205(02)01680-6", "volume": "71", "author": "DW Boulton", "year": "2002", "unstructured": "Boulton DW, DeVane CL, Listion HL, Markowitz JS (2002) In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci 71:163\u2013169", "journal-title": "Life Sci"}, {"key": "7_CR39", "doi-asserted-by": "publisher", "first-page": "139", "DOI": "10.1007/BF00568401", "volume": "19", "author": "G Nyberg", "year": "1981", "unstructured": "Nyberg G, Axelsson R, Martensson E (1981) Cerebrospinal fluid concentrations of thioridazine and its many metabolites in psychiatric patients. Eur J Clin Pharmacol 19:139\u2013148", "journal-title": "Eur J Clin Pharmacol"}, {"key": "7_CR40", "first-page": "599", "volume": "24", "author": "DH Wiles", "year": "1980", "unstructured": "Wiles DH, Gelder MG (1980) Plasma fluphenazine levels by radioimmunoassay in schizophrenic patients treated with depot fluphenazine. Adv Biochem Psychopharmacol 24:599\u2013602", "journal-title": "Adv Biochem Psychopharmacol"}, {"key": "7_CR41", "doi-asserted-by": "publisher", "first-page": "4", "DOI": "10.1097/JCP.0b013e318204d9e2", "volume": "31", "author": "E Skogh", "year": "2011", "unstructured": "Skogh E, Sjodin I, Josefsson M, Dahl ML (2011) High correlation between serum and cerebrospinal fluid olanzapine concentrations in patients with schizophrenia or schizoaffective disorder medicating with oral olanzapine as the only antipsychotic drug. J Clin Psychopharmacol 31:4\u20139", "journal-title": "J Clin Psychopharmacol"}, {"key": "7_CR42", "first-page": "161", "volume": "27", "author": "SD Hall", "year": "1999", "unstructured": "Hall SD, Thummel KE, Watkins PB et al (1999) Molecular and physical mechanisms of first-pass extraction. Drug Metab Dispos 27:161\u2013166", "journal-title": "Drug Metab Dispos"}, {"key": "7_CR43", "doi-asserted-by": "publisher", "first-page": "157", "DOI": "10.1016/j.euroneuro.2007.06.003", "volume": "18", "author": "K Linnet", "year": "2008", "unstructured": "Linnet K, Ejsing TB (2008) A review on the impact of P-glycoprotein on the penetration of drugs into the brain. Focus on psychotropic drugs. Eur Neuropsychopharmacol 18:157\u2013169", "journal-title": "Eur Neuropsychopharmacol"}, {"key": "7_CR44", "doi-asserted-by": "publisher", "first-page": "163", "DOI": "10.1515/dmdi-2013-0008", "volume": "28", "author": "N Gonzalez-Vacarezza", "year": "2013", "unstructured": "Gonzalez-Vacarezza N, Dorado P, Penas-Lledo EM, Farinas H, Estevez-Carrizo FE, Llerena A (2013) MDR-1 genotypes and quetiapine pharmacokinetics in health volunteers. Drug Metabol Drug Interact 28:163\u2013166", "journal-title": "Drug Metabol Drug Interact"}, {"key": "7_CR45", "doi-asserted-by": "publisher", "first-page": "1267", "DOI": "10.2217/pgs.09.51", "volume": "10", "author": "G Consoli", "year": "2009", "unstructured": "Consoli G, Lastella M, Ciapparelli A et al (2009) ABCB1 polymorphisms are associated with clozapine plasma levels in psychotic patients. Pharmacogenomics 10:1267\u20131276", "journal-title": "Pharmacogenomics"}, {"key": "7_CR46", "doi-asserted-by": "publisher", "first-page": "319", "DOI": "10.1097/JCP.0b013e3181acc372", "volume": "29", "author": "E Jaquenoud Sirot", "year": "2009", "unstructured": "Jaquenoud Sirot E, Knezevic B, Morena GP et al (2009) ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine. J Clin Psychopharmacol 29:319\u2013326", "journal-title": "J Clin Psychopharmacol"}, {"key": "7_CR47", "doi-asserted-by": "publisher", "first-page": "569", "DOI": "10.1111/j.1365-2125.2003.02061.x", "volume": "57", "author": "N Yasui-Furukori", "year": "2004", "unstructured": "Yasui-Furukori N, Mihara K, Takahata T et al (2004) Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes. Br J Clin Pharmacol 57:569\u2013575", "journal-title": "Br J Clin Pharmacol"}, {"key": "7_CR48", "doi-asserted-by": "publisher", "first-page": "411", "DOI": "10.1097/JCP.0b013e31828ecd52", "volume": "33", "author": "Y Suzuki", "year": "2013", "unstructured": "Suzuki Y, Tsuneyama N, Fukui N et al (2013) Impact of the ABCB1 gene polymorphism on plasma 9-hydroxyrisperidone and active moiety levels in Japanese patients with schizophrenia. J Clin Psychopharmacol 33:411\u2013414", "journal-title": "J Clin Psychopharmacol"}, {"key": "7_CR49", "doi-asserted-by": "publisher", "first-page": "107", "DOI": "10.1007/BF02253726", "volume": "101", "author": "MW Jann", "year": "1990", "unstructured": "Jann MW, Lam YQF, Chang WH (1990) Reversible metabolism of haloperidol and reduced haloperidol in Chinese schizophrenic patients. Psychopharmacol 101:107\u2013111", "journal-title": "Psychopharmacol"}, {"key": "7_CR50", "doi-asserted-by": "publisher", "first-page": "161", "DOI": "10.2165/00003088-199324020-00005", "volume": "24", "author": "MW Jann", "year": "1993", "unstructured": "Jann MW, Grimsely SR, Gray EC, Chang WH (1993) Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinet 24:161\u2013176", "journal-title": "Clin Pharmacokinet"}, {"key": "7_CR51", "doi-asserted-by": "publisher", "first-page": "181", "DOI": "10.1097/00004714-200004000-00010", "volume": "20", "author": "RA Sweet", "year": "2000", "unstructured": "Sweet RA, Pollock BG, Mulsant BH et al (2000) Pharmacologic profile of perphenazine\u2019s metabolites. J Clin Psychopharmacol 20:181\u2013187", "journal-title": "J Clin Psychopharmacol"}, {"key": "7_CR52", "doi-asserted-by": "publisher", "first-page": "301", "DOI": "10.2146/ajhp100079", "volume": "68", "author": "SA Arif", "year": "2011", "unstructured": "Arif SA, Mitchell MM (2011) Iloperidone: a new drug for the treatment of schizophrenia. Am Health Syst Pharm 68:301\u2013308", "journal-title": "Am Health Syst Pharm"}, {"key": "7_CR53", "doi-asserted-by": "publisher", "first-page": "189", "DOI": "10.1111/j.1742-1241.2010.02587.x", "volume": "65", "author": "L Citrome", "year": "2011", "unstructured": "Citrome L (2011) Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract 65:189\u2013210", "journal-title": "Int J Clin Pract"}, {"key": "7_CR54", "doi-asserted-by": "publisher", "first-page": "2235", "DOI": "10.1017/S1461145713000680", "volume": "16", "author": "S Nyberg", "year": "2013", "unstructured": "Nyberg S, Jucaite A, Takano A et al (2013) Norepinephrine transporter occupancy in the human brain after oral quetiapine XR. Int J Neuropsychopharmacol 16:2235\u20132244", "journal-title": "Int J Neuropsychopharmacol"}, {"key": "7_CR55", "doi-asserted-by": "publisher", "first-page": "403", "DOI": "10.2146/ajhp070261", "volume": "65", "author": "C Dolder", "year": "2008", "unstructured": "Dolder C, Nelson M, Deyo Z (2008) Paliperidone for schizophrenia. Am J Health Syst Pharm 65:403\u2013413", "journal-title": "Am J Health Syst Pharm"}, {"key": "7_CR56", "doi-asserted-by": "publisher", "first-page": "1853", "DOI": "10.1016/j.clinthera.2011.10.027", "volume": "33", "author": "E Stip", "year": "2011", "unstructured": "Stip E, Zhornitsky S, Moteshafi H et al (2011) Ziprasidone for psychotic disorders: a meta-analysis and systematic review of the relationship between pharmacokinetics, pharmacodynamics, and clinical profile. Clin Ther 33:1853\u20131867", "journal-title": "Clin Ther"}, {"key": "7_CR57", "doi-asserted-by": "publisher", "first-page": "53", "DOI": "10.1097/00004714-198802000-00010", "volume": "8", "author": "MJ Gitlin", "year": "1988", "unstructured": "Gitlin MJ, Midha KK, Fogelson D, Nuechtterlin K (1988) Persistence of fluphenazine in plasma after decanoate withdrawal. J Clin Psychopharmacol 8:53\u201356", "journal-title": "J Clin Psychopharmacol"}, {"key": "7_CR58", "doi-asserted-by": "publisher", "first-page": "35", "DOI": "10.1016/0920-9964(93)90007-6", "volume": "9", "author": "WH Chang", "year": "1993", "unstructured": "Chang WH, Lin SK, Juang DJ et al (1993) Prolonged haloperidol and reduced haloperidol plasma concentrations after decanoate withdrawal. Schizophr Res 9:35\u201340", "journal-title": "Schizophr Res"}, {"key": "7_CR59", "doi-asserted-by": "publisher", "first-page": "97", "DOI": "10.1002/(SICI)1099-1077(199603)11:2<97::AID-HUP759>3.0.CO;2-7", "volume": "11", "author": "P Glue", "year": "1996", "unstructured": "Glue P, Banfield C (1996) Psychiatry, psychopharmacology, and P450\u2019s. Hum Psychopharmacol 11:97\u2013114", "journal-title": "Hum Psychopharmacol"}, {"key": "7_CR60", "doi-asserted-by": "publisher", "first-page": "118", "DOI": "10.1097/00007691-200002000-00025", "volume": "22", "author": "K Otani", "year": "2000", "unstructured": "Otani K, Aoshima T (2000) Pharmacogenetics of classical and atypical antipsychotic drugs. Ther Drug Monit 22:118\u2013121", "journal-title": "Ther Drug Monit"}, {"key": "7_CR61", "doi-asserted-by": "publisher", "first-page": "1", "DOI": "10.1016/j.schres.2013.06.035", "volume": "149", "author": "D Ravyn", "year": "2013", "unstructured": "Ravyn D, Ravyn V, Lowney R, Nasrallah HA (2013) CYP450 pharmacogenetic treatment strategies for antipsychotics: a review of the evidence. Schizophr Res 149:1\u201314", "journal-title": "Schizophr Res"}, {"key": "7_CR62", "doi-asserted-by": "publisher", "first-page": "500", "DOI": "10.1097/00004714-200110000-00008", "volume": "21", "author": "HL Liston", "year": "2001", "unstructured": "Liston HL, Markowitz JS, DeVane CL (2001) Drug glucuronidation in clinical pharmacology. J Clin Psychopharmacol 21:500\u2013515", "journal-title": "J Clin Psychopharmacol"}, {"key": "7_CR63", "doi-asserted-by": "publisher", "first-page": "1319", "DOI": "10.2217/pgs.13.120", "volume": "14", "author": "MM Soderberg", "year": "2013", "unstructured": "Soderberg MM, Dahl ML (2013) Pharmacogenetics of olanzapine metabolism. Pharmacogenomics 14:1319\u20131336", "journal-title": "Pharmacogenomics"}, {"key": "7_CR64", "doi-asserted-by": "publisher", "first-page": "761", "DOI": "10.2165/11318070-000000000-00000", "volume": "48", "author": "SF Zhou", "year": "2009", "unstructured": "Zhou SF (2009) Polymorphism of human cytochrome P450 2D6 and its clinical significance. Part II. Clin Pharmacokinet 48:761\u2013804", "journal-title": "Clin Pharmacokinet"}, {"key": "7_CR65", "doi-asserted-by": "publisher", "first-page": "71", "DOI": "10.1111/j.1365-2125.1994.tb04242.x", "volume": "37", "author": "ML Dahl", "year": "1994", "unstructured": "Dahl ML, Llerena A, Bondesson U et al (1994) Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms. Br J Clin Pharmacol 37:71\u201374", "journal-title": "Br J Clin Pharmacol"}, {"key": "7_CR66", "doi-asserted-by": "publisher", "first-page": "563", "DOI": "10.1046/j.1365-2125.2000.00298.x", "volume": "50", "author": "OV Olesen", "year": "2000", "unstructured": "Olesen OV, Linnet K (2000) Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine. Br J Clin Pharmacol 50:563\u2013571", "journal-title": "Br J Clin Pharmacol"}, {"key": "7_CR67", "doi-asserted-by": "publisher", "first-page": "78", "DOI": "10.1038/clpt.1989.109", "volume": "46", "author": "ML Dahl-Puustinen", "year": "1989", "unstructured": "Dahl-Puustinen ML, Liden A, Alm C et al (1989) Disposition of perphenazine is related to polymorphic debrisoquine hydroxylation in human beings. Clin Pharmacol Ther 46:78\u201381", "journal-title": "Clin Pharmacol Ther"}, {"key": "7_CR68", "doi-asserted-by": "publisher", "first-page": "41", "DOI": "10.1016/S0009-9236(96)90165-4", "volume": "60", "author": "K Linnet", "year": "1996", "unstructured": "Linnet K, Wilborg O (1996) Steady-state serum concentrations of the neuroleptic perphenazine in relation to CYP2D6 genetic polymorphism. Clin Pharmacol Ther 60:41\u201347", "journal-title": "Clin Pharmacol Ther"}, {"key": "7_CR69", "doi-asserted-by": "publisher", "first-page": "423", "DOI": "10.1016/S0009-9236(96)90111-3", "volume": "59", "author": "M Jerling", "year": "1996", "unstructured": "Jerling M, Dahl ML, Aberg-Wistedt A et al (1996) The CYP2D6 genotype predicts the oral clearance of neuroleptic agents perphenazine and zuclopenthixol. Clin Pharmacol Ther 59:423\u2013428", "journal-title": "Clin Pharmacol Ther"}, {"key": "7_CR70", "doi-asserted-by": "crossref", "first-page": "45", "DOI": "10.1007/s00228-003-0576-4", "volume": "59", "author": "R Berecz", "year": "2003", "unstructured": "Berecz R, de la Rubia A, Dorado P et al (2003) Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype. Eur J Clin Pharmacol 59:45\u201350", "journal-title": "Eur J Clin Pharmacol"}, {"key": "7_CR71", "doi-asserted-by": "publisher", "first-page": "234", "DOI": "10.1038/clpt.1991.22", "volume": "49", "author": "C Bahr Von", "year": "1991", "unstructured": "Von Bahr C, Movin G, Nordin C et al (1991) Plasma levels of thioridazine and metabolites are influenced by the debrisoquine hydroxylation phenotype. Clin Pharmacol Ther 49:234\u2013240", "journal-title": "Clin Pharmacol Ther"}, {"key": "7_CR72", "doi-asserted-by": "publisher", "first-page": "1083", "DOI": "10.2217/pgs.09.57", "volume": "10", "author": "P Dorado", "year": "2009", "unstructured": "Dorado P, Penas-Lledo EM, de la Rubia A, Llerena A (2009) Relevance of CYP2D6 \u2013 1584C\u2009>\u2009G polymorphism for thioridazine: mesoridazine plasma concentration ratio in psychiatric patients. Pharmacogenomics 10:1083\u20131089", "journal-title": "Pharmacogenomics"}, {"key": "7_CR73", "first-page": "463", "volume": "42", "author": "S Gershon", "year": "1981", "unstructured": "Gershon S, Sakalis G, Bowers PA (1981) Mesoridazine \u2013 a pharmacodynamics and pharmacokinetic profile. J Clin Psychiatry 42:463\u2013469", "journal-title": "J Clin Psychiatry"}, {"key": "7_CR74", "first-page": "33", "volume": "11", "author": "LA Gottschalk", "year": "1975", "unstructured": "Gottschalk LA, Dinovo E, Bierner R (1975) Plasma levels of mesoridazine and its metabolites and clinical response in acute schizophrenia after a single intramuscular drug dose. Psychopharmacol Bull 11:33\u201334", "journal-title": "Psychopharmacol Bull"}, {"key": "7_CR75", "doi-asserted-by": "publisher", "first-page": "616", "DOI": "10.1097/00007691-200112000-00004", "volume": "23", "author": "A Llerena", "year": "2001", "unstructured": "Llerena A, Berecz R, de la Rubia A et al (2001) Effect of thioridazine dosage on debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes. Ther Drug Monit 23:616\u2013620", "journal-title": "Ther Drug Monit"}, {"key": "7_CR76", "doi-asserted-by": "publisher", "first-page": "398", "DOI": "10.1002/bdd.768", "volume": "32", "author": "JP Luo", "year": "2011", "unstructured": "Luo JP, Vasishtha SC, Hawes EM et al (2011) In vitro identification of the human cytochrome p450 enzymes involved in the oxidative metabolism of loxapine. Biopharm Drug Dispos 32:398\u2013407", "journal-title": "Biopharm Drug Dispos"}, {"key": "7_CR77", "doi-asserted-by": "publisher", "first-page": "1165", "DOI": "10.1176/ajp.139.9.1165", "volume": "139", "author": "BM Cohen", "year": "1982", "unstructured": "Cohen BM, Harris PQ, Altesman RI, Cole J (1982) Amoxapine: neuroleptic as well as antidepressant. Am J Psychiatry 139:1165\u20131167", "journal-title": "Am J Psychiatry"}, {"key": "7_CR78", "doi-asserted-by": "publisher", "first-page": "26", "DOI": "10.2174/187231212800229255", "volume": "6", "author": "A Reed", "year": "2012", "unstructured": "Reed A, Huie K, Perloff ES, Cassella JV, Takahashi LH (2012) Loxapine p-glycoprotein interactions in vitro. Drug Metab Lett 6:26\u201332", "journal-title": "Drug Metab Lett"}, {"key": "7_CR79", "doi-asserted-by": "publisher", "first-page": "92", "DOI": "10.1097/00007691-199204000-00003", "volume": "14", "author": "A Llerena", "year": "1992", "unstructured": "Llerena A, Alm C, Dahl ML et al (1992) Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther Drug Monit 14:92\u201397", "journal-title": "Ther Drug Monit"}, {"key": "7_CR80", "doi-asserted-by": "publisher", "first-page": "105", "DOI": "10.1016/S0165-1781(96)02999-X", "volume": "69", "author": "HY Lane", "year": "1997", "unstructured": "Lane HY, Hu OYP, Jann MW et al (1997) Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients. Psychiatry Res 69:105\u2013111", "journal-title": "Psychiatry Res"}, {"key": "7_CR81", "doi-asserted-by": "publisher", "first-page": "315", "DOI": "10.1046/j.0306-5251.2003.01872.x", "volume": "56", "author": "T Ohnuma", "year": "2003", "unstructured": "Ohnuma T, Shibata N, Matsubara Y, Arai H (2003) Haloperidol plasma concentration in Japanese psychiatric subjects with gene duplication of CYP2D6. Br J Clin Pharmacol 56:315\u2013320", "journal-title": "Br J Clin Pharmacol"}, {"key": "7_CR82", "doi-asserted-by": "publisher", "first-page": "417", "DOI": "10.1097/FTD.0b013e31811f394d", "volume": "29", "author": "G Panagiotidis", "year": "2007", "unstructured": "Panagiotidis G, Arthur HW, Kindh JD, Dahl ML, Sjoqvist F (2007) Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome. Ther Drug Monit 29:417\u2013422", "journal-title": "Ther Drug Monit"}, {"key": "7_CR83", "doi-asserted-by": "publisher", "first-page": "69", "DOI": "10.1055/s-2004-815528", "volume": "37", "author": "A Llerena", "year": "2004", "unstructured": "Llerena A, ed la Rubia A, Berecz R, Dorado P (2004) Relationship between haloperidol plasma concentration, debrisoquine metabolic ration, CYP2D6 and CYP2C9 genotypes in psychiatric patients. Pharmacopsychiatry 37:69\u201373", "journal-title": "Pharmacopsychiatry"}, {"key": "7_CR84", "doi-asserted-by": "publisher", "first-page": "537", "DOI": "10.1097/JCP.0b013e3181c17df0", "volume": "29", "author": "M Hendset", "year": "2009", "unstructured": "Hendset M, Molden E, Refsum H, Hermann M (2009) Impact of CYP2D6 genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisperidone in patients using long-acting injectable risperidone. J Clin Psychopharmacol 29:537\u2013541", "journal-title": "J Clin Psychopharmacol"}, {"key": "7_CR85", "first-page": "80", "volume": "36", "author": "H Hendset", "year": "2014", "unstructured": "Hendset H, Molden E, Kanpe M, Hermann M (2014) Serum concentrations of risperidone and aripiprazole in subgroups encoding CYP2D6 intermediate metabolizer phenotype. Ther Drug Monit 36:80\u201385", "journal-title": "Ther Drug Monit"}, {"key": "7_CR86", "doi-asserted-by": "publisher", "first-page": "177", "DOI": "10.2217/pgs.12.201", "volume": "14", "author": "A Llerena", "year": "2013", "unstructured": "Llerena A, Berecz R, Penas-Lledo E, Suveges A, Farinas H (2013) Pharmacogenetics of clinical response to risperidone. Pharmacogenomics 14:177\u2013194", "journal-title": "Pharmacogenomics"}, {"key": "7_CR87", "doi-asserted-by": "publisher", "first-page": "155", "DOI": "10.2165/11208400-000000000-00000", "volume": "26", "author": "JD Croxtall", "year": "2012", "unstructured": "Croxtall JD (2012) Aripiprazole: a review of its use in the management of schizophrenia in adults. CNS Drugs 26:155\u2013183", "journal-title": "CNS Drugs"}, {"key": "7_CR88", "doi-asserted-by": "publisher", "first-page": "358", "DOI": "10.2133/dmpk.22.358", "volume": "22", "author": "M Kubo", "year": "2007", "unstructured": "Kubo M, Koue T, Maune H, Fukuda T, Azuma J (2007) Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism. Drug Metab Pharmacokinet 22:358\u2013366", "journal-title": "Drug Metab Pharmacokinet"}, {"key": "7_CR89", "doi-asserted-by": "publisher", "first-page": "21", "DOI": "10.1097/FTD.0b013e3182031021", "volume": "33", "author": "T Suzuki", "year": "2011", "unstructured": "Suzuki T, Mihara K, Nakamura A et al (2011) Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia. Ther Drug Monit 33:21\u201324", "journal-title": "Ther Drug Monit"}, {"issue": "5", "key": "7_CR90", "doi-asserted-by": "publisher", "first-page": "651", "DOI": "10.1097/FTD.0000000000000070", "volume": "36", "author": "T Suzuki", "year": "2014", "unstructured": "Suzuki T, Mihara K, Nakamura A et al (2014) Effects of genetic polymorphism of CYP2D6, CYP3A5, and ABCB1 on the steady-state plasma concentrations of aripiprazole and its active metabolite dehydroaripiprazole, in Japanese patients with schizophrenia. Ther Drug Monit 36(5):651\u2013655", "journal-title": "Ther Drug Monit"}, {"key": "7_CR91", "doi-asserted-by": "publisher", "first-page": "493", "DOI": "10.1007/s002280100343", "volume": "57", "author": "S Haag", "year": "2001", "unstructured": "Haag S, Spigset O, Lakso HA et al (2001) Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes. Eur J Clin Pharmacol 57:493\u2013497", "journal-title": "Eur J Clin Pharmacol"}, {"key": "7_CR92", "unstructured": "Shirley KL, Hon YY, Penzak SR et al (2003) Correlation of cytochrome P450 (CYP) 1A2 activity with olanzapine disposition in healthy volunteers. Neuropsychopharmacol. TBD 28:961\u2013966"}, {"key": "7_CR93", "doi-asserted-by": "crossref", "first-page": "1115", "DOI": "10.1517/17425255.2013.795540", "volume": "9", "author": "V Perera", "year": "2013", "unstructured": "Perera V, Gross AS, Polasek TM et al (2013) Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia. Expert Opin Drug Metab Toxicol 9:1115\u20131137", "journal-title": "Expert Opin Drug Metab Toxicol"}, {"key": "7_CR94", "doi-asserted-by": "publisher", "first-page": "471", "DOI": "10.1111/j.1365-2125.1994.tb04385.x", "volume": "37", "author": "L Bertilsson", "year": "1994", "unstructured": "Bertilsson L, Carillo JA, Dahl ML et al (1994) Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol 37:471\u2013473", "journal-title": "Br J Clin Pharmacol"}, {"key": "7_CR95", "first-page": "203", "volume": "37", "author": "MW Jann", "year": "1985", "unstructured": "Jann MW, Ludden TM, Ereshefsky L, Saklad SR, Richards AL (1985) Preliminary analysis of haloperidol population kinetics in schizophrenics. Clin Pharmacol Ther 37:203", "journal-title": "Clin Pharmacol Ther"}, {"key": "7_CR96", "doi-asserted-by": "publisher", "first-page": "685", "DOI": "10.1097/00004714-200012000-00016", "volume": "20", "author": "E Yukawa", "year": "2000", "unstructured": "Yukawa E, Hokazono T, Funakoshi A et al (2000) Epidemiologic investigation of the relative clearance of haloperidol by mixed-effect modeling using routine clinical pharmacokinetic data in Japanese patients. J Clin Psychopharmacol 20:685\u2013690", "journal-title": "J Clin Psychopharmacol"}, {"key": "7_CR97", "doi-asserted-by": "publisher", "first-page": "182", "DOI": "10.1097/FTD.0b013e3182489a6f", "volume": "34", "author": "H Uchida", "year": "2012", "unstructured": "Uchida H, Mamo DC, Pollock BG et al (2012) Predicting plasma concentrating of risperidone associated with dosage change: a population pharmacokinetic study. Ther Drug Monit 34:182\u2013187", "journal-title": "Ther Drug Monit"}, {"key": "7_CR98", "doi-asserted-by": "publisher", "first-page": "1453", "DOI": "10.1016/j.pnpbp.2008.04.018", "volume": "32", "author": "S Botts", "year": "2008", "unstructured": "Botts S, Diaz FJ, Santoro V et al (2008) Estimating the effects of co-medications on plasma olanzapine concentrations by using a mixed model. Prog Neuropsychopharmacol Biol Psychiatry 32:1453\u20131458", "journal-title": "Prog Neuropsychopharmacol Biol Psychiatry"}, {"key": "7_CR99", "doi-asserted-by": "publisher", "first-page": "802", "DOI": "10.1111/j.1365-2125.2008.03223.x", "volume": "66", "author": "JR Kim", "year": "2008", "unstructured": "Kim JR, Seo HB, Cho JY et al (2008) Population pharmacokinetic modelling of aripiprazole and its active metabolite dehydroaripiprazole in psychiatric patients. Br J Clin Pharmacol 66:802\u2013810", "journal-title": "Br J Clin Pharmacol"}, {"key": "7_CR100", "doi-asserted-by": "publisher", "first-page": "360", "DOI": "10.1097/FTD.0b013e31819c7037", "volume": "31", "author": "W Ng", "year": "2009", "unstructured": "Ng W, Uchida H, Ismail Z et al (2009) Clozapine exposure and the impact of smoking and gender: a population pharmacokinetic study. Ther Drug Monit 31:360\u2013366", "journal-title": "Ther Drug Monit"}, {"key": "7_CR101", "doi-asserted-by": "publisher", "first-page": "183", "DOI": "10.1007/s10928-006-9040-2", "volume": "34", "author": "A Vermeulen", "year": "2007", "unstructured": "Vermeulen A, Piotrovsky V, Ludwig EA (2007) Population pharmacokinetics of risperidone and 9-hydroxyrisperidone in patients with acute episodes associated with bipolar I disorder. J Pharmacokinet Pharmacodyn 34:183\u2013206", "journal-title": "J Pharmacokinet Pharmacodyn"}, {"key": "7_CR102", "doi-asserted-by": "publisher", "first-page": "585", "DOI": "10.2165/11316870-000000000-00000", "volume": "48", "author": "M Samtani", "year": "2009", "unstructured": "Samtani M, Vermeulen A, Stuyckens K (2009) Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia. Clin Pharmacokinet 48:585\u2013600", "journal-title": "Clin Pharmacokinet"}, {"key": "7_CR103", "doi-asserted-by": "publisher", "first-page": "377", "DOI": "10.1185/03007990903482772", "volume": "26", "author": "S Gopal", "year": "2010", "unstructured": "Gopal S, Gassmann-Mayer C, Palumbo J, Samtani MN, Shiwach R, Alphs L (2010) Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia. Curr Med Res Opin 26:377\u2013387", "journal-title": "Curr Med Res Opin"}, {"key": "7_CR104", "doi-asserted-by": "publisher", "first-page": "243", "DOI": "10.1055/s-2004-832687", "volume": "37", "author": "P Baumann", "year": "2004", "unstructured": "Baumann P, Hiemke C, Ulrich S et al (2004) The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 37:243\u2013265", "journal-title": "Pharmacopsychiatry"}, {"key": "7_CR105", "doi-asserted-by": "publisher", "first-page": "797", "DOI": "10.1007/s00228-010-0812-7", "volume": "66", "author": "Y Nazirizadeh", "year": "2010", "unstructured": "Nazirizadeh Y, Vogel F, Bader W et al (2010) Serum concentrations of paliperidone versus risperidone and clinical effects. Eur J Clin Pharmacol 66:797\u2013803", "journal-title": "Eur J Clin Pharmacol"}, {"key": "7_CR106", "doi-asserted-by": "publisher", "first-page": "1447", "DOI": "10.4088/JCP.09r05060gre", "volume": "71", "author": "A Sparshatt", "year": "2010", "unstructured": "Sparshatt A, Taylor D, Patel MX, Kapur S (2010) A systematic review of aripiprazole \u2013 dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring. J Clin Psychiatry 71:1447\u20131456", "journal-title": "J Clin Psychiatry"}, {"key": "7_CR107", "doi-asserted-by": "publisher", "first-page": "368", "DOI": "10.1016/j.schres.2013.04.002", "volume": "147", "author": "LV Lopez", "year": "2013", "unstructured": "Lopez LV, Kane JM (2013) Plasma levels of second-generation antipsychotics and clinical response in acute psychosis: a review of the literature. Schizophr Res 147:368\u2013374", "journal-title": "Schizophr Res"}, {"issue": "4", "key": "7_CR108", "doi-asserted-by": "publisher", "first-page": "486", "DOI": "10.1097/FTD.0000000000000041", "volume": "36", "author": "L Best-Shaw", "year": "2014", "unstructured": "Best-Shaw L, Gudbrandsen M, Nagar J, Rose D, David AS, Patel MX (2014) Psychiatrists\u2019 perspectives on antipsychotic dose and the role of plasma concentration therapeutic drug monitoring. Ther Drug Monit 36(4):486\u2013493", "journal-title": "Ther Drug Monit"}, {"key": "7_CR109", "doi-asserted-by": "publisher", "first-page": "205", "DOI": "10.1007/BF00422403", "volume": "73", "author": "MW Dysken", "year": "1981", "unstructured": "Dysken MW, Javaid JL, Chang SS et al (1981) Fluphenazine pharmacokinetics and therapeutic response. Psychopharmacol 73:205\u2013210", "journal-title": "Psychopharmacol"}, {"key": "7_CR110", "first-page": "370", "volume": "45", "author": "ML Mavroidis", "year": "1984", "unstructured": "Mavroidis ML, Kanter DR, Hirschowitz J et al (1984) Fluphenazine plasma levels and clinical response. J Clin Psychiatry 45:370\u2013373", "journal-title": "J Clin Psychiatry"}, {"key": "7_CR111", "first-page": "91", "volume": "27", "author": "T Putten Van", "year": "1991", "unstructured": "Van Putten T, Avavagri M, Marder SR et al (1991) Plasma fluphenazine levels and newly admitted schizophrenic patients. Psychopharmacol Bull 27:91\u201396", "journal-title": "Psychopharmacol Bull"}, {"key": "7_CR112", "doi-asserted-by": "publisher", "first-page": "35", "DOI": "10.1176/ajp.151.1.35", "volume": "151", "author": "AR Koreen", "year": "1994", "unstructured": "Koreen AR, Lieberman J, Alvir J et al (1994) Relationship of plasma fluphenazine levels to treatment response and extrapyramidal side effects in first-episode schizophrenic patients. Am J Psychiatry 151:35\u201339", "journal-title": "Am J Psychiatry"}, {"key": "7_CR113", "first-page": "756", "volume": "152", "author": "D Levinson", "year": "1995", "unstructured": "Levinson D, Simpson G, Lo ES et al (1995) Fluphenazine plasma levels, dosage, efficacy, and side effects. Am J Psychiatry 152:756\u2013771", "journal-title": "Am J Psychiatry"}, {"key": "7_CR114", "first-page": "197", "volume": "17", "author": "T Putten Van", "year": "1991", "unstructured": "Van Putten T, Marder SR, Wirshing WC et al (1991) Neuroleptic plasma levels. Psychopharmacol Bull 17:197\u2013216", "journal-title": "Psychopharmacol Bull"}, {"key": "7_CR115", "doi-asserted-by": "publisher", "first-page": "193", "DOI": "10.1016/0278-5846(92)90070-U", "volume": "16", "author": "MW Jann", "year": "1992", "unstructured": "Jann MW, Chang WH, Lam YWF et al (1992) Comparative analysis of haloperidol and reduced haloperidol in different ethnic populations. Prog Neuropsychopharmacol Biol Psychiatry 16:193\u2013202", "journal-title": "Prog Neuropsychopharmacol Biol Psychiatry"}, {"key": "7_CR116", "doi-asserted-by": "publisher", "first-page": "45", "DOI": "10.1016/0165-1781(89)90170-4", "volume": "30", "author": "MW Jann", "year": "1989", "unstructured": "Jann MW, Chang WH, Davis CM et al (1989) Haloperidol and reduced haloperidol plasma levels in Chinese and non-Chinese psychiatric patients. Psychiatry Res 30:45\u201352", "journal-title": "Psychiatry Res"}, {"key": "7_CR117", "doi-asserted-by": "publisher", "first-page": "287", "DOI": "10.1016/0920-9964(91)90160-S", "volume": "4", "author": "R Conley", "year": "1991", "unstructured": "Conley R, An Nguyen J, Tamminga C (1991) Haloperidol kinetics and clinical response. Schizophr Res 4:287 (Abstract)", "journal-title": "Schizophr Res"}, {"key": "7_CR118", "doi-asserted-by": "publisher", "first-page": "299", "DOI": "10.1016/S0278-5846(97)00007-9", "volume": "21", "author": "HY Lane", "year": "1997", "unstructured": "Lane HY, Lin HY, OYP H et al (1997) Blood levels of reduced haloperidol versus clinical effects and extrapyramidal side effects of haloperidol. Prog Neuropsychopharmacol Biol Psychiatry 21:299\u2013311", "journal-title": "Prog Neuropsychopharmacol Biol Psychiatry"}, {"key": "7_CR119", "doi-asserted-by": "publisher", "first-page": "153", "DOI": "10.1016/j.neuro.2013.09.005", "volume": "39", "author": "JJ Crowley", "year": "2013", "unstructured": "Crowley JJ, Ashraf-Khorassani M, Castagnoli N, Sullivan PF (2013) Brain levels of the neurotoxic pyridinium metabolite HPP+ and extrapyramidal symptoms in haloperidol-treated mice. Neurotoxic 39:153\u2013157", "journal-title": "Neurotoxic"}, {"key": "7_CR120", "doi-asserted-by": "publisher", "first-page": "306", "DOI": "10.1007/BF00432736", "volume": "74", "author": "LB Hansen", "year": "1981", "unstructured": "Hansen LB, Larsen NE, Vastergard P (1981) Plasma levels of perphenazine (Trilafon) related to development of extrapyramidal side effects. Psychopharmacol 74:306\u2013309", "journal-title": "Psychopharmacol"}, {"key": "7_CR121", "doi-asserted-by": "publisher", "first-page": "112", "DOI": "10.1007/BF00432245", "volume": "78", "author": "LB Hansen", "year": "1982", "unstructured": "Hansen LB, Larsen NE, Gulmann N (1982) Dose-dependent response relationship of perphenazine in the treatment of acute psychoses. Psychopharmacol 78:112\u2013115", "journal-title": "Psychopharmacol"}, {"key": "7_CR122", "author": "R Axelsson", "first-page": "165", "year": "1983", "unstructured": "Axelsson R, Martensson E (1983) Clinical effects related to the serum concentrations of thioridazine and its metabolites. In: Gram LF et al (eds) Clinical pharmacology in psychiatry. McMillan, London, pp 165\u2013174", "volume-title": "Clinical pharmacology in psychiatry", "DOI": "10.1007/978-1-349-06671-1_15", "doi-asserted-by": "publisher"}, {"key": "7_CR123", "first-page": "375", "volume": "47", "author": "J Vtial-Herne", "year": "1986", "unstructured": "Vtial-Herne J, Gerbino L, Kay SR et al (1986) Mesoridazine and thioridazine: clinical effects and blood levels in refractory schizophrenics. J Clin Psychiatry 47:375\u2013379", "journal-title": "J Clin Psychiatry"}, {"key": "7_CR124", "doi-asserted-by": "publisher", "first-page": "744", "DOI": "10.1097/01.ftd.0000249944.42859.bf", "volume": "28", "author": "E Molden", "year": "2006", "unstructured": "Molden E, Lunde H, Lunder N et al (2006) Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients. Ther Drug Monit 28:744\u2013749", "journal-title": "Ther Drug Monit"}, {"key": "7_CR125", "doi-asserted-by": "publisher", "first-page": "758", "DOI": "10.1097/JCP.0b013e3182356255", "volume": "31", "author": "SK Lin", "year": "2011", "unstructured": "Lin SK, Chen CK, Liu YL (2011) Aripiprazole and dehydroaripiprazole plasma concentrations and clinical responses in patients with schizophrenia. J Clin Psychopharmacol 31:758\u2013762", "journal-title": "J Clin Psychopharmacol"}, {"key": "7_CR126", "first-page": "231", "volume": "48", "author": "PJ Perry", "year": "1991", "unstructured": "Perry PJ, Miller DD, Arndt SV et al (1991) Clozapine and norclozapine plasma concentrations and clinical response in treatment-refractory schizophrenics. Am J Psychiatry 48:231\u2013235", "journal-title": "Am J Psychiatry"}, {"key": "7_CR127", "doi-asserted-by": "publisher", "first-page": "167", "DOI": "10.2165/00023210-200013030-00003", "volume": "13", "author": "PJ Perry", "year": "2000", "unstructured": "Perry PJ (2000) Therapeutic monitoring of atypical antipsychotics: is it of potential clinical value? CNS Drugs 13:167\u2013171", "journal-title": "CNS Drugs"}, {"key": "7_CR128", "doi-asserted-by": "publisher", "first-page": "200", "DOI": "10.1097/00007691-199604000-00015", "volume": "18", "author": "HC Liu", "year": "1996", "unstructured": "Liu HC, Chang WH, Wei FC et al (1996) Monitoring of plasma clozapine levels and its metabolites in refractory schizophrenics. Ther Drug Monit 18:200\u2013207", "journal-title": "Ther Drug Monit"}, {"key": "7_CR129", "doi-asserted-by": "publisher", "first-page": "472", "DOI": "10.1097/00004714-199712000-00006", "volume": "17", "author": "PJ Perry", "year": "1997", "unstructured": "Perry PJ, Sanger T, Beasley C (1997) Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients. J Clin Psychopharmacol 17:472\u2013477", "journal-title": "J Clin Psychopharmacol"}, {"key": "7_CR130", "doi-asserted-by": "publisher", "first-page": "14", "DOI": "10.1097/00004714-200102000-00004", "volume": "21", "author": "PJ Perry", "year": "2001", "unstructured": "Perry PJ, Lund BC, Sanger T, Beasley C (2001) Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial. J Clin Psychopharmacol 21:14\u201320", "journal-title": "J Clin Psychopharmacol"}, {"key": "7_CR131", "doi-asserted-by": "publisher", "first-page": "278", "DOI": "10.1097/JCP.0b013e3181a289cb", "volume": "29", "author": "L Citrome", "year": "2009", "unstructured": "Citrome L, Stauffer VL, Chen L et al (2009) Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia. J Clin Psychopharmacol 29:278\u2013283", "journal-title": "J Clin Psychopharmacol"}, {"key": "7_CR132", "doi-asserted-by": "publisher", "first-page": "518", "DOI": "10.1097/00007691-200208000-00010", "volume": "24", "author": "E Skogh", "year": "2002", "unstructured": "Skogh E, Reis M, Dahl ML, Lundmark J, Bengtsson F (2002) Therapeutic drug monitoring data on olanzapine and its N-desmethyl metabolite in the naturalistic clinical setting. Ther Drug Monit 24:518\u2013526", "journal-title": "Ther Drug Monit"}, {"key": "7_CR133", "doi-asserted-by": "publisher", "first-page": "329", "DOI": "10.1097/JCP.0b013e31828b28d5", "volume": "33", "author": "D Bishara", "year": "2013", "unstructured": "Bishara D, Olofinjana O, Sparshatt A, Kapur S, Taylor D, Patel MX (2013) Olanzapine: a systematic review and meta-regression of the relationships between dose, plasma concentration, receptor occupancy and response. J Clin Psychopharmacol 33:329\u2013335", "journal-title": "J Clin Psychopharmacol"}, {"key": "7_CR134", "doi-asserted-by": "publisher", "first-page": "1108", "DOI": "10.4088/JCP.09r05739yel", "volume": "72", "author": "A Sparshatt", "year": "2011", "unstructured": "Sparshatt A, Talyor D, Patel MX, Kapur S (2011) Relationship between daily dose, plasma concentrations, dopamine receptor occupancy, and clinical response to quetiapine: a review. J Clin Psychiatry 72:1108\u20131123", "journal-title": "J Clin Psychiatry"}, {"key": "7_CR135", "doi-asserted-by": "publisher", "first-page": "72", "DOI": "10.1055/s-2007-972573", "volume": "40", "author": "M Gerlach", "year": "2007", "unstructured": "Gerlach M, Hunnerkopf R, Rothenhofer S et al (2007) Therapeutic drug monitoring of quetiapine and adolescents with psychotic disorders. Pharmacopsychiatry 40:72\u201376", "journal-title": "Pharmacopsychiatry"}, {"key": "7_CR136", "doi-asserted-by": "publisher", "first-page": "349", "DOI": "10.1097/FTD.0b013e3182577c43", "volume": "34", "author": "SV Bowskill", "year": "2012", "unstructured": "Bowskill SV, Handley SA, Fsher DS, Flanagan RJ, Patel MX (2012) Risperidone and total 9-hydroxyrisperidone in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 2002\u20132010. Ther Drug Monit 34:349\u2013355", "journal-title": "Ther Drug Monit"}, {"key": "7_CR137", "doi-asserted-by": "publisher", "first-page": "275", "DOI": "10.1097/FTD.0b013e3182126d83", "volume": "33", "author": "K Seto", "year": "2011", "unstructured": "Seto K, Dumontet J, Enson MHH (2011) Risperidone in schizophrenia: is there a role for therapeutic drug monitoring? Ther Drug Monit 33:275\u2013283", "journal-title": "Ther Drug Monit"}, {"key": "7_CR138", "doi-asserted-by": "publisher", "first-page": "89", "DOI": "10.1055/s-2007-973835", "volume": "40", "author": "MC Mauri", "year": "2007", "unstructured": "Mauri MC, Colasanti A, Rossattini M et al (2007) Ziprasidone outcome and tolerability: a practical clinical trial with plasma drug levels. Pharmacopsychiatry 40:89\u201392", "journal-title": "Pharmacopsychiatry"}, {"key": "7_CR139", "doi-asserted-by": "publisher", "first-page": "143", "DOI": "10.1016/j.eurpsy.2008.09.003", "volume": "24", "author": "F Vogel", "year": "2009", "unstructured": "Vogel F, Gansmuller R, Leiblein T et al (2009) The use of ziprasidone in clinical practice: analysis of pharmacokinetic and pharmacodynamics aspects from the data of a drug monitoring survey. Eur Psychiatry 24:143\u2013148", "journal-title": "Eur Psychiatry"}, {"key": "7_CR140", "doi-asserted-by": "publisher", "first-page": "516", "DOI": "10.1097/JCP.0000000000000125", "volume": "34", "author": "AM Strien Van", "year": "2014", "unstructured": "Van Strien AM, van den Tweel AVW, van den Heuvel ML, di Biase M, van den Brule AJC, van Marum RJ (2014) Correlation of haloperidol concentration in blood and cerebrospinal fluid. J Clin Psychopharmacol 34:516\u2013517", "journal-title": "J Clin Psychopharmacol"}, {"issue": "suppl. 10", "key": "7_CR141", "first-page": "5", "volume": "60", "author": "E Richelson", "year": "1999", "unstructured": "Richelson E (1999) Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiatry 60(suppl 10):5\u201314", "journal-title": "J Clin Psychiatry"}, {"key": "7_CR142", "doi-asserted-by": "publisher", "first-page": "29", "DOI": "10.1016/S0024-3205(00)00911-5", "volume": "68", "author": "E Richelson", "year": "2000", "unstructured": "Richelson E, Sounder T (2000) Binding of antipsychotic drugs to human brain receptors \u2013 focus on newer generation compounds. Life Sci 68:29\u201339", "journal-title": "Life Sci"}, {"key": "7_CR143", "doi-asserted-by": "publisher", "first-page": "1243", "DOI": "10.4088/JCP.10ac06470yel", "volume": "71", "author": "E Richelson", "year": "2010", "unstructured": "Richelson E (2010) New antipsychotic drugs: how do their receptor-binding profiles compare? J Clin Psychiatry 71:1243\u20131244", "journal-title": "J Clin Psychiatry"}, {"key": "7_CR144", "first-page": "1019", "volume-title": "Pharmacotherapy \u2013 a pathophysiologic approach", "author": "ML Crismon", "year": "2014", "unstructured": "Crismon ML, Argo TR, Buckley PF (2014) Chapter 50: Schizophrenia. In: DiPiro JT, Talbert RL, Yee GC et al (eds) Pharmacotherapy \u2013 a pathophysiologic approach, 9th edn. McGraw Hill, New York, pp 1019\u20131045", "edition": "9"}, {"key": "7_CR145", "doi-asserted-by": "publisher", "first-page": "519", "DOI": "10.1038/sj.npp.1300027", "volume": "28", "author": "WK Kroeze", "year": "2003", "unstructured": "Kroeze WK, Hufeisen SJ, Popadak BA et al (2003) H1 histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacol 28:519\u2013526", "journal-title": "Neuropsychopharmacol"}, {"key": "7_CR146", "doi-asserted-by": "publisher", "first-page": "71", "DOI": "10.1001/archpsyc.1988.01800250087012", "volume": "45", "author": "L Farde", "year": "1988", "unstructured": "Farde L, Wiessel FA, Halldin C, Sedvall G (1988) Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45:71\u201376", "journal-title": "Arch Gen Psychiatry"}, {"key": "7_CR147", "doi-asserted-by": "publisher", "first-page": "339", "DOI": "10.1007/s002130050301", "volume": "131", "author": "B Andree", "year": "1997", "unstructured": "Andree B, Halldin C, Vries MZ, Farde L (1997) Central 5Ht2A and D2 dopamine receptor occupancy after sublingual administration of ORG 5222 in healthy men. Psychopharmacol 131:339\u2013345", "journal-title": "Psychopharmacol"}, {"key": "7_CR148", "doi-asserted-by": "publisher", "first-page": "245", "DOI": "10.1007/s00213-013-3103-z", "volume": "229", "author": "DF Wong", "year": "2013", "unstructured": "Wong DF, Kuwabara H, Brasic JB et al (2013) Determination of dopamine D2 receptor occupancy by lurasidone using positron emission tomography in healthy male subjects. Psychopharmacol 229:245\u2013252", "journal-title": "Psychopharmacol"}, {"key": "7_CR149", "doi-asserted-by": "publisher", "first-page": "869", "DOI": "10.1176/ajp.156.6.869", "volume": "156", "author": "S Nyberg", "year": "1999", "unstructured": "Nyberg S, Eriksson B, Oxenstierna G, Halldin C, Farde L (1999) Suggested minimal effective doses of risperidone based on PET-measured D2 and 5HT2A receptor occupancy in schizophrenic patients. Am J Psychiatry 156:869\u2013875", "journal-title": "Am J Psychiatry"}, {"key": "7_CR150", "doi-asserted-by": "publisher", "first-page": "L103", "DOI": "10.1016/0024-3205(95)02037-J", "volume": "57", "author": "S Kapur", "year": "1995", "unstructured": "Kapur S, Remington G, Zipursky RB, Wilson AA, Houle S (1995) The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: A PET study. Life Sci 57:L103\u2013L107", "journal-title": "Life Sci"}, {"key": "7_CR151", "doi-asserted-by": "publisher", "first-page": "267", "DOI": "10.1007/s10928-013-9320-6", "volume": "40", "author": "K Varnas", "year": "2013", "unstructured": "Varnas K, Varrone A, Farde L (2013) Modeling of PET data in CNS drug discovery and development. J Pharmacokinet Pharmacodyn 40:267\u2013279", "journal-title": "J Pharmacokinet Pharmacodyn"}, {"key": "7_CR152", "doi-asserted-by": "publisher", "first-page": "725", "DOI": "10.1097/JCP.0b013e3182a88654", "volume": "33", "author": "JS Barrett", "year": "2013", "unstructured": "Barrett JS, McGuire J, Vezina H, Spitsin S, Douglas SD (2013) PET measurement of receptor occupancy as a tool to guide dose selection in neuropharmacology: are we asking the right questions? J Clin Psychopharmacol 33:725\u2013728", "journal-title": "J Clin Psychopharmacol"}, {"key": "7_CR153", "doi-asserted-by": "publisher", "first-page": "497", "DOI": "10.1097/JCP.0b013e3182214aad", "volume": "31", "author": "H Uchida", "year": "2011", "unstructured": "Uchida H, Takeuchi H, Graff-Guerro A et al (2011) Dopamine D2 receptor occupancy and clinical effects. J Clin Psychopharmacol 31:497\u2013502", "journal-title": "J Clin Psychopharmacol"}, {"key": "7_CR154", "doi-asserted-by": "publisher", "first-page": "1525", "DOI": "10.1176/ajp.154.11.1525", "volume": "154", "author": "S Kapur", "year": "1997", "unstructured": "Kapur S, Zipursky R, Remington G, Jones C, McKay G, Houle S (1997) PET evidence that loxapine is an equipotent blocker of 5HT2 and D2 receptors: implications for the therapeutics in schizophrenia. Am J Psychiatry 154:1525\u20131529", "journal-title": "Am J Psychiatry"}, {"key": "7_CR155", "doi-asserted-by": "publisher", "first-page": "229", "DOI": "10.1007/s00213-007-1029-z", "volume": "197", "author": "R Arakawa", "year": "2008", "unstructured": "Arakawa R, Ito H, Takano A et al (2008) Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. Psychopharmacol 197:229\u2013235", "journal-title": "Psychopharmacol"}, {"key": "7_CR156", "doi-asserted-by": "publisher", "first-page": "992", "DOI": "10.4088/JCP.v63n1106", "volume": "63", "author": "S Tauscher-Wisiewski", "year": "2002", "unstructured": "Tauscher-Wisiewski S, Kapur S, Tauscher T et al (2002) Quetiapine: an effective antipsychotics in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade. J Clin Psychiatry 63:992\u2013997", "journal-title": "J Clin Psychiatry"}, {"key": "7_CR157", "doi-asserted-by": "publisher", "first-page": "818", "DOI": "10.1176/appi.ajp.161.5.818", "volume": "161", "author": "D Mamo", "year": "2004", "unstructured": "Mamo D, Kapur S, Shammi CM et al (2004) A PET study of dopamine D2 and serotonin 5-Ht2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry 161:818\u2013825", "journal-title": "Am J Psychiatry"}, {"key": "7_CR158", "unstructured": "Uchida H, Suzuki T (2014) Dose and dosing frequency of long-acting injectable antipsychotics. J Clin Psychopharmacol. [Epub ahead]", "DOI": "10.1097/JCP.0000000000000065", "doi-asserted-by": "crossref"}, {"issue": "3", "key": "7_CR159", "doi-asserted-by": "crossref", "first-page": "318", "DOI": "10.1097/JCP.0b013e318218d339", "volume": "31", "author": "Hiroyuki Uchida", "year": "2011", "unstructured": "Uchida H, Takeuchi H, Graff-Guerrero A et al (2011) Predicting dopamine D2 receptor occupancy from plasma levels of antipsychotic drugs a systematic review of pooled analysis. J Clin Psychopharmacol 31:318\u2013325", "journal-title": "Journal of Clinical Psychopharmacology"}, {"key": "7_CR160", "doi-asserted-by": "publisher", "first-page": "682", "DOI": "10.1097/JCP.0b013e3182979a0a", "volume": "33", "author": "S Moriguchi", "year": "2013", "unstructured": "Moriguchi S, Bies RR, Remington G et al (2013) Estimated dopamine D2 receptor occupancy and remission in schizophrenia: analysis of the CATIE data. J Clin Psychopharmacol 33:682\u2013685", "journal-title": "J Clin Psychopharmacol"}, {"key": "7_CR161", "doi-asserted-by": "publisher", "first-page": "933", "DOI": "10.2165/11595380-000000000-00000", "volume": "25", "author": "MJ Arranz", "year": "2011", "unstructured": "Arranz MJ, Rivera M, Munro JC (2011) Pharmacogenetics of response to antipsychotics in patients with schizophrenia. CNS Drugs 25:933\u2013969", "journal-title": "CNS Drugs"}, {"key": "7_CR162", "doi-asserted-by": "publisher", "first-page": "869", "DOI": "10.2217/pgs.14.50", "volume": "15", "author": "MD Brennan", "year": "2014", "unstructured": "Brennan MD (2014) Pharmacogenetics of second-generation antipsychotics. Pharmacogenomics 15:869\u2013884", "journal-title": "Pharmacogenomics"}, {"key": "7_CR163", "doi-asserted-by": "publisher", "first-page": "183", "DOI": "10.1517/17425255.2013.736964", "volume": "9", "author": "JP Zhang", "year": "2013", "unstructured": "Zhang JP, Malhostra AK (2013) Pharmacogenetics of antipsychotics: recent progress and methodological issues. Expert Opin Drug Metab Toxicol 9:183\u2013191", "journal-title": "Expert Opin Drug Metab Toxicol"}, {"key": "7_CR164", "doi-asserted-by": "publisher", "first-page": "1551", "DOI": "10.2217/pgs.13.150", "volume": "14", "author": "P Gasso", "year": "2013", "unstructured": "Gasso P, Papagianni K, Mas S et al (2013) Relationship between CYP2D6 genotype and haloperidol pharmacokinetics and extrapyramidal symptoms in healthy volunteers. Pharmacogenomic 14:1551\u20131563", "journal-title": "Pharmacogenomic"}, {"key": "7_CR165", "doi-asserted-by": "publisher", "first-page": "593", "DOI": "10.1097/JCP.0b013e31829abec9", "volume": "33", "author": "M Zivkovic", "year": "2013", "unstructured": "Zivkovic M, Mihaljevic-Peles A, Bozina M et al (2013) The association study of polymorphisms in DAT, DRD2, and COMT genes and acute extrapyramidal adverse events in male schizophrenic patients treated with haloperidol. J Clin Psychopharmacol 33:593\u2013599", "journal-title": "J Clin Psychopharmacol"}, {"key": "7_CR166", "doi-asserted-by": "publisher", "first-page": "50", "DOI": "10.1097/YIC.0b013e32835ac9da", "volume": "28", "author": "AP Rajkumar", "year": "2013", "unstructured": "Rajkumar AP, Poonkuzhali B, Kuruvilla A, Jacob M, Jacob KS (2013) Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia. Int Clin Psychopharmacol 28:50\u201356", "journal-title": "Int Clin Psychopharmacol"}, {"key": "7_CR167", "doi-asserted-by": "publisher", "first-page": "505", "DOI": "10.1007/s00213-012-2922-7", "volume": "225", "author": "G Remington", "year": "2013", "unstructured": "Remington G, Agid O, Foussias G, Ferguson L, McDonald K, Powell V (2013) Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold? Psychopharmacol 225:505\u2013518", "journal-title": "Psychopharmacol"}, {"key": "7_CR168", "doi-asserted-by": "publisher", "first-page": "26", "DOI": "10.1186/1471-244X-12-26", "volume": "12", "author": "D Coppola", "year": "2012", "unstructured": "Coppola D, Liu Y, Gopal S et al (2012) A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia. BMC Psychiatry 12:26", "journal-title": "BMC Psychiatry"}, {"key": "7_CR169", "doi-asserted-by": "publisher", "first-page": "205", "DOI": "10.1002/hup.2308", "volume": "28", "author": "T Cabaleiro", "year": "2013", "unstructured": "Cabaleiro T, Lopez-Rodriguez RL, Ochoa D, Roman M, NovLBOS J, Abad-Santos F (2013) Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects. Hum Psychopharmacol Clin Exp 28:205\u2013214", "journal-title": "Hum Psychopharmacol Clin Exp"}, {"key": "7_CR170", "doi-asserted-by": "publisher", "first-page": "255", "DOI": "10.1038/tpj.2010.91", "volume": "12", "author": "S Mas", "year": "2012", "unstructured": "Mas S, Gasso P, Alvarez S et al (2012) Intuitive pharmacogenetics: spontaneous risperidone dosage is related to CYP2D6, CYP3A5, and ABCB1 genotypes. Pharmacogenomics J 12:255\u2013259", "journal-title": "Pharmacogenomics J"}, {"key": "7_CR171", "doi-asserted-by": "publisher", "first-page": "350", "DOI": "10.1345/aph.1R333", "volume": "47", "author": "AL Cartwright", "year": "2013", "unstructured": "Cartwright AL, Wilby KJ, Corrgian S, Enson MHH (2013) Pharmacogenetics of risperidone: a systematic review of the clinical effects of CYP2D6 polymorphisms. Ann Pharmacther 47:350\u2013360", "journal-title": "Ann Pharmacther"}, {"key": "7_CR172", "doi-asserted-by": "publisher", "first-page": "627", "DOI": "10.1097/FPC.0b013e3283659a94", "volume": "23", "author": "B Almoguera", "year": "2013", "unstructured": "Almoguera B, Riveiro-Alvarez R, Lopez-Castroman J et al (2013) CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment. Pharmacogenet Genomics 23:627\u2013630. V", "journal-title": "Pharmacogenet Genomics"}, {"key": "7_CR173", "doi-asserted-by": "publisher", "first-page": "289", "DOI": "10.1097/JCP.0b013e31828f62cd", "volume": "33", "author": "E Choong", "year": "2013", "unstructured": "Choong E, Polari A, Kamdem RH et al (2013) Pharmacogenetic study on risperidone long-acting injection: influence of cytochrome P450 2D6 and pregnane X receptor on risperidone exposure and drug-induced side-effects. J Clin Psychopharmacol 33:289\u2013298", "journal-title": "J Clin Psychopharmacol"}, {"key": "7_CR174", "doi-asserted-by": "publisher", "first-page": "215", "DOI": "10.2165/00002018-200023030-00004", "volume": "23", "author": "NA Buckley", "year": "2000", "unstructured": "Buckley NA, Sanders P (2000) Cardiovascular adverse effects of antipsychotic drugs. Drug Safe 23:215\u2013228", "journal-title": "Drug Safe"}, {"key": "7_CR175", "doi-asserted-by": "publisher", "first-page": "257", "DOI": "10.1097/00004714-200106000-00002", "volume": "21", "author": "K Hatta", "year": "2001", "unstructured": "Hatta K, Takahashi T, Nakamura H et al (2001) The association between intravenous haloperidol and prolonged QT interval. J Clin Psychopharmacol 21:257\u2013261", "journal-title": "J Clin Psychopharmacol"}, {"key": "7_CR176", "doi-asserted-by": "publisher", "first-page": "1310", "DOI": "10.1177/00912700122012896", "volume": "41", "author": "JE Tisdale", "year": "2001", "unstructured": "Tisdale JE, Rasty S, Padhi ID et al (2001) The effect of intravenous haloperidol on QT interval dispersion in critically ill patients: comparison with QT interval prolongation and assessment of risk of Torsades de Pointes. J Clin Pharmacol 41:1310\u20131318", "journal-title": "J Clin Pharmacol"}, {"key": "7_CR177", "doi-asserted-by": "publisher", "first-page": "1774", "DOI": "10.1176/appi.ajp.158.11.1774", "volume": "158", "author": "AH Glassman", "year": "2001", "unstructured": "Glassman AH, Bigger JT (2001) Antipsychotic drugs: prolonged QTc interval, Torsades de Pointes, and sudden death. Am J Psychiatry 158:1774\u20131782", "journal-title": "Am J Psychiatry"}, {"key": "7_CR178", "doi-asserted-by": "publisher", "first-page": "665", "DOI": "10.1002/jcph.257", "volume": "54", "author": "DA Spyker", "year": "2014", "unstructured": "Spyker DA, Voloshko P, Heyman ER, Cassella JV (2014) Loxapine delivered as a thermally generated aerosol does not prolong QTc in a through QT/QTc study in healthy subjects. J Clin Pharmacol 54:665\u2013674", "journal-title": "J Clin Pharmacol"}, {"key": "7_CR179", "doi-asserted-by": "publisher", "first-page": "3", "DOI": "10.1097/JCP.0b013e31827c0314", "volume": "33", "author": "SG Potkin", "year": "2013", "unstructured": "Potkin SG, Preskorn S, Hochfeld M, Meng X (2013) A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP3A4 and a comparison to quetiapine and ziprasidone. J Clin Psychopharmacol 33:3\u201310", "journal-title": "J Clin Psychopharmacol"}, {"key": "7_CR180", "doi-asserted-by": "publisher", "first-page": "105", "DOI": "10.1038/sj.tpj.6500160", "volume": "3", "author": "M Desai", "year": "2003", "unstructured": "Desai M, Tanus-Santos JE, Li L et al (2003) Pharmacokinetics and QT interval pharmacodynamics of oral haloperidol in poor and extensive metabolizers of CYP2D6. Pharmacogenomics J 3:105\u2013113", "journal-title": "Pharmacogenomics J"}, {"key": "7_CR181", "first-page": "1", "volume": "4", "author": "Y Suzuki", "year": "2014", "unstructured": "Suzuki Y, Tsuneyama N, Kukui N et al (2014) Effect of risperidone metabolism and P-glycoprotein gene polymorphism on QT interval in patients with schizophrenia. Pharmacogenomics J 4:1\u20135", "journal-title": "Pharmacogenomics J"}, {"key": "7_CR182", "first-page": "421", "volume": "28", "author": "J Peuskens", "year": "2014", "unstructured": "Peuskens J, Pani L, Detraux J, De Hert M (2014) The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs 28:421\u2013453", "journal-title": "CNS Drugs"}, {"key": "7_CR183", "doi-asserted-by": "publisher", "first-page": "131", "DOI": "10.1136/bjo.56.2.131", "volume": "56", "author": "ME Cameron", "year": "1972", "unstructured": "Cameron ME, Lawrence JM, Olrich JG (1972) Thioridazine (Mellaril retinopathy). Br J Opthal 56:131\u2013134", "journal-title": "Br J Opthal"}, {"key": "7_CR184", "doi-asserted-by": "publisher", "first-page": "823", "DOI": "10.1016/S0033-3182(85)72796-X", "volume": "26", "author": "JD Hamilton", "year": "1985", "unstructured": "Hamilton JD (1985) Thioridazine retinopathy within the upper dosage limit. Psychosomatics 26:823\u2013824", "journal-title": "Psychosomatics"}, {"key": "7_CR185", "doi-asserted-by": "publisher", "first-page": "533", "DOI": "10.1046/j.1442-9071.2003.00716.x", "volume": "31", "author": "PW Hadden", "year": "2003", "unstructured": "Hadden PW, Tay-Kearney MLT, Barry CJ, Constable IJ (2003) Thioridazine retinopathy. Clin Exp Opthal 31:533\u2013534", "journal-title": "Clin Exp Opthal"}, {"key": "7_CR186", "doi-asserted-by": "publisher", "first-page": "994", "DOI": "10.1001/archopht.120.7.994", "volume": "120", "author": "N Borodoker", "year": "2002", "unstructured": "Borodoker N, Del Priore LV, Caevallo CA, Yannuzzi LA (2002) Retinopathy as a result of long-term use of thioridazine. Arch Opthal 120:994\u2013995", "journal-title": "Arch Opthal"}, {"key": "7_CR187", "doi-asserted-by": "publisher", "first-page": "143", "DOI": "10.1016/0163-7258(82)90051-1", "volume": "16", "author": "NHG Holford", "year": "1982", "unstructured": "Holford NHG, Sheiner LB (1982) Kinetics of pharmacologic response. Pharmacol Ther 16:143\u2013166", "journal-title": "Pharmacol Ther"}, {"key": "7_CR188", "doi-asserted-by": "publisher", "first-page": "445", "DOI": "10.1007/BF01061728", "volume": "5", "author": "LB Sheiner", "year": "1977", "unstructured": "Sheiner LB, Rosenberg B, Marathe VV (1977) Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm 5:445\u2013479", "journal-title": "J Pharmacokinet Biopharm"}, {"key": "7_CR189", "doi-asserted-by": "publisher", "first-page": "355", "DOI": "10.2165/00003088-198308040-00006", "volume": "8", "author": "TH Grasela", "year": "1983", "unstructured": "Grasela TH, Sheiner LB, Rambeck HE et al (1983) Steady-state pharmacokinetics of phenytoin from routinely collected patient data. Clin Pharmacokinet 8:355\u2013364", "journal-title": "Clin Pharmacokinet"}, {"key": "7_CR190", "doi-asserted-by": "publisher", "first-page": "81", "DOI": "10.1055/s-2007-1004591", "volume": "41", "author": "FJ Diaz", "year": "2008", "unstructured": "Diaz FJ, Santoro V, Spina E et al (2008) Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables. Pharmacopsychiatry 41:81\u201391", "journal-title": "Pharmacopsychiatry"}, {"key": "7_CR191", "doi-asserted-by": "publisher", "first-page": "535", "DOI": "10.1097/FTD.0b013e318261c240", "volume": "34", "author": "CMT Sherwin", "year": "2013", "unstructured": "Sherwin CMT, Saldana SN, Bies RR, Aman MG, Vinks AA (2013) Population pharmacokinetic modeling of risperidone and 9-hydroxyrisperidone to estimate CYP2D6 subpopulations in children and adolescents. Ther Drug Monit 34:535\u2013544", "journal-title": "Ther Drug Monit"}, {"key": "7_CR192", "doi-asserted-by": "publisher", "first-page": "318", "DOI": "10.1016/j.ejphar.2008.02.005", "volume": "584", "author": "CK Olsen", "year": "2008", "unstructured": "Olsen CK, Brennum LT, Kreilgaard M (2008) Using pharmacokinetic-pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics. Eur J Pharmacol 584:318\u2013327", "journal-title": "Eur J Pharmacol"}, {"key": "7_CR193", "doi-asserted-by": "publisher", "first-page": "261", "DOI": "10.2165/11598460-000000000-00000", "volume": "51", "author": "V Pilla Reddy", "year": "2012", "unstructured": "Pilla Reddy V, Kozielska M, Johnson M et al (2012) Modeling and simulation of the positive and negative syndrome scale (PANSS) time course and dropout hazard in placebo arms of schizophrenia clinical trials. Clin Pharmacokinet 51:261\u2013275", "journal-title": "Clin Pharmacokinet"}, {"key": "7_CR194", "doi-asserted-by": "publisher", "first-page": "e1", "DOI": "10.1038/psp.2012.9", "volume": "1", "author": "V Pilla Reddy", "year": "2012", "unstructured": "Pilla Reddy V, Petersson KJ, Suleiman AA, Vereulen A, Proost JH, Friberg LE (2012) Pharmacokinetic-pharmacodynamic modeling of severity levels of extrapyramidal side effects with Markov elements. Clin Pharmacol Ther 1:e1. doi:\n                  10.1038/psp.2012.9", "journal-title": "Clin Pharmacol Ther"}, {"key": "7_CR195", "doi-asserted-by": "publisher", "first-page": "153", "DOI": "10.1016/j.schres.2013.02.010", "volume": "146", "author": "V Pilla Reddy", "year": "2013", "unstructured": "Pilla Reddy V, Kozielska M, Suleiman AA et al (2013) Pharmacokinetic-pharmacodynamic modeling of antipsychotic drugs in patients with schizophrenia: Part II: the use of subscales of the PANSS score. Schizophr Res 146:153\u2013161", "journal-title": "Schizophr Res"}, {"key": "7_CR196", "doi-asserted-by": "publisher", "first-page": "731", "DOI": "10.1097/JCP.0b013e3182a4ee2c", "volume": "33", "author": "V Pilla Reddy", "year": "2013", "unstructured": "Pilla Reddy V, Kozielska M, Johnson M et al (2013) Population pharmacokinetic-pharmacodynamic modeling of haloperidol in patients with schizophrenia using positive and negative syndrome rating scale. J Clin Psychopharmacol 33:731\u2013739", "journal-title": "J Clin Psychopharmacol"}], "container-title": ["Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents"], "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/978-3-319-27883-4_7", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 6, 1]], "date-time": "2019-06-01T16:44:08Z", "timestamp": 1559407448000}, "score": 32.3601, "issued": {"date-parts": [[2016]]}, "ISBN": ["9783319278810", "9783319278834"], "references-count": 196, "URL": "http://dx.doi.org/10.1007/978-3-319-27883-4_7", "relation": {"cites": []}}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T12:21:24Z", "timestamp": 1574770884334}, "publisher-location": "Cham", "reference-count": 121, "publisher": "Springer International Publishing", "isbn-type": [{"value": "9783319278810", "type": "print"}, {"value": "9783319278834", "type": "electronic"}], "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2016, 1, 1]], "date-time": "2016-01-01T00:00:00Z", "timestamp": 1451606400000}, "delay-in-days": 0, "content-version": "unspecified"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2016]]}, "DOI": "10.1007/978-3-319-27883-4_15", "type": "book-chapter", "created": {"date-parts": [[2016, 3, 2]], "date-time": "2016-03-02T13:04:48Z", "timestamp": 1456923888000}, "page": "373-394", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Anesthetic Drugs Pharmacokinetics and Pharmacodynamics"], "prefix": "10.1007", "author": [{"given": "Michael W.", "family": "Jann", "sequence": "first", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2016, 3, 3]]}, "reference": [{"key": "15_CR1", "unstructured": "Eilers H Niemann (2003) Clinically important drug interactions with intravenous anesthetic agents in older patients. Drug Aging 20:969\u2013980", "DOI": "10.2165/00002512-200320130-00002", "doi-asserted-by": "crossref"}, {"key": "15_CR2", "doi-asserted-by": "publisher", "first-page": "1", "DOI": "10.1097/00000542-199507000-00001", "volume": "83", "author": "DR Stanski", "year": "1995", "unstructured": "Stanski DR, Shafer SL (1995) Quantifying anesthetic drug interactions. Anesthesiology 83:1\u20135", "journal-title": "Anesthesiology"}, {"key": "15_CR3", "doi-asserted-by": "publisher", "first-page": "155", "DOI": "10.1093/bja/49.2.155", "volume": "49", "author": "A Feingold", "year": "1997", "unstructured": "Feingold A, Holaday DA (1997) The pharmacokinetics of metabolism of inhalation anaesthetics. Br J Anaesth 49:155\u2013162", "journal-title": "Br J Anaesth"}, {"key": "15_CR4", "doi-asserted-by": "publisher", "first-page": "587", "DOI": "10.1213/00000539-198207000-00007", "volume": "61", "author": "G Tanner", "year": "1982", "unstructured": "Tanner G (1982) Pharmacokinetics of inhalation anesthetics: a three-compartment linear model. Anesth Analg 61:587\u2013594", "journal-title": "Anesth Analg"}, {"key": "15_CR5", "first-page": "5", "volume": "25", "author": "A Doenicke", "year": "1975", "unstructured": "Doenicke A (1975) Etomidate: a new intravenous hypnotic. Acta Anaesthesia Belg 25:5\u20138", "journal-title": "Acta Anaesthesia Belg"}, {"key": "15_CR6", "doi-asserted-by": "publisher", "first-page": "955", "DOI": "10.1016/S0140-6736(75)92011-5", "volume": "1", "author": "N Morgan", "year": "1975", "unstructured": "Morgan N, Lumley J, Whitwam JA (1975) Etomidate, a new water insoluble nonbarbiturate intravenous induction agent. Lancet 1:955\u2013956", "journal-title": "Lancet"}, {"key": "15_CR7", "doi-asserted-by": "publisher", "first-page": "251", "DOI": "10.1002/j.1875-9114.1983.tb03266.x", "volume": "3", "author": "JL Geise", "year": "1983", "unstructured": "Geise JL, Stanley TH (1983) Etomidate: a new intravenous anesthetic induction agent. Pharmacotherapy 3:251\u2013258", "journal-title": "Pharmacotherapy"}, {"key": "15_CR8", "doi-asserted-by": "publisher", "first-page": "274", "DOI": "10.1097/00000542-197810000-00010", "volume": "49", "author": "MJ Hamme Van", "year": "1978", "unstructured": "Van Hamme MJ, Ghoneim MM, Ambre JJ (1978) Pharmacokinetics of etomidate, a new intravenous anesthetic. Anesthesiology 49:274\u2013277", "journal-title": "Anesthesiology"}, {"key": "15_CR9", "doi-asserted-by": "publisher", "first-page": "213", "DOI": "10.1093/bja/48.3.213", "volume": "48", "author": "B Kay", "year": "1976", "unstructured": "Kay B (1976) A dose-response relationship for etomidate, with some observations on cumulation. Br J Anaesth 48:213\u2013216", "journal-title": "Br J Anaesth"}, {"key": "15_CR10", "first-page": "479", "volume": "56", "author": "MM Ghoneim", "year": "1977", "unstructured": "Ghoneim MM, Yamada T (1977) Etomidate: a clinical and electroencephalographic comparison to thiopental. Anesthesia Analg 56:479\u2013485", "journal-title": "Anesthesia Analg"}, {"key": "15_CR11", "doi-asserted-by": "publisher", "first-page": "943", "DOI": "10.1136/bmj.2.6041.943-b", "volume": "2", "author": "KR Austin", "year": "1976", "unstructured": "Austin KR (1976) Ketamine hydrochloride: a potent analgesic. Br Med J 2:943\u2013945", "journal-title": "Br Med J"}, {"key": "15_CR12", "first-page": "27", "volume": "16", "author": "RH Kronenberg", "year": "2002", "unstructured": "Kronenberg RH (2002) Ketamine as an analgesic: parenteral, oral, rectal, subcutaneous, transdermal, and intranasal administration. J Pain Palliat Care Pharmacother 16:27\u201335", "journal-title": "J Pain Palliat Care Pharmacother"}, {"key": "15_CR13", "first-page": "835", "volume": "162", "author": "RC Hatch", "year": "1973", "unstructured": "Hatch RC (1973) Ketamine \u2013 excellent anesthetic. J Am Vet Assoc 162:835", "journal-title": "J Am Vet Assoc"}, {"key": "15_CR14", "doi-asserted-by": "publisher", "first-page": "27", "DOI": "10.1093/bja/53.1.27", "volume": "53", "author": "JA Clements", "year": "1981", "unstructured": "Clements JA, Nimmo WS (1981) Pharmacokinetics and analgesic effect of ketamine in man. Br J Anaesth 53:27\u201330", "journal-title": "Br J Anaesth"}, {"key": "15_CR15", "doi-asserted-by": "publisher", "first-page": "805", "DOI": "10.1093/bja/53.8.805", "volume": "53", "author": "IS Grant", "year": "1981", "unstructured": "Grant IS, Nimmo WS, Clements JA (1981) Pharmacokinetics and analgesic effects of IM and oral ketamine. Br J Anaesth 53:805\u2013810", "journal-title": "Br J Anaesth"}, {"key": "15_CR16", "doi-asserted-by": "publisher", "first-page": "539", "DOI": "10.1002/jps.2600710516", "volume": "71", "author": "JA Clements", "year": "1982", "unstructured": "Clements JA, Nimmo WS, Grant IS (1982) Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans. J Pharm Sci 71:539\u2013541", "journal-title": "J Pharm Sci"}, {"key": "15_CR17", "first-page": "1209", "volume": "260", "author": "I Oye", "year": "1992", "unstructured": "Oye I, Paulsen O, Maurset A (1992) Effects of ketamine on sensory perception: evidence for a role of NMDA receptors. J Pharmacol Exp Ther 260:1209\u20131213", "journal-title": "J Pharmacol Exp Ther"}, {"key": "15_CR18", "doi-asserted-by": "publisher", "first-page": "155", "DOI": "10.1016/0014-2999(92)90248-3", "volume": "213", "author": "HU Zeilhofer", "year": "1992", "unstructured": "Zeilhofer HU, Swandulala D, Geisslinger G, Brune K (1992) Differential effects of ketamine enantiomers on NMDA receptor currents in cultured neurons. Eur J Pharmacol 213:155\u2013158", "journal-title": "Eur J Pharmacol"}, {"key": "15_CR19", "doi-asserted-by": "publisher", "first-page": "853", "DOI": "10.1124/dmd.30.7.853", "volume": "30", "author": "Y Hijazi", "year": "2002", "unstructured": "Hijazi Y, Boulieu R (2002) Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos 30:853\u2013858", "journal-title": "Drug Metab Dispos"}, {"key": "15_CR20", "doi-asserted-by": "publisher", "first-page": "666", "DOI": "10.1093/bja/70.6.666", "volume": "70", "author": "G Geisslinger", "year": "1993", "unstructured": "Geisslinger G, Hering W, Thomann P et al (1993) Pharmacokinetics and pharmacodynamics of ketamine enantiomers in surgical patients using a stereoselective analytical method. Br J Anaesth 70:666\u2013671", "journal-title": "Br J Anaesth"}, {"key": "15_CR21", "doi-asserted-by": "publisher", "first-page": "431", "DOI": "10.1067/mcp.2001.119722", "volume": "70", "author": "H Ihmsen", "year": "2001", "unstructured": "Ihmsen H, Geisslinger G, Schuttler J (2001) Stereoselective pharmacokinetics of ketamine: R(\u2212) ketamine inhibits the elimination of S(+) ketamine. Clin Pharmacol Ther 70:431\u2013438", "journal-title": "Clin Pharmacol Ther"}, {"key": "15_CR22", "doi-asserted-by": "publisher", "first-page": "138", "DOI": "10.1002/j.1875-9114.1985.tb03411.x", "volume": "5", "author": "JH Kanto", "year": "1985", "unstructured": "Kanto JH (1985) Midazolam: the first water-soluble benzodiazepine. Pharmacotherapy 5:138\u2013155", "journal-title": "Pharmacotherapy"}, {"key": "15_CR23", "first-page": "460", "volume": "21", "author": "JH Kanto", "year": "1983", "unstructured": "Kanto JH, Allonen H (1983) Pharmacokinetics and the sedative effect of midazolam. Int J Clin Pharmacol Ther Toxic 21:460\u2013463", "journal-title": "Int J Clin Pharmacol Ther Toxic"}, {"key": "15_CR24", "doi-asserted-by": "publisher", "first-page": "271", "DOI": "10.1007/BF00562804", "volume": "19", "author": "MH Smith", "year": "1981", "unstructured": "Smith MH, Eadie MJ, Brophy TO (1981) The pharmacokinetic of midazolam in man. Eur J Clin Pharmacol 19:271\u2013278", "journal-title": "Eur J Clin Pharmacol"}, {"key": "15_CR25", "doi-asserted-by": "publisher", "first-page": "43S", "DOI": "10.1111/j.1365-2125.1983.tb02270.x", "volume": "16", "author": "P Heizmann", "year": "1983", "unstructured": "Heizmann P, Eckert M, Ziegler WH (1983) Pharmacokinetics and bioavailability in man. Br J Clin Pharmacol 16:43S\u201349S", "journal-title": "Br J Clin Pharmacol"}, {"key": "15_CR26", "first-page": "89", "volume": "30", "author": "T Kronbach", "year": "1989", "unstructured": "Kronbach T, Mathys D, Umeno M et al (1989) Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 30:89\u201396", "journal-title": "Mol Pharmacol"}, {"key": "15_CR27", "doi-asserted-by": "publisher", "first-page": "310", "DOI": "10.1097/00000542-198503000-00017", "volume": "62", "author": "JG Reves", "year": "1985", "unstructured": "Reves JG, Fragen RJ, Vinik R, Greenblatt DJ (1985) Midazolam: pharmacology and uses. Anesthesiology 62:310\u2013324", "journal-title": "Anesthesiology"}, {"key": "15_CR28", "doi-asserted-by": "publisher", "first-page": "51S", "DOI": "10.1111/j.1365-2125.1983.tb02271.x", "volume": "16", "author": "C Crevoisier", "year": "1983", "unstructured": "Crevoisier C, Ziegler WH, Eckert M, Heizmann P (1983) Relationship between plasma concentration and effect of midazolam after oral and intravenous administration. Br J Clin Pharmacol 16:51S\u201361S", "journal-title": "Br J Clin Pharmacol"}, {"key": "15_CR29", "doi-asserted-by": "publisher", "first-page": "187S", "DOI": "10.1111/j.1365-2125.1983.tb02293.x", "volume": "16", "author": "M Gemperle", "year": "1983", "unstructured": "Gemperle M, Kapp WK (1983) Midazolam and anaesthesia. Br J Clin Pharmacol 16:187S\u2013190S", "journal-title": "Br J Clin Pharmacol"}, {"key": "15_CR30", "doi-asserted-by": "publisher", "first-page": "907", "DOI": "10.1093/bja/52.9.907", "volume": "52", "author": "A Forster", "year": "1980", "unstructured": "Forster A, Gardaz JP, Suter PM, Gemperle M (1980) IV midazolam as an induction agent for anaesthesia: a study in volunteers. Br J Anaesth 52:907\u2013911", "journal-title": "Br J Anaesth"}, {"key": "15_CR31", "doi-asserted-by": "publisher", "first-page": "561", "DOI": "10.1111/j.1365-2125.1988.tb03346.x", "volume": "25", "author": "M Sunzel", "year": "1988", "unstructured": "Sunzel M, Paalzow L, Berggren L, Eriksson I (1988) Respiratory and cardiovascular effects in relation to plasma levels of midazolam and diazepam. Br J Clin Pharmacol 25:561\u2013569", "journal-title": "Br J Clin Pharmacol"}, {"key": "15_CR32", "doi-asserted-by": "publisher", "first-page": "494", "DOI": "10.1097/00000542-198012000-00010", "volume": "53", "author": "A Forster", "year": "1980", "unstructured": "Forster A, Gardaz JP, Suter PM, Gemperle M (1980) Respirator depression by midazolam and diazepam. Anesthesiology 53:494\u2013497", "journal-title": "Anesthesiology"}, {"key": "15_CR33", "doi-asserted-by": "publisher", "first-page": "125", "DOI": "10.1097/00000542-198208000-00011", "volume": "57", "author": "CB Caldwell", "year": "1982", "unstructured": "Caldwell CB, Gross JB (1982) Physostigmine reversal of midazolam-induced sedation. Anesthesiology 57:125\u2013127", "journal-title": "Anesthesiology"}, {"key": "15_CR34", "doi-asserted-by": "publisher", "first-page": "713", "DOI": "10.1097/00000542-199610000-00005", "volume": "85", "author": "JB Gross", "year": "1996", "unstructured": "Gross JB, Blouin RT, Zandsberg S et al (1996) Effect of flumazenil on ventilatory drive during sedation with midazolam and alfentanil. Anesthesiology 85:713\u2013720", "journal-title": "Anesthesiology"}, {"key": "15_CR35", "doi-asserted-by": "publisher", "first-page": "25", "DOI": "10.2165/00003088-198106010-00002", "volume": "6", "author": "MJ Ramzan", "year": "1981", "unstructured": "Ramzan MJ, Somogyi AA, Walker JS et al (1981) Clinical pharmacokinetics of the non-depolarising muscle relaxants. Clin Pharamcokinet 6:25\u201360", "journal-title": "Clin Pharamcokinet"}, {"key": "15_CR36", "doi-asserted-by": "publisher", "first-page": "22", "DOI": "10.1007/BF03016739", "volume": "3", "author": "W Kalow", "year": "1956", "unstructured": "Kalow W (1956) The relation of plasma cholinesterases to response to clinical doses of succinylcholine. J Arch Can Anaesth 3:22\u201330", "journal-title": "J Arch Can Anaesth"}, {"key": "15_CR37", "doi-asserted-by": "publisher", "first-page": "330", "DOI": "10.2165/00003088-197702050-00002", "volume": "2", "author": "LB Wingard", "year": "1977", "unstructured": "Wingard LB, Cook DR (1977) Clinical pharmacokinetics of muscle relaxants. Clin Pharmacokinet 2:330\u2013343", "journal-title": "Clin Pharmacokinet"}, {"key": "15_CR38", "doi-asserted-by": "publisher", "first-page": "94", "DOI": "10.2165/00003088-199222020-00002", "volume": "22", "author": "S Agoston", "year": "1992", "unstructured": "Agoston S, Vandenbrom RH, Wierda JM (1992) Clinical pharmacokinetics of neuromuscular blocking drugs. Clin Pharmacokinet 22:94\u2013115", "journal-title": "Clin Pharmacokinet"}, {"key": "15_CR39", "doi-asserted-by": "publisher", "first-page": "169", "DOI": "10.2165/00003088-199936030-00001", "volume": "36", "author": "D Paul", "year": "1999", "unstructured": "Paul D, Atherton L, Huter JM (1999) Clinical pharmacokinetics of the newer neuromuscular blocking drugs. Clin Pharmacokinet 36:169\u2013189", "journal-title": "Clin Pharmacokinet"}, {"key": "15_CR40", "doi-asserted-by": "publisher", "first-page": "483", "DOI": "10.2165/00003088-199834060-00004", "volume": "34", "author": "J Guay", "year": "1998", "unstructured": "Guay J, Grenier Y, Varin F (1998) Clinical pharmacokinetics of neuromuscular relaxants in pregnancy. Clin Pharmacokinet 34:483\u2013497", "journal-title": "Clin Pharmacokinet"}, {"key": "15_CR41", "doi-asserted-by": "publisher", "first-page": "239", "DOI": "10.1111/j.1469-1809.1959.tb01467.x", "volume": "23", "author": "W Kalow", "year": "1959", "unstructured": "Kalow W, Gunn DR (1959) Some statistical data on atypical cholinesterase of human serum. Am J Hum Genet 23:239\u2013250", "journal-title": "Am J Hum Genet"}, {"key": "15_CR42", "doi-asserted-by": "publisher", "first-page": "287", "DOI": "10.1093/bja/36.5.287", "volume": "38", "author": "AR Ryan", "year": "1964", "unstructured": "Ryan AR (1964) Tubocurarine administration based upon its disappearance and accumulation curves in anaesthesized man. Br J Anaesth 38:287", "journal-title": "Br J Anaesth"}, {"key": "15_CR43", "doi-asserted-by": "publisher", "first-page": "440", "DOI": "10.1097/00000542-197411000-00006", "volume": "41", "author": "RS Matteo", "year": "1974", "unstructured": "Matteo RS, Spector S, Horowitz PE (1974) Relation of serum d-tubocurarine concentration to neuromuscular block in man. Anesthesiology 41:440\u2013448", "journal-title": "Anesthesiology"}, {"key": "15_CR44", "doi-asserted-by": "publisher", "first-page": "893", "DOI": "10.1093/bja/52.9.893", "volume": "52", "author": "MI Ramzan", "year": "1980", "unstructured": "Ramzan MI, Shanks CA, Triggs EJ (1980) Pharmacokinetics of tubocurarine administered by combined IV bolus and infusion. Br J Anaesth 52:893\u2013899", "journal-title": "Br J Anaesth"}, {"key": "15_CR45", "doi-asserted-by": "publisher", "first-page": "203", "DOI": "10.1097/00000542-198209000-00009", "volume": "57", "author": "DM Fisher", "year": "1982", "unstructured": "Fisher DM, O\u2019Keefe C, Stanski DR et al (1982) Pharmacokinetics and pharmacodynamics of d-tubocurarine in infants, children, and adults. Anesthesiology 57:203\u2013208", "journal-title": "Anesthesiology"}, {"key": "15_CR46", "doi-asserted-by": "publisher", "first-page": "631", "DOI": "10.1097/00000542-198155060-00005", "volume": "55", "author": "J Ham", "year": "1981", "unstructured": "Ham J, Stanski DR, Newfield P, Miller RD (1981) Pharmacokinetics and dynamics of d-tubocurarine during hypothermia in humans. Anesthesiology 55:631\u2013633", "journal-title": "Anesthesiology"}, {"key": "15_CR47", "doi-asserted-by": "publisher", "first-page": "358", "DOI": "10.1002/cpt1979253358", "volume": "25", "author": "LB Sheiner", "year": "1979", "unstructured": "Sheiner LB, Stanski DR, Vozeh S et al (1979) Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 25:358\u2013371", "journal-title": "Clin Pharmacol Ther"}, {"key": "15_CR48", "doi-asserted-by": "publisher", "first-page": "493", "DOI": "10.1007/s001010050429", "volume": "46L", "author": "F Ltorre", "year": "1997", "unstructured": "Ltorre F, deAlemeida MC, Stanek A, Kleeman PP (1997) The effect of smoking on neuromuscular transmission after rocuronium. Anaesthesist 46L:493\u2013495", "journal-title": "Anaesthesist"}, {"key": "15_CR49", "doi-asserted-by": "publisher", "first-page": "353", "DOI": "10.1007/BF03017322", "volume": "49", "author": "A Drage", "year": "2002", "unstructured": "Drage A, Varin F, Plaud B, Donati F (2002) Rocuronium pharmacokinetics-pharmacodynamic relationship under stable propofol or isoflurane anesthesia. Can J Anesth 49:353\u2013360", "journal-title": "Can J Anesth"}, {"key": "15_CR50", "doi-asserted-by": "publisher", "first-page": "139", "DOI": "10.1046/j.1365-2125.1997.00653.x", "volume": "44", "author": "MM Miert Van", "year": "1997", "unstructured": "Van Miert MM, Estwood NB, Boyd AH et al (1997) The pharmacokinetic and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. Br J Clin Pharmacol 44:139\u2013144", "journal-title": "Br J Clin Pharmacol"}, {"key": "15_CR51", "doi-asserted-by": "publisher", "first-page": "e78052", "DOI": "10.1371/journal.pone.0078052", "volume": "8", "author": "ZM Wang", "year": "2013", "unstructured": "Wang ZM, Zhang P, Lin MJ et al (2013) Influence of obstructive jaundice on pharmacodynamics of rocuronium. PLoS One 8:e78052", "journal-title": "PLoS One"}, {"key": "15_CR52", "first-page": "1216", "volume": "270", "author": "JE Caldwell", "year": "1994", "unstructured": "Caldwell JE, Szenohradszky J, Segredo V et al (1994) The pharmacodynamics and pharmacokinetics of the metabolite 3-desacetylvencuronium (ORG 7268) and its parent compound, vecuronium, in human volunteers. J Pharm Exp Ther 270:1216\u20131222", "journal-title": "J Pharm Exp Ther"}, {"key": "15_CR53", "doi-asserted-by": "publisher", "first-page": "703", "DOI": "10.1093/bja/55.8.703", "volume": "55", "author": "IG Marshall", "year": "1983", "unstructured": "Marshall IG, Gibb AJ, Durant NN (1983) Neuromuscular and vagal blocking actions of pancuronium bromide, its metabolites, and vecuronium bromide (Org NC45) and its potential metabolites in the anesthetized cat. Br J Anaesth 55:703\u2013714", "journal-title": "Br J Anaesth"}, {"key": "15_CR54", "doi-asserted-by": "publisher", "first-page": "405", "DOI": "10.1097/00000542-198305000-00002", "volume": "58", "author": "R Cronnelly", "year": "1983", "unstructured": "Cronnelly R, Fisher DM, Miller RD et al (1983) Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC 45) and pancuronium in anaesthesized patients. Anesthesiology 58:405\u2013408", "journal-title": "Anesthesiology"}, {"key": "15_CR55", "first-page": "1319", "volume": "65", "author": "C Meistelman", "year": "1996", "unstructured": "Meistelman C, Agoston S, Kersten UW et al (1996) Pharmacokinetics and pharmacodynamics of vencuronium and pancuronium in anesthetized children. Anesth Analg 65:1319\u20131322", "journal-title": "Anesth Analg"}, {"key": "15_CR56", "doi-asserted-by": "publisher", "first-page": "45", "DOI": "10.1097/00000542-198707000-00008", "volume": "67", "author": "SM Rupp", "year": "1987", "unstructured": "Rupp SM, Castagnoili KP, Fisher DM, Miller RD (1987) Pancuronium and vencuronium pharmacokinetics and pharmacodynamics in younger and elderly adults. Anesthesiology 67:45\u201349", "journal-title": "Anesthesiology"}, {"key": "15_CR57", "doi-asserted-by": "publisher", "first-page": "227", "DOI": "10.1097/00000542-198808000-00012", "volume": "69", "author": "DP Lyman", "year": "1988", "unstructured": "Lyman DP, Cronnelly R, Castagnoli KP et al (1988) The pharmacodynamics and pharmacokinetics of vecuronium in patients anesthetized with isoflurane with normal renal function or with renal failure. Anesthesiology 69:227\u2013231", "journal-title": "Anesthesiology"}, {"key": "15_CR58", "doi-asserted-by": "publisher", "first-page": "304", "DOI": "10.1093/bja/aet309", "volume": "112", "author": "KR Vego-villa", "year": "2014", "unstructured": "Vego-villa KR, Kaneda K, Yamashita S et al (2014) Vecuronium pharmacokinetics in patients with major burns. Br J Anaesthesia 112:304\u2013310", "journal-title": "Br J Anaesthesia"}, {"key": "15_CR59", "doi-asserted-by": "publisher", "first-page": "18", "DOI": "10.2165/00003088-198611010-00002", "volume": "11", "author": "PJ Davis", "year": "1986", "unstructured": "Davis PJ, Cook DR (1986) Clinical pharmacokinetics of the newer intravenous anaesthetic agents. Clin Pharmacokinet 11:18\u201335", "journal-title": "Clin Pharmacokinet"}, {"key": "15_CR60", "first-page": "239", "volume": "22", "author": "JS Willens", "year": "1993", "unstructured": "Willens JS, Myslinski NR (1993) Pharmacodynamics, pharmacokinetics, and clinical uses of fentanyl, sufentanil, and alfentanil. Heart Lung 22:239\u2013251", "journal-title": "Heart Lung"}, {"key": "15_CR61", "doi-asserted-by": "publisher", "first-page": "652", "DOI": "10.1002/j.1552-4604.1980.tb01682.x", "volume": "20", "author": "DL Fung", "year": "1980", "unstructured": "Fung DL, Eisele JH (1980) Fentanyl pharmacokinetics in awake volunteers. J Clin Pharmacol 20:652\u2013658", "journal-title": "J Clin Pharmacol"}, {"key": "15_CR62", "doi-asserted-by": "publisher", "first-page": "1194", "DOI": "10.1097/00000542-199512000-00010", "volume": "83", "author": "E Gepts", "year": "1998", "unstructured": "Gepts E, Shafer SL, Camu F et al (1998) Linearity of pharmacokinetics and model estimation of sufentanil. Anesthesiology 83:1194\u20131204", "journal-title": "Anesthesiology"}, {"key": "15_CR63", "doi-asserted-by": "publisher", "first-page": "1559", "DOI": "10.1097/00000542-200006000-00012", "volume": "92", "author": "C Metz", "year": "2000", "unstructured": "Metz C, Gobel L, Gruber M et al (2000) Pharmacokinetics of human cerebral opioid extraction: a comparative study on sufentanil, fentanyl, and alfentanil in a patient after severe head injury. Anesthesiology 92:1559\u20131567", "journal-title": "Anesthesiology"}, {"key": "15_CR64", "first-page": "4", "volume": "257", "author": "WE Meuldermans", "year": "1982", "unstructured": "Meuldermans WE, Hurkmans RM, Heykants JJ (1982) Plasma protein binding and distribution of fentanyl, sufentanil, alfentanil and lofentanil in blood. Arch Int Pharmacodyn Ther 257:4\u201319", "journal-title": "Arch Int Pharmacodyn Ther"}, {"key": "15_CR65", "first-page": "1072", "volume": "25", "author": "RB Labroo", "year": "1997", "unstructured": "Labroo RB, Paine FP, Thummel KE, Khararsch ED (1997) Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy, and drug interactions. Drug Metab Dispos 25:1072\u20131080", "journal-title": "Drug Metab Dispos"}, {"key": "15_CR66", "doi-asserted-by": "publisher", "first-page": "467", "DOI": "10.1097/00000542-199209000-00011", "volume": "77", "author": "CH Yun", "year": "1992", "unstructured": "Yun CH, Wood M, Wood AJ (1992) Identification of the pharmacogenetic determination of alfentanil metabolism cytochrome P450 3A4. An explanation of the variable elimination clearance. Anesthesiology 77:467\u2013474", "journal-title": "Anesthesiology"}, {"key": "15_CR67", "doi-asserted-by": "publisher", "first-page": "11", "DOI": "10.1002/j.1875-9114.1984.tb03304.x", "volume": "4", "author": "CE Roscow", "year": "1984", "unstructured": "Roscow CE (1984) Sufentanil citrate: a new opioid analgesic for use in anesthesia. Pharmacotherapy 4:11\u201319", "journal-title": "Pharmacotherapy"}, {"key": "15_CR68", "doi-asserted-by": "publisher", "first-page": "274", "DOI": "10.1111/j.1460-9592.2010.03411.x", "volume": "21", "author": "S Lundberg", "year": "2011", "unstructured": "Lundberg S, Roelofse JA (2011) Aspects of pharmacokinetics and pharmacodynamics of sufentanil in pediatric practice. Paediatr Anaesth 21:274\u2013279", "journal-title": "Paediatr Anaesth"}, {"key": "15_CR69", "doi-asserted-by": "publisher", "first-page": "260", "DOI": "10.1097/00000542-199302000-00008", "volume": "78", "author": "RR Bartkowski", "year": "1993", "unstructured": "Bartkowski RR, Goldberg ME, Huffnagle S, Epstein RH (1993) Sufentanil disposition. Is it affected by erythromycin administration? Anesthesiology 78:260\u2013265", "journal-title": "Anesthesiology"}, {"key": "15_CR70", "doi-asserted-by": "publisher", "first-page": "853", "DOI": "10.1097/00000542-200304000-00011", "volume": "98", "author": "AE Ibrahim", "year": "2003", "unstructured": "Ibrahim AE, Feldman J, Karim A, Kharasch ED (2003) Simultaneous assessment of drug interactions with low and high extraction opioids. Anesthesiology 98:853\u2013861", "journal-title": "Anesthesiology"}, {"key": "15_CR71", "doi-asserted-by": "publisher", "first-page": "913", "DOI": "10.1097/00000542-200204000-00019", "volume": "96", "author": "C Wandel", "year": "2002", "unstructured": "Wandel C, Kim R, Wood M, Wood A (2002) Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein. Anesthesiology 96:913\u2013920", "journal-title": "Anesthesiology"}, {"key": "15_CR72", "doi-asserted-by": "publisher", "first-page": "1021", "DOI": "10.1213/00000539-198610000-00005", "volume": "65", "author": "A Shafer", "year": "1986", "unstructured": "Shafer A, Sung ML, White PF (1986) Pharmacokinetic and pharmacodynamics of alfentanil infusions during general anesthesia. Anesth Analg 65:1021\u20131028", "journal-title": "Anesth Analg"}, {"key": "15_CR73", "doi-asserted-by": "publisher", "first-page": "852", "DOI": "10.1097/00000542-199810000-00009", "volume": "89", "author": "IR Thomson", "year": "1998", "unstructured": "Thomson IR, Henderson BT, Singh K, Hudson RJ (1998) Concentration-response relationship for fentanyl and sufentanil in patients undergoing coronary artery bypass grafting. Anesthesiology 89:852\u2013861", "journal-title": "Anesthesiology"}, {"key": "15_CR74", "doi-asserted-by": "publisher", "first-page": "652", "DOI": "10.1053/jcan.2000.18307", "volume": "14", "author": "IR Thompson", "year": "2000", "unstructured": "Thompson IR, Harding G, Hudson RJ (2000) A comparison of fentanyl and sufentanil in patients undergoing coronary artery bypass graft surgery. J Cardiothoracic Vas Anesth 14:652\u2013656", "journal-title": "J Cardiothoracic Vas Anesth"}, {"key": "15_CR75", "doi-asserted-by": "publisher", "first-page": "698", "DOI": "10.1093/bja/aes253", "volume": "109", "author": "C Jeleazcov", "year": "2012", "unstructured": "Jeleazcov C, Saari TI, Ihmsen H et al (2012) Changes in total and unbound concentrations of sufentanil during target controlled infusion for cardiac surgery with cardiopulmonary bypass. Br J Anaesth 109:698\u2013706", "journal-title": "Br J Anaesth"}, {"key": "15_CR76", "doi-asserted-by": "publisher", "first-page": "275", "DOI": "10.2165/00003088-199631040-00004", "volume": "31", "author": "J Scholz", "year": "1996", "unstructured": "Scholz J, Steinfath M, Schulz M (1996) Clinical pharmacokinetics of alfentanil, fentanyl, and sufentanil. An update. Clin Pharmacokinet 31:275\u2013292", "journal-title": "Clin Pharmacokinet"}, {"key": "15_CR77", "doi-asserted-by": "publisher", "first-page": "A758", "DOI": "10.1097/00000542-198809010-00758", "volume": "69", "author": "PJ Davis", "year": "1988", "unstructured": "Davis PJ, Killian A, Stiller RL et al (1988) Alfentanil pharmacokinetics in premature infants and older children. Anesthesiology 69:A758", "journal-title": "Anesthesiology"}, {"key": "15_CR78", "doi-asserted-by": "publisher", "first-page": "14", "DOI": "10.1007/BF03008666", "volume": "39", "author": "J Guay", "year": "1992", "unstructured": "Guay J, Gaudreault P, Tang A et al (1992) Pharmacokinetics of sufentanil in normal children. Can J Anaesth 39:14\u201320", "journal-title": "Can J Anaesth"}, {"key": "15_CR79", "first-page": "159", "volume": "240", "author": "JC Scott", "year": "1987", "unstructured": "Scott JC, Stanski DR (1987) Decreased fentanyl and alfentanil dose requirements with age: a simultaneous pharmacokinetic and pharmacodynamics evaluation. J Pharmacol Exp Ther 240:159\u2013163", "journal-title": "J Pharmacol Exp Ther"}, {"key": "15_CR80", "doi-asserted-by": "publisher", "first-page": "502", "DOI": "10.1097/00000542-198411000-00004", "volume": "61", "author": "JG Bovill", "year": "1984", "unstructured": "Bovill JG, Sebel PS, Blackburn CL, Oei-Lim V, Heykants JJ (1984) The pharmacokinetics of sufentanil in surgical patients. Anesthesiology 61:502\u2013506", "journal-title": "Anesthesiology"}, {"key": "15_CR81", "doi-asserted-by": "publisher", "first-page": "426", "DOI": "10.1097/00000542-198903000-00011", "volume": "70", "author": "RJ Hudson", "year": "1989", "unstructured": "Hudson RJ, Bergstrom RG, Thomson IR et al (1989) Pharmacokinetics of sufentanil in patients undergoing abdominal aortic surgery. Anesthesiology 70:426\u2013431", "journal-title": "Anesthesiology"}, {"key": "15_CR82", "doi-asserted-by": "publisher", "first-page": "61", "DOI": "10.1007/BF03009165", "volume": "38", "author": "RJ Hudson", "year": "1991", "unstructured": "Hudson RJ, Thomson IR, Burgess PM, Rosenbloom M (1991) Alfentanil pharmacokinetics in patients undergoing abdominal aortic surgery. Can J Anaesth 38:61\u201367", "journal-title": "Can J Anaesth"}, {"key": "15_CR83", "doi-asserted-by": "publisher", "first-page": "10", "DOI": "10.2165/00003088-198917010-00002", "volume": "17", "author": "WA Baylaen", "year": "1989", "unstructured": "Baylaen WA, Herregods LL, Mortier EP et al (1989) Cardiopulmonary bypass and the pharmacokinetics of drugs. An update. Clin Pharmacokinet 17:10\u201322", "journal-title": "Clin Pharmacokinet"}, {"key": "15_CR84", "doi-asserted-by": "publisher", "first-page": "747", "DOI": "10.1007/BF03008453", "volume": "38", "author": "R Hall", "year": "1991", "unstructured": "Hall R (1991) The pharmacokinetic behavior of opioids administered during cardiac surgery. Can J Anaesth 38:747\u2013756", "journal-title": "Can J Anaesth"}, {"key": "15_CR85", "doi-asserted-by": "publisher", "first-page": "1168", "DOI": "10.1111/j.1365-2044.1984.tb06425.x", "volume": "39", "author": "GC Cummings", "year": "1984", "unstructured": "Cummings GC, Dixon J, Kay NH et al (1984) Dose requirements of ICI 35868 (propofol, Diprivan) in a new formulation for induction of anaesthesia. Anaesthesia 39:1168\u20131173", "journal-title": "Anaesthesia"}, {"key": "15_CR86", "doi-asserted-by": "publisher", "first-page": "1075", "DOI": "10.1093/bja/58.10.1075", "volume": "58", "author": "NH Kay", "year": "1986", "unstructured": "Kay NH, Sear JW, Uppington J et al (1986) Disposition of propofol in patients undergoing surgery. Br J Anaesth 58:1075\u20131079", "journal-title": "Br J Anaesth"}, {"key": "15_CR87", "doi-asserted-by": "publisher", "first-page": "146", "DOI": "10.1093/bja/60.2.146", "volume": "60", "author": "T Kirkpatirck", "year": "1988", "unstructured": "Kirkpatirck T, Cockshott ID, Douglas EJ, Nimmo WS (1988) Pharmacokinetics of propofol (Diprivan) in elderly patients. Br J Anaesth 60:146\u2013150", "journal-title": "Br J Anaesth"}, {"key": "15_CR88", "doi-asserted-by": "publisher", "first-page": "1170", "DOI": "10.1097/00000542-199805000-00006", "volume": "88", "author": "TW Schnider", "year": "1998", "unstructured": "Schnider TW, Minto CF, Gambus PL et al (1998) The influence of method of administration and covariates on the pharmacokinetics of propofol in adult volunteers. Anesthesiology 88:1170\u20131182", "journal-title": "Anesthesiology"}, {"key": "15_CR89", "doi-asserted-by": "publisher", "first-page": "41", "DOI": "10.1093/bja/67.1.41", "volume": "67", "author": "B Marsh", "year": "1991", "unstructured": "Marsh B, White M, Morton N, Kenny GNC (1991) Pharmacokinetic model driven infusion of propofol in children. Br J Anaesth 67:41\u201348", "journal-title": "Br J Anaesth"}, {"key": "15_CR90", "doi-asserted-by": "publisher", "first-page": "402", "DOI": "10.4103/0253-7613.96348", "volume": "44", "author": "A Puri", "year": "2012", "unstructured": "Puri A, Medhi B, Panda NB et al (2012) Propofol pharmacokinetics in young healthy Indian subjects. Indian J Pharmacol 44:402\u2013406", "journal-title": "Indian J Pharmacol"}, {"key": "15_CR91", "doi-asserted-by": "publisher", "first-page": "393", "DOI": "10.4103/0253-7613.96346", "volume": "44", "author": "HB Ye", "year": "2012", "unstructured": "Ye HB, Li JH, Rui JZ et al (2012) Propofol pharmacokinetics in China: a multicentric study. Indian J Pharmacol 44:393\u2013397", "journal-title": "Indian J Pharmacol"}, {"key": "15_CR92", "doi-asserted-by": "publisher", "first-page": "110", "DOI": "10.1097/00000542-200101000-00021", "volume": "94", "author": "MH Court", "year": "2001", "unstructured": "Court MH, Duan SX, Hesse LM et al (2001) Cytochrome P450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes. Anesthesiology 94:110\u2013119", "journal-title": "Anesthesiology"}, {"key": "15_CR93", "doi-asserted-by": "publisher", "first-page": "788", "DOI": "10.1093/bja/80.6.788", "volume": "80", "author": "J Guitton", "year": "1998", "unstructured": "Guitton J, Buronfosse T, Desage M et al (1998) Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth 80:788\u2013795", "journal-title": "Br J Anaesth"}, {"key": "15_CR94", "doi-asserted-by": "publisher", "first-page": "185", "DOI": "10.1515/dmdi-2012-0027", "volume": "27", "author": "M Turpeinen", "year": "2012", "unstructured": "Turpeinen M, Zanger UM (2012) Cytochrome P450 2B6: function, genetics, and clinical relevance. Drug Metab Drug Interact 27:185\u2013197", "journal-title": "Drug Metab Drug Interact"}, {"key": "15_CR95", "doi-asserted-by": "publisher", "first-page": "532", "DOI": "10.2133/dmpk.DMPK-11-RG-039", "volume": "26", "author": "F Kansaku", "year": "2011", "unstructured": "Kansaku F, Kuma T, Sasaki K et al (2011) Individual differences in pharmacokinetics and pharmacodynamics of anesthetic agent propofol with regard to CYP2B6 and UGR1A9 genotype and patient age. Drug Metab Pharmacokinet 26:532\u2013537", "journal-title": "Drug Metab Pharmacokinet"}, {"key": "15_CR96", "doi-asserted-by": "publisher", "first-page": "137", "DOI": "10.2165/11596980-000000000-00000", "volume": "51", "author": "JF Coetzee", "year": "2012", "unstructured": "Coetzee JF (2012) Allometric or lean body mass scaling of propofol pharmacokinetics. Clin Pharmacokinet 51:137\u2013145", "journal-title": "Clin Pharmacokinet"}, {"key": "15_CR97", "doi-asserted-by": "publisher", "first-page": "1132", "DOI": "10.1111/anae.12384", "volume": "68", "author": "I Martin-Mateos", "year": "2013", "unstructured": "Martin-Mateos I, Perez JAM, Reboso JA, Leon A (2013) Modeling propofol pharmacodynamics using BIS-guided anaesthesia. Anaesthesia 68:1132\u20131140", "journal-title": "Anaesthesia"}, {"key": "15_CR98", "doi-asserted-by": "publisher", "first-page": "823", "DOI": "10.1213/ANE.0b013e31825d6254", "volume": "115", "author": "CG Echevarria", "year": "2012", "unstructured": "Echevarria CG, Elgueta MF, Donoso MT et al (2012) The effective effect-site propofol concentration for induction and intubation with two pharmacokinetic models in morbidly obese patients using total body weight. Anesth Analg 115:823\u2013829", "journal-title": "Anesth Analg"}, {"key": "15_CR99", "doi-asserted-by": "publisher", "first-page": "543", "DOI": "10.1007/BF03261930", "volume": "51", "author": "J Diepstraten", "year": "2012", "unstructured": "Diepstraten J, Chidambaran V, Sadhasivan S et al (2012) Propofol clearance in morbidly obese children and adolescents. Clin Pharmacokinet 51:543\u2013551", "journal-title": "Clin Pharmacokinet"}, {"key": "15_CR100", "doi-asserted-by": "publisher", "first-page": "1", "DOI": "10.1186/1471-2253-13-8", "volume": "13", "author": "V Chidambaran", "year": "2013", "unstructured": "Chidambaran V, Sadhasivan S, Diepstraten J et al (2013) Evaluation of propofol anesthesia in morbidly obese children and adolescents. BMC Anesthesiol 13:1\u20139", "journal-title": "BMC Anesthesiol"}, {"key": "15_CR101", "doi-asserted-by": "publisher", "first-page": "397", "DOI": "10.1007/s00228-011-1132-2", "volume": "68", "author": "I Loryan", "year": "2012", "unstructured": "Loryan I, Lindqvist M, Johansson I et al (2012) Influence of sex on propofol metabolism, a pilot study: implications for propofol anesthesia. Eur J Clin Pharmacol 68:397\u2013406", "journal-title": "Eur J Clin Pharmacol"}, {"key": "15_CR102", "doi-asserted-by": "publisher", "first-page": "126", "DOI": "10.1111/bcpt.12070", "volume": "113", "author": "E Choong", "year": "2013", "unstructured": "Choong E, Loryan I, Lindqvist M et al (2013) Sex difference in formation of propofol metabolites: a replication study. Basic Clin Pharmacol Toxic 113:126\u2013131", "journal-title": "Basic Clin Pharmacol Toxic"}, {"key": "15_CR103", "doi-asserted-by": "publisher", "first-page": "324", "DOI": "10.1016/j.clpt.2003.12.004", "volume": "75", "author": "H Hiraoka", "year": "2004", "unstructured": "Hiraoka H, Yamamoto K, Okana N et al (2004) Changes in drug plasma concentrations of an extensively bound and highly extracted drug propofol, in response to altered plasma binding. Clin Pharmacol Ther 75:324\u2013330", "journal-title": "Clin Pharmacol Ther"}, {"key": "15_CR104", "doi-asserted-by": "publisher", "first-page": "643", "DOI": "10.1093/bja/aei243", "volume": "95", "author": "D Takizawa", "year": "2005", "unstructured": "Takizawa D, Sato E, Hiraoka H et al (2005) Changes in apparent systemic clearance of propofol during transplantation of living related donor liver. Br J Anaesth 95:643\u2013647", "journal-title": "Br J Anaesth"}, {"key": "15_CR105", "doi-asserted-by": "publisher", "first-page": "111", "DOI": "10.1007/s10928-015-9404-6", "volume": "42", "author": "K Przybylowski", "year": "2015", "unstructured": "Przybylowski K, Tyczka J, Szczesny D et al (2015) Pharmacokinetic and pharmacodynamics of propofol in cancer patients undergoing major kung surgery. J Pharmacokinet Pharmacodyn 42:111\u2013122", "journal-title": "J Pharmacokinet Pharmacodyn"}, {"key": "15_CR106", "doi-asserted-by": "publisher", "first-page": "535", "DOI": "10.1213/ANE.0b013e31829c653c", "volume": "117", "author": "JB Glen", "year": "2013", "unstructured": "Glen JB (2013) Propofol effect-site concentration: hunt the Keo. Anesth Anal 117:535\u2013536", "journal-title": "Anesth Anal"}, {"key": "15_CR107", "author": "F Guerra", "first-page": "143", "year": "1980", "unstructured": "Guerra F (1980) Thiopental forever after. In: Aldrete JA, Stanley TH (eds) Trends in intravenous anesthesia. Yearbook, Chicago, pp 143\u2013151", "volume-title": "Trends in intravenous anesthesia"}, {"key": "15_CR108", "doi-asserted-by": "publisher", "first-page": "1346", "DOI": "10.1002/jps.2600570814", "volume": "57", "author": "KB Bischoff", "year": "1968", "unstructured": "Bischoff KB, Dedrick RL (1968) Thiopental pharmacokinetics. J Pharm Sci 57:1346\u20131351", "journal-title": "J Pharm Sci"}, {"key": "15_CR109", "doi-asserted-by": "publisher", "first-page": "468", "DOI": "10.1097/00000542-198106000-00005", "volume": "54", "author": "DJ Morgan", "year": "1981", "unstructured": "Morgan DJ, Blackman GL, Paull JD et al (1981) Pharmacokinetics and plasma binding of thiopental. I. Studies in surgical patients. Anesthesiology 54:468\u2013473", "journal-title": "Anesthesiology"}, {"key": "15_CR110", "doi-asserted-by": "publisher", "first-page": "446", "DOI": "10.1097/00000542-198106000-00002", "volume": "54", "author": "DR Stanski", "year": "1981", "unstructured": "Stanski DR (1981) Pharmacokinetic modelling of thiopental. Anesthesiology 54:446\u2013448", "journal-title": "Anesthesiology"}, {"key": "15_CR111", "doi-asserted-by": "publisher", "first-page": "146", "DOI": "10.1097/00000542-198302000-00008", "volume": "58", "author": "PG Burch", "year": "1983", "unstructured": "Burch PG, Stanski DR (1983) The role of metabolism and protein binding in thiopental anesthesia. Anesthesiology 58:146\u2013152", "journal-title": "Anesthesiology"}, {"key": "15_CR112", "doi-asserted-by": "publisher", "first-page": "937", "DOI": "10.1002/jps.2600720824", "volume": "72", "author": "DR Stanski", "year": "1983", "unstructured": "Stanski DR, Burch PG, Harapat S, Richards RK (1983) Pharmacokinetics and anesthetic potency of a thiopental isomer. J Pharm Sci 72:937\u2013940", "journal-title": "J Pharm Sci"}, {"key": "15_CR113", "doi-asserted-by": "publisher", "first-page": "913", "DOI": "10.1093/bja/52.9.913", "volume": "52", "author": "JH Christensen", "year": "1980", "unstructured": "Christensen JH, Andreasen F, Jansen JA (1980) Pharmacokinetics of thiopentone in a group of young women and a group of young men. Br J Anesth 52:913\u2013918", "journal-title": "Br J Anesth"}, {"key": "15_CR114", "doi-asserted-by": "publisher", "first-page": "666", "DOI": "10.1097/00000542-198412000-00007", "volume": "61", "author": "S Sorbo", "year": "1984", "unstructured": "Sorbo S, Hudson RJ, Loomis JC (1984) The pharmacokinetics of thiopental in pediatric surgical patients. Anesthesiology 61:666\u2013670", "journal-title": "Anesthesiology"}, {"key": "15_CR115", "doi-asserted-by": "publisher", "first-page": "1189", "DOI": "10.1093/bja/53.11.1189", "volume": "53", "author": "JH Christensen", "year": "1981", "unstructured": "Christensen JH, Andreasen F, Jansen JA (1981) Influence of age and sex on the pharmacokinetics of thiopentone. Br J Anesth 53:1189\u20131195", "journal-title": "Br J Anesth"}, {"key": "15_CR116", "doi-asserted-by": "publisher", "first-page": "398", "DOI": "10.1111/j.1365-2044.1982.tb01148.x", "volume": "37", "author": "JH Christensen", "year": "1982", "unstructured": "Christensen JH, Andreasen F, Jansen JA (1982) Pharmacokinetics and pharmacodynamics of thiopentone, a comparison between young and elderly patients. Anaesthesia 37:398\u2013404", "journal-title": "Anaesthesia"}, {"key": "15_CR117", "doi-asserted-by": "publisher", "first-page": "513", "DOI": "10.1111/j.1399-6576.1983.tb01998.x", "volume": "27", "author": "JH Christensen", "year": "1983", "unstructured": "Christensen JH, Andreasen F, Jansen JA (1983) Pharmacokinetics and pharmacodynamics of thiopentone in patients undergoing renal transplantation. Acta Anaesthesiol Scand 27:513\u2013518", "journal-title": "Acta Anaesthesiol Scand"}, {"key": "15_CR118", "doi-asserted-by": "publisher", "first-page": "123", "DOI": "10.1097/00000542-198308000-00010", "volume": "59", "author": "G Pandele", "year": "1985", "unstructured": "Pandele G, Chaux F, Salvadori C et al (1985) Thiopental pharmacokinetics in patients with cirrhosis. Anesthesiology 59:123\u2013125", "journal-title": "Anesthesiology"}, {"key": "15_CR119", "doi-asserted-by": "publisher", "first-page": "1393", "DOI": "10.1093/bja/56.12.1393", "volume": "56", "author": "E Couderc", "year": "1984", "unstructured": "Couderc E, Ferrier C, Haberer JP et al (1984) Thiopentone pharmacokinetics in patients with chronic alcoholism. Br J Anaesth 56:1393\u20131397", "journal-title": "Br J Anaesth"}, {"key": "15_CR121", "doi-asserted-by": "publisher", "first-page": "36", "DOI": "10.1097/00000542-199707000-00006", "volume": "87", "author": "KD Kharasch", "year": "1997", "unstructured": "Kharasch KD, Russell M, Mautz D et al (1997) The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. Anesthesiology 87:36\u201350", "journal-title": "Anesthesiology"}, {"key": "15_CR123", "unstructured": "Santamaria R, Pailleux F, Beaudry F (2013) In vitro ketamine CYP3A-mediated metabolism study using mammalian liver S9 fractions, cDNA expressed enzymes and liquid chromatography tandem mass spectrometry. Biomed Chromatogr. doi:\n                  10.1002/bmc3199", "DOI": "10.1002/bmc3199", "doi-asserted-by": "publisher"}], "container-title": ["Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents"], "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/978-3-319-27883-4_15", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 6, 1]], "date-time": "2019-06-01T16:54:22Z", "timestamp": 1559408062000}, "score": 27.27422, "issued": {"date-parts": [[2016]]}, "ISBN": ["9783319278810", "9783319278834"], "references-count": 121, "URL": "http://dx.doi.org/10.1007/978-3-319-27883-4_15", "relation": {"cites": []}}, {"indexed": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T15:44:37Z", "timestamp": 1574178277586}, "reference-count": 84, "publisher": "Springer Science and Business Media LLC", "issue": "10", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Clinical Pharmacokinetics"], "published-print": {"date-parts": [[2002]]}, "DOI": "10.2165/00003088-200241100-00003", "type": "journal-article", "created": {"date-parts": [[2006, 1, 19]], "date-time": "2006-01-19T11:48:30Z", "timestamp": 1137671310000}, "page": "719-739", "source": "Crossref", "is-referenced-by-count": 203, "title": ["Clinical Pharmacokinetics and Pharmacodynamics of Cholinesterase Inhibitors"], "prefix": "10.1007", "volume": "41", "author": [{"given": "Michael W.", "family": "Jann", "sequence": "first", "affiliation": []}, {"given": "Kara L.", "family": "Shirley", "sequence": "additional", "affiliation": []}, {"given": "Gary W.", "family": "Small", "sequence": "additional", "affiliation": []}], "member": "297", "reference": [{"key": "R1-3", "author": "Martin", "volume": "340", "first-page": "1970", "year": "1999", "journal-title": "N Engl J Med", "DOI": "10.1056/NEJM199906243402507", "doi-asserted-by": "crossref"}, {"key": "R2-3", "author": "Parnetti", "volume": "53", "first-page": "752", "year": "1997", "journal-title": "Drugs", "DOI": "10.2165/00003495-199753050-00003", "doi-asserted-by": "crossref"}, {"key": "R3-3", "author": "Sramek", "volume": "14", "first-page": "359", "year": "1999", "journal-title": "Drugs Aging", "DOI": "10.2165/00002512-199914050-00004", "doi-asserted-by": "crossref"}, {"key": "R4-3", "author": "VanDenBerg", "volume": "16", "first-page": "123", "year": "2000", "journal-title": "Drugs Aging", "DOI": "10.2165/00002512-200016020-00004", "doi-asserted-by": "crossref"}, {"key": "R5-3", "author": "Court", "volume": "2", "first-page": "216", "year": "1994", "journal-title": "CNS Drugs", "DOI": "10.2165/00023210-199402030-00006", "doi-asserted-by": "crossref"}, {"key": "R6-3", "author": "Practico", "volume": "109", "first-page": "577", "year": "2000", "journal-title": "Am J Med", "DOI": "10.1016/S0002-9343(00)00547-7", "doi-asserted-by": "crossref"}, {"key": "R7-3", "author": "Jick", "volume": "356", "first-page": "1627", "year": "2000", "journal-title": "Lancet", "DOI": "10.1016/S0140-6736(00)03155-X", "doi-asserted-by": "crossref"}, {"key": "R8-3", "author": "Small", "volume": "278", "first-page": "1363", "year": "1997", "journal-title": "JAMA", "DOI": "10.1001/jama.1997.03550160083043", "doi-asserted-by": "crossref"}, {"key": "R10-3", "author": "Imbimbo", "volume": "15", "first-page": "375", "year": "2001", "journal-title": "CNS Drugs", "DOI": "10.2165/00023210-200115050-00004", "doi-asserted-by": "crossref"}, {"key": "R11-3", "author": "Cummings", "volume": "157", "first-page": "4", "year": "2000", "journal-title": "Am J Psychiatry", "DOI": "10.1176/ajp.157.1.4", "doi-asserted-by": "crossref"}, {"key": "R12-3", "author": "Crismon", "volume": "28", "first-page": "744", "year": "1994", "journal-title": "Ann Pharmacother", "DOI": "10.1177/106002809402800612", "doi-asserted-by": "crossref"}, {"key": "R13-3", "author": "Parnetti", "volume": "29", "first-page": "110", "year": "1995", "journal-title": "Clin Pharmacokinet", "DOI": "10.2165/00003088-199529020-00005", "doi-asserted-by": "crossref"}, {"key": "R14-3", "author": "Forsyth", "volume": "46", "first-page": "634", "year": "1989", "journal-title": "Clin Pharmacol Ther", "DOI": "10.1038/clpt.1989.199", "doi-asserted-by": "crossref"}, {"key": "R15-3", "author": "Cutler", "volume": "26", "first-page": "231", "year": "1990", "journal-title": "Psychopharmacol Bull"}, {"key": "R16-3", "author": "Hartvig", "volume": "38", "first-page": "259", "year": "1990", "journal-title": "Eur J Clin Pharmacol", "DOI": "10.1007/BF00315027", "doi-asserted-by": "crossref"}, {"key": "R17-3", "author": "Madden", "volume": "28", "first-page": "449", "year": "1995", "journal-title": "Clin Pharmacokinet", "DOI": "10.2165/00003088-199528060-00003", "doi-asserted-by": "crossref"}, {"key": "R18-3", "author": "Nordberg", "volume": "19", "first-page": "465", "year": "1998", "journal-title": "Drug Saf", "DOI": "10.2165/00002018-199819060-00004", "doi-asserted-by": "crossref"}, {"key": "R19-3", "author": "Wagstaff", "volume": "4", "first-page": "1", "year": "1994", "journal-title": "Drugs Aging", "DOI": "10.2165/00002512-199404060-00006", "doi-asserted-by": "crossref"}, {"key": "R20-3", "author": "Makela", "volume": "38", "first-page": "489P", "year": "1994", "journal-title": "Br J Clin Pharmacol", "DOI": "10.1111/j.1365-2125.1994.tb04389.x", "doi-asserted-by": "crossref"}, {"key": "R21-3", "author": "Grothe", "volume": "18", "first-page": "78", "year": "1998", "journal-title": "J Clin Psychopharmacol", "DOI": "10.1097/00004714-199802000-00013", "doi-asserted-by": "crossref"}, {"key": "R22-3", "author": "Simon", "volume": "67", "first-page": "432", "year": "2000", "journal-title": "Clin Pharmacol Ther", "DOI": "10.1067/mcp.2000.104944", "doi-asserted-by": "crossref"}, {"key": "R23-3", "author": "McGleenon", "volume": "48", "first-page": "471", "year": "1999", "journal-title": "Br J Clin Pharmacol", "DOI": "10.1046/j.1365-2125.1999.00026.x", "doi-asserted-by": "crossref"}, {"key": "R24-3", "author": "Murphy", "volume": "640", "first-page": "253", "year": "1991", "journal-title": "Ann N Y Acad Sci", "DOI": "10.1111/j.1749-6632.1991.tb00229.x", "doi-asserted-by": "crossref"}, {"key": "R25-3", "author": "Dooley", "volume": "16", "first-page": "199", "year": "2000", "journal-title": "Drugs Aging", "DOI": "10.2165/00002512-200016030-00005", "doi-asserted-by": "crossref"}, {"key": "R26-3", "author": "Barner", "volume": "32", "first-page": "70", "year": "1998", "journal-title": "Ann Pharmacother", "DOI": "10.1345/aph.17150", "doi-asserted-by": "crossref"}, {"key": "R29-3", "author": "Rogers", "volume": "158", "first-page": "1021", "year": "1998", "journal-title": "Arch Intern Med", "DOI": "10.1001/archinte.158.9.1021", "doi-asserted-by": "crossref"}, {"key": "R30-3", "author": "Shintani", "volume": "54", "first-page": "2805", "year": "1997", "journal-title": "Am J Health Syst Pharm", "DOI": "10.1093/ajhp/54.24.2805", "doi-asserted-by": "crossref"}, {"key": "R32-3", "author": "Ohnishi", "volume": "33", "first-page": "1086", "year": "1993", "journal-title": "J Clin Pharmacol", "DOI": "10.1002/j.1552-4604.1993.tb01945.x", "doi-asserted-by": "crossref"}, {"key": "R35-3", "author": "Jann", "volume": "20", "first-page": "1", "year": "2000", "journal-title": "Pharmacotherapy", "DOI": "10.1592/phco.20.1.1.34664", "doi-asserted-by": "crossref"}, {"key": "R36-3", "author": "Sramek", "volume": "58", "first-page": "1201", "year": "1996", "journal-title": "Life Sci", "DOI": "10.1016/0024-3205(96)00081-1", "doi-asserted-by": "crossref"}, {"key": "R37-3", "author": "Spencer", "volume": "13", "first-page": "391", "year": "1998", "journal-title": "Drugs Aging", "DOI": "10.2165/00002512-199813050-00005", "doi-asserted-by": "crossref"}, {"key": "R38-3", "author": "Kennedy", "volume": "19", "first-page": "513", "year": "1999", "journal-title": "J Clin Psychopharmacol", "DOI": "10.1097/00004714-199912000-00005", "doi-asserted-by": "crossref"}, {"key": "R39-3", "author": "Cutler", "volume": "97", "first-page": "244", "year": "1998", "journal-title": "Acta Neurol Scand", "DOI": "10.1111/j.1600-0404.1998.tb00645.x", "doi-asserted-by": "crossref"}, {"key": "R40-3", "author": "Schran", "volume": "13", "first-page": "S", "year": "1996", "journal-title": "Pharm Res"}, {"key": "R41-3", "author": "Scott", "volume": "60", "first-page": "1095", "year": "2000", "journal-title": "Drugs", "DOI": "10.2165/00003495-200060050-00008", "doi-asserted-by": "crossref"}, {"key": "R42-3", "author": "Mihailova", "volume": "39", "first-page": "50", "year": "1989", "journal-title": "Pharmacology", "DOI": "10.1159/000138571", "doi-asserted-by": "crossref"}, {"key": "R43-3", "author": "Johansson", "volume": "149", "first-page": "22", "year": "1993", "journal-title": "Acta Neurol Scand"}, {"key": "R44-3", "author": "Bickel", "volume": "50", "first-page": "420", "year": "1991", "journal-title": "Clin Pharmacol Ther", "DOI": "10.1038/clpt.1991.159", "doi-asserted-by": "crossref"}, {"key": "R45-3", "author": "Davidson", "volume": "30", "first-page": "157", "year": "2001", "journal-title": "Neurosci Lett", "DOI": "10.1016/S0304-3940(01)01586-5", "doi-asserted-by": "crossref"}, {"key": "R46-3", "author": "Bachus", "volume": "9", "first-page": "661", "year": "1999", "journal-title": "Pharmacogenetics", "DOI": "10.1097/00008571-199912000-00001", "doi-asserted-by": "crossref"}, {"key": "R47-3", "author": "Fontana", "volume": "46", "first-page": "221", "year": "1998", "journal-title": "Br J Clin Pharmacol", "DOI": "10.1046/j.1365-2125.1998.00776.x", "doi-asserted-by": "crossref"}, {"key": "R48-3", "author": "Ford", "volume": "53", "first-page": "691", "year": "1993", "journal-title": "Clin Pharmacol Ther", "DOI": "10.1038/clpt.1993.91", "doi-asserted-by": "crossref"}, {"key": "R49-3", "author": "Welty", "volume": "10", "first-page": "S344", "year": "1993", "journal-title": "Pharm Res"}, {"key": "R51-3", "author": "Forgue", "volume": "59", "first-page": "444", "year": "1998", "journal-title": "Clin Pharmacol Ther", "DOI": "10.1016/S0009-9236(96)90114-9", "doi-asserted-by": "crossref"}, {"key": "R52-3", "author": "Laine", "volume": "66", "first-page": "602", "year": "1999", "journal-title": "Clin Pharmacol Ther", "DOI": "10.1053/cp.1999.v66.103404001", "doi-asserted-by": "crossref"}, {"key": "R53-3", "author": "Becquemont", "volume": "8", "first-page": "101", "year": "1998", "journal-title": "Pharmacogenetics", "DOI": "10.1097/00008571-199804000-00002", "doi-asserted-by": "crossref"}, {"key": "R54-3", "author": "Becquemont", "volume": "61", "first-page": "619", "year": "1997", "journal-title": "Clin Pharmacol Ther", "DOI": "10.1016/S0009-9236(97)90095-3", "doi-asserted-by": "crossref"}, {"key": "R57-3", "author": "Carrier", "volume": "47", "first-page": "1037", "year": "1999", "journal-title": "J Am Geriatr Soc", "DOI": "10.1111/j.1532-5415.1999.tb01306.x", "doi-asserted-by": "crossref"}, {"key": "R58-3", "author": "Rojas-Fernandez", "volume": "48", "first-page": "597", "year": "2000", "journal-title": "J Am Geriatr Soc", "DOI": "10.1111/j.1532-5415.2000.tb05016.x", "doi-asserted-by": "crossref"}, {"key": "R59-3", "author": "Verrico", "volume": "48", "first-page": "1659", "year": "2000", "journal-title": "J Am Geriatr Soc", "DOI": "10.1111/j.1532-5415.2000.tb03879.x", "doi-asserted-by": "crossref"}, {"key": "R60-3", "author": "Ravic", "volume": "69", "first-page": "P44", "year": "2001", "journal-title": "Clin Pharmacol Ther"}, {"key": "R61-3", "author": "Reyes", "volume": "69", "first-page": "P44", "year": "2001", "journal-title": "Clin Pharmacol Ther"}, {"key": "R64-3", "author": "Grosssberg", "volume": "15", "first-page": "242", "year": "2000", "journal-title": "Int J Geriatr Psychiatr", "DOI": "10.1002/(SICI)1099-1166(200003)15:3<242::AID-GPS110>3.0.CO;2-7", "doi-asserted-by": "crossref"}, {"key": "R67-3", "author": "Taylor", "volume": "34", "first-page": "281", "year": "1994", "journal-title": "Annu Rev Pharmacol Toxic", "DOI": "10.1146/annurev.pa.34.040194.001433", "doi-asserted-by": "crossref"}, {"key": "R68-3", "author": "Guillozet", "volume": "42", "first-page": "909", "year": "1997", "journal-title": "Ann Neurol", "DOI": "10.1002/ana.410420613", "doi-asserted-by": "crossref"}, {"key": "R69-3", "author": "Giacobini", "volume": "15", "first-page": "85", "year": "2001", "journal-title": "CNS Drugs", "DOI": "10.2165/00023210-200115020-00001", "doi-asserted-by": "crossref"}, {"key": "R71-3", "author": "Maelicke", "volume": "49", "first-page": "279", "year": "2001", "journal-title": "Biol Psychiatry", "DOI": "10.1016/S0006-3223(00)01109-4", "doi-asserted-by": "crossref"}, {"key": "R72-3", "author": "Mant", "volume": "38", "first-page": "610", "year": "1998", "journal-title": "J Clin Pharmacol", "DOI": "10.1002/j.1552-4604.1998.tb04467.x", "doi-asserted-by": "crossref"}, {"key": "R73-3", "author": "Rogers", "volume": "50", "first-page": "136", "year": "1998", "journal-title": "Neurology", "DOI": "10.1212/WNL.50.1.136", "doi-asserted-by": "crossref"}, {"key": "R74-3", "author": "Davis", "volume": "30", "first-page": "339", "year": "1996", "journal-title": "Drug Inf J", "DOI": "10.1177/009286159603000202", "doi-asserted-by": "crossref"}, {"key": "R75-3", "author": "Rosen", "volume": "141", "first-page": "1356", "year": "1984", "journal-title": "Am J Psychiatry", "DOI": "10.1176/ajp.141.11.1356", "doi-asserted-by": "crossref"}, {"key": "R76-3", "author": "Schneider", "volume": "11", "first-page": "S22", "year": "1997", "journal-title": "Alzheimer Dis Assoc Disord", "DOI": "10.1097/00002093-199700112-00004", "doi-asserted-by": "crossref"}, {"key": "R77-3", "author": "Giacobini", "volume": "32", "first-page": "413", "year": "1998", "journal-title": "Neurochem Lett", "DOI": "10.1016/S0197-0186(97)00124-1", "doi-asserted-by": "crossref"}, {"key": "R78-3", "author": "Folstein", "volume": "12", "first-page": "189", "year": "1975", "journal-title": "J Psychiatr Res", "DOI": "10.1016/0022-3956(75)90026-6", "doi-asserted-by": "crossref"}, {"key": "R79-3", "author": "Cummings", "volume": "44", "first-page": "2308", "year": "1994", "journal-title": "Neurology", "DOI": "10.1212/WNL.44.12.2308", "doi-asserted-by": "crossref"}, {"key": "R80-3", "author": "DeJong", "volume": "11", "first-page": "545", "year": "1989", "journal-title": "Clin Ther"}, {"key": "R81-3", "author": "Krall", "volume": "33", "first-page": "441", "year": "1999", "journal-title": "Ann Pharmacother", "DOI": "10.1345/aph.18211", "doi-asserted-by": "crossref"}, {"key": "R83-3", "author": "Knapp", "volume": "271", "first-page": "985", "year": "1994", "journal-title": "JAMA", "DOI": "10.1001/jama.1994.03510370037029", "doi-asserted-by": "crossref"}, {"key": "R84-3", "author": "Corey-Bloom", "volume": "1", "first-page": "55", "year": "1999", "journal-title": "Int J Geriatr Psychopharmacol"}, {"key": "R85-3", "author": "Tariot", "volume": "54", "first-page": "2269", "year": "2000", "journal-title": "Neurology", "DOI": "10.1212/WNL.54.12.2269", "doi-asserted-by": "crossref"}, {"key": "R86-3", "author": "Anand", "volume": "2", "first-page": "68", "year": "2000", "journal-title": "Int J Geriatr Psychopharmacol"}, {"key": "R87-3", "author": "Raskind", "volume": "54", "first-page": "2261", "year": "2000", "journal-title": "Neurology", "DOI": "10.1212/WNL.54.12.2261", "doi-asserted-by": "crossref"}, {"key": "R88-3", "author": "Kaufer", "volume": "9", "first-page": "1", "year": "1996", "journal-title": "J Geriatr Psychiatry Neurol", "DOI": "10.1177/089198879600900101", "doi-asserted-by": "crossref"}, {"key": "R89-3", "author": "Weiner", "volume": "61", "first-page": "487", "year": "2000", "journal-title": "J Clin Psychiatry", "DOI": "10.4088/JCP.v61n0705", "doi-asserted-by": "crossref"}, {"key": "R90-3", "author": "Hunter", "volume": "158", "first-page": "351", "year": "1991", "journal-title": "Br J Psychiatry", "DOI": "10.1192/bjp.158.3.351", "doi-asserted-by": "crossref"}, {"key": "R91-3", "author": "Cohen", "volume": "17", "first-page": "312", "year": "1992", "journal-title": "Clin Nucl Med", "DOI": "10.1097/00003072-199204000-00012", "doi-asserted-by": "crossref"}, {"key": "R92-3", "author": "Bookheimer", "volume": "343", "first-page": "450", "year": "2000", "journal-title": "New Engl J Med", "DOI": "10.1056/NEJM200008173430701", "doi-asserted-by": "crossref"}, {"key": "R94-3", "author": "Farlow", "volume": "268", "first-page": "2523", "year": "1992", "journal-title": "JAMA", "DOI": "10.1001/jama.1992.03490180055026", "doi-asserted-by": "crossref"}, {"key": "R95-3", "author": "Burns", "volume": "10", "first-page": "237", "year": "1999", "journal-title": "Dement Geriatr Cogn Disord", "DOI": "10.1159/000017126", "doi-asserted-by": "crossref"}, {"key": "R96-3", "author": "Rosler", "volume": "318", "first-page": "633", "year": "1999", "journal-title": "BMJ", "DOI": "10.1136/bmj.318.7184.633", "doi-asserted-by": "crossref"}, {"key": "R97-3", "author": "Watkins", "volume": "271", "first-page": "992", "year": "1994", "journal-title": "JAMA", "DOI": "10.1001/jama.1994.03510370044030", "doi-asserted-by": "crossref"}, {"key": "R98-3", "author": "Green", "volume": "39", "first-page": "411", "year": "1995", "journal-title": "Br J Clin Pharmacol", "DOI": "10.1111/j.1365-2125.1995.tb04470.x", "doi-asserted-by": "crossref"}, {"key": "R99-3", "volume": "154", "issue": "5", "first-page": "1", "year": "1997", "journal-title": "Am J Psychiatry", "DOI": "10.1176/ajp.154.5.1", "doi-asserted-by": "crossref"}, {"key": "R100-3", "author": "Steele", "volume": "6", "first-page": "52", "year": "1999", "journal-title": "J Clin Outcome Management"}], "container-title": ["Clinical Pharmacokinetics"], "language": "en", "deposited": {"date-parts": [[2019, 3, 21]], "date-time": "2019-03-21T12:53:41Z", "timestamp": 1553172821000}, "score": 27.154732, "subtitle": [""], "issued": {"date-parts": [[2002]]}, "references-count": 84, "journal-issue": {"issue": "10"}, "URL": "http://dx.doi.org/10.2165/00003088-200241100-00003", "relation": {"cites": []}, "ISSN": ["0312-5963"], "issn-type": [{"value": "0312-5963", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T11:36:21Z", "timestamp": 1574336181207}, "reference-count": 0, "publisher": "Springer Science and Business Media LLC", "issue": "6", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Clinical Pharmacokinetics"], "published-print": {"date-parts": [[1995, 6]]}, "DOI": "10.2165/00003088-199528060-00007", "type": "journal-article", "created": {"date-parts": [[2007, 12, 5]], "date-time": "2007-12-05T10:37:53Z", "timestamp": 1196851073000}, "page": "494-504", "source": "Crossref", "is-referenced-by-count": 14, "title": ["Emergency Treatment of Psychotic Symptoms"], "prefix": "10.1007", "volume": "28", "author": [{"given": "Grace V.", "family": "Milton", "sequence": "first", "affiliation": []}, {"given": "Michael W.", "family": "Jann", "sequence": "additional", "affiliation": []}], "member": "297", "container-title": ["Clinical Pharmacokinetics"], "language": "en", "deposited": {"date-parts": [[2013, 1, 20]], "date-time": "2013-01-20T14:17:07Z", "timestamp": 1358691427000}, "score": 26.536852, "subtitle": ["Pharmacokinetic Considerations for Antipsychotic Drugs"], "issued": {"date-parts": [[1995, 6]]}, "references-count": 0, "journal-issue": {"issue": "6"}, "URL": "http://dx.doi.org/10.2165/00003088-199528060-00007", "ISSN": ["0312-5963"], "issn-type": [{"value": "0312-5963", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 21]], "date-time": "2019-11-21T11:36:17Z", "timestamp": 1574336177067}, "reference-count": 0, "publisher": "Springer Science and Business Media LLC", "issue": "6", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Clinical Pharmacokinetics"], "published-print": {"date-parts": [[1989, 12]]}, "DOI": "10.2165/00003088-198917060-00004", "type": "journal-article", "created": {"date-parts": [[2007, 12, 5]], "date-time": "2007-12-05T10:33:50Z", "timestamp": 1196850830000}, "page": "396-423", "source": "Crossref", "is-referenced-by-count": 86, "title": ["Pharmacokinetics of Haloperidol"], "prefix": "10.1007", "volume": "17", "author": [{"given": "J.S.", "family": "Froemming", "sequence": "first", "affiliation": []}, {"given": "Y.W. Francis", "family": "Lam", "sequence": "additional", "affiliation": []}, {"given": "M.W.", "family": "Jann", "sequence": "additional", "affiliation": []}, {"given": "C.M.", "family": "Davis", "sequence": "additional", "affiliation": []}], "member": "297", "container-title": ["Clinical Pharmacokinetics"], "language": "en", "deposited": {"date-parts": [[2013, 1, 20]], "date-time": "2013-01-20T14:57:11Z", "timestamp": 1358693831000}, "score": 26.440342, "subtitle": [""], "issued": {"date-parts": [[1989, 12]]}, "references-count": 0, "journal-issue": {"issue": "6"}, "URL": "http://dx.doi.org/10.2165/00003088-198917060-00004", "ISSN": ["0312-5963"], "issn-type": [{"value": "0312-5963", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T12:21:25Z", "timestamp": 1574770885296}, "publisher-location": "Cham", "reference-count": 102, "publisher": "Springer International Publishing", "isbn-type": [{"value": "9783319278810", "type": "print"}, {"value": "9783319278834", "type": "electronic"}], "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2016, 1, 1]], "date-time": "2016-01-01T00:00:00Z", "timestamp": 1451606400000}, "delay-in-days": 0, "content-version": "unspecified"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2016]]}, "DOI": "10.1007/978-3-319-27883-4_14", "type": "book-chapter", "created": {"date-parts": [[2016, 3, 2]], "date-time": "2016-03-02T13:04:48Z", "timestamp": 1456923888000}, "page": "351-372", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Anti-addiction Agents"], "prefix": "10.1007", "author": [{"given": "Michael W.", "family": "Jann", "sequence": "first", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2016, 3, 3]]}, "reference": [{"key": "14_CR1", "unstructured": "Doering PL, Li RM (2014) Chapter 49. Substance-related disorders II. In: DiPiro JT, Talbert RL, Yee GC et al. (eds) Pharmacotherapy, 9th edn. McGraw Hill, New York. pp. 1003\u20131018"}, {"key": "14_CR2", "doi-asserted-by": "publisher", "first-page": "1038", "DOI": "10.2165/00003495-199753060-00008", "volume": "53", "author": "MI Wilde", "year": "1997", "unstructured": "Wilde MI, Wagstaff AJ (1997) Acamprosate. Drugs 53:1038\u20131053", "journal-title": "Drugs"}, {"key": "14_CR3", "doi-asserted-by": "publisher", "first-page": "445", "DOI": "10.2165/00023210-200519050-00006", "volume": "19", "author": "LJ Scott", "year": "2005", "unstructured": "Scott LJ, Figgitt DP, Keam SJ, Waugh J (2005) Acamprosate. CNS Drugs 19:445\u2013464", "journal-title": "CNS Drugs"}, {"issue": "Suppl 20", "key": "14_CR4", "first-page": "42", "volume": "62", "author": "BJ Mason", "year": "2001", "unstructured": "Mason BJ (2001) Treatment of alcohol-dependent outpatients with acamprosate: a clinical review. J Clin Psychiatry 62(Suppl 20):42\u201348", "journal-title": "J Clin Psychiatry"}, {"key": "14_CR5", "doi-asserted-by": "publisher", "first-page": "331", "DOI": "10.2165/00003088-199835050-00001", "volume": "35", "author": "S Saivin", "year": "1998", "unstructured": "Saivin S, Hulot T, Chabac S et al (1998) Clinical pharmacokinetics of acamprosate. Clin Pharmacokinet 35:331\u2013345", "journal-title": "Clin Pharmacokinet"}, {"key": "14_CR6", "doi-asserted-by": "publisher", "first-page": "21", "DOI": "10.1097/00004714-198101000-00005", "volume": "1", "author": "JE Peachy", "year": "1981", "unstructured": "Peachy JE, Brien JF, Roach CA, Loomis CW (1981) A comparative review of the pharmacological and toxicological properties of disulfiram and calcium carbimide. J Clin Psychopharmacol 1:21\u201326", "journal-title": "J Clin Psychopharmacol"}, {"key": "14_CR7", "doi-asserted-by": "publisher", "first-page": "89", "DOI": "10.1016/0163-7258(81)90018-8", "volume": "15", "author": "JE Peachy", "year": "1981", "unstructured": "Peachy JE, Sellers EM (1981) The disulfiram and calcium carbimide acetaldehyde-mediated ethanol reactions. Pharmacol Ther 15:89\u201397", "journal-title": "Pharmacol Ther"}, {"key": "14_CR8", "doi-asserted-by": "publisher", "first-page": "15", "DOI": "10.1111/j.1600-0447.1992.tb03310.x", "volume": "369", "author": "B Johnansson", "year": "1992", "unstructured": "Johnansson B (1992) A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites. Acta Psychiatr Scand Suppl 369:15\u201326", "journal-title": "Acta Psychiatr Scand Suppl"}, {"key": "14_CR9", "first-page": "885", "volume-title": "Handbook of nonprescription drugs", "author": "KS Hudmon", "year": "2012", "unstructured": "Hudmon KS, Kroon LA, Corelli RL (2012) Chapter 47. Smoking cessation. In: Krinsky DL, Berardi RR, Ferreri SP (eds) Handbook of nonprescription drugs, 17th edn. American Pharmacists Association, Washington DC, pp 885\u2013910", "edition": "17"}, {"key": "14_CR10", "doi-asserted-by": "publisher", "first-page": "30", "DOI": "10.2165/00003088-198712010-00003", "volume": "12", "author": "CK Svensson", "year": "1987", "unstructured": "Svensson CK (1987) Clinical pharmacokinetics of nicotine. Clin Pharmacokinet 12:30\u201340", "journal-title": "Clin Pharmacokinet"}, {"key": "14_CR11", "doi-asserted-by": "publisher", "first-page": "29", "DOI": "10.1007/978-3-540-69248-5_2", "volume": "192", "author": "NL Benowitz", "year": "2009", "unstructured": "Benowitz NL, Hukkanen J, Jacob P III (2009) Nicotine chemistry, metabolism, kinetics, and biomarkers. Handb Exp Pharmacol 192:29\u201360", "journal-title": "Handb Exp Pharmacol"}, {"key": "14_CR12", "doi-asserted-by": "publisher", "first-page": "799", "DOI": "10.2165/11537850-000000000-00000", "volume": "49", "author": "HM Faessel", "year": "2010", "unstructured": "Faessel HM, Obach RS, Rollema H et al (2010) A review of the clinical pharmacokinetics and pharmacodynamics of varenicline for smoking cessation. Clin Pharmacokinet 49:799\u2013816", "journal-title": "Clin Pharmacokinet"}, {"key": "14_CR13", "doi-asserted-by": "publisher", "first-page": "567", "DOI": "10.1038/sj.clpt.6100405", "volume": "83", "author": "B Feng", "year": "2008", "unstructured": "Feng B, Obach RS, Burstein AH et al (2008) Effect of human renal cationic transporter inhibition on the pharmacokinetics of varenicline, a new therapy for smoking cessation: an in vitro \u2013 in vivo study. Clin Pharmacol Ther 83:567\u2013576", "journal-title": "Clin Pharmacol Ther"}, {"key": "14_CR14", "doi-asserted-by": "publisher", "first-page": "669", "DOI": "10.1111/j.1365-2125.2009.03520.x", "volume": "68", "author": "P Ravva", "year": "2009", "unstructured": "Ravva P, Gastonguay MR, Tensfeldt TG, Faessel HM (2009) Population pharmacokinetic analysis of varenicline in adult smokers. Br J Clin Pharmacol 68:669\u2013681", "journal-title": "Br J Clin Pharmacol"}, {"key": "14_CR15", "doi-asserted-by": "publisher", "first-page": "1439", "DOI": "10.1177/0091270006292624", "volume": "46", "author": "HM Faessel", "year": "2006", "unstructured": "Faessel HM, Gibbs MA, Clark DJ et al (2006) Multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers. J Clin Pharmacol 46:1439\u20131448", "journal-title": "J Clin Pharmacol"}, {"key": "14_CR16", "doi-asserted-by": "publisher", "first-page": "527", "DOI": "10.1177/0091270010372388", "volume": "51", "author": "H Kikkawa", "year": "2011", "unstructured": "Kikkawa H, Maruyama N, Fujimoto Y, Hasunuma T (2011) Single and multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy Japanese adult smokers. J Clin Pharmacol 51:527\u2013537", "journal-title": "J Clin Pharmacol"}, {"issue": "1", "key": "14_CR17", "doi-asserted-by": "publisher", "first-page": "106", "DOI": "10.1093/ntr/ntu154", "volume": "17", "author": "P Ravva", "year": "2014", "unstructured": "Ravva P, Gastonguay MR, Faessel HM, Lee TC, Niaura R (2014) Pharmacokinetic-pharmacodynamic modeling of the effect of varenicline on nicotine craving in adult smokers. Nicotine Tob Res 17(1):106\u2013113. doi:\n                  10.1093/intr/ntu154", "journal-title": "Nicotine Tob Res"}, {"key": "14_CR18", "doi-asserted-by": "publisher", "first-page": "641", "DOI": "10.1038/npp.2011.232", "volume": "37", "author": "DP King", "year": "2012", "unstructured": "King DP, Paciga S, Pickering E et al (2012) Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials. Neuropsychopharmacol 37:641\u2013650", "journal-title": "Neuropsychopharmacol"}, {"key": "14_CR19", "doi-asserted-by": "publisher", "first-page": "755", "DOI": "10.3181/00379727-123-31595", "volume": "123", "author": "H Blumberg", "year": "1966", "unstructured": "Blumberg H, Dayton HB, Wolf PS (1966) Counteraction of narcotic antagonist by the narcotic antagonist Naloxone. Proc Soc Exp Biol Med 123:755\u2013758", "journal-title": "Proc Soc Exp Biol Med"}, {"issue": "7601", "key": "14_CR20", "doi-asserted-by": "publisher", "first-page": "452", "DOI": "10.1016/S0140-6736(73)91879-5", "volume": "1", "author": "LE Evans", "year": "1973", "unstructured": "Evans LE, Swainson CP, Roscoe P, Prescott LF (1973) Treatment of drug overdose with naloxone, a specific narcotic antagonist. Lancet 1(7601):452\u2013455", "journal-title": "Lancet"}, {"key": "14_CR21", "doi-asserted-by": "publisher", "first-page": "438", "DOI": "10.1016/S0196-0644(83)80343-6", "volume": "12", "author": "KA Handal", "year": "1983", "unstructured": "Handal KA, Schauben JL, Salamone FR (1983) Naloxone. Ann Emerg Med 12:438\u2013445", "journal-title": "Ann Emerg Med"}, {"key": "14_CR22", "doi-asserted-by": "publisher", "first-page": "219", "DOI": "10.2165/00003088-197601030-00004", "volume": "1", "author": "BA Berkowitz", "year": "1976", "unstructured": "Berkowitz BA (1976) The relationship of pharmacokinetics to pharmacologic activity: morphine, methadone, and naloxone. Clin Pharmacokinet 1:219\u2013230", "journal-title": "Clin Pharmacokinet"}, {"key": "14_CR23", "first-page": "575", "volume": "187", "author": "J Fishman", "year": "1973", "unstructured": "Fishman J, Roffwarg H, Hellman L (1973) Disposition of naloxone in normal narcotic dependent men. J Pharmacol Exp Ther 187:575\u2013580", "journal-title": "J Pharmacol Exp Ther"}, {"key": "14_CR24", "doi-asserted-by": "publisher", "first-page": "1567", "DOI": "10.1002/jps.2600601030", "volume": "60", "author": "SH Weinstein", "year": "1971", "unstructured": "Weinstein SH, Pfeffer M, Schor JM et al (1971) Metabolites of naloxone in human urine. J Pharm Sci 60:1567\u20131568", "journal-title": "J Pharm Sci"}, {"key": "14_CR25", "doi-asserted-by": "publisher", "first-page": "398", "DOI": "10.1097/00000542-197605000-00008", "volume": "44", "author": "SH Ngal", "year": "1976", "unstructured": "Ngal SH, Berkowitz BA, Yang JC, Hempstead J, Spector S (1976) Pharmacokinetics of naloxone in rats and man. Anesthesiology 44:398\u2013401", "journal-title": "Anesthesiology"}, {"key": "14_CR26", "first-page": "499", "volume": "195", "author": "BA Berkowitz", "year": "1975", "unstructured": "Berkowitz BA, Ngal SH, Hempstead J, Spector S (1975) Disposition of naloxone: use of a new radioimmunoassay. J Pharmacol Exp Ther 195:499\u2013504", "journal-title": "J Pharmacol Exp Ther"}, {"key": "14_CR27", "doi-asserted-by": "publisher", "first-page": "355", "DOI": "10.1016/S0021-9673(00)87795-X", "volume": "129", "author": "EF Cone", "year": "1976", "unstructured": "Cone EF (1976) General procedure for the isolation and identification of a 6-\u03b1 and 6-\u03b2 hydroxyl metabolites of narcotic agonists and antagonists with a hydroxymorphine structure. J Chromatogr 129:355\u2013361", "journal-title": "J Chromatogr"}, {"key": "14_CR28", "doi-asserted-by": "publisher", "first-page": "459", "DOI": "10.1007/BF00549595", "volume": "27", "author": "LA Asali", "year": "1984", "unstructured": "Asali LA, Brown KF (1984) Naloxone protein binding in adult and foetal plasma. Eur J Clin Pharmacol 27:459\u2013463", "journal-title": "Eur J Clin Pharmacol"}, {"key": "14_CR29", "doi-asserted-by": "publisher", "first-page": "543", "DOI": "10.1111/j.1472-8206.2009.00724.x", "volume": "23", "author": "M Kanaan", "year": "2009", "unstructured": "Kanaan M, Daali Y, Dayer P, Desmeules J (2009) P-glycoprotein is not involved in the differential oral potency of naloxone and naltrexone. Fundam Clin Pharmacol 23:543\u2013548", "journal-title": "Fundam Clin Pharmacol"}, {"key": "14_CR30", "first-page": "490", "volume": "30", "author": "J Dowling", "year": "2008", "unstructured": "Dowling J, Isbister GK, Kirkpatrick CM, Naidoo D, Graudins A (2008) Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers. Ther Drug Monit 30:490\u2013496", "journal-title": "Ther Drug Monit"}, {"key": "14_CR31", "doi-asserted-by": "publisher", "first-page": "132", "DOI": "10.1016/j.ijpharm.2011.10.042", "volume": "422", "author": "R Yamamoto", "year": "2012", "unstructured": "Yamamoto R, Takasuga S, Yoshida Y et al (2012) In vitro and in vivo transdermal iontophoretic delivery of naloxone, an opioid antagonist. Int J Pharm 422:132\u2013138", "journal-title": "Int J Pharm"}, {"key": "14_CR32", "doi-asserted-by": "publisher", "first-page": "187", "DOI": "10.1016/j.ijpharm.2012.02.045", "volume": "428", "author": "H Sanaei-Zadeh", "year": "2012", "unstructured": "Sanaei-Zadeh H (2012) Is transdermal iontophoretic delivery of naloxone sufficient for the management of intoxication in opioid-overdosed patients? Int J Pharm 428:187", "journal-title": "Int J Pharm"}, {"key": "14_CR33", "doi-asserted-by": "publisher", "first-page": "2129", "DOI": "10.2146/ajhp130798", "volume": "71", "author": "A Robinson", "year": "2014", "unstructured": "Robinson A, Wermeling DP (2014) Intranasal naloxone administration for treatment of opioid overdose. Am J Health Syst Pharm 71:2129\u20132135", "journal-title": "Am J Health Syst Pharm"}, {"key": "14_CR34", "doi-asserted-by": "publisher", "first-page": "289", "DOI": "10.1016/S0196-0644(80)80060-6", "volume": "9", "author": "MI Greenberg", "year": "1980", "unstructured": "Greenberg MI, Roberts JR, Baskin SI (1980) Endotracheal naloxone reversal of morphine-induced respiratory depression in rabbits. Ann Emerg Med 9:289\u2013292", "journal-title": "Ann Emerg Med"}, {"key": "14_CR35", "doi-asserted-by": "publisher", "first-page": "566", "DOI": "10.1016/S0196-0644(86)80994-5", "volume": "15", "author": "L Goldfrank", "year": "1986", "unstructured": "Goldfrank L, Weisman RS, Errick JK, Lo MW (1986) A dosing nomogram for continuous infusion intravenous naloxone. Ann Emerg Med 15:566\u2013570", "journal-title": "Ann Emerg Med"}, {"key": "14_CR36", "doi-asserted-by": "publisher", "first-page": "751", "DOI": "10.1097/00003246-198708000-00008", "volume": "15", "author": "JS Groeger", "year": "1987", "unstructured": "Groeger JS, Inturrisi CE (1987) High-dose naloxone: pharmacokinetics in patients in septic shock. Crti Care Med 15:751\u2013756", "journal-title": "Crti Care Med"}, {"key": "14_CR37", "doi-asserted-by": "publisher", "first-page": "897", "DOI": "10.1592/phco.19.10.897.31557", "volume": "19", "author": "SD Hanes", "year": "1999", "unstructured": "Hanes SD, Franklin M, Kuhl DA, Headley AS (1999) Prolonged opioid antagonist with naloxone in chronic renal failure. Pharmacother 19:897\u2013901", "journal-title": "Pharmacother"}, {"key": "14_CR38", "doi-asserted-by": "publisher", "first-page": "1417", "DOI": "10.1097/ALN.0b013e3181d5e29d", "volume": "112", "author": "E Olofsen", "year": "2010", "unstructured": "Olofsen E, van Dorp E, Teppema L et al (2010) Naloxone reversal of morphine and morphine-6-glucuronide-induced respiratory depression in healthy volunteers. Anesthesiology 112:1417\u20131427", "journal-title": "Anesthesiology"}, {"key": "14_CR39", "doi-asserted-by": "publisher", "first-page": "965", "DOI": "10.2165/00003088-200746110-00004", "volume": "46", "author": "A Yassan", "year": "2007", "unstructured": "Yassan A, Oolofsen E, van Dorp E et al (2007) Mechanism-based pharmacokinetic-pharmacodynamic modeling of the reversal of buprenorphine-induced respiratory depression by naloxone: a study in healthy volunteers. Clin Pharmacokinet 46:965\u2013980", "journal-title": "Clin Pharmacokinet"}, {"key": "14_CR40", "doi-asserted-by": "publisher", "first-page": "90", "DOI": "10.1038/clpt.1992.106", "volume": "52", "author": "JA Culpepper-Morgan", "year": "1992", "unstructured": "Culpepper-Morgan JA, Inturrisi CE, Portenoy RK et al (1992) Treatment of opioid-induced constipation with oral naloxone: a pilot study. Clin Pharmacol Ther 52:90\u201395", "journal-title": "Clin Pharmacol Ther"}, {"key": "14_CR41", "doi-asserted-by": "publisher", "first-page": "803", "DOI": "10.1016/j.jcrc.2014.04.005", "volume": "29", "author": "CM Gibson", "year": "2014", "unstructured": "Gibson CM, Pass SE (2014) Enteral naloxone for the treatment of opioid-induced constipation in the medical intensive care unit. J Crit Care 29:803\u2013807", "journal-title": "J Crit Care"}, {"key": "14_CR42", "doi-asserted-by": "publisher", "first-page": "784", "DOI": "10.1001/archpsyc.1973.01750360022003", "volume": "28", "author": "WR Martin", "year": "1973", "unstructured": "Martin WR, Jasinski DR, Mansky PA (1973) Naltrexone, an antagonist for the treatment of heroin dependence in man. Arch Gen Psychiatry 28:784\u2013791", "journal-title": "Arch Gen Psychiatry"}, {"key": "14_CR43", "doi-asserted-by": "publisher", "first-page": "192", "DOI": "10.2165/00003495-198835030-00002", "volume": "35", "author": "JP Gonzalez", "year": "1988", "unstructured": "Gonzalez JP, Brogden RN (1988) Naltrexone: a review of its pharmacodynamics and pharmacokinetic properties and therapeutic efficacy in the management of opioid-dependence. Drugs 35:192\u2013313", "journal-title": "Drugs"}, {"key": "14_CR44", "doi-asserted-by": "publisher", "first-page": "443", "DOI": "10.3181/00379727-148-38558", "volume": "148", "author": "JM Fujimoto", "year": "1975", "unstructured": "Fujimoto JM, Roerig S, Wang RI, Cahtterjie N, Inturrisi CE (1975) Narcotic antagonistic activity of several metabolites of naloxone and naltrexone tested in morphine dependent mice (38558). Proc Soc Exp Biol Med 148:443\u2013448", "journal-title": "Proc Soc Exp Biol Med"}, {"key": "14_CR45", "first-page": "506", "volume": "2", "author": "EJ Cone", "year": "1974", "unstructured": "Cone EJ, Gorodedtzky CW, Yeh S (1974) The urinary excretion profile of naltrexone and metabolites in man. Drug Metab Dispos 2:506\u2013512", "journal-title": "Drug Metab Dispos"}, {"key": "14_CR46", "doi-asserted-by": "publisher", "first-page": "315", "DOI": "10.1002/cpt1976203315", "volume": "20", "author": "K Verebey", "year": "1976", "unstructured": "Verebey K, Volavka J, Mule SJ, Resnick RB (1976) Naltrexone: disposition, metabolism, and effects after acute and chronic dosing. Clin Pharmacol Ther 20:315\u2013328", "journal-title": "Clin Pharmacol Ther"}, {"key": "14_CR47", "first-page": "1207", "volume": "29", "author": "MC Lee", "year": "1988", "unstructured": "Lee MC, Wagner HN, Tanada S et al (1988) Duration of occupancy of opiate receptors by naltrexone. J Nucl Med 29:1207\u20131211", "journal-title": "J Nucl Med"}, {"key": "14_CR48", "doi-asserted-by": "publisher", "first-page": "18", "DOI": "10.1186/1471-244X-5-18", "volume": "5", "author": "GP Galloway", "year": "2005", "unstructured": "Galloway GP, Koch M, Cello R, Smith DE (2005) Pharmacokinetics, safety, and tolerability of a depot formulation naltrexone in alcoholics: an open-label trial. BMC Psychiatry 5:18. doi:\n                  10.1186/1471-244X-5-18", "journal-title": "BMC Psychiatry"}, {"key": "14_CR49", "doi-asserted-by": "publisher", "first-page": "862", "DOI": "10.15288/jsad.2007.68.862", "volume": "68", "author": "JL Dunbar", "year": "2007", "unstructured": "Dunbar JL, Truncliff RZ, Hayes SC, Farrell CB (2007) Population pharmacokinetics of extended-release injectable naltrexone (XR-NTX) in patients with alcohol dependence. J Stud Alcohol Drugs 68:862\u2013870", "journal-title": "J Stud Alcohol Drugs"}, {"key": "14_CR50", "doi-asserted-by": "publisher", "first-page": "480", "DOI": "10.1111/j.1530-0277.2006.00052.x", "volume": "30", "author": "JL Dunbar", "year": "2006", "unstructured": "Dunbar JL, Turncliff RZ, Dong Q et al (2006) Single and multiple-dose pharmacokinetics of long-acting injectable naltrexone. Alcohol Clin Exp Res 30:480\u2013490", "journal-title": "Alcohol Clin Exp Res"}, {"key": "14_CR51", "doi-asserted-by": "publisher", "first-page": "1259", "DOI": "10.1177/0091270005280199", "volume": "45", "author": "RZ Turncliff", "year": "2005", "unstructured": "Turncliff RZ, Dunbar JL, Dong Q et al (2005) Pharmacokinetics of long-acting naltrexone in subjects with mild to moderate hepatic impairment. J Clin Pharmacol 45:1259\u20131267", "journal-title": "J Clin Pharmacol"}, {"key": "14_CR52", "doi-asserted-by": "publisher", "first-page": "207", "DOI": "10.1080/10550887.2012.694598", "volume": "31", "author": "G Bart", "year": "2012", "unstructured": "Bart G (2012) Maintenance medication for opiate addiction: the foundation of recovery. J Addcit Dis 31:207\u2013225", "journal-title": "J Addcit Dis"}, {"key": "14_CR53", "doi-asserted-by": "publisher", "first-page": "67", "DOI": "10.1016/0736-4679(90)90391-8", "volume": "8", "author": "KR Challoner", "year": "1990", "unstructured": "Challoner KR, McCarron MM, Newton EJ (1990) Pentazocine (Talwin) intoxication: report of 57 cases. J Emerg Med 8:67\u201374", "journal-title": "J Emerg Med"}, {"key": "14_CR54", "doi-asserted-by": "publisher", "first-page": "63", "DOI": "10.1016/S0196-0644(83)80130-9", "volume": "12", "author": "SM Stahl", "year": "1983", "unstructured": "Stahl SM, Kasser IS (1983) Pentazocine overdose. Ann Emerg Med 12:63\u201365", "journal-title": "Ann Emerg Med"}, {"key": "14_CR55", "first-page": "11", "volume": "271", "author": "J Legros", "year": "1984", "unstructured": "Legros J, Khalili-Varasteh H, Margetts G (1984) Pharmacologic study of pentazocine-naloxone combination: interest as a potentially nonabusable oral form of pentazocine. Arch Int Pharmacodyn Ther 271:11\u201321", "journal-title": "Arch Int Pharmacodyn Ther"}, {"key": "14_CR56", "first-page": "1048", "volume": "14", "author": "JQ Swift", "year": "1993", "unstructured": "Swift JQ, Hargreaves KM (1993) Pentazocine analgesia: is there a niche for Talwin Nx? Compendium 14:1048", "journal-title": "Compendium"}, {"key": "14_CR57", "doi-asserted-by": "publisher", "first-page": "1163", "DOI": "10.3109/10826088709027478", "volume": "22", "author": "HW Lahmeyer", "year": "1987", "unstructured": "Lahmeyer HW, Craig RJ (1987) Pentazocine-naloxone: another \u201caddiction-proof\u201d drug of abuse. Int J Addict 22:1163\u20131166", "journal-title": "Int J Addict"}, {"key": "14_CR58", "first-page": "426", "volume": "102", "author": "C Baum", "year": "1987", "unstructured": "Baum C, Hsu JP, Nelson RC (1987) The impact of the addition of naloxone on the use and abuse of pentazocine. Public Health Rep 102:426\u2013429", "journal-title": "Public Health Rep"}, {"key": "14_CR59", "doi-asserted-by": "publisher", "first-page": "2562", "DOI": "10.1001/jama.1986.03380180124033", "volume": "256", "author": "DA Reed", "year": "1986", "unstructured": "Reed DA, Schnoll SH (1986) Abuse of pentazocine-naloxone combination. JAMA 256:2562\u20132564", "journal-title": "JAMA"}, {"key": "14_CR60", "doi-asserted-by": "publisher", "first-page": "1574", "DOI": "10.1172/JCI113768", "volume": "82", "author": "JD Levine", "year": "1988", "unstructured": "Levine JD, Gordon CG, Taiwo YO, Coderra TJ (1988) Potentiation of pentazocine analgesia by low-dose naloxone. J Clin Invest 82:1574\u20131577", "journal-title": "J Clin Invest"}, {"key": "14_CR61", "doi-asserted-by": "publisher", "first-page": "577", "DOI": "10.2165/00003495-200969050-00006", "volume": "69", "author": "JS Orman", "year": "2009", "unstructured": "Orman JS, Keating GM (2009) Buprenorphine/naloxone. Drugs 69:577\u2013607", "journal-title": "Drugs"}, {"key": "14_CR62", "doi-asserted-by": "publisher", "first-page": "1460", "DOI": "10.1111/j.1360-0443.2011.03424.x", "volume": "106", "author": "LS Middleton", "year": "2011", "unstructured": "Middleton LS, Nuzzo PA, Lofwall MR, Moody DE, Walsh SL (2011) The pharmacodynamics and pharmacokinetic profile of intranasal crushed buprenorphine/naloxone tablets in opioid-abusers. Addiction 106:1460\u20131473", "journal-title": "Addiction"}, {"key": "14_CR63", "doi-asserted-by": "publisher", "first-page": "619", "DOI": "10.1177/00912709922008236", "volume": "39", "author": "RP Nath", "year": "1999", "unstructured": "Nath RP, Upton RA, Everhart ET et al (1999) Buprenorphine pharmacokinetics: relative bioavailability of sublingual tablet and liquid formulations. J Clin Pharmacol 39:619\u2013623", "journal-title": "J Clin Pharmacol"}, {"key": "14_CR64", "unstructured": "Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review: application number: 20\u2013732, 20\u2013733 (Suboxone\u00ae) [online]. Available from URL: \n                  http://fda.gov/cder\n                  \n                . Accessed 22 Nov 2014"}, {"key": "14_CR65", "unstructured": "Suboxone commercial web page (2014) Reckitt-Benckiser Inc. Available from: \n                  http://www.suboxone.com/\n                  \n                . Accessed 22 Nov 2014"}, {"issue": "1", "key": "14_CR66", "doi-asserted-by": "publisher", "first-page": "79", "DOI": "10.3109/03639045.2013.846365", "volume": "41", "author": "A Fischer", "year": "2015", "unstructured": "Fischer A, Jonsson M, Hjelmstrom P (2015) Pharmaceutical and pharmacokinetic characterization of a novel sublingual buprenorphine/naloxone tablet formulation in healthy volunteers. Drug Dev Ind Pharm 41(1):79\u201384; early on-line 1\u20136", "journal-title": "Drug Dev Ind Pharm"}, {"key": "14_CR67", "doi-asserted-by": "publisher", "first-page": "S29", "DOI": "10.1016/S0376-8716(03)00057-7", "volume": "70", "author": "J Mendelson", "year": "2003", "unstructured": "Mendelson J, Jones RT (2003) Clinical and pharmacologic evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment. Drug Alcohol Depend 70:S29\u2013S37", "journal-title": "Drug Alcohol Depend"}, {"key": "14_CR68", "doi-asserted-by": "publisher", "first-page": "S39", "DOI": "10.1016/S0376-8716(03)00058-9", "volume": "70", "author": "CN Chaing", "year": "2003", "unstructured": "Chaing CN, Hawks RL (2003) Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug Alcohol Depend 70:S39\u2013S47", "journal-title": "Drug Alcohol Depend"}, {"key": "14_CR69", "doi-asserted-by": "publisher", "first-page": "205", "DOI": "10.1016/j.drugalcdep.2003.12.008", "volume": "74", "author": "MZ Mintzer", "year": "2004", "unstructured": "Mintzer MZ, Correia CJ, Strain EC (2004) A dose-effect study of repeated administration of buprenorphine/naloxone on performance in opioid-dependent volunteers. Drug Alcohol Depend 74:205\u2013209", "journal-title": "Drug Alcohol Depend"}, {"key": "14_CR70", "doi-asserted-by": "publisher", "first-page": "329", "DOI": "10.2165/00003088-200443050-00005", "volume": "43", "author": "DS Harris", "year": "2004", "unstructured": "Harris DS, Mendelson JE, Lin ET, Upton RA, Jones RT (2004) Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone. Clin Pharmacokinet 43:329\u2013340", "journal-title": "Clin Pharmacokinet"}, {"key": "14_CR71", "doi-asserted-by": "publisher", "first-page": "85", "DOI": "10.1016/S0376-8716(00)00126-5", "volume": "61", "author": "DS Harris", "year": "2000", "unstructured": "Harris DS, Jones RT, Wlem S et al (2000) Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine. Drug Alcohol Depend 61:85\u201394", "journal-title": "Drug Alcohol Depend"}, {"key": "14_CR72", "doi-asserted-by": "publisher", "first-page": "941", "DOI": "10.1002/cpt1973146941", "volume": "14", "author": "SD Parwatikar", "year": "1973", "unstructured": "Parwatikar SD, Knowles RR (1973) Methadone-naloxone in combination for the treatment of heroin addicts. Clin Pharmacol Ther 14:941\u2013948", "journal-title": "Clin Pharmacol Ther"}, {"key": "14_CR73", "doi-asserted-by": "publisher", "first-page": "156", "DOI": "10.1002/cpt1974152156", "volume": "15", "author": "JG Nutt", "year": "1974", "unstructured": "Nutt JG, Jasinski DR (1974) Methadone-naloxone mixtures for use in methadone maintenance programs. Clin Pharmacol Ther 15:156\u2013166", "journal-title": "Clin Pharmacol Ther"}, {"key": "14_CR74", "doi-asserted-by": "publisher", "first-page": "157", "DOI": "10.1016/0740-5472(91)90007-W", "volume": "8", "author": "N Loimer", "year": "1991", "unstructured": "Loimer N, Presslich O, Grunberger J, Linzmayer L (1991) Combined naloxone-methadone preparations for opiate substitution therapy. J Subst Abuse Treat 8:157\u2013160", "journal-title": "J Subst Abuse Treat"}, {"key": "14_CR75", "doi-asserted-by": "publisher", "first-page": "146", "DOI": "10.1037/a0016302", "volume": "17", "author": "J Bell", "year": "2009", "unstructured": "Bell J, Shearer J, Ryan A et al (2009) The acceptability, safety, and tolerability of methadone-naloxone in a 50:1 ratio. Exp Clin Psychopharmacol 17:146\u2013153", "journal-title": "Exp Clin Psychopharmacol"}, {"key": "14_CR76", "doi-asserted-by": "publisher", "first-page": "581", "DOI": "10.1007/s12325-010-0057-y", "volume": "27", "author": "S Mueller-Lissner", "year": "2010", "unstructured": "Mueller-Lissner S (2010) Fixed combination of oxycodone with naloxone: a new way to prevent and treat opioid-induced constipation. Adv Ther 27:581\u2013590", "journal-title": "Adv Ther"}, {"key": "14_CR77", "doi-asserted-by": "publisher", "first-page": "124", "DOI": "10.2174/13894501113149990210", "volume": "15", "author": "W Leppert", "year": "2014", "unstructured": "Leppert W (2014) Oxycodone/naloxone in the management of patients with pain and opioid-induced bowel dysfunction. Curr Drug Targets 15:124\u2013135", "journal-title": "Curr Drug Targets"}, {"key": "14_CR78", "doi-asserted-by": "publisher", "first-page": "56", "DOI": "10.1016/j.ejpain.2008.06.012", "volume": "13", "author": "W Meissner", "year": "2009", "unstructured": "Meissner W, Leyendecker P, Mueller-Lissner S et al (2009) A randomized controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain 13:56\u201364", "journal-title": "Eur J Pain"}, {"key": "14_CR79", "doi-asserted-by": "publisher", "first-page": "1144", "DOI": "10.1016/j.jpain.2008.06.014", "volume": "9", "author": "D Vondrackova", "year": "2008", "unstructured": "Vondrackova D, Leyendecker P, Meissner W et al (2008) Analgesic effect and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J Pain 9:1144\u20131154", "journal-title": "J Pain"}, {"key": "14_CR80", "doi-asserted-by": "publisher", "first-page": "2051", "DOI": "10.1016/j.clinthera.2008.11.008", "volume": "30", "author": "K Smith", "year": "2008", "unstructured": "Smith K, Hopp M, Mundin G et al (2008) Single- and multiple dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers. Clin Ther 30:2051\u20132068", "journal-title": "Clin Ther"}, {"key": "14_CR81", "doi-asserted-by": "publisher", "first-page": "427", "DOI": "10.1517/13543784.2011.563236", "volume": "20", "author": "K Smith", "year": "2011", "unstructured": "Smith K, Hopp M, Mundin G et al (2011) Naloxone as part of a prolonged release oxycodone/naloxone combination reduces oxycodone-induced slowing of gastrointestinal transit in healthy volunteers. Expert Opin Investig Drugs 20:427\u2013439", "journal-title": "Expert Opin Investig Drugs"}, {"key": "14_CR82", "doi-asserted-by": "publisher", "first-page": "1471", "DOI": "10.1007/s00520-011-1205-x", "volume": "19", "author": "S Mercadante", "year": "2011", "unstructured": "Mercadante S, Ferrera P, Adile C (2011) High doses of oxycodone-naloxone combination may provide poor analgesia. Support Care Cancer 19:1471\u20131472", "journal-title": "Support Care Cancer"}, {"key": "14_CR83", "doi-asserted-by": "publisher", "first-page": "527", "DOI": "10.2165/11204620-000000000-00000", "volume": "24", "author": "ST Duggan", "year": "2010", "unstructured": "Duggan ST, Scott LJ (2010) Morphine/Naltrexone. CNS Drugs 24:527\u2013538", "journal-title": "CNS Drugs"}, {"key": "14_CR84", "first-page": "391", "volume": "14", "author": "F Johnson", "year": "2011", "unstructured": "Johnson F, Setnik B (2011) Morphine sulfate and naltrexone hydrochloride extended release capsules: naltrexone release, pharmacodynamics and tolerability. Pain Physician 14:391\u2013406", "journal-title": "Pain Physician"}, {"key": "14_CR85", "doi-asserted-by": "publisher", "first-page": "846", "DOI": "10.1007/s12325-010-0074-x", "volume": "27", "author": "F Johnson", "year": "2010", "unstructured": "Johnson F, Ciric S, Boudriau S, Swearingen D, Stauffer J (2010) Food effects on the pharmacokinetics of morphine sulfate and naltrexone hydrochloride extended release capsules. Adv Ther 27:846\u2013858", "journal-title": "Adv Ther"}, {"key": "14_CR86", "doi-asserted-by": "publisher", "first-page": "1149", "DOI": "10.1016/j.clinthera.2010.05.011", "volume": "32", "author": "FK Johnson", "year": "2010", "unstructured": "Johnson FK, Stark JG, Bieberdorf FA, Stauffer J (2010) Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers. Clin Ther 32:1149\u20131164", "journal-title": "Clin Ther"}, {"key": "14_CR87", "doi-asserted-by": "publisher", "first-page": "303", "DOI": "10.1016/j.jpain.2009.07.017", "volume": "11", "author": "N Katz", "year": "2010", "unstructured": "Katz N, Sun S, Jonhson F, Stauffer J (2010) ALO-01 (morphine sulfate and naltrexone hydrochloride) extended release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: pharmacokinetics, efficacy, and safety. J Pain 11:303\u2013311", "journal-title": "J Pain"}, {"key": "14_CR88", "unstructured": "King Pharmaceuticals Inc. Embeda\u00ae (morphine sulfate and naltrexone hydrochloride) extended release capsules for oral use [online]. Available from URL: \n                  http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/"}, {"key": "14_CR89", "doi-asserted-by": "publisher", "first-page": "777", "DOI": "10.2165/11530800-000000000-00000", "volume": "29", "author": "J Stauffer", "year": "2009", "unstructured": "Stauffer J, Setnik B, Sokolowski M (2009) Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-controlled, crossover study. Clin Drug Investig 29:777\u2013790", "journal-title": "Clin Drug Investig"}, {"key": "14_CR90", "doi-asserted-by": "publisher", "first-page": "559", "DOI": "10.1016/S0740-5472(97)00176-1", "volume": "14", "author": "P Finn", "year": "1997", "unstructured": "Finn P, Wolcock K (1997) Levo-alpha acetyl methadol (LAAM). J Subst Abuse Treat 14:559\u2013564", "journal-title": "J Subst Abuse Treat"}, {"key": "14_CR91", "unstructured": "Center for Substance Abuse Treatment (1995). Treatment Improvement Protocol (TIP) Series, No 22. LAAM in the treatment of opiate addiction. Rockville, MD: Department of Health and Human Services"}, {"key": "14_CR92", "doi-asserted-by": "publisher", "first-page": "7", "DOI": "10.1186/2047-783X-14-1-7", "volume": "14", "author": "H Weineke", "year": "2009", "unstructured": "Weineke H, Conrads H, Wolstein J et al (2009) Levo-\u03b1-acetylmethadol (LAAM) induced QTc prolongation \u2013 results from a controlled clinical trial. Eur J Med Res 14:7\u201312", "journal-title": "Eur J Med Res"}, {"key": "14_CR93", "unstructured": "US Food and Drug Administration: Product Discontinuation Notice (2003) ORLAAM\u00ae (Levomethadyl hydrochloride) Oral Solution, 10 mg/mL, CII. Available at \n                  http://www.fda.gov"}, {"key": "14_CR94", "doi-asserted-by": "publisher", "first-page": "731", "DOI": "10.2165/00003088-200544070-00005", "volume": "44", "author": "ED Kharasch", "year": "2005", "unstructured": "Kharasch ED, Whittington D, Hoffer C et al (2005) Paradoxical role of cytochrome P450 3A in the bioactivation and clinical effects of levo-\u03b1-acetylmethadol. Clin Pharmacokinet 44:731\u2013751", "journal-title": "Clin Pharmacokinet"}, {"key": "14_CR95", "doi-asserted-by": "publisher", "first-page": "16", "DOI": "10.1002/cpt197721116", "volume": "21", "author": "GL Henderson", "year": "1977", "unstructured": "Henderson GL, Wilson BK, Lau DH (1977) Plasma l-alpha-acetylmethadol (LAAM) after acute and chronic administration. Clin Pharmacol Ther 21:16\u201325", "journal-title": "Clin Pharmacol Ther"}, {"key": "14_CR96", "doi-asserted-by": "publisher", "first-page": "304", "DOI": "10.1159/000107104", "volume": "80", "author": "S Crettol", "year": "2007", "unstructured": "Crettol S, Digon P, Golay KP, Brawand M, Eap CB (2007) In vitro P-glycoprotein-mediated transport of (R), (S), (R, S)-methadone, LAAM and their main metabolites. Pharmacology 80:304\u2013311", "journal-title": "Pharmacology"}, {"key": "14_CR97", "doi-asserted-by": "publisher", "first-page": "154", "DOI": "10.1016/j.clpt.2004.04.004", "volume": "76", "author": "DE Moody", "year": "2004", "unstructured": "Moody DE, Walsh SL, Rollins DE, Neff JA, Huang W (2004) Ketoconazole, a cytochrome P450 3A4 inhibitor, markedly increases concentrations of levo-acetyl-alpha-methadol in opioid-na\u00efve individuals. Clin Pharmacol Ther 76:154\u2013166", "journal-title": "Clin Pharmacol Ther"}, {"key": "14_CR98", "doi-asserted-by": "publisher", "first-page": "10", "DOI": "10.1002/jps.10263", "volume": "92", "author": "W Huang", "year": "2003", "unstructured": "Huang W, Bemis PA, Slawson MH, Moody DE (2003) Determination of l-\u03b1-acetylmethadol (LAAM), norLAAL, and dinorLAAM in clinical and in vitro samples using liquid chromatography with electrospray ionization and tandem mass spectrometry. J Pharm Sci 92:10\u201320", "journal-title": "J Pharm Sci"}, {"key": "14_CR99", "first-page": "936", "volume": "289", "author": "T Eissenberg", "year": "1999", "unstructured": "Eissenberg T, Stitzer ML, Bigelow GE, Buchhalter AR, Walsh SL (1999) Relative potency of levo-\u03b1-acetylmethadol and methadone in humans under acute dosing conditions. J Pharmacol Exp Ther 289:936\u2013945", "journal-title": "J Pharmacol Exp Ther"}, {"key": "14_CR100", "first-page": "321", "volume": "5", "author": "GL Henderson", "year": "1977", "unstructured": "Henderson GL, North-Root H, Kuttab SH (1977) Metabolism and disposition of l-\u03b1-acetylmethadol in the rat. Drug Metab Dispos 5:321\u2013328", "journal-title": "Drug Metab Dispos"}, {"key": "14_CR101", "first-page": "71", "volume": "285", "author": "SL Walsh", "year": "1998", "unstructured": "Walsh SL, Johnson RE, Cone EJ, Begelow GE (1998) Intravenous and oral l-\u03b1-acetylmethadol: pharmacodynamics and pharmacokinetics in humans. J Pharmacol Exp Ther 285:71\u201382", "journal-title": "J Pharmacol Exp Ther"}, {"key": "14_CR102", "doi-asserted-by": "publisher", "first-page": "63", "DOI": "10.1016/j.drugalcdep.2004.04.004", "volume": "76", "author": "DA Newcombe", "year": "2004", "unstructured": "Newcombe DA, Bochner F, White JM, Somogyi AA (2004) Evaluation of levo-alpha-acetylmethadol (LAAM) as an alternative treatment for methadone maintenance patients who regularly experience withdrawal: a pharmacokinetic and pharmacodynamic analysis. Drug Alcohol Depend 76:63\u201372", "journal-title": "Drug Alcohol Depend"}], "container-title": ["Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents"], "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/978-3-319-27883-4_14", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 6, 1]], "date-time": "2019-06-01T17:16:48Z", "timestamp": 1559409408000}, "score": 25.809406, "issued": {"date-parts": [[2016]]}, "ISBN": ["9783319278810", "9783319278834"], "references-count": 102, "URL": "http://dx.doi.org/10.1007/978-3-319-27883-4_14", "relation": {"cites": []}}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T12:21:24Z", "timestamp": 1574770884758}, "publisher-location": "Cham", "reference-count": 121, "publisher": "Springer International Publishing", "isbn-type": [{"value": "9783319278810", "type": "print"}, {"value": "9783319278834", "type": "electronic"}], "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2016, 1, 1]], "date-time": "2016-01-01T00:00:00Z", "timestamp": 1451606400000}, "delay-in-days": 0, "content-version": "unspecified"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2016]]}, "DOI": "10.1007/978-3-319-27883-4_24", "type": "book-chapter", "created": {"date-parts": [[2016, 3, 2]], "date-time": "2016-03-02T13:04:48Z", "timestamp": 1456923888000}, "page": "579-601", "source": "Crossref", "is-referenced-by-count": 1, "title": ["Clinically Significant Interactions with Anesthetic Agents"], "prefix": "10.1007", "author": [{"given": "Michael W.", "family": "Jann", "sequence": "first", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2016, 3, 3]]}, "reference": [{"key": "24_CR1", "doi-asserted-by": "publisher", "first-page": "1", "DOI": "10.1097/00000542-199507000-00001", "volume": "83", "author": "DR Stanski", "year": "1995", "unstructured": "Stanski DR, Shafer SL (1995) Quantifying anesthetic drug interaction. Anesthesiology 83:1\u20135", "journal-title": "Anesthesiology"}, {"key": "24_CR2", "doi-asserted-by": "publisher", "first-page": "969", "DOI": "10.2165/00002512-200320130-00002", "volume": "20", "author": "H Eilers", "year": "2003", "unstructured": "Eilers H, Niemann CU (2003) Clinically important drug interactions with intravenous anesthetics in older patients. Drugs Aging 20:969\u2013980", "journal-title": "Drugs Aging"}, {"key": "24_CR3", "doi-asserted-by": "publisher", "first-page": "108", "DOI": "10.1177/155005940603700208", "volume": "37", "author": "MJ Barbanoj", "year": "2006", "unstructured": "Barbanoj MJ, Antonijoan RM, Riba J, Valle M, Romero S, Jane F (2006) Quantifying drug-drug interactions in pharmaco-EEG. Clin EEG Neurosci 37:108\u2013120", "journal-title": "Clin EEG Neurosci"}, {"key": "24_CR4", "doi-asserted-by": "publisher", "first-page": "1603", "DOI": "10.1097/00000542-200006000-00017", "volume": "92", "author": "CF Minto", "year": "2000", "unstructured": "Minto CF, Schnider TW, Short TG et al (2000) Response surface model for anesthetic drug interactions. Anesthesiology 92:1603\u20131616", "journal-title": "Anesthesiology"}, {"issue": "Suppl D", "key": "24_CR5", "first-page": "129", "volume": "24", "author": "M Valle", "year": "2002", "unstructured": "Valle M, Barbanoj MJ, Jane F (2002) Pharmaco-EEG and pharmacokinetic/pharmacodynamics modeling in basic research: focus on human pharmacology. Methods Find Exp Clin Pharmacol 24(Suppl D):129\u2013137", "journal-title": "Methods Find Exp Clin Pharmacol"}, {"key": "24_CR6", "doi-asserted-by": "publisher", "first-page": "251", "DOI": "10.1002/j.1875-9114.1983.tb03266.x", "volume": "3", "author": "JL Giese", "year": "1983", "unstructured": "Giese JL, Stanley TH (1983) Etomidate: a new intravenous anesthetic induction agent. Pharmacotherapy 3:251\u2013258", "journal-title": "Pharmacotherapy"}, {"key": "24_CR7", "doi-asserted-by": "publisher", "first-page": "12", "DOI": "10.1111/j.1365-2044.1984.tb09446.x", "volume": "39", "author": "JW Sear", "year": "1984", "unstructured": "Sear JW, Walters FJ, Wilkins DG, Willatss SM (1984) Etomidate by infusion for neuroanesthesia kinetic and dynamic interactions with nitrous oxide. Anaesthesia 39:12\u201318", "journal-title": "Anaesthesia"}, {"key": "24_CR8", "first-page": "11", "volume": "23", "author": "O Richter", "year": "1985", "unstructured": "Richter O, Klatte A, Abel J et al (1985) Pharmacokinetic data analysis of Alfentanil after multiple injections and Etomidate-infusion in patients undergoing orthopedic surgery. Int J Clin Pharmacol Ther Toxic 23:11\u201315", "journal-title": "Int J Clin Pharmacol Ther Toxic"}, {"key": "24_CR9", "doi-asserted-by": "publisher", "first-page": "379", "DOI": "10.5055/jom.2013.0180", "volume": "9", "author": "QA Tawfic", "year": "2013", "unstructured": "Tawfic QA (2013) A review of the use of ketamine in pain management. J Opioid Manag 9:379\u2013388", "journal-title": "J Opioid Manag"}, {"key": "24_CR10", "first-page": "496", "volume": "53", "author": "RR Johnston", "year": "1974", "unstructured": "Johnston RR, Miller RD, Way WL (1974) The interaction of ketamine with d-tubocurarine, pancuronium, and succinylcholine in man. Anesth Analg 53:496\u2013501", "journal-title": "Anesth Analg"}, {"key": "24_CR11", "doi-asserted-by": "publisher", "first-page": "579", "DOI": "10.1067/mem.2000.111131", "volume": "36", "author": "JE Wathen", "year": "2000", "unstructured": "Wathen JE, Roback MG, Mackenzie T, Bothner JP (2000) Does midazolam alter the clinical effects of intravenous ketamine sedation in children? A double-blind, randomized, controlled, emergency department trial. Ann Emerg Med 36:579\u2013588", "journal-title": "Ann Emerg Med"}, {"key": "24_CR12", "doi-asserted-by": "publisher", "first-page": "1781", "DOI": "10.1097/01.PRS.0000162105.17815.5A", "volume": "115", "author": "EA Pechter", "year": "2005", "unstructured": "Pechter EA (2005) Safety of ketamine and diazepam in anesthesia. Plast Reconstr Surg 115:1781\u20131782", "journal-title": "Plast Reconstr Surg"}, {"key": "24_CR13", "doi-asserted-by": "publisher", "first-page": "47", "DOI": "10.1016/S0304-3959(01)00472-9", "volume": "98", "author": "AE Bossard", "year": "2002", "unstructured": "Bossard AE, Guirmand F, Fletcher D et al (2002) Interaction of a combination of morphine and ketamine on the nociceptive flexion reflex in human volunteers. Pain 98:47\u201357", "journal-title": "Pain"}, {"key": "24_CR14", "first-page": "426P", "volume": "67", "author": "D Lawrence", "year": "1979", "unstructured": "Lawrence D, Livingston A (1979) The effect of physostigmine and neostigmine on ketamine anesthesia and analgesia. Br J Pharmacol 67:426P", "journal-title": "Br J Pharmacol"}, {"key": "24_CR15", "doi-asserted-by": "publisher", "first-page": "399", "DOI": "10.1007/BF02244110", "volume": "102", "author": "M Mimura", "year": "1990", "unstructured": "Mimura M, Namiki A, Kishi R, Ikeda T, Miyake H (1990) Antagonistic effect of physostigmine on ketamine-induced anesthesia. Psychopharmacology 102:399\u2013403", "journal-title": "Psychopharmacology"}, {"key": "24_CR16", "unstructured": "Santamaria R, Pailleux F, Beaudry F (2013) In vitro ketamine CYP3A4 mediated metabolism study using mammalian liver S9 fractions, cDNA expressed enzymes and liquid chromatography tandem mass spectrometry. Biomed Chromatogr, 1002/bmc3199"}, {"key": "24_CR17", "doi-asserted-by": "publisher", "first-page": "853", "DOI": "10.1124/dmd.30.7.853", "volume": "30", "author": "Y Hijazi", "year": "2002", "unstructured": "Hijazi Y, Boulieu R (2002) Contribution of CYP3A4, CYP2B6, CYP2C19 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos 30:853\u2013858", "journal-title": "Drug Metab Dispos"}, {"key": "24_CR18", "doi-asserted-by": "publisher", "first-page": "1076", "DOI": "10.3109/00498254.2012.685777", "volume": "42", "author": "Z Desta", "year": "2012", "unstructured": "Desta Z, Moaddel R, Ogburn ET et al (2012) Stereoselective and regiospecific hydroxylation of ketamine and norketamine. Xenobiotica 42:1076\u20131087", "journal-title": "Xenobiotica"}, {"key": "24_CR19", "doi-asserted-by": "publisher", "first-page": "325", "DOI": "10.1111/j.1742-7843.2012.00908.x", "volume": "111", "author": "TI Peltoniemi Saari", "year": "2012", "unstructured": "Peltoniemi Saari TI, Hagelberg NM et al (2012) Rifampicin has a profound effect on the pharmacokinetics of oral S-ketamine and less on intravenous S-ketamine. Basic Clin Pharmacol Toxic 111:325\u2013332", "journal-title": "Basic Clin Pharmacol Toxic"}, {"key": "24_CR20", "doi-asserted-by": "publisher", "first-page": "743", "DOI": "10.1111/j.1472-8206.2011.00954.x", "volume": "26", "author": "MA Peltoniemi", "year": "2012", "unstructured": "Peltoniemi MA, Saari TI, Hagelberg NM et al (2012) St. John\u2019s Wort greatly decreases the plasma concentrations of oral S-ketamine. Fundam Clin Pharmacol 26:743\u2013750", "journal-title": "Fundam Clin Pharmacol"}, {"key": "24_CR21", "doi-asserted-by": "publisher", "first-page": "979", "DOI": "10.1007/s00228-012-1214-9", "volume": "68", "author": "MA Peltoniemi", "year": "2012", "unstructured": "Peltoniemi MA, Saari TI, Hagelberg NM et al (2012) S-ketamine concentrations are greatly increased by grapefruit juice. Eur J Clin Pharmacol 68:979\u2013986", "journal-title": "Eur J Clin Pharmacol"}, {"key": "24_CR22", "doi-asserted-by": "publisher", "first-page": "625", "DOI": "10.1016/j.ejpain.2009.10.003", "volume": "14", "author": "NM Hagelberg", "year": "2010", "unstructured": "Hagelberg NM, Peltoniemi MA, Saari TI et al (2010) Clarithromycin, a potent inhibitor of CYP3A, greatly increases exposure to oral S-ketamine. Eur J Pain 14:625\u2013629", "journal-title": "Eur J Pain"}, {"key": "24_CR23", "doi-asserted-by": "publisher", "first-page": "296", "DOI": "10.1038/clpt.2011.140", "volume": "90", "author": "MA Peltoniemi", "year": "2011", "unstructured": "Peltoniemi MA, Saari TI, Hagelberg NM et al (2011) Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine. Clin Pharmacol Ther 90:296\u2013302", "journal-title": "Clin Pharmacol Ther"}, {"key": "24_CR24", "doi-asserted-by": "publisher", "first-page": "728", "DOI": "10.1124/dmd.109.030957", "volume": "38", "author": "X Qi", "year": "2010", "unstructured": "Qi X, Evans AM, Miners JO, Upton RN, Miline RW (2010) Inhibition of morphine metabolism by ketamine. Drug Metab Dispos 38:728\u2013731", "journal-title": "Drug Metab Dispos"}, {"key": "24_CR25", "doi-asserted-by": "publisher", "first-page": "1324", "DOI": "10.1124/dmd.111.039727", "volume": "39", "author": "V Uchaipichat", "year": "2011", "unstructured": "Uchaipichat V, Raungrut P, Chau N et al (2011) Effects of ketamine on human UDP-glucuronosyltransferases in vitro predict potential drug-drug interactions arising from ketamine inhibition of codeine and morphine glucuronidation. Drug Metab Dispos 39:1324\u20131328", "journal-title": "Drug Metab Dispos"}, {"key": "24_CR26", "first-page": "38", "volume": "60", "author": "D Broderick", "year": "2014", "unstructured": "Broderick D, Clarke M, Stassen L (2014) Midazolam and drug-drug interactions in dental conscious sedation. J Ir Dent Assoc 60:38\u201343", "journal-title": "J Ir Dent Assoc"}, {"key": "24_CR27", "first-page": "89", "volume": "36", "author": "T Kronbach", "year": "1989", "unstructured": "Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA (1989) Oxidation of midazolam and triazolam by human liver microsomes cytochrome IIIA4. Mol Pharmacol 36:89\u201396", "journal-title": "Mol Pharmacol"}, {"key": "24_CR28", "first-page": "571", "volume": "101", "author": "AF Merry", "year": "1988", "unstructured": "Merry AF, Clapham GJ, Walker JS (1988) The reversal of midazolam sedation with the benzodiazepine antagonist flumazenil. NZ Med J 101:571\u2013572", "journal-title": "NZ Med J"}, {"key": "24_CR29", "doi-asserted-by": "publisher", "first-page": "853", "DOI": "10.1097/00000542-200304000-00011", "volume": "98", "author": "AE Ibrahim", "year": "2003", "unstructured": "Ibrahim AE, Feldman J, Karim A, Kharasch ED (2003) Simultaneous assessment of drug interactions with low \u2013 high extraction opioids. Anesthesiology 98:853\u2013861", "journal-title": "Anesthesiology"}, {"key": "24_CR30", "doi-asserted-by": "publisher", "first-page": "289", "DOI": "10.1016/S0014-2999(98)00607-4", "volume": "358", "author": "M Takano", "year": "1998", "unstructured": "Takano M, Hasegawa R, Fukuda T et al (1998) Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells. Eur J Pharmacol 358:289\u2013294", "journal-title": "Eur J Pharmacol"}, {"key": "24_CR31", "doi-asserted-by": "publisher", "first-page": "20", "DOI": "10.1016/0009-9236(95)90068-3", "volume": "58", "author": "HH Kupferschmidt", "year": "1995", "unstructured": "Kupferschmidt HH, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S (1995) Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther 58:20\u201328", "journal-title": "Clin Pharmacol Ther"}, {"key": "24_CR32", "doi-asserted-by": "publisher", "first-page": "501", "DOI": "10.1007/s002280050148", "volume": "50", "author": "J Vanakoski", "year": "1996", "unstructured": "Vanakoski J, Mattila MJ, Seppala T (1996) Grapefruit juice does not enhance the effects of midazolam and triazolam in man. Eur J Clin Pharmacol 50:501\u2013508", "journal-title": "Eur J Clin Pharmacol"}, {"key": "24_CR33", "first-page": "365", "volume": "23", "author": "C Goho", "year": "2001", "unstructured": "Goho C (2001) Oral midazolam-grapefruit juice drug interaction. Pediatr Dent 23:365\u2013366", "journal-title": "Pediatr Dent"}, {"key": "24_CR34", "doi-asserted-by": "publisher", "first-page": "945", "DOI": "10.1124/dmd.31.7.945", "volume": "31", "author": "K Ito", "year": "2003", "unstructured": "Ito K, Ogihara K, Kanamitsu S, Itoh T (2003) Prediction of in vivo interaction between midazolam and macrolides based upon in vitro studies using human liver microsomes. Drug Metab Dispos 31:945\u2013954", "journal-title": "Drug Metab Dispos"}, {"key": "24_CR35", "doi-asserted-by": "publisher", "first-page": "444", "DOI": "10.1007/BF03009515", "volume": "40", "author": "P Narchi", "year": "1993", "unstructured": "Narchi P, Benhamou D, Elhaddoury M, Locatelli C, Fernandez H (1993) Interactions of pre-operative erythromycin administration with general anesthesia. Can J Anesth 40:444\u2013447", "journal-title": "Can J Anesth"}, {"key": "24_CR36", "doi-asserted-by": "publisher", "first-page": "826", "DOI": "10.1093/bja/65.6.826", "volume": "65", "author": "A Hiller", "year": "1990", "unstructured": "Hiller A, Olkkola KT, Isohanni L, Saarnivaara A (1990) Unconsciousness associated with midazolam and erythromycin. Br J Anesth 65:826\u2013828", "journal-title": "Br J Anesth"}, {"key": "24_CR37", "doi-asserted-by": "publisher", "first-page": "298", "DOI": "10.1038/clpt.1993.25", "volume": "53", "author": "KT Olkkola", "year": "1993", "unstructured": "Olkkola KT, Aranko K, Luurila H et al (1993) A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 53:298\u2013305", "journal-title": "Clin Pharmacol Ther"}, {"key": "24_CR38", "doi-asserted-by": "publisher", "first-page": "98", "DOI": "10.1111/j.1365-2125.2007.02970.x", "volume": "65", "author": "SK Quinney", "year": "2007", "unstructured": "Quinney SK, Haehner BD, Rhoades M et al (2007) Interaction between midazolam and clarithromycin in the elderly. Br J Clin Pharmacol 65:98\u2013109", "journal-title": "Br J Clin Pharmacol"}, {"key": "24_CR39", "doi-asserted-by": "publisher", "first-page": "49", "DOI": "10.1007/BF00193477", "volume": "47", "author": "MJ Mattila", "year": "1994", "unstructured": "Mattila MJ, Vanakoski J, Idanpaan-Heikkila JJ (1994) Azithromycin does not alter the effects of oral midazolam on human performance. Eur J Clin Pharmacol 47:49\u201352", "journal-title": "Eur J Clin Pharmacol"}, {"key": "24_CR40", "doi-asserted-by": "crossref", "first-page": "270", "DOI": "10.1111/j.1365-2125.1995.tb00001.x", "volume": "40", "author": "J Ahonen", "year": "1995", "unstructured": "Ahonen J, Olkkola KT, Neuvonen PJ (1995) Effect of itraconazole and terfinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers. Br J Clin Pharmacol 40:270\u2013272", "journal-title": "Br J Clin Pharmacol"}, {"key": "24_CR41", "doi-asserted-by": "publisher", "first-page": "53", "DOI": "10.1007/s002280050420", "volume": "54", "author": "JT Backman", "year": "1998", "unstructured": "Backman JT, Kivisto KT, Olkkola KT, Neuvonen PJ (1998) The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol 54:53\u201358", "journal-title": "Eur J Clin Pharmacol"}, {"key": "24_CR42", "first-page": "511", "volume": "82", "author": "KT Olkkola", "year": "1996", "unstructured": "Olkkola KT, Ahonen J, Neuvonen PJ (1996) The effect of the systemic antimycotics, itraconazole, and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg 82:511\u2013516", "journal-title": "Anesth Analg"}, {"key": "24_CR43", "first-page": "518", "volume": "33", "author": "J Vanakoski", "year": "1995", "unstructured": "Vanakoski J, Mattila MJ, Vanio P, Idaanpaan-Heikkila JJ, Tornwall M (1995) 150 mg fluconazole does not substantially increase the effects of 10 mg midazolam or plasma midazolam concentrations in healthy subjects. Int J Clin Phrmacol Ther 33:518\u2013523", "journal-title": "Int J Clin Phrmacol Ther"}, {"key": "24_CR44", "doi-asserted-by": "publisher", "first-page": "130", "DOI": "10.1016/S0952-8180(97)00237-7", "volume": "9", "author": "DJ Reinhart", "year": "1997", "unstructured": "Reinhart DJ, Grum DR, Berry J et al (1997) Outpatient general anesthesia: a comparison of a combination of midazolam plus propofol and propofol alone. J Clin Anesth 9:130\u2013137", "journal-title": "J Clin Anesth"}, {"key": "24_CR45", "doi-asserted-by": "publisher", "first-page": "195", "DOI": "10.1097/01.mpg.0000228099.04702.39", "volume": "43", "author": "GA Paspatis", "year": "2006", "unstructured": "Paspatis GA, Charoniti I, Manolaraki M et al (2006) Synergistic sedation with oral midazolam as a premedication and intravenous propofol versus intravenous propofol alone in upper gastrointestinal endoscopies in children: a prospective randomized study. J Pediatr Gastroenterol Nutr 43:195\u2013199", "journal-title": "J Pediatr Gastroenterol Nutr"}, {"key": "24_CR46", "first-page": "213", "volume": "69", "author": "HR Vinil", "year": "1989", "unstructured": "Vinil HR, Bradley EL, Kissin I (1989) Midazolam-alfentanil synergism for anesthetic induction in patients. Anesth Analg 69:213\u2013217", "journal-title": "Anesth Analg"}, {"key": "24_CR47", "first-page": "182", "volume": "85", "author": "I Kissin", "year": "1997", "unstructured": "Kissin I, Lee SS, Arthur GR et al (1997) Effect of midazolam on development of acute tolerance to alfentanil: the role of pharmacokinetic interactions. Anesth Analg 85:182\u2013187", "journal-title": "Anesth Analg"}, {"key": "24_CR48", "doi-asserted-by": "publisher", "first-page": "367", "DOI": "10.1016/0952-8180(91)90177-O", "volume": "3", "author": "I Kissin", "year": "1991", "unstructured": "Kissin I, Vinik HR, Bradley EL (1991) Midazolam potentiates thiopental sodium anesthetic induction in patients. J Clin Anesth 3:367\u2013370", "journal-title": "J Clin Anesth"}, {"key": "24_CR49", "first-page": "342", "volume": "67", "author": "M Tverskoy", "year": "1988", "unstructured": "Tverskoy M, Fleyshman G, Bradley EL, Kissin I (1988) Midazolam-thiopental anesthetic induction in patients. Anesth Analg 67:342\u2013345", "journal-title": "Anesth Analg"}, {"key": "24_CR50", "doi-asserted-by": "publisher", "first-page": "354", "DOI": "10.1213/00000539-199402000-00026", "volume": "78", "author": "HR Vinik", "year": "1994", "unstructured": "Vinik HR, Bradley EL, Kissin I (1994) Triple anesthetic combination: propofol-midazolam-alfentanil. Anesth Analg 78:354\u2013358", "journal-title": "Anesth Analg"}, {"key": "24_CR51", "doi-asserted-by": "publisher", "first-page": "213", "DOI": "10.1124/dmd.113.054874", "volume": "42", "author": "F Li", "year": "2014", "unstructured": "Li F, Lu J, Ma X (2014) CYP3A4 mediated \u03b1-hydroxyaldehyde formation in saquinavir metabolism. Drug Metab Dispos 42:213\u2013220", "journal-title": "Drug Metab Dispos"}, {"key": "24_CR52", "doi-asserted-by": "publisher", "first-page": "33", "DOI": "10.1016/S0009-9236(99)70051-2", "volume": "66", "author": "VJ Palkama", "year": "1999", "unstructured": "Palkama VJ, Ahonen J, Neuvonen PJ, Olkkola KT (1999) Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam. Clin Pharmacol Ther 66:33\u201339", "journal-title": "Clin Pharmacol Ther"}, {"key": "24_CR53", "first-page": "667", "volume": "95", "author": "A Ibrahim", "year": "2002", "unstructured": "Ibrahim A, Karim A, Feldman J, Kharasch E (2002) The influence of parecoxib, a parenteral cyclooxygenase-2 specific inhibitor on the pharmacokinetics and clinical effects of midazolam. Anesth Analg 95:667\u2013673", "journal-title": "Anesth Analg"}, {"key": "24_CR54", "doi-asserted-by": "publisher", "first-page": "353", "DOI": "10.1007/BF03017322", "volume": "49", "author": "A Drague", "year": "2002", "unstructured": "Drague A, Varin F, Plaud B, Donati F (2002) Rocuronium pharmacokinetic and pharmacodynamics relationship under stable propofol or isoflurane anesthesia. Can J Anesth 49:353\u2013360", "journal-title": "Can J Anesth"}, {"key": "24_CR55", "doi-asserted-by": "publisher", "first-page": "509", "DOI": "10.1097/00000542-197111000-00011", "volume": "35", "author": "RD Miller", "year": "1971", "unstructured": "Miller RD, Way WL, Dolan WM et al (1971) Comparative neuromuscular effects of pancuronium, gallamine, and succinylcholine during Forane and halothane anesthesia in man. Anesthesiology 35:509\u2013514", "journal-title": "Anesthesiology"}, {"key": "24_CR56", "doi-asserted-by": "publisher", "first-page": "536", "DOI": "10.1213/00000539-199210000-00012", "volume": "75", "author": "GJ McCarthy", "year": "1992", "unstructured": "McCarthy GJ, Mirakhur RK, Pandit SK (1992) Lack of interaction between propofol and vecuronium. Anesth Analg 75:536\u2013538", "journal-title": "Anesth Analg"}, {"key": "24_CR57", "doi-asserted-by": "publisher", "first-page": "493", "DOI": "10.1007/s001010050429", "volume": "46", "author": "F Latorre", "year": "1997", "unstructured": "Latorre F, de Almeida MC, Stanek A, Kleemann PP (1997) The interaction between rocuronium and smoking. The effect of smoking on neuromuscular transmission after rocuronium. Anaesthesist 46:493\u2013495", "journal-title": "Anaesthesist"}, {"issue": "4", "key": "24_CR58", "doi-asserted-by": "publisher", "first-page": "504", "DOI": "10.1093/bja/80.4.504", "volume": "80", "author": "T Fuchs-Buder", "year": "1998", "unstructured": "Fuchs-Buder T, Sparr HJ, Ziegenfub T (1998) Thiopental or etomidate for rapid sequence induction with rocuronium. Br J Anesth 80(4):504\u2013506", "journal-title": "Br J Anesth"}, {"key": "24_CR59", "doi-asserted-by": "publisher", "first-page": "275", "DOI": "10.2165/00003088-199631040-00004", "volume": "31", "author": "J Scholz", "year": "1996", "unstructured": "Scholz J, Steinfath M, Schulz M (1996) Clinical pharmacokinetics of alfentanil, fentanyl, and sufentanil. An update. Clin Pharmacokinet 31:275\u2013292", "journal-title": "Clin Pharmacokinet"}, {"issue": "Suppl 11", "key": "24_CR60", "first-page": "S276", "volume": "17", "author": "BR Overholsen", "year": "2011", "unstructured": "Overholsen BR, Foster DR (2011) Opioid pharmacokinetic drug-drug interactions. Am J Manag Care 17(Suppl 11):S276\u2013S287", "journal-title": "Am J Manag Care"}, {"key": "24_CR61", "first-page": "1072", "volume": "25", "author": "RB Labroo", "year": "1997", "unstructured": "Labroo RB, Paine MF, Thummel KE, Kharasch ED (1997) Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy, and drug interactions. Drug Metab Dispos 25:1072\u20131080", "journal-title": "Drug Metab Dispos"}, {"key": "24_CR62", "doi-asserted-by": "publisher", "first-page": "100", "DOI": "10.1038/clpt.2011.59", "volume": "90", "author": "ED Kharasch", "year": "2011", "unstructured": "Kharasch ED, Francis A, London A et al (2011) Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimal and noninvasive probes for hepatic and first-pass CYP3A induction. Clin Pharmacol Ther 90:100\u2013108", "journal-title": "Clin Pharmacol Ther"}, {"key": "24_CR63", "doi-asserted-by": "publisher", "first-page": "260", "DOI": "10.1097/00000542-199302000-00008", "volume": "78", "author": "RR Bartkowski", "year": "1993", "unstructured": "Bartkowski RR, Goldberg ME, Huffnagle S, Epstein RH (1993) Sufentanil disposition. Is it affected by erythromycin administration? Anesthesiology 78:260\u2013265", "journal-title": "Anesthesiology"}, {"key": "24_CR64", "doi-asserted-by": "publisher", "first-page": "598", "DOI": "10.1093/bja/81.4.598", "volume": "81", "author": "VJ Palkama", "year": "1998", "unstructured": "Palkama VJ, Neuvonen PJ, Olkkola KT (1998) The CYP3A4 inhibitor itraconazole has no effect on the pharmacokinetics of iv fentanyl. Br J Anaesth 81:598\u2013600", "journal-title": "Br J Anaesth"}, {"key": "24_CR65", "doi-asserted-by": "publisher", "first-page": "913", "DOI": "10.1097/00000542-200204000-00019", "volume": "96", "author": "C Wandel", "year": "2002", "unstructured": "Wandel C, Kim R, Wood M, Wood A (2002) Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein. Anesthesiology 96:913\u2013920", "journal-title": "Anesthesiology"}, {"key": "24_CR66", "doi-asserted-by": "publisher", "first-page": "99", "DOI": "10.1038/clpt.1989.112", "volume": "46", "author": "RR Bartkowski", "year": "1989", "unstructured": "Bartkowski RR, Goldberg ME, Larijani GE, Boerner T (1989) Inhibition of alfentanil metabolism by erythromycin. Clin Pharmacol Ther 46:99\u2013102", "journal-title": "Clin Pharmacol Ther"}, {"key": "24_CR67", "doi-asserted-by": "publisher", "first-page": "36", "DOI": "10.1097/00000542-199707000-00006", "volume": "87", "author": "ED Kharasch", "year": "1997", "unstructured": "Kharasch ED, Russell M, Mautz D et al (1997) The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. Anesthesiology 87:36\u201350", "journal-title": "Anesthesiology"}, {"key": "24_CR68", "first-page": "581", "volume": "10", "author": "MA Clotz", "year": "1991", "unstructured": "Clotz MA, Nahata MC (1991) Clinical uses of fentanyl, sufentanil, and alfentanil. Clin Pharm 10:581\u2013593", "journal-title": "Clin Pharm"}, {"key": "24_CR69", "doi-asserted-by": "publisher", "first-page": "1441", "DOI": "10.1086/598327", "volume": "48", "author": "RJ Bruggemann", "year": "2009", "unstructured": "Bruggemann RJ, Alffenaar JW, Blijilevens NM et al (2009) Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 48:1441\u20131458", "journal-title": "Clin Infect Dis"}, {"key": "24_CR70", "first-page": "190", "volume": "87", "author": "VJ Palkama", "year": "1998", "unstructured": "Palkama VJ, Isohanni MH, Neuvonen PJ, Olkkola KT (1998) The effect of intravenous and oral fluconazole on the pharmacokinetics and pharmacodynamics of intravenous alfentanil. Anesth Analg 87:190\u2013194", "journal-title": "Anesth Analg"}, {"key": "24_CR71", "doi-asserted-by": "publisher", "first-page": "2592", "DOI": "10.1093/jac/dkt229", "volume": "68", "author": "MJ Geist", "year": "2013", "unstructured": "Geist MJ, Eqerer G, Burhenne J et al (2013) Steady-state pharmacokinetics and metabolism of voriconazole in patients. J Antimicrob Chemother 68:2592\u20132599", "journal-title": "J Antimicrob Chemother"}, {"key": "24_CR72", "doi-asserted-by": "publisher", "first-page": "502", "DOI": "10.1016/j.clpt.2006.07.008", "volume": "80", "author": "TI Saari", "year": "2006", "unstructured": "Saari TI, Laine K, Leino K et al (2006) Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life. Clin Pharmacol Ther 80:502\u2013508", "journal-title": "Clin Pharmacol Ther"}, {"key": "24_CR73", "doi-asserted-by": "publisher", "first-page": "1246", "DOI": "10.1097/00000542-199612000-00004", "volume": "85", "author": "J Ahonen", "year": "1996", "unstructured": "Ahonen J, Olkkola KT, Salmenpera M, Hynyen M, Neuvonen PJ (1996) Effect of diltiazem on midazolam and alfentanil disposition in patients undergoing coronary artery bypass grafting. Anesthesiology 85:1246\u20131252", "journal-title": "Anesthesiology"}, {"key": "24_CR74", "doi-asserted-by": "publisher", "first-page": "662", "DOI": "10.1097/00003643-200308000-00013", "volume": "20", "author": "CG McDonnell", "year": "2003", "unstructured": "McDonnell CG, Malan D, Van Pelt FD, Shorten GD (2003) Elimination of alfentanil delivered by infusion is not altered by the chronic administration of atorvastatin. Eur J Anaesthesiol 20:662\u2013667", "journal-title": "Eur J Anaesthesiol"}, {"key": "24_CR75", "doi-asserted-by": "publisher", "first-page": "23", "DOI": "10.1213/00000539-199401000-00006", "volume": "78", "author": "CL Westmoreland", "year": "1994", "unstructured": "Westmoreland CL, Sbel PS, Gropper A (1994) Fentanyl or alfentanil decreases the minimum alveolar anesthetic concentration of isoflurane in surgical patients. Anesth Analg 78:23\u201328", "journal-title": "Anesth Analg"}, {"key": "24_CR76", "doi-asserted-by": "publisher", "first-page": "681", "DOI": "10.1097/00000542-199909000-00020", "volume": "91", "author": "KT Olkkola", "year": "1999", "unstructured": "Olkkola KT, Palkama VJ, Neuvonen PJ (1999) Ritonavir\u2019s role in reducing fentanyl clearance and prolonging its half-life. Anesthesiology 91:681\u2013685", "journal-title": "Anesthesiology"}, {"key": "24_CR77", "doi-asserted-by": "publisher", "first-page": "185", "DOI": "10.1515/dmdi-2012-0027", "volume": "27", "author": "M Turpeinen", "year": "2012", "unstructured": "Turpeinen M, Zanger M (2012) Cytochrome P4502B6: function, genetics, and clinical relevance. Drug Metabol Drug Interact 27:185\u2013197", "journal-title": "Drug Metabol Drug Interact"}, {"key": "24_CR78", "doi-asserted-by": "publisher", "first-page": "227", "DOI": "10.1007/978-3-540-74806-9_11", "volume": "182", "author": "C Vanlersberghne", "year": "2008", "unstructured": "Vanlersberghne C, Camu F (2008) Prpofol. Handb Exp Pharmacol 182:227\u2013252", "journal-title": "Handb Exp Pharmacol"}, {"key": "24_CR79", "doi-asserted-by": "publisher", "first-page": "692", "DOI": "10.1038/npp.2010.202", "volume": "36", "author": "JY Khokhar", "year": "2011", "unstructured": "Khokhar JY, Tyndale RF (2011) Drug metabolism within the bran changes drug response: selective manipulation of brain CYP2B alters propofol effects. Neuropsychopharmacology 36:692\u2013700", "journal-title": "Neuropsychopharmacology"}, {"issue": "Suppl 1", "key": "24_CR80", "doi-asserted-by": "publisher", "first-page": "35", "DOI": "10.1111/j.1365-2044.1998.53s109.x", "volume": "53", "author": "J Vuyk", "year": "1998", "unstructured": "Vuyk J (1998) TCI: supplementation and drug interactions. Anesthesia 53(Suppl 1):35\u201341", "journal-title": "Anesthesia"}, {"key": "24_CR81", "first-page": "445", "volume": "52", "author": "J Vuyk", "year": "2001", "unstructured": "Vuyk J (2001) Clinical interpretation of pharmacokinetic and pharmacodynamics propofol-opioid interactions. Acta Anaesthesiol Belg 52:445\u2013451", "journal-title": "Acta Anaesthesiol Belg"}, {"key": "24_CR82", "doi-asserted-by": "publisher", "first-page": "252", "DOI": "10.1097/ALN.0b013e31825fb1b2", "volume": "117", "author": "CD LaPierre", "year": "2012", "unstructured": "LaPierre CD, Johnson KB, Randall BR, Egan TD (2012) A simulation study of common propofol and propofol-opioid dosing regimens for upper endoscopy. Anesthesiology 117:252\u2013262", "journal-title": "Anesthesiology"}, {"key": "24_CR83", "doi-asserted-by": "publisher", "first-page": "288", "DOI": "10.1097/00000542-199602000-00006", "volume": "81", "author": "J Vuyk", "year": "1996", "unstructured": "Vuyk J, Engbers FH, Burn AG et al (1996) Pharmacodynamic interaction between propofol and alfentanil when given for induction of anesthesia. Anesthesiology 81:288\u2013299", "journal-title": "Anesthesiology"}, {"key": "24_CR84", "doi-asserted-by": "publisher", "first-page": "727", "DOI": "10.1097/00000542-200003000-00017", "volume": "92", "author": "J Schutter", "year": "2000", "unstructured": "Schutter J, Ihmsen H (2000) Population pharmacokinetics of propofol: a multicenter study. Anesthesiology 92:727\u2013738", "journal-title": "Anesthesiology"}, {"key": "24_CR85", "doi-asserted-by": "publisher", "first-page": "981", "DOI": "10.1007/BF01700659", "volume": "21", "author": "C Fenkel", "year": "1995", "unstructured": "Fenkel C, Schutter J, Ihmsen H, Heye H, Rommelsheim K (1995) Pharmacokinetics and pharmacodynamics of propofol/alfentanil infusions for sedation in ICU patients. Intensive Care Med 21:981\u2013988", "journal-title": "Intensive Care Med"}, {"key": "24_CR86", "doi-asserted-by": "publisher", "first-page": "795", "DOI": "10.1097/00000542-200404000-00008", "volume": "100", "author": "MJ Mertens", "year": "2004", "unstructured": "Mertens MJ, Olofsen E, Burn AG, Bovill JG, Vuyk J (2004) Mixed-effects modeling of the influence of alfentanil on propofol pharmacokinetics. Anesthesiology 100:795\u2013805", "journal-title": "Anesthesiology"}, {"key": "24_CR87", "doi-asserted-by": "publisher", "first-page": "23", "DOI": "10.1097/00000542-199601000-00004", "volume": "84", "author": "DJ Pavlin", "year": "1996", "unstructured": "Pavlin DJ, Coda B, Shen DD et al (1996) Effects of combining propofol and alfentanil on ventilation, analgesia, sedation, and emesis in human volunteers. Anesthesiology 84:23\u201337", "journal-title": "Anesthesiology"}, {"key": "24_CR88", "doi-asserted-by": "publisher", "first-page": "1377", "DOI": "10.1097/00000542-200406000-00007", "volume": "100", "author": "SE Kern", "year": "2004", "unstructured": "Kern SE, Xie G, Whiye D, Egan TD (2004) A response surface analysis of propofol-alfentanil pharmacodynamics interaction. Anesthesiology 100:1377\u20131381", "journal-title": "Anesthesiology"}, {"key": "24_CR89", "doi-asserted-by": "publisher", "first-page": "208", "DOI": "10.1093/bja/aeq334", "volume": "106", "author": "S Yufune", "year": "2011", "unstructured": "Yufune S, Takamatsu I, Masui K, Kazama T (2011) Effect of remifentanil on plasma propofol concentration and bispectral during propofol anesthesia. Br J Anesth 106:208\u2013214", "journal-title": "Br J Anesth"}, {"key": "24_CR90", "doi-asserted-by": "publisher", "first-page": "240", "DOI": "10.1093/bja/69.3.240", "volume": "69", "author": "S McClune", "year": "1992", "unstructured": "McClune S, McKay AC, Wright PM et al (1992) Synergistic interaction between midazolam and propofol. Br J Aneasth 69:240\u2013245", "journal-title": "Br J Aneasth"}, {"key": "24_CR91", "doi-asserted-by": "publisher", "first-page": "618", "DOI": "10.1007/s00540-011-1176-6", "volume": "25", "author": "J Ohmori", "year": "2011", "unstructured": "Ohmori J, Maeda S, Higuchi H et al (2011) Propofol increases the rate of albumin-unbound free midazolam in serum albumin solution. J Anesth 25:618\u2013620", "journal-title": "J Anesth"}, {"key": "24_CR92", "doi-asserted-by": "publisher", "first-page": "324", "DOI": "10.1016/j.clpt.2003.12.004", "volume": "75", "author": "H Hiraoka", "year": "2004", "unstructured": "Hiraoka H, Yamamoto K, Okano N et al (2004) Changes in drug plasma concentrations of an extensively bound and highly extracted drug, propofol, in response to altered plasma binding. Clin Pharmacol Ther 75:324\u2013330", "journal-title": "Clin Pharmacol Ther"}, {"key": "24_CR93", "doi-asserted-by": "publisher", "first-page": "1522", "DOI": "10.1213/ane.0b013e31819e4058", "volume": "108", "author": "J Vuyk", "year": "2009", "unstructured": "Vuyk J, Lichtenbelt BJ, Olofsen E, van Kleef JW, Dahan A (2009) Mixed-effects modeling of the influence of midazolam on propofol pharmacokinetics. Anesth Analg 108:1522\u20131530", "journal-title": "Anesth Analg"}, {"key": "24_CR94", "doi-asserted-by": "publisher", "first-page": "1597", "DOI": "10.1213/ANE.0b013e3181da91bb", "volume": "110", "author": "BJ Lichtenbelt", "year": "2010", "unstructured": "Lichtenbelt BJ, Olofsen E, Dahan A et al (2010) Propofol reduces the distribution and clearance of midazolam. Anesth Analg 110:1597\u20131606", "journal-title": "Anesth Analg"}, {"key": "24_CR95", "doi-asserted-by": "publisher", "first-page": "364", "DOI": "10.1097/00000542-199702000-00011", "volume": "86", "author": "JW Johnson", "year": "1997", "unstructured": "Johnson JW, Flaishon R, Sebel PS (1997) Esmolol reduces anesthetic requirement for skin incision during propofol/nitrous oxide/morphine anesthesia. Anesthesiology 86:364\u2013371", "journal-title": "Anesthesiology"}, {"key": "24_CR96", "doi-asserted-by": "publisher", "first-page": "458", "DOI": "10.1111/j.1399-6576.1993.tb03746.x", "volume": "37", "author": "JA Davison", "year": "1993", "unstructured": "Davison JA, MacLeod AD, Howie JC, White M, Kenny GN (1993) Effective concentration 50 for propofol with and without 67% nitrous oxide. Acta Anesthesiol Scand 37:458\u2013464", "journal-title": "Acta Anesthesiol Scand"}, {"key": "24_CR97", "doi-asserted-by": "publisher", "first-page": "61", "DOI": "10.1213/ANE.0b013e318292cbd0", "volume": "117", "author": "H Mirzakhani", "year": "2013", "unstructured": "Mirzakhani H, Nozari A, Ehremfeld JM et al (2013) Profound hypotension after anesthetic induction with propofol in patients treated with rifampin. Anesth Analg 117:61\u201364", "journal-title": "Anesth Analg"}, {"key": "24_CR98", "doi-asserted-by": "publisher", "first-page": "885", "DOI": "10.1007/s00540-013-1625-5", "volume": "27", "author": "T Toyoda", "year": "2013", "unstructured": "Toyoda T, Terao Y, Oji M et al (2013) The interaction of antiemetic dose of droperidol with propofol on QT interval during anesthetic induction. J Anesth 27:885\u2013889", "journal-title": "J Anesth"}, {"key": "24_CR99", "doi-asserted-by": "publisher", "first-page": "88", "DOI": "10.1097/00000542-200201000-00020", "volume": "96", "author": "A Ibrahim", "year": "2002", "unstructured": "Ibrahim A, Park S, Feldman J, Karin A, Kharasch ED (2002) Effects of parecoxib, a parenteral COX-2 specific inhibitor, on the pharmacokinetics and pharmacodynamics of propofol. Anesthesiology 96:88\u201395", "journal-title": "Anesthesiology"}, {"key": "24_CR100", "doi-asserted-by": "publisher", "first-page": "1448", "DOI": "10.1126/science.6258230", "volume": "211", "author": "P Skolnick", "year": "1981", "unstructured": "Skolnick P, Moncada V, Barker JL, Paul SM (1981) Pentobarbital: dual actions in increase benzodiazepine receptor affinity. Science 211:1448\u20131450", "journal-title": "Science"}, {"key": "24_CR101", "doi-asserted-by": "publisher", "first-page": "493", "DOI": "10.1002/jps.2600820512", "volume": "82", "author": "H Russo", "year": "1993", "unstructured": "Russo H, Audran M, Bressolle F, Bres J, Mailols H (1993) Displacement of thiopental from human serum albumin by associated drugs. J Pharm Sci 82:493\u2013497", "journal-title": "J Pharm Sci"}, {"key": "24_CR102", "doi-asserted-by": "publisher", "first-page": "4", "DOI": "10.1093/bja/67.1.4", "volume": "67", "author": "M Naguib", "year": "1991", "unstructured": "Naguib M, Sari-Kouzel AS (1991) Thiopental-propofol hypnotic synergism in patients. Br J Anesth 67:4\u20136", "journal-title": "Br J Anesth"}, {"key": "24_CR103", "doi-asserted-by": "publisher", "first-page": "590", "DOI": "10.1093/bja/83.4.590", "volume": "83", "author": "OH Wilder-Smith", "year": "1999", "unstructured": "Wilder-Smith OH, Rvussin PA, Decosterd LA et al (1999) Midazolam premedication and thiopental induction of anesthesia: interactions at multiple end-points. Br J Anesth 83:590\u2013595", "journal-title": "Br J Anesth"}, {"key": "24_CR104", "doi-asserted-by": "publisher", "first-page": "523", "DOI": "10.1213/00000539-199210000-00010", "volume": "75", "author": "R Telford", "year": "1992", "unstructured": "Telford R, Glass PSA, Goodman D, Jacobs JR (1992) Fentanyl does not alter the \u201csleep\u201d plasma concentration of thiopental. Anesth Analg 75:523\u2013529", "journal-title": "Anesth Analg"}, {"key": "24_CR105", "doi-asserted-by": "publisher", "first-page": "1448", "DOI": "10.1213/01.ane.0000244534.24216.3a", "volume": "103", "author": "M Naguib", "year": "2006", "unstructured": "Naguib M, Samarkandi AH, Moniem MA et al (2006) The effects of melatonin premedication on propofol and thiopental induction dose-response curves: a prospective, randomized, double-blind study. Anesth Analg 103:1448\u20131452", "journal-title": "Anesth Analg"}, {"key": "24_CR106", "doi-asserted-by": "publisher", "first-page": "28", "DOI": "10.1097/00000542-199307000-00007", "volume": "79", "author": "JL Lichtor", "year": "1993", "unstructured": "Lichtor JL, Zacny JP, Coalson DW et al (1993) The interaction between alcohol and the residual effects of thiopental anesthesia. Anesthesiology 79:28\u201335", "journal-title": "Anesthesiology"}, {"key": "24_CR107", "doi-asserted-by": "publisher", "first-page": "36", "DOI": "10.1097/00000542-198601000-00007", "volume": "64", "author": "M Ghigone", "year": "1986", "unstructured": "Ghigone M, Quintin L, Duke PC et al (1986) Effects of clonidine on narcotic requirements and hemodynamic response during induction of fentanyl anesthesia and endotracheal intubation. Anesthesiology 64:36\u201342", "journal-title": "Anesthesiology"}, {"key": "24_CR108", "doi-asserted-by": "publisher", "first-page": "530", "DOI": "10.1213/00000539-199210000-00011", "volume": "75", "author": "K Leslie", "year": "1992", "unstructured": "Leslie K, Mooney PH, Silbert BS (1992) Effect of intravenous clonidine on the dose of thiopental required to induce anesthesia. Anesth Analg 75:530\u2013535", "journal-title": "Anesth Analg"}, {"key": "24_CR109", "doi-asserted-by": "publisher", "first-page": "537", "DOI": "10.1038/clpt.1992.182", "volume": "52", "author": "H Schein", "year": "1992", "unstructured": "Schein H, Karhuvaara S, Olkkola KT et al (1992) Pharmacodynamics and pharmacokinetics of intramuscular dexmedetomidine. Clin Pharmacol Ther 52:537\u2013546", "journal-title": "Clin Pharmacol Ther"}, {"key": "24_CR110", "doi-asserted-by": "publisher", "first-page": "1216", "DOI": "10.1097/00000542-199406000-00008", "volume": "80", "author": "M Buhrer", "year": "1994", "unstructured": "Buhrer M, Mappes A, Lauber R, Stanski DR, Mailtre PO (1994) Dexmedetomidine decreases thiopental dose requirements and alter distribution pharmacokinetics. Anesthesiology 80:1216\u20131227", "journal-title": "Anesthesiology"}, {"key": "24_CR111", "first-page": "307", "volume": "9", "author": "L Roytbalt", "year": "1992", "unstructured": "Roytbalt L, Katz J, Rozentsveig V (1992) Anesthetic interaction between thiopentone and ketamine. Eur J Anesth 9:307\u2013312", "journal-title": "Eur J Anesth"}, {"key": "24_CR112", "first-page": "43", "volume": "9", "author": "G Manani", "year": "1992", "unstructured": "Manani G, Valenti S, Vincenti E et al (1992) Interaction between thiopentone and subhypnotic doses of ketamine. Eur J Anesth 9:43\u201347", "journal-title": "Eur J Anesth"}, {"key": "24_CR113", "doi-asserted-by": "publisher", "first-page": "609", "DOI": "10.1034/j.1399-6576.2002.460522.x", "volume": "46", "author": "O Stibolt", "year": "2002", "unstructured": "Stibolt O, Wachowiak-Andersen G (2002) Altered response to intravenous thiopental and succinylcholine in acute amphetamine abuse. Acta Anesthesiol Scand 46:609\u2013610", "journal-title": "Acta Anesthesiol Scand"}, {"key": "24_CR114", "doi-asserted-by": "publisher", "first-page": "437", "DOI": "10.1517/17425255.2014.882317", "volume": "10", "author": "M Christofaki", "year": "2014", "unstructured": "Christofaki M, Papaionnou A (2014) Ondansetron: a review of pharmacokinetic and clinical experience in postoperative nausea and vomiting. Exp Opin Drug Metab Toxic 10:437\u2013444", "journal-title": "Exp Opin Drug Metab Toxic"}, {"key": "24_CR115", "first-page": "825", "volume": "38", "author": "G Kostopanagiotou", "year": "1998", "unstructured": "Kostopanagiotou G, Pouriezis T, Theodoraki K et al (1998) Influence of ondansetron on thiopental hypnotic requirements. J Clin Pharmacol 38:825\u2013829", "journal-title": "J Clin Pharmacol"}, {"key": "24_CR116", "doi-asserted-by": "publisher", "first-page": "1667", "DOI": "10.1007/s00228-013-1527-3", "volume": "69", "author": "A Marsot", "year": "2013", "unstructured": "Marsot A, Goirand F, Milesi N et al (2013) Interaction of thiopental with esomeprazole in critically ill patients. Eur J Clin Pharmacol 69:1667\u20131672", "journal-title": "Eur J Clin Pharmacol"}, {"key": "24_CR117", "doi-asserted-by": "publisher", "first-page": "784", "DOI": "10.1213/00000539-199310000-00023", "volume": "77", "author": "D Mehta", "year": "1993", "unstructured": "Mehta D, Bradley EL, Kissin I (1993) Metoclopramide decreases thiopental hypnotic requirements. Anesth Analg 77:784\u2013787", "journal-title": "Anesth Analg"}, {"key": "24_CR118", "doi-asserted-by": "publisher", "first-page": "231", "DOI": "10.1111/j.1399-6576.1993.tb03707.x", "volume": "37", "author": "LQ Christensen", "year": "1993", "unstructured": "Christensen LQ, Bonde J, Kampmann JP (1993) Drug interactions with inhalational anaesthetics. Acta Anaesthesiol Scand 37:231\u2013244", "journal-title": "Acta Anaesthesiol Scand"}, {"key": "24_CR119", "doi-asserted-by": "publisher", "first-page": "285", "DOI": "10.2165/00003088-199121040-00005", "volume": "21", "author": "M Wood", "year": "1991", "unstructured": "Wood M (1991) Pharmacokinetic drug interactions in anaesthetic practice. Clin Pharmacokinet 21:285\u2013307", "journal-title": "Clin Pharmacokinet"}, {"key": "24_CR120", "doi-asserted-by": "publisher", "first-page": "494", "DOI": "10.1213/ane.0b013e31817b859e", "volume": "107", "author": "JF Hendricks", "year": "2008", "unstructured": "Hendricks JF, Eger EI, Sonner JM, Shafer SL (2008) Is synergy the rule? A review of anesthetic interactions producing hypnosis and immobility. Anesth Analg 107:494\u2013506", "journal-title": "Anesth Analg"}, {"key": "24_CR121", "doi-asserted-by": "publisher", "first-page": "18", "DOI": "10.2165/00003088-198611010-00002", "volume": "11", "author": "PJ Davis", "year": "1986", "unstructured": "Davis PJ, Cook DR (1986) Clinical pharmacokinetics of the newer intravenous anaesthetic agents. Clin Pharmacokinet 11:18\u201335", "journal-title": "Clin Pharmacokinet"}], "container-title": ["Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents"], "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/978-3-319-27883-4_24", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 9, 5]], "date-time": "2019-09-05T05:19:41Z", "timestamp": 1567660781000}, "score": 24.483189, "issued": {"date-parts": [[2016]]}, "ISBN": ["9783319278810", "9783319278834"], "references-count": 121, "URL": "http://dx.doi.org/10.1007/978-3-319-27883-4_24", "relation": {"cites": []}}, {"indexed": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T21:00:33Z", "timestamp": 1574283633839}, "reference-count": 0, "publisher": "Springer Science and Business Media LLC", "issue": "2", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Clinical Pharmacokinetics"], "published-print": {"date-parts": [[1993, 2]]}, "DOI": "10.2165/00003088-199324020-00005", "type": "journal-article", "created": {"date-parts": [[2009, 3, 5]], "date-time": "2009-03-05T00:04:24Z", "timestamp": 1236211464000}, "page": "161-176", "source": "Crossref", "is-referenced-by-count": 122, "title": ["Pharmacokinetics and Pharmacodynamics of Clozapine"], "prefix": "10.1007", "volume": "24", "author": [{"given": "Michael W.", "family": "Jann", "sequence": "first", "affiliation": []}, {"given": "Sara R.", "family": "Grimsley", "sequence": "additional", "affiliation": []}, {"given": "Eric C.", "family": "Gray", "sequence": "additional", "affiliation": []}, {"given": "Wen-Ho", "family": "Chang", "sequence": "additional", "affiliation": []}], "member": "297", "container-title": ["Clinical Pharmacokinetics"], "language": "en", "deposited": {"date-parts": [[2013, 1, 20]], "date-time": "2013-01-20T14:58:48Z", "timestamp": 1358693928000}, "score": 23.044146, "subtitle": [""], "issued": {"date-parts": [[1993, 2]]}, "references-count": 0, "journal-issue": {"issue": "2"}, "URL": "http://dx.doi.org/10.2165/00003088-199324020-00005", "ISSN": ["0312-5963"], "issn-type": [{"value": "0312-5963", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T07:14:06Z", "timestamp": 1574147646208}, "reference-count": 80, "publisher": "Wiley", "issue": "12", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 3926, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Pharmacotherapy"], "published-print": {"date-parts": [[2004, 12]]}, "DOI": "10.1592/phco.24.17.1759.52346", "type": "journal-article", "created": {"date-parts": [[2004, 11, 15]], "date-time": "2004-11-15T20:10:40Z", "timestamp": 1100549440000}, "page": "1759-1783", "source": "Crossref", "is-referenced-by-count": 31, "title": ["Implications for Atypical Antipsychotics in the Treatment of Schizophrenia: Neurocognition Effects and a Neuroprotective Hypothesis"], "prefix": "10.1002", "volume": "24", "author": [{"given": "Michael W.", "family": "Jann", "sequence": "first", "affiliation": []}], "member": "311", "reference": [{"key": "ref3", "DOI": "10.1016/S0006-3223(01)01303-8", "doi-asserted-by": "publisher"}, {"key": "ref4", "author": "Green", "volume": "153", "first-page": "321", "year": "1996", "journal-title": "Am J Psychiatry", "DOI": "10.1176/ajp.153.3.321", "doi-asserted-by": "crossref"}, {"key": "ref5", "DOI": "10.1016/S0006-3223(01)01293-8", "doi-asserted-by": "publisher"}, {"key": "ref6", "DOI": "10.1124/mi.3.1.27", "doi-asserted-by": "publisher"}, {"key": "ref7", "DOI": "10.1126/science.1092132", "doi-asserted-by": "publisher"}, {"key": "ref8", "DOI": "10.1001/archpsyc.58.2.148", "doi-asserted-by": "publisher"}, {"key": "ref9", "DOI": "10.1002/syn.890010203", "doi-asserted-by": "publisher"}, {"key": "ref10", "DOI": "10.1016/S0006-3223(02)01541-X", "doi-asserted-by": "publisher"}, {"key": "ref11", "DOI": "10.1016/S0006-3223(02)01675-X", "doi-asserted-by": "publisher"}, {"key": "ref12", "DOI": "10.1016/S0006-3223(03)00185-9", "doi-asserted-by": "publisher"}, {"key": "ref13", "author": "Stanley", "volume": "52", "first-page": "399", "year": "1995", "journal-title": "Arch Gen Psychiatry", "DOI": "10.1001/archpsyc.1995.03950170073010", "doi-asserted-by": "crossref"}, {"key": "ref14", "DOI": "10.1016/S0006-3223(01)01252-5", "doi-asserted-by": "publisher"}, {"key": "ref15", "DOI": "10.1176/appi.ajp.159.4.652", "doi-asserted-by": "publisher"}, {"key": "ref16", "DOI": "10.1016/S0006-3223(02)01416-6", "doi-asserted-by": "publisher"}, {"key": "ref17", "DOI": "10.1016/S0006-3223(01)01251-3", "doi-asserted-by": "publisher"}, {"key": "ref18", "DOI": "10.1016/S0920-9964(97)00079-0", "doi-asserted-by": "publisher"}, {"key": "ref19", "author": "Tamminga", "volume": "12", "first-page": "21", "year": "1998", "journal-title": "Crit Rev Neurobiol", "DOI": "10.1615/CritRevNeurobiol.v12.i1-2.20", "doi-asserted-by": "crossref"}, {"key": "ref20", "DOI": "10.1345/aph.19146", "doi-asserted-by": "publisher"}, {"key": "ref21", "DOI": "10.1176/appi.ajp.158.9.1367", "doi-asserted-by": "publisher"}, {"key": "ref22", "author": "Leveque", "volume": "20", "first-page": "4011", "year": "2000", "journal-title": "J Neurosci", "DOI": "10.1523/JNEUROSCI.20-11-04011.2000", "doi-asserted-by": "crossref"}, {"key": "ref23", "DOI": "10.1124/jpet.103.052597", "doi-asserted-by": "publisher"}, {"key": "ref24", "DOI": "10.1177/0269881103017001700", "doi-asserted-by": "publisher"}, {"key": "ref25", "DOI": "10.1046/j.1471-4159.1998.71041643.x", "doi-asserted-by": "publisher"}, {"key": "ref26", "DOI": "10.1046/j.1471-4159.2001.00654.x", "doi-asserted-by": "publisher"}, {"key": "ref27", "DOI": "10.1073/pnas.071056198", "doi-asserted-by": "publisher"}, {"key": "ref28", "DOI": "10.1016/S0006-3223(02)01976-5", "doi-asserted-by": "publisher"}, {"key": "ref29", "DOI": "10.1046/j.1471-4159.2003.01866.x", "doi-asserted-by": "publisher"}, {"key": "ref30", "DOI": "10.1016/S0920-9964(01)00378-4", "doi-asserted-by": "publisher"}, {"key": "ref31", "DOI": "10.1016/S0006-3223(03)00075-1", "doi-asserted-by": "publisher"}, {"key": "ref32", "DOI": "10.1124/jpet.102.041616", "doi-asserted-by": "publisher"}, {"key": "ref33", "DOI": "10.1007/s00213-002-1230-z", "doi-asserted-by": "publisher"}, {"key": "ref34", "DOI": "10.1038/sj.npp.1300039", "doi-asserted-by": "publisher"}, {"key": "ref35", "author": "Nemeroff", "volume": "225", "first-page": "337", "year": "1983", "journal-title": "J Pharmacol Exp Ther"}, {"key": "ref36", "DOI": "10.1016/S0006-3223(01)01211-2", "doi-asserted-by": "publisher"}, {"key": "ref37", "DOI": "10.1111/j.1749-6632.1992.tb27350.x", "doi-asserted-by": "publisher"}, {"key": "ref38", "DOI": "10.1126/science.1071553", "doi-asserted-by": "publisher"}, {"key": "ref39", "author": "Lewis", "volume": "3", "first-page": "32", "year": "2003", "journal-title": "Scientist"}, {"key": "ref40", "DOI": "10.1126/science.292.5517.624", "doi-asserted-by": "publisher"}, {"key": "ref41", "DOI": "10.1038/385434a0", "doi-asserted-by": "publisher"}, {"key": "ref42", "DOI": "10.1016/S0006-3223(00)00988-4", "doi-asserted-by": "publisher"}, {"key": "ref43", "DOI": "10.1038/scientificamerican0903-54", "doi-asserted-by": "publisher"}, {"key": "ref44", "DOI": "10.1002/jnr.10440", "doi-asserted-by": "publisher"}, {"key": "ref45", "DOI": "10.1016/S0304-3940(02)00034-4", "doi-asserted-by": "publisher"}, {"key": "ref46", "DOI": "10.1124/jpet.103.053694", "doi-asserted-by": "publisher"}, {"key": "ref47", "DOI": "10.1126/science.1071552", "doi-asserted-by": "publisher"}, {"key": "ref48", "DOI": "10.1002/(SICI)1097-4547(19990401)56:1<72::AID-JNR9>3.0.CO;2-0", "doi-asserted-by": "publisher"}, {"key": "ref49", "DOI": "10.1002/jnr.10290", "doi-asserted-by": "publisher"}, {"key": "ref50", "DOI": "10.1002/jnr.10668", "doi-asserted-by": "publisher"}, {"key": "ref51", "DOI": "10.1016/S0022-3956(02)00048-1", "doi-asserted-by": "publisher"}, {"key": "ref52", "DOI": "10.1046/j.1460-9568.2003.02590.x", "doi-asserted-by": "publisher"}, {"key": "ref53", "DOI": "10.1002/jnr.10281", "doi-asserted-by": "publisher"}, {"key": "ref54", "DOI": "10.1016/S0920-9964(02)00434-6", "doi-asserted-by": "publisher"}, {"key": "ref55", "DOI": "10.1016/S0006-3223(03)00233-6", "doi-asserted-by": "publisher"}, {"key": "ref56", "author": "Muly", "volume": "36", "first-page": "92", "year": "2002", "journal-title": "Psychopharmacol Bull"}, {"key": "ref57", "DOI": "10.1001/archpsyc.57.7.685", "doi-asserted-by": "publisher"}, {"key": "ref58", "DOI": "10.1046/j.1471-4159.2003.02067.x", "doi-asserted-by": "publisher"}, {"key": "ref59", "DOI": "10.1126/science.1089681", "doi-asserted-by": "publisher"}, {"key": "ref60", "DOI": "10.1126/science.1089662", "doi-asserted-by": "publisher"}, {"key": "ref61", "DOI": "10.1016/S0006-3223(02)01701-8", "doi-asserted-by": "publisher"}, {"key": "ref63", "DOI": "10.1016/S0920-9964(98)00166-2", "doi-asserted-by": "publisher"}, {"key": "ref66", "DOI": "10.1097/01.jcp.0000085414.08426.8f", "doi-asserted-by": "publisher"}, {"key": "ref67", "DOI": "10.1038/sj.npp.1300216", "doi-asserted-by": "publisher"}, {"key": "ref68", "DOI": "10.1097/00004714-200110000-00004", "doi-asserted-by": "publisher"}, {"key": "ref69", "DOI": "10.1016/S0920-9964(01)00195-5", "doi-asserted-by": "publisher"}, {"key": "ref70", "DOI": "10.1007/s00213-003-1505-z", "doi-asserted-by": "publisher"}, {"key": "ref71", "DOI": "10.1176/appi.ajp.159.6.1018", "doi-asserted-by": "publisher"}, {"key": "ref72", "DOI": "10.1016/S0006-3223(02)01370-7", "doi-asserted-by": "publisher"}, {"key": "ref74", "DOI": "10.1016/S0920-9964(01)00268-7", "doi-asserted-by": "publisher"}, {"issue": "1", "key": "ref75", "first-page": "S185", "volume": "5", "author": "Cornblatt", "year": "2002", "journal-title": "J Neuropsychopharmacol"}, {"key": "ref76", "DOI": "10.1016/j.schres.2003.07.009", "doi-asserted-by": "publisher"}, {"key": "ref77", "DOI": "10.1002/gps.929", "doi-asserted-by": "publisher"}, {"key": "ref78", "DOI": "10.1016/S0006-3223(98)00287-X", "doi-asserted-by": "publisher"}, {"key": "ref79", "DOI": "10.1097/00002826-200311000-00011", "doi-asserted-by": "publisher"}, {"key": "ref80", "DOI": "10.1056/NEJMoa013128", "doi-asserted-by": "publisher"}, {"key": "ref81", "DOI": "10.1097/00004714-200110000-00005", "doi-asserted-by": "publisher"}, {"key": "ref82", "DOI": "10.1126/science.1088545", "doi-asserted-by": "publisher"}, {"key": "ref83", "author": "Javih", "volume": "290", "first-page": "48", "year": "2004", "journal-title": "Sci Am"}, {"key": "ref84", "DOI": "10.1176/appi.ajp.160.1.24", "doi-asserted-by": "publisher"}, {"key": "ref85", "DOI": "10.1016/S0006-3223(02)01399-9", "doi-asserted-by": "publisher"}, {"key": "ref86", "DOI": "10.1016/S0006-3223(03)00321-4", "doi-asserted-by": "publisher"}], "container-title": ["Pharmacotherapy"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1592%2Fphco.24.17.1759.52346", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "https://onlinelibrary.wiley.com/doi/full/10.1592/phco.24.17.1759.52346", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2018, 12, 22]], "date-time": "2018-12-22T03:09:01Z", "timestamp": 1545448141000}, "score": 22.693768, "issued": {"date-parts": [[2004, 12]]}, "references-count": 80, "journal-issue": {"published-print": {"date-parts": [[2004, 12]]}, "issue": "12"}, "alternative-id": ["10.1592/phco.24.17.1759.52346"], "URL": "http://dx.doi.org/10.1592/phco.24.17.1759.52346", "relation": {"cites": []}, "ISSN": ["0277-0008"], "issn-type": [{"value": "0277-0008", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T12:21:25Z", "timestamp": 1574770885249}, "publisher-location": "Cham", "reference-count": 76, "publisher": "Springer International Publishing", "isbn-type": [{"value": "9783319278810", "type": "print"}, {"value": "9783319278834", "type": "electronic"}], "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2016, 1, 1]], "date-time": "2016-01-01T00:00:00Z", "timestamp": 1451606400000}, "delay-in-days": 0, "content-version": "unspecified"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2016]]}, "DOI": "10.1007/978-3-319-27883-4_13", "type": "book-chapter", "created": {"date-parts": [[2016, 3, 2]], "date-time": "2016-03-02T13:04:48Z", "timestamp": 1456923888000}, "page": "329-349", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Antidementia Drugs"], "prefix": "10.1007", "author": [{"given": "Chad M.", "family": "VanDenBerg", "sequence": "first", "affiliation": []}, {"given": "Michael W.", "family": "Jann", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2016, 3, 3]]}, "reference": [{"key": "13_CR1", "first-page": "817", "volume-title": "Pharmacotherapy: a pathophysiologic approach", "author": "PW Slattum", "year": "2014", "unstructured": "Slattum PW, Peron EP, Hill AM (2014) Alzheimer\u2019s disease. In: DiPiro JT, Talbert RL, Yee GC et al (eds) Pharmacotherapy: a pathophysiologic approach, 9th edn. McGraw-Hill, New York, pp 817\u2013833", "edition": "9"}, {"key": "13_CR2", "first-page": "52", "volume": "6", "author": "CD Steele", "year": "1999", "unstructured": "Steele CD, Steinberg M, Milles G, Jann MW (1999) Recognition and management of early Alzheimer\u2019s disease. JCOM 6:52\u201367", "journal-title": "JCOM"}, {"key": "13_CR3", "doi-asserted-by": "publisher", "first-page": "1011", "DOI": "10.1517/14656566.8.7.1011", "volume": "8", "author": "B Seltzer", "year": "2007", "unstructured": "Seltzer B (2007) Donepezil: an update. Expert Opin Pharmacother 8:1011\u20131023", "journal-title": "Expert Opin Pharmacother"}, {"key": "13_CR4", "doi-asserted-by": "publisher", "first-page": "391", "DOI": "10.1002/1531-8249(200009)48:3<391::AID-ANA17>3.0.CO;2-H", "volume": "48", "author": "DE Kuhl", "year": "2000", "unstructured": "Kuhl DE, Minoshima S, Frey KA, Foster NL, Kilbourn MR, Koeppe RA (2000) Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex. Ann Neurol 48:391\u2013395", "journal-title": "Ann Neurol"}, {"key": "13_CR5", "unstructured": "Jann MW, Small GW (2009) Cholinesterase inhibitors and similarly acting compounds. Chapter 31.15. In: Sadock BJ, Sadock VA, Ruiz R (eds) Comprehensive textbook of psychiatry, 9th edn. Lippincott, Williams, and Wilkens, Philadelphia, PA, pp. 3089\u20133099"}, {"key": "13_CR6", "doi-asserted-by": "publisher", "first-page": "225", "DOI": "10.1007/s40262-013-0038-9", "volume": "52", "author": "M Noetzli", "year": "2013", "unstructured": "Noetzli M, Eap CB (2013) Pharmacodynamic, pharmacokinetic, and pharmacogenetic aspects of drugs used in the treatment of Alzheimer\u2019s disease. Clin Pharmacokinet 52:225\u2013251", "journal-title": "Clin Pharmacokinet"}, {"issue": "Suppl 2", "key": "13_CR7", "doi-asserted-by": "crossref", "first-page": "S22", "DOI": "10.1093/ajhp/55.suppl_2.S22", "volume": "55", "author": "MW Jann", "year": "1998", "unstructured": "Jann MW (1998) Pharmacology and clinical efficacy of cholinesterase inhibitors. Am J Health Syst Pharm 55(Suppl 2):S22\u2013S25", "journal-title": "Am J Health Syst Pharm"}, {"issue": "Suppl B", "key": "13_CR8", "first-page": "7", "volume": "15", "author": "MW Jann", "year": "2000", "unstructured": "Jann MW, Grossberg G (2000) Cholinesterase inhibitors in the treatment of Alzheimer\u2019s disease. Consult Pharm 15(Suppl B):7\u201315", "journal-title": "Consult Pharm"}, {"issue": "5", "key": "13_CR9", "first-page": "223", "volume": "31", "author": "M Mihara", "year": "1993", "unstructured": "Mihara M, Ohnishi A, Tomono Y et al (1993) Pharmacokinetics of E2020, a new compound for Alzheimer\u2019s disease, in healthy male volunteers. Int J Clin Pharmacol Ther Toxicol 31(5):223\u2013229", "journal-title": "Int J Clin Pharmacol Ther Toxicol"}, {"issue": "Suppl 1", "key": "13_CR10", "first-page": "1", "volume": "46", "author": "SL Rogers", "year": "1998", "unstructured": "Rogers SL, Friedhoff LT (1998) Pharmacokinetic and pharmacodynamic profile of donepezil HCl following single oral doses. Br J Clin Pharmacol 46(Suppl 1):1\u20136", "journal-title": "Br J Clin Pharmacol"}, {"key": "13_CR11", "unstructured": "Eisai (2014) ARICEPT\u00ae (donepezil hydrochloride) tablets: prescribing information. Eisai Inc., Woodcliff Lake, NJ"}, {"key": "13_CR12", "unstructured": "FDA (2010) Application number: 022568. Center for Drug Evaluation and Research; Clinical Pharmacology and Biopharmaceutics Review(s)"}, {"issue": "S1", "key": "13_CR13", "doi-asserted-by": "publisher", "first-page": "7", "DOI": "10.1046/j.1365-2125.1998.0460s1007.x", "volume": "46", "author": "C Rogers", "year": "1998", "unstructured": "Rogers C, Sukovaty P, Lee F (1998) Pharmacokinetic and pharmacodynamic profile of donepezil HCl following multiple oral doses. Br J Clin Pharmacol 46(S1):7\u201312", "journal-title": "Br J Clin Pharmacol"}, {"issue": "Suppl 1", "key": "13_CR14", "first-page": "19", "volume": "46", "author": "PJ Tiseo", "year": "1998", "unstructured": "Tiseo PJ, Perdomo CA, Friedhoff LT (1998) Metabolism and elimination of 14C-donepezil in healthy volunteers: a single-dose study. Br J Clin Pharmacol 46(Suppl 1):19\u201324", "journal-title": "Br J Clin Pharmacol"}, {"key": "13_CR15", "doi-asserted-by": "publisher", "first-page": "1086", "DOI": "10.1002/j.1552-4604.1993.tb01945.x", "volume": "33", "author": "A Ohnishi", "year": "1993", "unstructured": "Ohnishi A, Mihara M, Kamakura H et al (1993) Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer\u2019s disease, in healthy young and elderly subjects. J Clin Pharmacol 33:1086\u20131091", "journal-title": "J Clin Pharmacol"}, {"key": "13_CR16", "doi-asserted-by": "publisher", "first-page": "273", "DOI": "10.1016/j.amjopharm.2006.09.009", "volume": "4", "author": "WM Haywood", "year": "2006", "unstructured": "Haywood WM, Mukaetova-Ladinska EB (2006) Sex influences on cholinesterase inhibitor treatment in elderly individuals with Alzheimer\u2019s disease. Am J Geriatr Pharmacother 4:273\u2013286", "journal-title": "Am J Geriatr Pharmacother"}, {"key": "13_CR17", "first-page": "1590", "volume": "98", "author": "P Griffith", "year": "2006", "unstructured": "Griffith P, Lichtenberg P, Goldman R, Payne-Parrish J (2006) Safety and efficacy of donepezil in African Americans with mild-to-moderate Alzheimer\u2019s disease. J Natl Med Assoc 98:1590\u20131597", "journal-title": "J Natl Med Assoc"}, {"issue": "Suppl 1", "key": "13_CR18", "doi-asserted-by": "publisher", "first-page": "18", "DOI": "10.1111/j.1365-2125.2004.01803.x", "volume": "58", "author": "CF Nagy", "year": "2004", "unstructured": "Nagy CF, Kumar D, Cullen EI et al (2004) Steady-state pharmacokinetics and safety of donepezil HCl in subjects with moderately impaired renal function. Br J Clini Pharmacol 58(Suppl 1):18\u201324", "journal-title": "Br J Clini Pharmacol"}, {"issue": "Suppl 1", "key": "13_CR19", "doi-asserted-by": "publisher", "first-page": "9", "DOI": "10.1111/j.1365-2125.2004.01802.x", "volume": "58", "author": "JF Reyes", "year": "2004", "unstructured": "Reyes JF, Vargas R, Kumar D, Cullen EI, Perdomo CA, Pratt RD (2004) Steady-state pharmacokinetics, pharmacodynamics and tolerability of donepezil hydrochloride in hepatically impaired patients. Br J Clin Pharmacol 58(Suppl 1):9\u201317", "journal-title": "Br J Clin Pharmacol"}, {"key": "13_CR20", "doi-asserted-by": "publisher", "first-page": "465", "DOI": "10.2165/00002018-199819060-00004", "volume": "19", "author": "A Nordberg", "year": "1998", "unstructured": "Nordberg A, Svensson A-L (1998) Cholinesterase inhibitors in the treatment of Alzheimer\u2019s disease. Drug Saf 19:465\u2013480", "journal-title": "Drug Saf"}, {"key": "13_CR21", "doi-asserted-by": "publisher", "first-page": "719", "DOI": "10.2165/00003088-200241100-00003", "volume": "41", "author": "MW Jann", "year": "2002", "unstructured": "Jann MW, Shirley KL, Small GW (2002) Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 41:719\u2013739", "journal-title": "Clin Pharmacokinet"}, {"key": "13_CR22", "doi-asserted-by": "publisher", "first-page": "634", "DOI": "10.1016/S0149-2918(98)80127-6", "volume": "20", "author": "RJ Polinsky", "year": "1998", "unstructured": "Polinsky RJ (1998) Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer\u2019s disease. Clin Ther 20:634\u2013647", "journal-title": "Clin Ther"}, {"key": "13_CR23", "first-page": "109", "volume": "8", "author": "R Anand", "year": "1996", "unstructured": "Anand R, Gharabawi G, Enz A (1996) Efficacy and safety results of the early phase studies with Exelon (TM)(ENA-713) in Alzheimer\u2019s disease: an overview. J Drug Dev Clin Pract 8:109\u2013116", "journal-title": "J Drug Dev Clin Pract"}, {"key": "13_CR24", "unstructured": "Novartis (2015) Exelon\u00ae Patch (rivastigmine transdermal system), full prescribing information. Novartis Pharmaceuticals Corporation, East Hanover, NJ"}, {"key": "13_CR25", "doi-asserted-by": "publisher", "first-page": "513", "DOI": "10.1097/00004714-199912000-00005", "volume": "19", "author": "JS Kennedy", "year": "1999", "unstructured": "Kennedy JS, Polinsky RJ, Johnson B et al (1999) Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans. J Clin Psychopharmacol 19:513\u2013521", "journal-title": "J Clin Psychopharmacol"}, {"key": "13_CR26", "doi-asserted-by": "publisher", "first-page": "391", "DOI": "10.2165/00002512-199813050-00005", "volume": "13", "author": "CM Spencer", "year": "1998", "unstructured": "Spencer CM, Noble S (1998) Rivastigmine. A review of its use in Alzheimer\u2019s disease. Drugs Aging 13:391\u2013411", "journal-title": "Drugs Aging"}, {"key": "13_CR27", "doi-asserted-by": "publisher", "first-page": "1634", "DOI": "10.1016/S0149-2918(03)80160-1", "volume": "25", "author": "BR Williams", "year": "2003", "unstructured": "Williams BR, Nazarians A, Gill MA (2003) A review of rivastigmine: a reversible cholinesterase inhibitor. Clin Ther 25:1634\u20131653", "journal-title": "Clin Ther"}, {"key": "13_CR28", "doi-asserted-by": "publisher", "first-page": "244", "DOI": "10.1111/j.1600-0404.1998.tb00645.x", "volume": "97", "author": "NR Cutler", "year": "1998", "unstructured": "Cutler NR, Polinsky RJ, Sramek JJ et al (1998) Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer\u2019s disease. Acta Neurol Scand 97:244\u2013250", "journal-title": "Acta Neurol Scand"}, {"key": "13_CR29", "doi-asserted-by": "publisher", "first-page": "441", "DOI": "10.1345/aph.18211", "volume": "33", "author": "WJ Krall", "year": "1999", "unstructured": "Krall WJ, Sramek JJ, Cutler NR (1999) Cholinesterase inhibitors: a therapeutic strategy for Alzheimer disease. Ann Pharmacother 33:441\u2013450", "journal-title": "Ann Pharmacother"}, {"key": "13_CR30", "unstructured": "Janssen (2013) RAZADYNE\u00ae ER (galantamine hydrobromide) full prescribing information. Janssen Pharmaceuticals, Inc., Titusville, NJ"}, {"key": "13_CR31", "doi-asserted-by": "publisher", "first-page": "1383", "DOI": "10.2165/00003088-200342150-00005", "volume": "42", "author": "MR Farlow", "year": "2003", "unstructured": "Farlow MR (2003) Clinical pharmacokinetics of galantamine. Clin Pharmacokinet 42:1383\u20131392", "journal-title": "Clin Pharmacokinet"}, {"key": "13_CR32", "doi-asserted-by": "publisher", "first-page": "123", "DOI": "10.2165/00002512-200016020-00004", "volume": "16", "author": "CM VanDenBerg", "year": "2000", "unstructured": "VanDenBerg CM, Kazmi Y, Jann MW (2000) Cholinesterase inhibitors for the treatment of Alzheimer\u2019s disease in the elderly. Drugs Aging 16:123\u2013138", "journal-title": "Drugs Aging"}, {"key": "13_CR33", "doi-asserted-by": "publisher", "first-page": "428", "DOI": "10.1177/00912700222011481", "volume": "42", "author": "Q Zhao", "year": "2002", "unstructured": "Zhao Q, Iyer GR, Verhaeghe T et al (2002) Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers. J Clin Pharmacol 42:428\u2013436", "journal-title": "J Clin Pharmacol"}, {"key": "13_CR34", "doi-asserted-by": "publisher", "first-page": "259", "DOI": "10.1016/j.amjopharm.2011.06.001", "volume": "9", "author": "JH Gomolin", "year": "2011", "unstructured": "Gomolin JH, Smith C, Jeitner TM (2011) Cholinesterase inhibitors: applying pharmacokinetics to clinical decision making. Am J Geriatr Pharmacother 9:259\u2013263", "journal-title": "Am J Geriatr Pharmacother"}, {"key": "13_CR35", "doi-asserted-by": "publisher", "first-page": "135", "DOI": "10.1111/bcp.12325", "volume": "78", "author": "M Noetzli", "year": "2014", "unstructured": "Noetzli M, Guidi M, Ebbing K et al (2014) Population pharmacokinetic approach to evaluate the effect of CYP2D6, CYP3A, ABCB1, POR, NR1/2 genotypes on donepezil clearance. Br J Clin Pharamacol 78:135\u2013144", "journal-title": "Br J Clin Pharamacol"}, {"key": "13_CR36", "doi-asserted-by": "publisher", "first-page": "514", "DOI": "10.1177/0091270003251853", "volume": "43", "author": "V Piotrovsky", "year": "2003", "unstructured": "Piotrovsky V, Van Peer A, Van Osselaer N et al (2003) Galantamine population pharmacokinetics in patients with Alzheimer\u2019s disease: modeling and simulation. J Clin Pharmacol 43:514\u2013523", "journal-title": "J Clin Pharmacol"}, {"key": "13_CR37", "doi-asserted-by": "publisher", "first-page": "1082", "DOI": "10.1177/00912700122012689", "volume": "41", "author": "JV Gobburu", "year": "2001", "unstructured": "Gobburu JV, Tammara V, Lesko L et al (2001) Pharmacokinetic-pharmacodynamic modeling of rivastigmine, a cholinesterase inhibitor, in patients with Alzheimer\u2019s disease. J Clin Pharmacol 41:1082\u20131090", "journal-title": "J Clin Pharmacol"}, {"key": "13_CR38", "doi-asserted-by": "publisher", "first-page": "225", "DOI": "10.2165/00003088-200241030-00006", "volume": "41", "author": "M Hossain", "year": "2002", "unstructured": "Hossain M, Jhee SS, Shiovitz T et al (2002) Estimation of the absolute bioavailability of rivastigmine in patients with mild-moderate dementia of the Alzheimer\u2019s type. Clin Pharmacokinet 41:225\u2013234", "journal-title": "Clin Pharmacokinet"}, {"key": "13_CR39", "doi-asserted-by": "publisher", "first-page": "143", "DOI": "10.1016/0163-7258(82)90051-1", "volume": "16", "author": "NH Holford", "year": "1982", "unstructured": "Holford NH, Sheiner LB (1982) Kinetics of pharmacologic response. Pharmacol Ther 16:143\u2013166", "journal-title": "Pharmacol Ther"}, {"key": "13_CR40", "doi-asserted-by": "publisher", "first-page": "216", "DOI": "10.1097/00002093-200010000-00006", "volume": "14", "author": "JJ Sramek", "year": "2000", "unstructured": "Sramek JJ, Cutler NR (2000) RBC cholinesterase inhibition: a useful surrogate marker for cholinesterase inhibitor activity in Alzheimer\u2019s disease therapy? Alzheimer\u2019s Dis Assoc Disord 14:216\u2013227", "journal-title": "Alzheimer\u2019s Dis Assoc Disord"}, {"key": "13_CR41", "doi-asserted-by": "publisher", "first-page": "307", "DOI": "10.2165/00023210-199912040-00005", "volume": "12", "author": "M Weinstock", "year": "1999", "unstructured": "Weinstock M (1999) Selectivity of cholinesterase inhibition: clinical implications for the treatment of Alzheimer\u2019s disease. CNS Drugs 12:307\u2013323", "journal-title": "CNS Drugs"}, {"key": "13_CR42", "doi-asserted-by": "publisher", "first-page": "1147", "DOI": "10.1007/s00228-011-1064-x", "volume": "67", "author": "C Chianella", "year": "2011", "unstructured": "Chianella C, Gragnaniello D, Maisanio Delser P et al (2011) BCHE and CYP2D6 genetic variation in Alzheimer\u2019s disease patients treated with cholinesterase inhibitors. Eur J Clin Pharmacol 67:1147\u20131157", "journal-title": "Eur J Clin Pharmacol"}, {"key": "13_CR43", "doi-asserted-by": "publisher", "first-page": "351", "DOI": "10.1097/JCP.0b013e31828b5087", "volume": "33", "author": "YH Yang", "year": "2013", "unstructured": "Yang YH, Chen CH, Chou MC et al (2013) Concentration of donepezil to the cognitive response in Alzheimer\u2019s disease. J Clin Psychopharmacol 33:351\u2013355", "journal-title": "J Clin Psychopharmacol"}, {"key": "13_CR44", "doi-asserted-by": "publisher", "first-page": "1", "DOI": "10.1592/phco.20.1.1.34664", "volume": "20", "author": "MW Jann", "year": "2000", "unstructured": "Jann MW (2000) Rivastigmine, a new generation cholinesterase inhibitor for the treatment of Alzheimer\u2019s disease. Pharmacotherapy 20:1\u201312", "journal-title": "Pharmacotherapy"}, {"key": "13_CR45", "doi-asserted-by": "publisher", "first-page": "1234", "DOI": "10.1016/j.clinthera.2010.06.019", "volume": "32", "author": "MR Farlow", "year": "2010", "unstructured": "Farlow MR, Salloway S, Tariot PN et al (2010) Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) in moderate to severe Alzheimer\u2019s disease: a 24-week, randomized, double-blind study. Clin Ther 32:1234\u20131251", "journal-title": "Clin Ther"}, {"key": "13_CR46", "doi-asserted-by": "publisher", "first-page": "110", "DOI": "10.3810/pgm.2012.11.2589", "volume": "124", "author": "DD Christensen", "year": "2012", "unstructured": "Christensen DD (2012) Higher dose (23 mg/day) donepezil formulation for the treatment of patients with moderate-severe Alzheimer\u2019s disease. Postgrad Med 124:110\u2013116", "journal-title": "Postgrad Med"}, {"key": "13_CR47", "doi-asserted-by": "publisher", "first-page": "472", "DOI": "10.1111/j.1365-2125.2007.03063.x", "volume": "65", "author": "N Okamura", "year": "2008", "unstructured": "Okamura N, Funaki Y, Tashiro M et al (2008) In vivo visualization of donepezil binding in the brain of patients with Alzheimer\u2019s disease. Br J Clin Pharmacol 65:472\u2013479", "journal-title": "Br J Clin Pharmacol"}, {"key": "13_CR48", "first-page": "11", "volume": "57", "author": "A Shimada", "year": "2011", "unstructured": "Shimada A, Hashimoto H, Kawabe J et al (2011) Evaluation of therapeutic response to donepezil by positron emission tomography. Osaka City Med J 57:11\u201319", "journal-title": "Osaka City Med J"}, {"key": "13_CR49", "doi-asserted-by": "publisher", "first-page": "113", "DOI": "10.1097/WAD.0b013e3182222bc0", "volume": "26", "author": "M Kasuya", "year": "2012", "unstructured": "Kasuya M, Meguro K, Okamura N et al (2012) Greater responsiveness to donepezil in Alzheimer\u2019s patients with higher levels of acetylcholinesterase based on attention task scores and a donepezil PET study. Alzheimer\u2019s Dis Assoc Disord 26:113\u2013118", "journal-title": "Alzheimer\u2019s Dis Assoc Disord"}, {"key": "13_CR50", "doi-asserted-by": "publisher", "first-page": "223", "DOI": "10.1017/S1461145701002528", "volume": "4", "author": "S Potkin", "year": "2001", "unstructured": "Potkin S, Anand R, Fleming K et al (2001) Brain metabolic and clinical effects of rivastigmine in Alzheimer\u2019s disease. Int J Neuropsychopharmacol 4:223\u2013230", "journal-title": "Int J Neuropsychopharmacol"}, {"key": "13_CR51", "doi-asserted-by": "publisher", "first-page": "205", "DOI": "10.1007/s00702-005-0312-6", "volume": "113", "author": "E Stefanova", "year": "2006", "unstructured": "Stefanova E, Wall A, Almkvist O et al (2006) Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer\u2019s disease. J Neural Transm 113:205\u2013218", "journal-title": "J Neural Transm"}, {"key": "13_CR52", "doi-asserted-by": "publisher", "first-page": "1005", "DOI": "10.1007/s00213-007-0725-z", "volume": "191", "author": "A Kadir", "year": "2007", "unstructured": "Kadir A, Darreh-Shori T, Almkvist O et al (2007) Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer\u2019s disease following rivastigmine treatment as assessed by PET. Psychopharmacology 191:1005\u20131014", "journal-title": "Psychopharmacology"}, {"key": "13_CR53", "doi-asserted-by": "publisher", "first-page": "721", "DOI": "10.1001/archneur.62.5.721", "volume": "62", "author": "MS Mega", "year": "2005", "unstructured": "Mega MS, Dinov ID, Porter V et al (2005) Metabolic patterns associated with the clinical response to galantamine therapy. Arch Neurol 62:721\u2013728", "journal-title": "Arch Neurol"}, {"key": "13_CR54", "doi-asserted-by": "publisher", "first-page": "168", "DOI": "10.1016/j.neurobiolaging.2006.09.020", "volume": "29", "author": "T Darreh-Shori", "year": "2008", "unstructured": "Darreh-Shori T, Kadir A, Almkvist O et al (2008) Inhibition of acetylcholinesterase in CS versus brain assessed by 11C-PMP PET in AD patients treated with galantamine. Neurobiol Aging 29:168\u2013184", "journal-title": "Neurobiol Aging"}, {"key": "13_CR55", "doi-asserted-by": "publisher", "first-page": "1204", "DOI": "10.1016/j.neurobiolaging.2007.02.020", "volume": "29", "author": "A Kadir", "year": "2008", "unstructured": "Kadir A, Darreh-Shori T, Almkvist O et al (2008) PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD. Neurobiol Aging 29:1204\u20131217", "journal-title": "Neurobiol Aging"}, {"key": "13_CR56", "doi-asserted-by": "publisher", "first-page": "881", "DOI": "10.2165/11201020-000000000-00000", "volume": "23", "author": "K McKeage", "year": "2009", "unstructured": "McKeage K (2009) Memantine: a review of its use in moderate to severe Alzheimer\u2019s disease. CNS Drugs 23:881\u2013897", "journal-title": "CNS Drugs"}, {"issue": "1", "key": "13_CR57", "doi-asserted-by": "publisher", "first-page": "28", "DOI": "10.1186/s13195-015-0109-2", "volume": "7", "author": "A Atri", "year": "2015", "unstructured": "Atri A, Hendrix SB, Pejovic V et al (2015) Cumulative, additive benefits of memantine-donepezil combination component monotherapies in moderate-to-severe Alzheimer\u2019s dementia: a pooled area under the curve analysis. Alzheimers Res Ther 7(1):28. doi:\n                  10.1186/s13195-015-0109-2", "journal-title": "Alzheimers Res Ther"}, {"key": "13_CR58", "doi-asserted-by": "publisher", "first-page": "599", "DOI": "10.2165/00003088-200746070-00005", "volume": "46", "author": "J Kornhuber", "year": "2001", "unstructured": "Kornhuber J, Kennepohl EM, Bleich S et al (2001) Memantine pharmacotherapy. Clin Pharmacokinet 46:599\u2013612", "journal-title": "Clin Pharmacokinet"}, {"key": "13_CR59", "doi-asserted-by": "publisher", "first-page": "134", "DOI": "10.1016/j.clpt.2005.10.005", "volume": "79", "author": "A Periclou", "year": "2006", "unstructured": "Periclou A, Ventura D, Rao N, Abramowitz W (2006) Pharmacokinetic study of memantine in healthy and renally impaired subjects. Clin Pharmacol Ther 79:134\u2013143", "journal-title": "Clin Pharmacol Ther"}, {"key": "13_CR60", "doi-asserted-by": "publisher", "first-page": "324", "DOI": "10.1254/jphs.12043FP", "volume": "119", "author": "T Moritoyo", "year": "2012", "unstructured": "Moritoyo T, Hasunuma T, Harada K et al (2012) Effect of renal impairment on the pharmacokinetics of memantine. J Pharmacol Sci 119:324\u2013329", "journal-title": "J Pharmacol Sci"}, {"key": "13_CR61", "doi-asserted-by": "publisher", "first-page": "211", "DOI": "10.1007/s40262-013-0032-2", "volume": "52", "author": "M Noetzli", "year": "2013", "unstructured": "Noetzli M, Guidi M, Ebbing K et al (2013) Population pharmacokinetic study of memantine: effects of clinical and genetic factors. Clin Pharmacokinet 52:211\u2013223", "journal-title": "Clin Pharmacokinet"}, {"key": "13_CR62", "doi-asserted-by": "publisher", "first-page": "1812", "DOI": "10.1111/j.1532-5415.2010.03048.x", "volume": "58", "author": "IH Gomolin", "year": "2010", "unstructured": "Gomolin IH, Smith C, Jietner TM (2010) Once-daily memantine pharmacokinetic and clinical considerations. JAGS 58:1812\u20131813", "journal-title": "JAGS"}, {"key": "13_CR63", "doi-asserted-by": "publisher", "first-page": "183", "DOI": "10.1111/jgs.13223", "volume": "63", "author": "S Lam", "year": "2015", "unstructured": "Lam S, Smith C, Gomolin IH (2015) Memantine standard tablet and extended-release dosing considerations: a pharmacokinetic analysis. JAGS 63:183\u2013184", "journal-title": "JAGS"}, {"key": "13_CR64", "doi-asserted-by": "publisher", "first-page": "137", "DOI": "10.1016/0304-3940(95)11785-U", "volume": "195", "author": "J Kornhuber", "year": "1995", "unstructured": "Kornhuber J, Quack G (1995) Cerebrospinal fluid and serum concentrations of the N-methyl-D-aspartate (NMDA) receptor antagonist memantine in man. Neurosci Lett 195:137\u2013139", "journal-title": "Neurosci Lett"}, {"key": "13_CR65", "doi-asserted-by": "publisher", "first-page": "258", "DOI": "10.1002/gps.1752", "volume": "22", "author": "RW Jones", "year": "2007", "unstructured": "Jones RW, Bayer A, Inglis F, Barkers A, Phul R (2007) Safety and tolerability on once-daily versus twice-daily memantine: a randomized, double-blind study in moderate to severe Alzheimer\u2019s disease. Int J Geriatr Psychiatry 22:258\u2013262", "journal-title": "Int J Geriatr Psychiatry"}, {"key": "13_CR66", "doi-asserted-by": "publisher", "first-page": "469", "DOI": "10.1007/s40263-013-0077-7", "volume": "27", "author": "GT Grossberg", "year": "2013", "unstructured": "Grossberg GT, Manes F, Allegri RF et al (2013) The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer\u2019s disease taking cholinesterase inhibitors. CNS Drugs 27:469\u2013478", "journal-title": "CNS Drugs"}, {"key": "13_CR67", "doi-asserted-by": "publisher", "first-page": "227", "DOI": "10.1016/S0969-8051(01)00293-1", "volume": "29", "author": "SM Ametamey", "year": "2002", "unstructured": "Ametamey SM, Bruehlmeier M, Kneifel S et al (2002) PET studies of 18F-memantine in healthy volunteers. Nucl Med Biol 29:227\u2013231", "journal-title": "Nucl Med Biol"}, {"key": "13_CR68", "doi-asserted-by": "publisher", "first-page": "415", "DOI": "10.2147/NDT.S22635", "volume": "7", "author": "TW Chow", "year": "2011", "unstructured": "Chow TW, Graff-Guerrero A, Verhoeff NP et al (2011) Open-label study of the short-term effects of memantine on FDG-PET in frontotemporal dementia. Neuropsychiatr Dis Treat 7:415\u2013424", "journal-title": "Neuropsychiatr Dis Treat"}, {"key": "13_CR69", "doi-asserted-by": "publisher", "first-page": "319", "DOI": "10.1002/gps.3832", "volume": "28", "author": "TW Chow", "year": "2013", "unstructured": "Chow TW, Farm D, Graff-Guerrero A et al (2013) FDG-PET in semantic dementia after 6 months of memantine: an open-label study. Int J Geriatr Psychiatry 28:319\u2013325", "journal-title": "Int J Geriatr Psychiatry"}, {"key": "13_CR70", "doi-asserted-by": "publisher", "first-page": "606", "DOI": "10.1097/JGP.0b013e3181ca3a4e", "volume": "18", "author": "DL Sultzer", "year": "2010", "unstructured": "Sultzer DL, Melrose RJ, Harwood DG, Campa O, Mandelkern MA (2010) Effects of memantine treatment on regional cortical metabolism in Alzheimer\u2019s disease. Am J Geriatr Psychiatry 18:606\u2013614", "journal-title": "Am J Geriatr Psychiatry"}, {"key": "13_CR71", "doi-asserted-by": "publisher", "first-page": "636", "DOI": "10.1097/JCP.0b013e31829a876a", "volume": "33", "author": "T Wang", "year": "2013", "unstructured": "Wang T, Huang Q, Reiman EM et al (2013) Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer\u2019s dementia. J Clin Psychopharmacol 33:636\u2013642", "journal-title": "J Clin Psychopharmacol"}, {"key": "13_CR72", "doi-asserted-by": "publisher", "first-page": "1039", "DOI": "10.1517/17425255.2014.915028", "volume": "10", "author": "D Prvulovic", "year": "2014", "unstructured": "Prvulovic D, Schneider B (2014) Pharmacokinetic and pharmacodynamics evaluation of donepezil for the treatment of Alzheimer\u2019s disease. Expert Opin Drug Metab Toxicol 10:1039\u20131050", "journal-title": "Expert Opin Drug Metab Toxicol"}, {"key": "13_CR73", "doi-asserted-by": "publisher", "first-page": "177", "DOI": "10.1016/j.jalz.2010.03.016", "volume": "7", "author": "GW Small", "year": "2011", "unstructured": "Small GW, Bullock R (2011) Defining optimal treatment with cholinesterase inhibitors in Alzheimer\u2019s disease. Alzheimer\u2019s Demen 7:177\u2013184", "journal-title": "Alzheimer\u2019s Demen"}, {"key": "13_CR74", "doi-asserted-by": "publisher", "first-page": "222", "DOI": "10.1097/MAJ.0b013e318255a8f9", "volume": "34", "author": "Y Zhong", "year": "2013", "unstructured": "Zhong Y, Zheng X, Miao Y et al (2013) Effect of CYP2D6*10 and APOE polymorphisms on the efficacy of donepezil in patients with Alzheimer\u2019s disease. Am J Med Sci 34:222\u2013226", "journal-title": "Am J Med Sci"}, {"key": "13_CR75", "doi-asserted-by": "publisher", "first-page": "270", "DOI": "10.1097/FTD.0b013e318282ff02", "volume": "35", "author": "M Noetzli", "year": "2013", "unstructured": "Noetzli M, Guidi M, Ebbing K et al (2013) Relationship of CYP2D6, CYP3A, POR, ABCB1, genotypes with galantamine steady-state plasma concentrations. Ther Drug Monit 35:270\u2013275", "journal-title": "Ther Drug Monit"}, {"key": "13_CR76", "doi-asserted-by": "publisher", "first-page": "1053", "DOI": "10.1007/s007020200089", "volume": "109", "author": "E Giacobini", "year": "2002", "unstructured": "Giacobini E, Spiegel R, Enz A, Veroff AE, Cutler NR (2002) Inhibition of acetyl \u2013 and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer\u2019s disease by rivastigmine: correlation with cognitive benefit. J Neural Transm 109:1053\u20131065", "journal-title": "J Neural Transm"}], "container-title": ["Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents"], "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/978-3-319-27883-4_13", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 6, 1]], "date-time": "2019-06-01T16:39:43Z", "timestamp": 1559407183000}, "score": 22.350971, "issued": {"date-parts": [[2016]]}, "ISBN": ["9783319278810", "9783319278834"], "references-count": 76, "URL": "http://dx.doi.org/10.1007/978-3-319-27883-4_13", "relation": {"cites": []}}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T05:16:15Z", "timestamp": 1574486175904}, "reference-count": 12, "publisher": "Wiley", "issue": "5", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 13088, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["British Journal of Clinical Pharmacology"], "published-print": {"date-parts": [[1979, 11]]}, "DOI": "10.1111/j.1365-2125.1979.tb01026.x", "type": "journal-article", "created": {"date-parts": [[2012, 7, 5]], "date-time": "2012-07-05T02:24:18Z", "timestamp": 1341455058000}, "page": "459-463", "source": "Crossref", "is-referenced-by-count": 12, "title": ["Pharmacokinetics of pemoline in plasma, saliva and urine following oral administration."], "prefix": "10.1111", "volume": "8", "author": [{"given": "NP", "family": "Vermeulen", "sequence": "first", "affiliation": []}, {"given": "MW", "family": "Teunissen", "sequence": "additional", "affiliation": []}, {"given": "DD", "family": "Breimer", "sequence": "additional", "affiliation": []}], "member": "311", "published-online": {"date-parts": [[2012, 7, 4]]}, "reference": [{"key": "10.1111/j.1365-2125.1979.tb01026.x-BIB1|cit2", "unstructured": "ABBOTT LABORATORIES. 1975 Cylert Drug Monograph"}, {"key": "10.1111/j.1365-2125.1979.tb01026.x-BIB2|cit3", "doi-asserted-by": "crossref", "first-page": "39", "DOI": "10.2165/00003088-197803010-00003", "article-title": "Therapeutic drug monitoring in saliva", "volume": "3", "author": "DANHOF", "year": "1978", "journal-title": "Clin. Pharmacokin."}, {"key": "10.1111/j.1365-2125.1979.tb01026.x-BIB3|cit4", "first-page": "1216", "article-title": "Kwaliteitsbeheersing van aminofyline zetpillen", "volume": "111", "author": "BLAEY", "year": "1976", "journal-title": "Pharm. Weekblad"}, {"key": "10.1111/j.1365-2125.1979.tb01026.x-BIB4|cit5", "first-page": "868", "article-title": "Pharmacokinetic interpretation of data gathered during therapeutic drug monitoring", "volume": "22", "author": "DVORCHIK", "year": "1976", "journal-title": "Clin. Chem."}, {"key": "10.1111/j.1365-2125.1979.tb01026.x-BIB5|cit6", "first-page": "1604", "article-title": "Quantitative Bestimmung von Pemoline in Serum und Harn nach Einnahme therapeutischer Dosen", "volume": "8", "author": "GOENECHA", "year": "1977", "journal-title": "Arzneim.-Forsch/Drug Res."}, {"key": "10.1111/j.1365-2125.1979.tb01026.x-BIB6|cit7", "doi-asserted-by": "crossref", "first-page": "1107", "DOI": "10.1016/0091-3057(75)90024-6", "article-title": "Effects of pemoline on hyperactive boys", "volume": "3", "author": "KNIGHTS", "year": "1975", "journal-title": "Pharm. Biochem. Behav."}, {"key": "10.1111/j.1365-2125.1979.tb01026.x-BIB7|cit8", "first-page": "157", "article-title": "Potentiation of l-dopa in treatment parkinsonism", "volume": "2", "author": "PLOTNIKOFF", "year": "1972", "journal-title": "Ger. Offen."}, {"key": "10.1111/j.1365-2125.1979.tb01026.x-BIB8|cit9", "doi-asserted-by": "crossref", "first-page": "209", "DOI": "10.1002/jps.2600560235", "article-title": "Pemoline and magnesium hydroxide versus pemoline: Enhancement of learning and memory of a conditioned avoidance response in rats", "volume": "56", "author": "PLOTNIKOFF", "year": "1967", "journal-title": "J. pharm. Sci."}, {"key": "10.1111/j.1365-2125.1979.tb01026.x-BIB9|cit10", "first-page": "423", "article-title": "5-Phenyl-2-imino-4-oxo-oxazolidin: ein zentral erregende Stoff", "volume": "6", "author": "SCHMIDT", "year": "1956", "journal-title": "Arzneim.-Forsch. Drug Res."}, {"key": "10.1111/j.1365-2125.1979.tb01026.x-BIB10|cit11", "doi-asserted-by": "crossref", "first-page": "445", "DOI": "10.1007/BF00403986", "article-title": "Tests of learning and memory with Cylert", "volume": "10", "author": "TALLAND", "year": "1967", "journal-title": "Psychopharmacologia"}, {"key": "10.1111/j.1365-2125.1979.tb01026.x-BIB11|cit12", "doi-asserted-by": "crossref", "first-page": "333", "DOI": "10.1016/S0021-9673(00)81356-4", "article-title": "Gas chromatographic determination of pemoline as 5-phenyl-2,4-oxazolidinedione in human urine", "volume": "137", "author": "VERMEULEN", "year": "1977", "journal-title": "J. Chromatogr."}, {"key": "10.1111/j.1365-2125.1979.tb01026.x-BIB12|cit13", "doi-asserted-by": "crossref", "first-page": "133", "DOI": "10.1016/S0021-9673(00)92329-X", "article-title": "Assay of pemoline in human plasma, saliva and urine by capillary gas chromatography with nitrogen-selective detection", "volume": "157", "author": "VERMEULEN", "year": "1978", "journal-title": "J. Chromatogr."}], "container-title": ["British Journal of Clinical Pharmacology"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1365-2125.1979.tb01026.x", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2017, 6, 20]], "date-time": "2017-06-20T20:55:15Z", "timestamp": 1497992115000}, "score": 22.155275, "issued": {"date-parts": [[1979, 11]]}, "references-count": 12, "journal-issue": {"published-print": {"date-parts": [[1979, 11]]}, "issue": "5"}, "URL": "http://dx.doi.org/10.1111/j.1365-2125.1979.tb01026.x", "relation": {"cites": []}, "ISSN": ["0306-5251"], "issn-type": [{"value": "0306-5251", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 26]], "date-time": "2019-11-26T06:11:02Z", "timestamp": 1574748662809}, "publisher-location": "Cham", "reference-count": 107, "publisher": "Springer International Publishing", "isbn-type": [{"value": "9783319247397", "type": "print"}, {"value": "9783319247410", "type": "electronic"}], "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2015, 12, 8]], "date-time": "2015-12-08T00:00:00Z", "timestamp": 1449532800000}, "delay-in-days": 0, "content-version": "unspecified"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[2016]]}, "DOI": "10.1007/978-3-319-24741-0_9", "type": "book-chapter", "created": {"date-parts": [[2015, 12, 8]], "date-time": "2015-12-08T17:18:00Z", "timestamp": 1449595080000}, "page": "167-189", "source": "Crossref", "is-referenced-by-count": 1, "title": ["Safety and Tolerability of Antipsychotics"], "prefix": "10.1007", "author": [{"given": "Michael W.", "family": "Jann", "sequence": "first", "affiliation": []}, {"given": "William K.", "family": "Kennedy", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2015, 12, 8]]}, "reference": [{"key": "9_CR1", "doi-asserted-by": "publisher", "first-page": "345", "DOI": "10.1016/j.biopsych.2006.09.023", "volume": "62", "author": "K Alper", "year": "2007", "unstructured": "Alper K, Schwartz KA, Kolts RL, Khan A (2007) Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approvals reports. Biol Psychiatry 62:345\u2013354", "journal-title": "Biol Psychiatry"}, {"key": "9_CR2", "doi-asserted-by": "publisher", "first-page": "43", "DOI": "10.2174/157488611794480070", "volume": "6", "author": "L Alphs", "year": "2011", "unstructured": "Alphs L, Gopal S, Karcher K et al (2011) Are the long-acting intramuscular formulations of risperidone or paliperidone palmitate associated with post-injection delirium/sedation syndrome? An assessment of safety databases. Curr Drug 6:43\u201345", "journal-title": "Curr Drug"}, {"issue": "Suppl 1", "key": "9_CR3", "doi-asserted-by": "publisher", "first-page": "S11", "DOI": "10.2337/dc10-S011", "volume": "33", "author": "American Diabetes Association", "year": "2010", "unstructured": "American Diabetes Association (2010) Standards of medical care in diabetes \u2013 2010. Diabetes Care 33(Suppl 1):S11\u2013S61", "journal-title": "Diabetes Care"}, {"key": "9_CR4", "doi-asserted-by": "publisher", "first-page": "596", "DOI": "10.2337/diacare.27.2.596", "volume": "27", "author": "American Diabetes Association", "year": "2004", "unstructured": "American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists et al (2004) Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27:596\u2013601", "journal-title": "Diabetes Care"}, {"issue": "4", "key": "9_CR5", "doi-asserted-by": "publisher", "first-page": "e94112", "DOI": "10.1371/journal.pone.0094112", "volume": "9", "author": "M Bak", "year": "2014", "unstructured": "Bak M, Fransen A, Janssen J, van Os J, Drukker M (2014) Almost all antipsychotics result in weight gain: a meta-analysis. PLoS 9(4):e94112. doi:\n                  10.1371/journal.pone.0094112", "journal-title": "PLoS"}, {"key": "9_CR6", "doi-asserted-by": "publisher", "first-page": "672", "DOI": "10.1192/bjp.154.5.672", "volume": "154", "author": "TR Barnes", "year": "1989", "unstructured": "Barnes TR (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154:672\u2013676", "journal-title": "Br J Psychiatry"}, {"key": "9_CR7", "doi-asserted-by": "publisher", "first-page": "1", "DOI": "10.1016/j.psym.2012.11.001", "volume": "54", "author": "SR Beach", "year": "2013", "unstructured": "Beach SR, Celano CM, Noseworthy PA, Januzzi JL, Huffman JC (2013) QTc prolongation, Torsades de Pointes, and psychotropic medications. Psychosomatics 54:1\u201313", "journal-title": "Psychosomatics"}, {"key": "9_CR8", "doi-asserted-by": "publisher", "first-page": "55", "DOI": "10.2174/157488612800492681", "volume": "7", "author": "D Berardis", "year": "2012", "unstructured": "Berardis D, Serroni N, Campanella D et al (2012) Update on the adverse effects of clozapine: focus on myocarditis. Curr Drug Saf 7:55\u201362", "journal-title": "Curr Drug Saf"}, {"key": "9_CR9", "doi-asserted-by": "publisher", "first-page": "2226", "DOI": "10.1002/mds.23828", "volume": "26", "author": "E Bondon-Guitton", "year": "2011", "unstructured": "Bondon-Guitton E, Perez-Lloret SP, Bagheri H, Brefel C, Rascol O, Montastruc JL (2011) Drug-induced Parkinsonism: a review of 17 years\u2019 experience in a regional pharmacovigilance center in France. Mov Disord 26:2226\u20132231", "journal-title": "Mov Disord"}, {"key": "9_CR10", "first-page": "79", "volume": "41", "author": "SN Caroff", "year": "1980", "unstructured": "Caroff SN (1980) The neuroleptic malignant syndrome. J Clin Psychiatry 41:79\u201383", "journal-title": "J Clin Psychiatry"}, {"key": "9_CR11", "first-page": "25", "volume": "24", "author": "SN Caroff", "year": "1988", "unstructured": "Caroff SN, Mann SC (1988) Neuroleptic malignant syndrome. Psychopharmacol Bull 24:25\u201329", "journal-title": "Psychopharmacol Bull"}, {"key": "9_CR12", "doi-asserted-by": "publisher", "first-page": "185", "DOI": "10.1016/S0025-7125(16)30278-4", "volume": "77", "author": "SN Caroff", "year": "1993", "unstructured": "Caroff SN, Mann SC (1993) Neuroleptic malignant syndrome. Med Clin N Am 77:185\u2013202", "journal-title": "Med Clin N Am"}, {"key": "9_CR13", "doi-asserted-by": "publisher", "first-page": "521", "DOI": "10.1002/hup.2257", "volume": "27", "author": "F Centorrino", "year": "2012", "unstructured": "Centorrino F, Masters GA, Talamo A, Baldessarini RJ, Ongur D (2012) Metabolic syndrome in psychiatrically hospitalized patients treated with antipsychotics and other psychotropics. Hum Psychopharmacol 27:521\u2013526", "journal-title": "Hum Psychopharmacol"}, {"key": "9_CR14", "doi-asserted-by": "publisher", "first-page": "366", "DOI": "10.1176/appi.ajp.2012.12081036", "volume": "170", "author": "D Cohen", "year": "2013", "unstructured": "Cohen D, Monden M (2013) White blood cell monitoring during long-term clozapine treatment. Am J Psychiatry 170:366\u2013369", "journal-title": "Am J Psychiatry"}, {"key": "9_CR15", "doi-asserted-by": "publisher", "first-page": "1307", "DOI": "10.4088/JCP.11r06977", "volume": "73", "author": "D Cohen", "year": "2012", "unstructured": "Cohen D, Bogers JPA, van Dijk D, Bakker B, Schulte PFJ (2012) Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy. J Clin Psychiatry 73:1307\u20131312", "journal-title": "J Clin Psychiatry"}, {"key": "9_CR16", "doi-asserted-by": "publisher", "first-page": "868", "DOI": "10.1016/j.jad.2013.04.053", "volume": "150", "author": "J Coplan", "year": "2013", "unstructured": "Coplan J, Gugger JJ, Tasleem H (2013) Tardive dyskinesia from atypical antipsychotic agents in patients with mood disorders in a clinical setting. J Affect Disord 150:868\u2013871", "journal-title": "J Affect Disord"}, {"key": "9_CR17", "doi-asserted-by": "publisher", "first-page": "151", "DOI": "10.1097/YCO.0b013e3282f53132", "volume": "21", "author": "CU Correll", "year": "2008", "unstructured": "Correll CU, Schenk EM (2008) Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 21:151\u2013156", "journal-title": "Curr Opin Psychiatry"}, {"key": "9_CR18", "doi-asserted-by": "publisher", "first-page": "1207", "DOI": "10.1136/bmj.322.7296.1207", "volume": "322", "author": "DM Coulter", "year": "2001", "unstructured": "Coulter DM, Bate A, Meyboom RHB, Lindquist M, Edwards IR (2001) Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study. BMJ 322:1207\u20131209", "journal-title": "BMJ"}, {"key": "9_CR19", "doi-asserted-by": "publisher", "first-page": "4", "DOI": "10.1186/1471-244X-10-43", "volume": "10", "author": "HC Detke", "year": "2010", "unstructured": "Detke HC, McDonnell DP, Brunner E et al (2010) Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection: I. Analysis of cases. BMC Psychiatry 10:4", "journal-title": "BMC Psychiatry"}, {"key": "9_CR20", "doi-asserted-by": "publisher", "first-page": "957", "DOI": "10.1176/appi.ajp.2013.13060767", "volume": "170", "author": "DP Devanand", "year": "2013", "unstructured": "Devanand DP (2013) Psychosis, agitation, and antipsychotic treatment in dementia. Am J Psychiatry 170:957\u2013958", "journal-title": "Am J Psychiatry"}, {"issue": "Suppl B", "key": "9_CR21", "first-page": "153", "volume": "55", "author": "O Devinsky", "year": "1994", "unstructured": "Devinsky O, Pacia SV (1994) Seizures during clozapine therapy. J Clin Psychiatry 55(Suppl B):153\u2013156", "journal-title": "J Clin Psychiatry"}, {"key": "9_CR22", "doi-asserted-by": "publisher", "first-page": "369", "DOI": "10.1212/WNL.41.3.369", "volume": "41", "author": "O Devinsky", "year": "1991", "unstructured": "Devinsky O, Honigfeld G, Patin J (1991) Clozapine-related seizures. Neurology 41:369\u2013371", "journal-title": "Neurology"}, {"key": "9_CR23", "unstructured": "Divac N, Prostran M, Jakovcevski I, Cerovac N (2014) Second-generation antipsychotics and extrapyramidal adverse effects. BioMed Res Int; \n                  http://dx.doi.org/10.1155/2014/656370", "DOI": "10.1155/2014/656370", "doi-asserted-by": "crossref"}, {"key": "9_CR24", "doi-asserted-by": "publisher", "first-page": "335", "DOI": "10.1177/1039856213491990", "volume": "21", "author": "L Drew", "year": "2013", "unstructured": "Drew L (2013) Clozapine and agranulocytosis. Aust Psychiatry 21:335\u2013337", "journal-title": "Aust Psychiatry"}, {"key": "9_CR25", "doi-asserted-by": "publisher", "first-page": "794", "DOI": "10.1002/pds.3366", "volume": "22", "author": "RA Epstein", "year": "2013", "unstructured": "Epstein RA, Bobo WV, Shelton RC et al (2013) Increasing use of atypical antipsychotics and anticonvulsants during pregnancy. Pharmacoepidemiol Drug Saf 22:794\u2013801", "journal-title": "Pharmacoepidemiol Drug Saf"}, {"key": "9_CR26", "doi-asserted-by": "publisher", "first-page": "27", "DOI": "10.1002/hup.917", "volume": "23", "author": "RJ Flanagan", "year": "2008", "unstructured": "Flanagan RJ, Dunk L (2008) Haematological toxicity of drugs used in psychiatry. Hum Psychopharmacol Clin Exp 23:27\u201341", "journal-title": "Hum Psychopharmacol Clin Exp"}, {"key": "9_CR27", "doi-asserted-by": "publisher", "first-page": "109", "DOI": "10.1016/j.psc.2010.11.004", "volume": "34", "author": "R Ganguli", "year": "2011", "unstructured": "Ganguli R, Strassnig M (2011) Prevention of metabolic syndrome in serious mental illness. Psychiatr Clin N Am 34:109\u2013125", "journal-title": "Psychiatr Clin N Am"}, {"key": "9_CR28", "doi-asserted-by": "publisher", "first-page": "287", "DOI": "10.2165/00044011-200323050-00001", "volume": "23", "author": "P Gareri", "year": "2003", "unstructured": "Gareri P, De Fazio P, Stilo M, Ferrei G, De Sarro G (2003) Conventional and atypical antipsychotics in the elderly. Clin Drug Invest 23:287\u2013322", "journal-title": "Clin Drug Invest"}, {"key": "9_CR29", "doi-asserted-by": "publisher", "first-page": "1774", "DOI": "10.1176/appi.ajp.158.11.1774", "volume": "158", "author": "AH Glassman", "year": "2001", "unstructured": "Glassman AH, Bigger JT (2001) Antipsychotic drugs: prolonged QTc interval, Torsade de Pointes, and sudden death. Am J Psychiatry 158:1774\u20131782", "journal-title": "Am J Psychiatry"}, {"key": "9_CR30", "doi-asserted-by": "publisher", "first-page": "603", "DOI": "10.1016/j.psym.2012.06.011", "volume": "53", "author": "N Guanci", "year": "2012", "unstructured": "Guanci N, Aggarwal R, Schleifer S (2012) Atypical neuroleptic malignant associated with iloperidone administration. Psychosomatics 53:603\u2013604", "journal-title": "Psychosomatics"}, {"key": "9_CR31", "doi-asserted-by": "publisher", "first-page": "1222", "DOI": "10.4088/JCP.10m06438", "volume": "72", "author": "RJ Gurrera", "year": "2011", "unstructured": "Gurrera RJ, Caroff SN, Cohen A et al (2011) An international consensus study of neuroleptic malignant syndrome diagnostic criteria suing the Delphi method. J Clin Psychiatry 72:1222\u20131228", "journal-title": "J Clin Psychiatry"}, {"key": "9_CR32", "unstructured": "Guy W (1976) AIMS. Abnormal Involuntary Movement Scale. Early Clinical Drug Evaluation Unit (ECDEU). In: Rockville MD (ed) Assessment manual for psychopharmacology, vol 338. NIMH, DHHS No. ADM 91\u2013338, pp 534\u2013537"}, {"key": "9_CR33", "doi-asserted-by": "publisher", "first-page": "569", "DOI": "10.2165/00002018-200730070-00002", "volume": "30", "author": "M Harrison-Woolrych", "year": "2007", "unstructured": "Harrison-Woolrych M, Garica-Quiroga J, Ashton J, Herbison P (2007) Safety and usage of atypical antipsychotic medicines in children. Drug Saf 30:569\u2013579", "journal-title": "Drug Saf"}, {"key": "9_CR34", "doi-asserted-by": "publisher", "first-page": "1122", "DOI": "10.1592/phco.24.13.1122.38098", "volume": "24", "author": "M Hauben", "year": "2004", "unstructured": "Hauben M (2004) Application of an empiric Bayesian data mining algorithm to reports of pancreatitis associated atypical antipsychotics. Pharmacotherapy 24:1122\u20131129", "journal-title": "Pharmacotherapy"}, {"key": "9_CR35", "doi-asserted-by": "publisher", "first-page": "242", "DOI": "10.7326/M13-2796", "volume": "161", "author": "YJ Hwang", "year": "2014", "unstructured": "Hwang YJ, Dixon SN, Reiss JP et al (2014) Atypical antipsychotic drugs and the risk for acute kidney injury and other adverse outcomes in older adults. Ann Intern Med 161:242\u2013248", "journal-title": "Ann Intern Med"}, {"key": "9_CR36", "doi-asserted-by": "publisher", "first-page": "611", "DOI": "10.1093/schbul/23.4.611", "volume": "23", "author": "TM Hyde", "year": "1997", "unstructured": "Hyde TM, Weinberger DR (1997) Seizures and schizophrenia. Schizophrenia Bull 23:611\u2013622", "journal-title": "Schizophrenia Bull"}, {"key": "9_CR37", "doi-asserted-by": "publisher", "first-page": "29", "DOI": "10.1097/00019442-200002000-00004", "volume": "8", "author": "D Jeste", "year": "2000", "unstructured": "Jeste D, Finkel S (2000) Psychosis of Alzheimer\u2019s Disease and related: diagnostic for a distinct syndrome. Am J Geriatr Psychiatry 8:29\u201334", "journal-title": "Am J Geriatr Psychiatry"}, {"key": "9_CR38", "doi-asserted-by": "publisher", "first-page": "957", "DOI": "10.1038/sj.npp.1301492", "volume": "33", "author": "DV Jeste", "year": "2008", "unstructured": "Jeste DV, Balzer D, Casey D et al (2008) ACNP white paper: update on the use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology 33:957\u2013970", "journal-title": "Neuropsychopharmacology"}, {"key": "9_CR39", "doi-asserted-by": "publisher", "first-page": "368", "DOI": "10.1177/0897190012442220", "volume": "25", "author": "UA Kagal", "year": "2012", "unstructured": "Kagal UA, Torgal SS, Patil NM, Malleshappa A (2012) Prevalence of the metabolic syndrome in schizophrenic patients receiving second-generation antipsychotic agents \u2013 a cross sectional study. J Pharm Pract 25:368\u2013373", "journal-title": "J Pharm Pract"}, {"key": "9_CR40", "first-page": "10", "volume": "64", "author": "RK Kalapatapu", "year": "2009", "unstructured": "Kalapatapu RK, Schimming C (2009) Update on neuropsychiatric symptoms of dementia: antipsychotic use. Geriatrics 64:10\u201318", "journal-title": "Geriatrics"}, {"key": "9_CR41", "doi-asserted-by": "publisher", "first-page": "2067", "DOI": "10.2217/pgs.13.207", "volume": "14", "author": "AC Kao", "year": "2013", "unstructured": "Kao AC, Muller DJ (2013) Genetics of antipsychotic-induced weight gain: update and current perspectives. Pharmacogenomics 14:2067\u20132083", "journal-title": "Pharmacogenomics"}, {"key": "9_CR42", "doi-asserted-by": "publisher", "first-page": "67", "DOI": "10.9758/cpn.2014.12.1.67", "volume": "12", "author": "K Kawabe", "year": "2014", "unstructured": "Kawabe K, Ueno SC (2014) A case of acute pancreatitis associated with risperidone treatment. Clin Psychopharmacol Neurosci 12:67\u201368", "journal-title": "Clin Psychopharmacol Neurosci"}, {"issue": "Suppl 4", "key": "9_CR43", "first-page": "33", "volume": "61", "author": "PE Keck", "year": "2000", "unstructured": "Keck PE, McElroy SL, Stakowski SM, Soutullo CA (2000) Antipsychotics in the treatment of mood disorders and the risk of tardive dyskinesia. J Clin Psychiatry 61(Suppl 4):33\u201338", "journal-title": "J Clin Psychiatry"}, {"issue": "1", "key": "9_CR44", "doi-asserted-by": "crossref", "first-page": "67", "DOI": "10.1177/0891988714541867", "volume": "28", "author": "Bruce J. Kinon", "year": "2014", "unstructured": "Kinon BJ, Kollack-Walker S, Jeste D et al (2015) Incidence of tardive dyskinesia in older adult patients treated with olanzapine or conventional antipsychotics. J Geriatr Psychiatry Neurol 28(1):67\u201379", "journal-title": "Journal of Geriatric Psychiatry and Neurology"}, {"key": "9_CR45", "doi-asserted-by": "publisher", "first-page": "1123", "DOI": "10.1592/phco.23.10.1123.32759", "volume": "23", "author": "EA Koller", "year": "2003", "unstructured": "Koller EA, Cross JT, Doraiswamy PM, Malozowski SN (2003) Pancreatitis associated with atypical antipsychotics: from the Food and Drug Administration\u2019s MedWatch surveillance system and published reports. Pharmacotherapy 23:1123\u20131130", "journal-title": "Pharmacotherapy"}, {"key": "9_CR46", "doi-asserted-by": "publisher", "first-page": "727", "DOI": "10.1016/j.chc.2013.06.002", "volume": "22", "author": "HN Kranzler", "year": "2013", "unstructured": "Kranzler HN, Cohen SD (2013) Psychopharmacologic treatment of psychosis in children and adolescents: efficacy and management. Child Adolesc Psychiatry N Am 22:727\u2013744", "journal-title": "Child Adolesc Psychiatry N Am"}, {"key": "9_CR47", "doi-asserted-by": "publisher", "first-page": "60", "DOI": "10.1093/schbul/sbm109", "volume": "34", "author": "S Kumra", "year": "2008", "unstructured": "Kumra S, Oberstar JV, Sikich L et al (2008) Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia. Schizopr Bull 34:60\u201371", "journal-title": "Schizopr Bull"}, {"key": "9_CR48", "doi-asserted-by": "publisher", "first-page": "146", "DOI": "10.1176/appi.ajp.2008.08020294", "volume": "166", "author": "HH Kyonmen", "year": "2009", "unstructured": "Kyonmen HH, Whitfield TH (2009) Psychosis in the elderly. Am J Psychiatry 166:146\u2013150", "journal-title": "Am J Psychiatry"}, {"key": "9_CR49", "doi-asserted-by": "publisher", "first-page": "214", "DOI": "10.1186/1471-244X-12-214", "volume": "12", "author": "J Langan", "year": "2012", "unstructured": "Langan J, Martin D, Shajahan P, Smith DJ (2012) Antipsychotic dose escalation as a trigger for neuroleptic malignant syndrome (NMS): literature review and case series report. BMC Psychiatry 12:214", "journal-title": "BMC Psychiatry"}, {"key": "9_CR50", "doi-asserted-by": "publisher", "first-page": "1182", "DOI": "10.1111/j.1532-5415.2011.03479.x", "volume": "59", "author": "L Laredo", "year": "2011", "unstructured": "Laredo L, Vargas E, Blasco AJ, Aguilar MD, Moreno A, Portoles A (2011) Risk of cerebrovascular accident associated with use of antipsychotics: population-based case-control study. JAGS 59:1182\u20131187", "journal-title": "JAGS"}, {"issue": "9", "key": "9_CR51", "doi-asserted-by": "crossref", "first-page": "918", "DOI": "10.1002/phar.1455", "volume": "34", "author": "Wan-Ju Lee", "year": "2014", "unstructured": "Lee WJ, Lee TA, Pickhard AS, Caskey RN, Schumock GT (2014) Drugs associated with adverse events in children and adolescents. Pharmacotherapy 34(9):918\u2013926", "journal-title": "Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"}, {"key": "9_CR52", "first-page": "1", "volume": "10", "author": "CE Leonard", "year": "2013", "unstructured": "Leonard CE, Freeman CP, Newcomb CW et al (2013) Antipsychotics and risk of sudden cardiac death and all-cause death: cohort studies in Medicaid and dually-eligible Medicaid-Medicare beneficiaries of five states. J Clin Exp Cardiol Suppl 10:1\u20139", "journal-title": "J Clin Exp Cardiol Suppl"}, {"key": "9_CR53", "doi-asserted-by": "publisher", "first-page": "141", "DOI": "10.1016/j.seizure.2012.10.009", "volume": "22", "author": "U Lertxundi", "year": "2013", "unstructured": "Lertxundi U, Hernandez R, Medrano J, Domingo-Echaburu S, Garcia M, Aguirre C (2013) Antipsychotics and seizures: higher risk with atypicals? Seizure 22:141\u2013153", "journal-title": "Seizure"}, {"key": "9_CR54", "doi-asserted-by": "publisher", "first-page": "951", "DOI": "10.1016/S0140-6736(13)60733-3", "volume": "382", "author": "S Leucht", "year": "2013", "unstructured": "Leucht S, Cipriani A, Spineli L et al (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382:951\u2013962", "journal-title": "Lancet"}, {"key": "9_CR55", "doi-asserted-by": "publisher", "first-page": "1051", "DOI": "10.1176/appi.ajp.2013.12081046", "volume": "170", "author": "OL Lopez", "year": "2013", "unstructured": "Lopez OL, Becker JT, Chang YF et al (2013) The long-term effects of conventional and atypical antipsychotics in patients with probable Alzheimer\u2019s Disease. Am J Psychiatry 170:1051\u20131058", "journal-title": "Am J Psychiatry"}, {"key": "9_CR56", "doi-asserted-by": "publisher", "first-page": "101", "DOI": "10.2165/00023210-200721020-00002", "volume": "21", "author": "S Madhusoodanan", "year": "2007", "unstructured": "Madhusoodanan S, Shah P, Brenner R, Gupta S (2007) Pharmacological treatment of psychosis of Alzheimer\u2019s disease. CNS Drugs 21:101\u2013115", "journal-title": "CNS Drugs"}, {"key": "9_CR57", "doi-asserted-by": "publisher", "first-page": "1359", "DOI": "10.1001/jama.2011.1360", "volume": "306", "author": "AR Maher", "year": "2011", "unstructured": "Maher AR, Magione M, Bagley S et al (2011) Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults. JAMA 306:1359\u20131369", "journal-title": "JAMA"}, {"key": "9_CR58", "doi-asserted-by": "publisher", "first-page": "936", "DOI": "10.4088/JCP.10m06244gry", "volume": "72", "author": "P Manu", "year": "2011", "unstructured": "Manu P, Kane JM, Correll CU (2011) Sudden deaths in psychiatric patients. J Clin Psychiatry 72:936\u2013941", "journal-title": "J Clin Psychiatry"}, {"key": "9_CR59", "doi-asserted-by": "publisher", "first-page": "460", "DOI": "10.4088/JCP.10m06822", "volume": "73", "author": "P Manu", "year": "2012", "unstructured": "Manu P, Corrll CU, van Winkel R, Wampers M, De Hert M (2012) Prediabetes in patients treated with antipsychotic drugs. J Clin Psychiatry 73:460\u2013466", "journal-title": "J Clin Psychiatry"}, {"issue": "6", "key": "9_CR60", "doi-asserted-by": "publisher", "first-page": "322", "DOI": "10.1097/YIC.0000000000000038", "volume": "29", "author": "DP McDonnell", "year": "2014", "unstructured": "McDonnell DP, Landry J, Detke HC (2014) Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study. Int Clin Psychopharmacol 29(6):322\u2013331", "journal-title": "Int Clin Psychopharmacol"}, {"key": "9_CR61", "doi-asserted-by": "publisher", "first-page": "395", "DOI": "10.1016/0893-133X(95)00276-J", "volume": "15", "author": "HY Melzter", "year": "1996", "unstructured": "Melzter HY, Cola PA, Parsa M (1996) Marked elevations of serum creatine kinase activity associated with antipsychotic drug treatment. Neuropsychopharmacology 15:395\u2013405", "journal-title": "Neuropsychopharmacology"}, {"key": "9_CR62", "doi-asserted-by": "publisher", "first-page": "806", "DOI": "10.1007/s11096-011-9541-y", "volume": "33", "author": "C Meyer-Massetti", "year": "2011", "unstructured": "Meyer-Massetti C, Vaerini S, Ratz Bravo AE et al (2011) Comparative safety of antipsychotics in the WHO pharmacovigilance database: the haloperidol case. Int J Clin Pharm 33:806\u2013814", "journal-title": "Int J Clin Pharm"}, {"key": "9_CR63", "doi-asserted-by": "publisher", "first-page": "306", "DOI": "10.1093/schbul/sbr148", "volume": "39", "author": "AJ Mitchell", "year": "2013", "unstructured": "Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, De Hert M (2013) Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders \u2013 a systematic review and meta-analysis. Schizophr Bull 39:306\u2013318", "journal-title": "Schizophr Bull"}, {"key": "9_CR64", "doi-asserted-by": "publisher", "first-page": "28", "DOI": "10.1176/appi.ps.201100445", "volume": "64", "author": "D Mittal", "year": "2013", "unstructured": "Mittal D, Li C, Williams JS, Viverito K, Landes RD, Owen RR (2013) Monitoring veterans for metabolic side effects when prescribing antipsychotics. Psychiatr Serv 64:28\u201335", "journal-title": "Psychiatr Serv"}, {"key": "9_CR65", "author": "TA Munshi", "volume": "20", "year": "2014", "unstructured": "Munshi TA, Volochniouk D, Hassan T, Mazhar N (2014) Clozapine-induced myocarditis: is mandatory monitoring warranted for its early recognition? Case Rep Psychiatry 20, 513108", "journal-title": "Case Rep Psychiatry"}, {"key": "9_CR66", "first-page": "25", "volume": "7", "author": "P Narang", "year": "2010", "unstructured": "Narang P, El-Refai M, Parlapalli R et al (2010) Antipsychotic drugs: sudden cardiac death among elderly patients. Psychiatry 7:25\u201329", "journal-title": "Psychiatry"}, {"key": "9_CR67", "doi-asserted-by": "publisher", "first-page": "1071", "DOI": "10.4088/JCP.v66n0817", "volume": "66", "author": "JC Nelson", "year": "2005", "unstructured": "Nelson JC (2005) Increased risk of cerebrovascular adverse events and death in elderly demented patients treated with atypical antipsychotics: what\u2019s a clinician to do? J Clin Psychiatry 66:1071", "journal-title": "J Clin Psychiatry"}, {"key": "9_CR68", "doi-asserted-by": "publisher", "first-page": "1794", "DOI": "10.1001/jama.298.15.1794", "volume": "298", "author": "JW Newcomer", "year": "2007", "unstructured": "Newcomer JW, Hennekens CH (2007) Severe mental illness and risk of cardiovascular disease. JAMA 298:1794\u20131796", "journal-title": "JAMA"}, {"key": "9_CR69", "doi-asserted-by": "publisher", "first-page": "112", "DOI": "10.1002/hup.1181", "volume": "26", "author": "PMM Nooijen", "year": "2011", "unstructured": "Nooijen PMM, Carvalho F, Flanagan RJ (2011) Haematological toxicity of clozapine and some other drugs used in psychiatry. Hum Psychopharmacol Clin Exp 26:112\u2013119", "journal-title": "Hum Psychopharmacol Clin Exp"}, {"key": "9_CR70", "doi-asserted-by": "publisher", "first-page": "59", "DOI": "10.1097/WNF.0b013e3182854f70", "volume": "36", "author": "V Novakovic", "year": "2013", "unstructured": "Novakovic V, Adel T, Peselow E, Lindenmayer JP (2013) Long-acting injectable antipsychotics and the development of post injection delirium/sedation syndrome (PDSS). Clin Neuropharmacol 36:59\u201362", "journal-title": "Clin Neuropharmacol"}, {"key": "9_CR71", "doi-asserted-by": "publisher", "first-page": "401", "DOI": "10.1016/j.pnpbp.2010.01.008", "volume": "34", "author": "Y Ozeki", "year": "2010", "unstructured": "Ozeki Y, Fujii K, Kurimoto N et al (2010) QTc prolongation and antipsychotic medications in a sample of 1017 patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 34:401\u2013405", "journal-title": "Prog Neuropsychopharmacol Biol Psychiatry"}, {"key": "9_CR72", "doi-asserted-by": "publisher", "first-page": "2247", "DOI": "10.1212/WNL.44.12.2247", "volume": "44", "author": "SV Pacia", "year": "1994", "unstructured": "Pacia SV, Devinsky O (1994) Clozapine-induced seizures: experience with 5,629 patients. Neurology 44:2247\u20132249", "journal-title": "Neurology"}, {"issue": "5", "key": "9_CR73", "doi-asserted-by": "publisher", "first-page": "501", "DOI": "10.1177/0897190013516509", "volume": "27", "author": "K Packhard", "year": "2014", "unstructured": "Packhard K, Price P, Hanson A (2014) Antipsychotic use and risk of rhabdomyolysis. J Pharm Pract 27(5):501\u2013512", "journal-title": "J Pharm Pract"}, {"key": "9_CR74", "doi-asserted-by": "publisher", "first-page": "187", "DOI": "10.1186/2193-1801-3-187", "volume": "3", "author": "I Palanca-Maresca", "year": "2014", "unstructured": "Palanca-Maresca I, Ruiz-Antorian B, Centeno-Soto G et al (2014) SENTA: a systematic online monitoring registry for children and adolescents treated with antipsychotics. SpingerPlus 3:187", "journal-title": "SpingerPlus"}, {"key": "9_CR75", "doi-asserted-by": "publisher", "first-page": "759", "DOI": "10.4088/JCP.v69n0509", "volume": "69", "author": "SE Palerm", "year": "2008", "unstructured": "Palerm SE, McLean RM, Ellis PM, Harrison-Woolrych M (2008) Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases. J Clin Psychiatry 69:759\u2013769", "journal-title": "J Clin Psychiatry"}, {"key": "9_CR76", "doi-asserted-by": "publisher", "first-page": "33", "DOI": "10.1177/2045125312464385", "volume": "3", "author": "E Papanastasiou", "year": "2013", "unstructured": "Papanastasiou E (2013) The prevalence and mechanism of metabolic syndrome in schizophrenia: a review. Ther Adv Psychopharmacol 3:33\u201351", "journal-title": "Ther Adv Psychopharmacol"}, {"key": "9_CR77", "doi-asserted-by": "publisher", "first-page": "387", "DOI": "10.1192/bjp.bp.111.101485", "volume": "200", "author": "MJ Peluso", "year": "2012", "unstructured": "Peluso MJ, Lewis SW, Barnes TR, Jones PB (2012) Extrapyramidal motor side effects of first-generation and second-generation antipsychotic drugs. Br J Psychiatry 200:387\u2013392", "journal-title": "Br J Psychiatry"}, {"key": "9_CR78", "first-page": "813", "volume-title": "Applied pharmacokinetics and pharmacodynamics \u2013 principles of therapeutic drug monitoring", "author": "JM Perel", "year": "2006", "unstructured": "Perel JM, Jann MW (2006) Antipsychtoics. In: Burton ME, Shaw LM, Schentag JJ, Evans WE (eds) Applied pharmacokinetics and pharmacodynamics \u2013 principles of therapeutic drug monitoring, 4th ed. Lippincott Williams and Wilkins, Baltimore, pp 813\u2013838", "edition": "4"}, {"key": "9_CR79", "first-page": "421", "volume": "28", "author": "J Peuskens", "year": "2014", "unstructured": "Peuskens J, Pani L, Detraux J, De Hert M (2014) The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs 28:421\u2013453", "journal-title": "CNS Drugs"}, {"key": "9_CR80", "doi-asserted-by": "publisher", "first-page": "948", "DOI": "10.1002/pds.1801", "volume": "18", "author": "H Peyriere", "year": "2009", "unstructured": "Peyriere H, Roux C, Ferard C et al (2009) Antipsychotic-induced ischaemic colitis and gastrointestinal necrosis: a review of the French pharmacovigilance database. Pharmacoepidemiol Drug Saf 18:948\u2013955", "journal-title": "Pharmacoepidemiol Drug Saf"}, {"key": "9_CR81", "doi-asserted-by": "publisher", "first-page": "153", "DOI": "10.4103/0253-7176.92067", "volume": "33", "author": "KG Piparva", "year": "2011", "unstructured": "Piparva KG, Buch JG, Chandrani KV (2011) Analysis of adverse drug reactions of atypical antipsychotic drugs in psychiatry OPD. Indian J Psychol Med 33:153\u2013157", "journal-title": "Indian J Psychol Med"}, {"key": "9_CR82", "doi-asserted-by": "publisher", "first-page": "91", "DOI": "10.2165/00002018-200225020-00004", "volume": "25", "author": "F Pisani", "year": "2002", "unstructured": "Pisani F, Oteri G, Costa C, Di Raimondo G, Di Perri R (2002) Effects of psychotropic drugs on seizure threshold. Drug Saf 25:91\u2013110", "journal-title": "Drug Saf"}, {"key": "9_CR83", "doi-asserted-by": "publisher", "first-page": "467", "DOI": "10.1007/s40264-013-0032-z", "volume": "36", "author": "E Poluzzi", "year": "2013", "unstructured": "Poluzzi E, Raschi E, Kochi A et al (2013) Antipsychotics and torsadogenic risk: signals emerging from the US FDA adverse events reporting system database. Drug Saf 36:467\u2013479", "journal-title": "Drug Saf"}, {"key": "9_CR84", "doi-asserted-by": "publisher", "first-page": "176", "DOI": "10.4103/0019-5545.130502", "volume": "56", "author": "RP Rajkumar", "year": "2014", "unstructured": "Rajkumar RP, Melvin G (2014) Pharmacovigilance for psychiatrists: an introduction. Ind J Psychiatry 56:176\u2013181", "journal-title": "Ind J Psychiatry"}, {"key": "9_CR85", "doi-asserted-by": "publisher", "first-page": "325", "DOI": "10.2165/00002018-200932040-00006", "volume": "32", "author": "FA Rani", "year": "2009", "unstructured": "Rani FA, Byrne PJ, Murray ML, Carter P, Wong ICK (2009) Paediatric atypical antipsychotic monitoring safety (PAMS) study. Drug Saf 32:325\u2013333", "journal-title": "Drug Saf"}, {"key": "9_CR86", "doi-asserted-by": "publisher", "first-page": "143", "DOI": "10.1097/01.pra.0000271655.02093.49", "volume": "13", "author": "PR Recupero", "year": "2007", "unstructured": "Recupero PR, Rainey SE (2007) Managing risk when considering the use of atypical antipsychotics for elderly patients with dementia-related psychosis. J Psychiatr Pract 13:143\u2013152", "journal-title": "J Psychiatr Pract"}, {"issue": "Suppl 10", "key": "9_CR87", "first-page": "5", "volume": "60", "author": "E Richelson", "year": "1999", "unstructured": "Richelson E (1999) Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiatry 60(Suppl 10):5\u201314", "journal-title": "J Clin Psychiatry"}, {"key": "9_CR88", "doi-asserted-by": "publisher", "first-page": "1243", "DOI": "10.4088/JCP.10ac06470yel", "volume": "71", "author": "E Richelson", "year": "2010", "unstructured": "Richelson E (2010) New antipsychotic drugs: how do their receptor-binding profiles compare? J Clin Psychiatry 71:1243\u20131244", "journal-title": "J Clin Psychiatry"}, {"key": "9_CR89", "doi-asserted-by": "publisher", "first-page": "29", "DOI": "10.1016/S0024-3205(00)00911-5", "volume": "68", "author": "E Richelson", "year": "2000", "unstructured": "Richelson E, Sounder T (2000) Binding of antipsychotic drugs to human brain receptors \u2013 focus on newer generation compounds. Life Sci 68:29\u201339", "journal-title": "Life Sci"}, {"key": "9_CR90", "first-page": "292", "volume": "4", "author": "HJ Riordan", "year": "2011", "unstructured": "Riordan HJ, Antonini P, Murphy MF (2011) Atypical antipsychotics and metabolic syndrome in patients with schizophrenia: risk factors, monitoring, and healthcare implications. Am Health Drug Benefits 4:292\u2013302", "journal-title": "Am Health Drug Benefits"}, {"key": "9_CR91", "doi-asserted-by": "publisher", "first-page": "1934", "DOI": "10.1001/jama.294.15.1934", "volume": "294", "author": "LSD Schneider", "year": "2005", "unstructured": "Schneider LSD, Dagerman KS, Insel P (2005) Risk of death with atypical antipsychotic drug treatment for dementia. JAMA 294:1934\u20131943", "journal-title": "JAMA"}, {"key": "9_CR92", "doi-asserted-by": "publisher", "first-page": "1525", "DOI": "10.1056/NEJMoa061240", "volume": "355", "author": "LS Schneider", "year": "2006", "unstructured": "Schneider LS, Tariot PN, Dagerman KS et al (2006) Effectiveness of atypical antipsychotic drugs in patients with Alzheimer\u2019s disease. NEJM 355:1525\u20131538", "journal-title": "NEJM"}, {"key": "9_CR93", "doi-asserted-by": "publisher", "first-page": "615", "DOI": "10.1177/0269881114533599", "volume": "28", "author": "C Schneider", "year": "2014", "unstructured": "Schneider C, Taylor D, Zalsman G, Frangou S, Kyriakopoulos M (2014) Antipsychotics use in children and adolescents: an on-going challenge in clinical practice. J Psychopharmacol 28:615\u2013623", "journal-title": "J Psychopharmacol"}, {"key": "9_CR94", "doi-asserted-by": "publisher", "first-page": "417", "DOI": "10.1097/JGP.0b013e31819b8936", "volume": "17", "author": "L Simoni-Wastila", "year": "2009", "unstructured": "Simoni-Wastila L, Ryder PT, Qian J et al (2009) Association of antipsychotic use with hospital events and mortality among Medicare beneficiaries residing in long-term care facilities. Am J Geriatr Psychiatry 17:417\u2013427", "journal-title": "Am J Geriatr Psychiatry"}, {"key": "9_CR95", "doi-asserted-by": "publisher", "first-page": "11", "DOI": "10.1111/j.1600-0447.1970.tb02066.x", "volume": "212", "author": "GM Simpson", "year": "1970", "unstructured": "Simpson GM, Angus JW (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212:11\u201319", "journal-title": "Acta Psychiatr Scand Suppl"}, {"key": "9_CR96", "doi-asserted-by": "publisher", "first-page": "440", "DOI": "10.1089/cap.2011.0134", "volume": "22", "author": "K Star", "year": "2012", "unstructured": "Star K, Iessa N, Almandil NB et al (2012) Rhabdomyolysis reported for children and adolescents treated with antipsychotic medicines: a case series analysis. J Child Adolesc Psychopharmacol 22:440\u2013451", "journal-title": "J Child Adolesc Psychopharmacol"}, {"key": "9_CR97", "doi-asserted-by": "publisher", "first-page": "790", "DOI": "10.1002/mds.23015", "volume": "25", "author": "C Stephanie", "year": "2010", "unstructured": "Stephanie C, Trenkwalder C (2010) Rhabdomyolysis after low dose quetiapine in a patient with Parkinson\u2019s disease with drug-induced psychosis. A case report. Mov Disorder 25:790\u2013791", "journal-title": "Mov Disorder"}, {"key": "9_CR98", "doi-asserted-by": "publisher", "first-page": "52", "DOI": "10.1111/acps.12222", "volume": "130", "author": "YP Su", "year": "2014", "unstructured": "Su YP, Chang CK, Hayes RD et al (2014) Retrospective chart review on exposure to psychotropic medications associated with neuroleptic malignant syndrome. Acta Psychiatr Scand 130:52\u201360", "journal-title": "Acta Psychiatr Scand"}, {"key": "9_CR99", "doi-asserted-by": "publisher", "first-page": "748", "DOI": "10.1592/phco.26.6.748", "volume": "26", "author": "A Szarfman", "year": "2006", "unstructured": "Szarfman A, Tonning JM, Levine J, Doraiswamy PM (2006) Atypical antipsychotics and pituitary tumors: a pharmacovigilance study. Pharmacotherapy 26:748\u2013758", "journal-title": "Pharmacotherapy"}, {"key": "9_CR100", "doi-asserted-by": "publisher", "first-page": "975", "DOI": "10.1001/archinte.1980.00040020975020", "volume": "140", "author": "CW Tam", "year": "1980", "unstructured": "Tam CW, Olin BR, Ruiz AE (1980) Loxapine-associated rhabdomyolysis and acute renal failure. Arch Int Med 140:975\u2013976", "journal-title": "Arch Int Med"}, {"key": "9_CR101", "doi-asserted-by": "publisher", "first-page": "52", "DOI": "10.1192/bjp.bp.111.105189", "volume": "201", "author": "JN Trollor", "year": "2012", "unstructured": "Trollor JN, Chen X, Chitty K, Sachdev PS (2012) Comparison of neuroleptic malignant syndrome induced by first- and second-generation antipsychotics. Br J Psychiatry 201:52\u201356", "journal-title": "Br J Psychiatry"}, {"key": "9_CR102", "unstructured": "US Food and Drug Administration (2003) Safety alert \u2013 risperdal (risperidone) [on line]. Available at \n                  http://www.fda.gov/cder/drug/advisory/antipsychotics.htm\n                  \n                . Accessed May 2014"}, {"key": "9_CR103", "unstructured": "US Food and Drug Administration (2014) FDA public health advisory: deaths with antipsychotics in elderly patients with behavioral disturbances. Available at \n                  http://www.fda.gov/cder/drug/advisory/antipsychotics.htm\n                  \n                . Accessed May 2014"}, {"key": "9_CR104", "doi-asserted-by": "publisher", "first-page": "2", "DOI": "10.4088/PCC.v05n0504", "volume": "5", "author": "WV Vieweg", "year": "2003", "unstructured": "Vieweg WV (2003) New generation antipsychotic drugs and QTc interval prolongation. Primary Care Companion J Clin Psychiatry 5:2\u20135, 215", "journal-title": "Primary Care Companion J Clin Psychiatry"}, {"key": "9_CR105", "doi-asserted-by": "publisher", "first-page": "1521", "DOI": "10.1176/ajp.155.11.1521", "volume": "155", "author": "MG Woerner", "year": "1998", "unstructured": "Woerner MG, Alvir JMJ, Saltz BL, Lieberman JA, Kane JM (1998) Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry 155:1521\u20131528", "journal-title": "Am J Psychiatry"}, {"key": "9_CR106", "doi-asserted-by": "publisher", "first-page": "1738", "DOI": "10.1038/npp.2011.55", "volume": "36", "author": "MG Woerner", "year": "2011", "unstructured": "Woerner MG, Correll CU, Alvir JMJ, Greenwald B, Delman H, Kane JM (2011) Incidence of tardive dyskinesia with risperidone or olanzapine in the elderly: results from a 2-year, prospective study in antipsychotic-na\u00efve patients. Neuropsychopharmacology 36:1738\u20131746", "journal-title": "Neuropsychopharmacology"}, {"key": "9_CR107", "first-page": "89", "volume": "6", "author": "FA Zarrouf", "year": "2007", "unstructured": "Zarrouf FA, Bhanot V (2007) Neuroleptic malignant syndrome: don\u2019t let your guard down yet. Curr Psychiatry 6:89\u201395", "journal-title": "Curr Psychiatry"}], "container-title": ["Pharmacovigilance in Psychiatry"], "link": [{"URL": "http://link.springer.com/content/pdf/10.1007/978-3-319-24741-0_9", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 31]], "date-time": "2019-05-31T21:26:44Z", "timestamp": 1559338004000}, "score": 21.686623, "issued": {"date-parts": [[2015, 12, 8]]}, "ISBN": ["9783319247397", "9783319247410"], "references-count": 107, "URL": "http://dx.doi.org/10.1007/978-3-319-24741-0_9", "relation": {"cites": []}}, {"indexed": {"date-parts": [[2019, 11, 20]], "date-time": "2019-11-20T16:44:33Z", "timestamp": 1574268273605}, "reference-count": 0, "publisher": "BMJ", "issue": "11", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Thorax"], "published-print": {"date-parts": [[1996, 11, 1]]}, "DOI": "10.1136/thx.51.11.1170-a", "type": "journal-article", "created": {"date-parts": [[2008, 12, 13]], "date-time": "2008-12-13T03:22:59Z", "timestamp": 1229138579000}, "page": "1170-1170", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Manual of Clinical Problems in Pulmonary Medicine"], "prefix": "10.1136", "volume": "51", "author": [{"name": "MW", "sequence": "first", "affiliation": []}], "member": "239", "container-title": ["Thorax"], "language": "en", "link": [{"URL": "https://syndication.highwire.org/content/doi/10.1136/thx.51.11.1170-a", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2016, 12, 23]], "date-time": "2016-12-23T19:05:18Z", "timestamp": 1482519918000}, "score": 20.249603, "issued": {"date-parts": [[1996, 11, 1]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[1996, 11, 1]]}, "issue": "11"}, "URL": "http://dx.doi.org/10.1136/thx.51.11.1170-a", "ISSN": ["0040-6376"], "issn-type": [{"value": "0040-6376", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T08:04:14Z", "timestamp": 1574496254532}, "reference-count": 0, "publisher": "Oxford University Press (OUP)", "issue": "Supplement_5", "content-domain": {"domain": [], "crossmark-restriction": false}, "published-print": {"date-parts": [[1987, 9, 1]]}, "DOI": "10.1093/clinids/9.supplement_5.s517", "type": "journal-article", "created": {"date-parts": [[2011, 2, 23]], "date-time": "2011-02-23T22:01:00Z", "timestamp": 1298498460000}, "page": "S517-S526", "source": "Crossref", "is-referenced-by-count": 72, "title": ["Polysaccharide Antigens of Escherichia coli"], "prefix": "10.1093", "volume": "9", "author": [{"given": "Klaus", "family": "Jann", "sequence": "first", "affiliation": []}, {"given": "Barbara", "family": "Jann", "sequence": "additional", "affiliation": []}], "member": "286", "published-online": {"date-parts": [[1987, 9]]}, "container-title": ["Clinical Infectious Diseases"], "language": "en", "link": [{"URL": "http://academic.oup.com/cid/article-pdf/9/Supplement_5/S517/20916807/9-Supplement_5-S517.pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2017, 10, 14]], "date-time": "2017-10-14T04:50:07Z", "timestamp": 1507956607000}, "score": 20.096645, "issued": {"date-parts": [[1987, 9, 1]]}, "references-count": 0, "journal-issue": {"published-online": {"date-parts": [[1987, 9]]}, "published-print": {"date-parts": [[1987, 9, 1]]}, "issue": "Supplement_5"}, "URL": "http://dx.doi.org/10.1093/clinids/9.supplement_5.s517", "ISSN": ["1537-6591", "1058-4838"], "issn-type": [{"value": "1058-4838", "type": "print"}, {"value": "1537-6591", "type": "electronic"}]}, {"indexed": {"date-parts": [[2019, 12, 4]], "date-time": "2019-12-04T04:39:02Z", "timestamp": 1575434342879}, "reference-count": 3, "publisher": "Wiley", "issue": "3", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2019, 4, 9]], "date-time": "2019-04-09T00:00:00Z", "timestamp": 1554768000000}, "delay-in-days": 0, "content-version": "tdm"}, {"URL": "http://onlinelibrary.wiley.com/termsAndConditions#vor", "start": {"date-parts": [[2019, 4, 9]], "date-time": "2019-04-09T00:00:00Z", "timestamp": 1554768000000}, "delay-in-days": 0, "content-version": "vor"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Nutrition in Clinical Practice"], "published-print": {"date-parts": [[2019, 6]]}, "DOI": "10.1002/ncp.10305", "type": "journal-article", "created": {"date-parts": [[2019, 4, 10]], "date-time": "2019-04-10T04:10:48Z", "timestamp": 1554869448000}, "page": "477-477", "source": "Crossref", "is-referenced-by-count": 0, "title": ["Assessing Evidence and the Need for High-Quality Research in Clinical Nutrition"], "prefix": "10.1002", "volume": "34", "author": [{"ORCID": "http://orcid.org/0000-0002-5783-9419", "authenticated-orcid": false, "given": "Jann", "family": "Arends", "sequence": "first", "affiliation": [{"name": "Klinik f\u00fcr Innere Medizin I; Universit\u00e4tsklinikum Freiburg; Freiburg im Breisgau Germany"}]}], "member": "311", "published-online": {"date-parts": [[2019, 4, 9]]}, "reference": [{"issue": "1", "key": "10.1002/ncp.10305-BIB0001|ncp10305-cit-0001", "doi-asserted-by": "crossref", "first-page": "60", "DOI": "10.1002/ncp.10227", "article-title": "Assessing the evidence in evidence-based medicine", "volume": "34", "author": "Koretz", "year": "2019", "journal-title": "Nutr Clin Pract."}, {"issue": "1", "key": "10.1002/ncp.10305-BIB0002|ncp10305-cit-0002", "doi-asserted-by": "crossref", "first-page": "11", "DOI": "10.1016/j.clnu.2016.07.015", "article-title": "ESPEN guidelines on nutrition in cancer patients", "volume": "36", "author": "Arends", "year": "2017", "journal-title": "Clin Nutr."}, {"issue": "5", "key": "10.1002/ncp.10305-BIB0003|ncp10305-cit-0003", "doi-asserted-by": "crossref", "first-page": "1141", "DOI": "10.1093/annonc/mdy114", "article-title": "Systematic review and meta-analysis of the evidence for oral nutritional intervention on nutritional and clinical outcomes during chemo(radio)therapy: current evidence and guidance for design of future trials", "volume": "29", "author": "van der Schueren", "year": "2018", "journal-title": "Ann Oncol."}], "container-title": ["Nutrition in Clinical Practice"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fncp.10305", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://onlinelibrary.wiley.com/wol1/doi/10.1002/ncp.10305/fullpdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 5, 14]], "date-time": "2019-05-14T19:26:42Z", "timestamp": 1557862002000}, "score": 19.556717, "issued": {"date-parts": [[2019, 4, 9]]}, "references-count": 3, "journal-issue": {"published-print": {"date-parts": [[2019, 6]]}, "issue": "3"}, "URL": "http://dx.doi.org/10.1002/ncp.10305", "archive": ["Portico"], "relation": {"cites": []}, "ISSN": ["0884-5336"], "issn-type": [{"value": "0884-5336", "type": "print"}], "subject": ["Nutrition and Dietetics", "Medicine (miscellaneous)"]}, {"indexed": {"date-parts": [[2019, 11, 19]], "date-time": "2019-11-19T15:47:11Z", "timestamp": 1574178431298}, "reference-count": 0, "publisher": "Springer Science and Business Media LLC", "issue": "3", "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["Disease Management and Health Outcomes"], "published-print": {"date-parts": [[1998]]}, "DOI": "10.2165/00115677-199803030-00002", "type": "journal-article", "created": {"date-parts": [[2006, 1, 20]], "date-time": "2006-01-20T05:12:02Z", "timestamp": 1137733922000}, "page": "115-129", "source": "Crossref", "is-referenced-by-count": 4, "title": ["Economic Considerations and Formulary Management of Oral Antipsychotics"], "prefix": "10.1007", "volume": "3", "author": [{"given": "Michael W.", "family": "Jann", "sequence": "first", "affiliation": []}, {"given": "Lawrence J.", "family": "Cohen", "sequence": "additional", "affiliation": []}], "member": "297", "container-title": ["Disease Management and Health Outcomes"], "language": "en", "deposited": {"date-parts": [[2013, 1, 20]], "date-time": "2013-01-20T14:17:36Z", "timestamp": 1358691456000}, "score": 19.124949, "subtitle": [""], "issued": {"date-parts": [[1998]]}, "references-count": 0, "journal-issue": {"issue": "3"}, "URL": "http://dx.doi.org/10.2165/00115677-199803030-00002", "ISSN": ["1173-8790"], "issn-type": [{"value": "1173-8790", "type": "print"}]}, {"indexed": {"date-parts": [[2019, 12, 2]], "date-time": "2019-12-02T06:32:21Z", "timestamp": 1575268341114}, "reference-count": 79, "publisher": "Springer Science and Business Media LLC", "issue": "3", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2018, 3, 1]], "date-time": "2018-03-01T00:00:00Z", "timestamp": 1519862400000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": ["link.springer.com"], "crossmark-restriction": false}, "short-container-title": ["CNS Drugs"], "published-print": {"date-parts": [[2018, 3]]}, "DOI": "10.1007/s40263-018-0508-6", "type": "journal-article", "created": {"date-parts": [[2018, 3, 22]], "date-time": "2018-03-22T14:23:44Z", "timestamp": 1521728624000}, "page": "241-257", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy", "source": "Crossref", "is-referenced-by-count": 6, "title": ["Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents"], "prefix": "10.1007", "volume": "32", "author": [{"given": "Michael W.", "family": "Jann", "sequence": "first", "affiliation": []}, {"given": "Scott R.", "family": "Penzak", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2018, 3, 22]]}, "reference": [{"key": "508_CR1", "doi-asserted-by": "publisher", "first-page": "637", "DOI": "10.1007/s40263-013-0083-9", "volume": "27", "author": "A Rauch", "year": "2013", "unstructured": "Rauch A, Fleischhacker WW. Long-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspective. CNS Drugs. 2013;27:637\u201352.", "journal-title": "CNS Drugs"}, {"key": "508_CR2", "doi-asserted-by": "publisher", "first-page": "310", "DOI": "10.2174/15748847113089990051", "volume": "9", "author": "S Spanarello", "year": "2014", "unstructured": "Spanarello S, La Ferla T. The pharmacokinetics of long-acting antipsychotic medications. Curr Clin Pharmacol. 2014;9:310\u20137.", "journal-title": "Curr Clin Pharmacol"}, {"key": "508_CR3", "doi-asserted-by": "publisher", "first-page": "S51", "DOI": "10.1192/bjp.195.52.s1", "volume": "195", "author": "MX Patel", "year": "2009", "unstructured": "Patel MX, Taylor M, David AS. Antipsychotic long-acting injections: mind the gap. Br J Psychiatry. 2009;195:S51\u20134.", "journal-title": "Br J Psychiatry"}, {"key": "508_CR4", "doi-asserted-by": "publisher", "first-page": "689", "DOI": "10.1007/s40263-016-0350-7", "volume": "30", "author": "E Parellada", "year": "2016", "unstructured": "Parellada E, Bioque M. Barriers to the use of long-acting injectable antipsychotics in the management of schizophrenia. CNS Drugs. 2016;30:689\u2013701.", "journal-title": "CNS Drugs"}, {"key": "508_CR5", "first-page": "35", "volume": "22", "author": "J Hunter", "year": "2008", "unstructured": "Hunter J. Intramuscular injection techniques. Nurs Stand. 2008;22:35\u201340.", "journal-title": "Nurs Stand"}, {"issue": "suppl. 3", "key": "508_CR6", "doi-asserted-by": "publisher", "first-page": "1", "DOI": "10.4088/JCP.15032su1", "volume": "77", "author": "CU Correll", "year": "2016", "unstructured": "Correll CU, Citrome L, Haddad PM, et al. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry. 2016;77(suppl. 3):1\u201324.", "journal-title": "J Clin Psychiatry"}, {"key": "508_CR7", "doi-asserted-by": "publisher", "first-page": "1739", "DOI": "10.1021/mp500070m", "volume": "11", "author": "JF Rememar", "year": "2014", "unstructured": "Rememar JF. Making the leap from daily oral dosing to long-acting injectables: lessons from the antipsychotics. Mol Pharm. 2014;11:1739\u201349.", "journal-title": "Mol Pharm"}, {"key": "508_CR8", "unstructured": "Risperdal\u00ae Consta\u00ae (risperidone) package insert, Ortho-McNeil Janssen Pharmaceuticals, Inc. revised 2010."}, {"key": "508_CR9", "unstructured": "Zyprexa\u00ae Relprevv\u00ae (olanzapine pamoate) package insert, Eli Lilly and Company, 2009."}, {"key": "508_CR10", "unstructured": "Invega\u00ae Sustenna\u00ae (paliperidone palmitate) package insert, Janssen Pharmaceuticals, Inc. 2009."}, {"key": "508_CR11", "unstructured": "Invega\u00ae Trinza\u2122 (paliperidone palmitate) package insert, Janssen Pharmaceuticals, Inc. 2015."}, {"key": "508_CR12", "doi-asserted-by": "publisher", "first-page": "1125", "DOI": "10.2147/NDT.S133433", "volume": "13", "author": "PM Salzman", "year": "2017", "unstructured": "Salzman PM, Raoufina A, Legacy S, Such P, Eramo A. Plasma concentrations and dosing of 2 long-acting injectable formulations of aripiprazole. Neuropsychiatr Dis Treat. 2017;13:1125\u20139.", "journal-title": "Neuropsychiatr Dis Treat"}, {"key": "508_CR13", "doi-asserted-by": "publisher", "first-page": "19", "DOI": "10.1016/j.rinphs.2014.04.002", "volume": "4", "author": "M Rohde", "year": "2014", "unstructured": "Rohde M, Mork N, Hakansson A, et al. Biological conversion of aripiprazole lauroxil\u2014an N-acyloxymethyl aripiprazole prodrug. Results Pharm Sci. 2014;4:19\u201325.", "journal-title": "Results Pharm Sci"}, {"key": "508_CR14", "unstructured": "Abilify\u00ae Maintena\u00ae (aripiprazole monohydrate) package insert, Otsuka Pharmaceuticals, 2017."}, {"key": "508_CR15", "unstructured": "Aristada\u2122 (aripiprazole lauroxil) package insert, Alkermes, Inc. 2015."}, {"key": "508_CR16", "first-page": "1", "volume": "11", "author": "WK Kennedy", "year": "2012", "unstructured": "Kennedy WK. Where and how to use long-acting injections. Curr Psychiatry. 2012;11:1\u20138.", "journal-title": "Curr Psychiatry"}, {"key": "508_CR17", "unstructured": "Hill CL, Phadke D, Boyce KM. Four-week iloperidone depot injectable: safety and pharmacokinetic profile in patients with schizophrenia and schizoaffective disorder. In: Poster presented at: 161st annual meeting of the American Psychiatric Association; May 3\u20138, 2008; Washington DC."}, {"key": "508_CR18", "doi-asserted-by": "publisher", "first-page": "315", "DOI": "10.2165/00003088-198510040-00003", "volume": "10", "author": "MW Jann", "year": "1985", "unstructured": "Jann MW, Ereshefsky L, Saklad SR. Clinical pharmacokinetics of the depot antipsychotics. Clin Pharmacokinet. 1985;10:315\u201333.", "journal-title": "Clin Pharmacokinet"}, {"key": "508_CR19", "doi-asserted-by": "publisher", "first-page": "493", "DOI": "10.2165/00003495-200363050-00004", "volume": "63", "author": "AC Altamura", "year": "2003", "unstructured": "Altamura AC, Sassella F, Santini A, et al. Intramuscular preparations of antipsychotics: uses and relevance in clinical practice. Drugs. 2003;63:493\u2013512.", "journal-title": "Drugs"}, {"key": "508_CR20", "author": "MW Jann", "first-page": "139", "year": "2016", "unstructured": "Jann MW, Antipsychotics Kennedy WK. In: Jann MW, Penzak SR, Cohen LJ, editors. Applied Clinical pharmacokinetics and pharmacodynamics of psychopharmacological agents. Switzerland: Springer International Publishing; 2016. p. 139\u201374.", "volume-title": "Applied Clinical pharmacokinetics and pharmacodynamics of psychopharmacological agents", "DOI": "10.1007/978-3-319-27883-4_7", "doi-asserted-by": "publisher"}, {"key": "508_CR21", "doi-asserted-by": "publisher", "first-page": "227", "DOI": "10.2165/11203810-000000000-00000", "volume": "24", "author": "SM Hoy", "year": "2010", "unstructured": "Hoy SM, Scott LJ. Keating GM Intramuscular paliperidone palmitate. CNS Drugs. 2010;24:227\u201344.", "journal-title": "CNS Drugs"}, {"key": "508_CR22", "doi-asserted-by": "publisher", "first-page": "140", "DOI": "10.1111/j.1742-1241.2008.01900.x", "volume": "63", "author": "L Citrome", "year": "2009", "unstructured": "Citrome L. Olanz2016apine pamoare: a stick in time? Int J Clin Pract. 2009;63:140\u201350.", "journal-title": "Int J Clin Pract"}, {"key": "508_CR23", "doi-asserted-by": "publisher", "first-page": "585", "DOI": "10.2165/11316870-000000000-00000", "volume": "48", "author": "MN Samtani", "year": "2009", "unstructured": "Samtani MN, Vermeulen A, Stuyckens K. Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia. Clin Pharmacokinet. 2009;48:585\u2013600.", "journal-title": "Clin Pharmacokinet"}, {"key": "508_CR24", "author": "MO Magnusson", "year": "2016", "unstructured": "Magnusson MO, Samtani MN, Plan EL, et al. Population pharmacokinetics of a novel once-every 3\u00a0months intramuscular formulation of paliperidone palmitate in patients with schizophrenia. Clin Pharmacokinet. 2016. \n                    https://doi.org/10.1007/s40262-016-0459-3\n                    \n                  .", "journal-title": "Clin Pharmacokinet", "DOI": "10.1007/s40262-016-0459-3", "doi-asserted-by": "publisher"}, {"key": "508_CR25", "doi-asserted-by": "publisher", "first-page": "211", "DOI": "10.1177/0091270002250613", "volume": "43", "author": "H Zhou", "year": "2003", "unstructured": "Zhou H. Pharmacokinetic strategies in deciphering atypical drug absorption profiles. J Clin Pharmacol. 2003;43:211\u201327.", "journal-title": "J Clin Pharmacol"}, {"key": "508_CR26", "doi-asserted-by": "publisher", "first-page": "44", "DOI": "10.1002/cpt197517144", "volume": "17", "author": "EF Evans", "year": "1975", "unstructured": "Evans EF, Proctor JD, Fratkin MJ, Velandia J, Wasserman AJ. Blood flow in muscle groups and drug absorption. Clin Pharmacol Ther. 1975;17:44\u20137.", "journal-title": "Clin Pharmacol Ther"}, {"key": "508_CR27", "doi-asserted-by": "publisher", "first-page": "1011", "DOI": "10.1177/0091270009355156", "volume": "50", "author": "A Thyssen", "year": "2010", "unstructured": "Thyssen A, Rusch S, Herben V, Quiroz J, Mannaert E. Risperidone long-acting injection: pharmacokinetics following administration in deltoid versus gluteal muscle in schizophrenic patients. J Clin Pharmacol. 2010;50:1011\u201321.", "journal-title": "J Clin Pharmacol"}, {"key": "508_CR28", "doi-asserted-by": "publisher", "first-page": "404", "DOI": "10.1016/j.schres.2014.09.021", "volume": "159", "author": "R Turncliff", "year": "2014", "unstructured": "Turncliff R, Hard M, Du Y, Risinger R, Ehrich EW. Relative bioavailability and safety of aripiprazole lauroxil, a novel once-monthly, long-acting injectable atypical antipsychotic, following deltoid and gluteal administration in adult subjects with schizophrenia. Schizophr Res. 2014;159:404\u201310.", "journal-title": "Schizophr Res"}, {"key": "508_CR29", "doi-asserted-by": "publisher", "first-page": "295", "DOI": "10.1093/ijnp/pyw116", "volume": "20", "author": "A Raoufina", "year": "2017", "unstructured": "Raoufina A, Peters-Strickland T, Nylander AG, et al. Aripiprazole mone-monthly 400\u00a0mg: comparison of pharmacokinetics, tolerability, and safety of deltoid versus gluteal administration. Int J Neuropsychopharmacol. 2017;20:295\u2013304.", "journal-title": "Int J Neuropsychopharmacol"}, {"key": "508_CR30", "doi-asserted-by": "publisher", "first-page": "1022", "DOI": "10.1016/j.pnpbp.2009.05.014", "volume": "33", "author": "D Hough", "year": "2009", "unstructured": "Hough D, Lindenmayer JP, Gopal S, et al. Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Prog Neuro-psychopharmacol Biol Psychiatry. 2009;33:1022\u201331.", "journal-title": "Prog Neuro-psychopharmacol Biol Psychiatry"}, {"key": "508_CR31", "doi-asserted-by": "publisher", "first-page": "1048", "DOI": "10.1002/jcph.295", "volume": "54", "author": "A Cleton", "year": "2014", "unstructured": "Cleton A, Rossenu S, Crauwels H, et al. A single-dose, open-label, parallel, randomized, dose-proportionality study of paliperidone after intramuscular injections of paliperidone palmitate in the deltoid or gluteal muscle in patients with schizophrenia. J Clin Pharmacol. 2014;54:1048\u201357.", "journal-title": "J Clin Pharmacol"}, {"key": "508_CR32", "doi-asserted-by": "publisher", "first-page": "330", "DOI": "10.1002/jcph.597", "volume": "56", "author": "P Ravenstin", "year": "2016", "unstructured": "Ravenstin P, Remmerie B, Eng C, et al. Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: a phase I, single-dose randomized, open-label study. J Clin Pharmacol. 2016;56:330\u20139.", "journal-title": "J Clin Pharmacol"}, {"key": "508_CR33", "doi-asserted-by": "publisher", "first-page": "659", "DOI": "10.1007/s13318-016-0348-z", "volume": "41", "author": "LHN Lee", "year": "2016", "unstructured": "Lee LHN, Choi C, Gershkovich P, et al. Proposing the use of partial AUC as an adjunctive measure in establishing bioequivalence between deltoid and gluteal administration of long-acting injectable antipsychotics. Eur J Drug Metab Pharmacokinet. 2016;41:659\u201364.", "journal-title": "Eur J Drug Metab Pharmacokinet"}, {"key": "508_CR34", "doi-asserted-by": "publisher", "first-page": "721", "DOI": "10.1177/0091270009350622", "volume": "50", "author": "ER Elliott", "year": "2010", "unstructured": "Elliott ER, Purvis TL, Nelson LA, Sommi RW. Inconsistency in risperidone long-acting injection steady-state plasma levels when switching from deltoid to gluteal administration. J Clin Pharmacol. 2010;50:721\u20134.", "journal-title": "J Clin Pharmacol"}, {"key": "508_CR35", "doi-asserted-by": "publisher", "first-page": "E56", "DOI": "10.1503/jpn.150206", "volume": "41", "author": "RM Procyshyn", "year": "2016", "unstructured": "Procyshyn RM, Banasch JL, Barr AM, Honer WG. Breakthrough symptoms after switching long-acting injectable paliperidone palmitate from gluteal to the deltoid site of administration. J Psychiatr Neurosci. 2016;41:E56\u20137.", "journal-title": "J Psychiatr Neurosci"}, {"key": "508_CR36", "first-page": "447", "volume": "35", "author": "J Yin", "year": "2015", "unstructured": "Yin J, Collier AC, Barr AM, Honer WG, Procyshyn RM. Paliperidone palmitate long-acting injectable given intramuscularly in the deltoid vesrus gluteal muscle. Are they therapeutically equivalent? J Clin Psychopharmacol. 2015;35:447\u20139.", "journal-title": "J Clin Psychopharmacol"}, {"key": "508_CR37", "doi-asserted-by": "publisher", "first-page": "195", "DOI": "10.1055/s-0031-1286287", "volume": "44", "author": "C Hiemke", "year": "2011", "unstructured": "Hiemke C, Baumann P, Bergemann N, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: an update 2011. Pharmacopsychiatry. 2011;44:195\u2013235.", "journal-title": "Pharmacopsychiatry"}, {"key": "508_CR38", "first-page": "1249", "volume": "76", "author": "LV Lopez", "year": "2015", "unstructured": "Lopez LV, Kane JM. Recommendations for the monitoring of serum concentrations of antipsychotic drugs in the treatment of schizophrenia. J Clin. 2015;76:1249\u201350.", "journal-title": "J Clin"}, {"key": "508_CR39", "doi-asserted-by": "publisher", "first-page": "349", "DOI": "10.1097/FTD.0b013e3182577c43", "volume": "34", "author": "SVJ Bowskill", "year": "2012", "unstructured": "Bowskill SVJ, Handley SA, Fisher DS, Flanagan RJ, Patel MX. Rsiperidone and total 9-hydroxyrisperidone in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 2002\u20132010. Ther Drug Monit. 2012;34:349\u201355.", "journal-title": "Ther Drug Monit"}, {"key": "508_CR40", "doi-asserted-by": "publisher", "first-page": "81", "DOI": "10.1124/jpet.111.189076", "volume": "341", "author": "EC Muly", "year": "2012", "unstructured": "Muly EC, Votaw JR, Ritchie J, Howell LL. Relationship between dose, drug levels, and D2 receptor occupancy for the atypical antipsychotics risperidone and paliperidone. J Pharmacol Exp Ther. 2012;341:81\u20139.", "journal-title": "J Pharmacol Exp Ther"}, {"key": "508_CR41", "doi-asserted-by": "publisher", "first-page": "229", "DOI": "10.1007/s00213-007-1029-z", "volume": "197", "author": "R Arakawa", "year": "2008", "unstructured": "Arakawa R, Ito H, Taknao A, et al. Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. Psychopharmacol. 2008;197:229\u201335.", "journal-title": "Psychopharmacol"}, {"key": "508_CR42", "doi-asserted-by": "publisher", "first-page": "675", "DOI": "10.1097/JCP.0b013e3182983ffa", "volume": "33", "author": "IM Lako", "year": "2013", "unstructured": "Lako IM, vanden Heuvel ER, Knegtering H, Bruggeman R, Taxis K. Estimating dopamine D2 receptor occupancy for doses of 8 antipsychotics. J Clin Psychopharmacol. 2013;33:675\u201381.", "journal-title": "J Clin Psychopharmacol"}, {"key": "508_CR43", "doi-asserted-by": "publisher", "first-page": "1447", "DOI": "10.4088/JCP.09r05060gre", "volume": "71", "author": "A Sparshatt", "year": "2010", "unstructured": "Sparshatt A, Taylor D, Patel MX, Kapur S. A systematic review of aripiprazole\u2014dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring. J Clin Psychiatry. 2010;71:1447\u201356.", "journal-title": "J Clin Psychiatry"}, {"key": "508_CR44", "doi-asserted-by": "publisher", "first-page": "221", "DOI": "10.1007/s00213-012-2953-0", "volume": "227", "author": "E Kim", "year": "2013", "unstructured": "Kim E, Howes OD, Turkheimer FE, et al. The relationship between antipsychotic D2 occupancy and change in frontal metabolism and working memory. Psychopharmacol. 2013;227:221\u20139.", "journal-title": "Psychopharmacol"}, {"key": "508_CR45", "doi-asserted-by": "publisher", "first-page": "235", "DOI": "10.1097/JCP.0b013e3181dd3103", "volume": "30", "author": "GJ Pandina", "year": "2010", "unstructured": "Pandina GJ, Lindenmayer JP, Lull J, et al. A randomized, placebo-controlled study to assess the efficacy and sagety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol. 2010;30:235\u201344.", "journal-title": "J Clin Psychopharmacol"}, {"key": "508_CR46", "doi-asserted-by": "publisher", "first-page": "107", "DOI": "10.1016/j.schres.2009.10.026", "volume": "116", "author": "D Hough", "year": "2010", "unstructured": "Hough D, Gopal S, Vijapurkar Y, et al. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res. 2010;116:107\u201317.", "journal-title": "Schizophr Res"}, {"key": "508_CR47", "doi-asserted-by": "publisher", "first-page": "273", "DOI": "10.1007/s40263-017-0416-1", "volume": "31", "author": "MO Magnusson", "year": "2017", "unstructured": "Magnusson MO, Santani MN, Plan EL, et al. Dosing and switching strategies of paliperidone palmitate 3-month formulation in patients with schizophrenia based on population pharmacokinetic modeling and simulation, and clinical trial data. CNS Drugs. 2017;31:273\u201388.", "journal-title": "CNS Drugs"}, {"key": "508_CR48", "doi-asserted-by": "publisher", "first-page": "830", "DOI": "10.1001/jamapsychiatry.2015.0241", "volume": "72", "author": "J Berwaerts", "year": "2015", "unstructured": "Berwaerts J, Yanning L, Gopal S, et al. Efficacy and safety of the 3-month formulation of paliperidone palmotate vs placebo for relapse prevention of schizophrenia. JAMA Psychiatry. 2015;72:830\u20139.", "journal-title": "JAMA Psychiatry"}, {"key": "508_CR49", "doi-asserted-by": "publisher", "first-page": "1", "DOI": "10.1093/ijnp/pyw018", "volume": "19", "author": "AJ Savitz", "year": "2016", "unstructured": "Savitz AJ, Xu H, Gopal S, et al. Efficacy and safety of paliperidone palmitate 3-month formulation for patients with schizophrenia: a randomized, multicenter, double-blind, noninferiority study. Int J Neuropsychopharmacol. 2016;19:1\u201314.", "journal-title": "Int J Neuropsychopharmacol"}, {"key": "508_CR50", "doi-asserted-by": "publisher", "first-page": "1763", "DOI": "10.1080/03007995.2017.1359516", "volume": "33", "author": "K Joshi", "year": "2017", "unstructured": "Joshi K, Lafeuille MH, Brown B, et al. Baseline characteristics and treatment patterns of patients with schizophrenia initiated on once-every-three months paliperidone palmitate in a real-world setting. Curr Med Res. 2017;33:1763\u201372.", "journal-title": "Curr Med Res"}, {"key": "508_CR51", "doi-asserted-by": "publisher", "first-page": "281", "DOI": "10.1016/j.schres.2013.06.041", "volume": "150", "author": "S Mallikaarjun", "year": "2013", "unstructured": "Mallikaarjun S, Kane JM, Bricmont P, et al. Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study. Schizophren Res. 2013;150:281\u20138.", "journal-title": "Schizophren Res"}, {"key": "508_CR52", "doi-asserted-by": "publisher", "first-page": "1254", "DOI": "10.4088/JCP.14m09168", "volume": "75", "author": "JM Kane", "year": "2014", "unstructured": "Kane JM, Peters-Strickland T, Baker RA, et al. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatr. 2014;75:1254\u201360.", "journal-title": "J Clin Psychiatr"}, {"key": "508_CR53", "doi-asserted-by": "publisher", "first-page": "347", "DOI": "10.1097/JCP.0000000000000710", "volume": "37", "author": "Z Ismail", "year": "2017", "unstructured": "Ismail Z, Peters-Strickland T, Miguelez M, et al. Aripiprazole once-monthly in the treatment of acute psychotic episodes in schizophrenia. J Clin Psychopharmacol. 2017;37:347\u201350.", "journal-title": "J Clin Psychopharmacol"}, {"key": "508_CR54", "doi-asserted-by": "publisher", "first-page": "617", "DOI": "10.4088/JCP.11m07530", "volume": "73", "author": "JM Kane", "year": "2012", "unstructured": "Kane JM, Sanchez R, Perry PP, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2012;73:617\u201324.", "journal-title": "J Clin Psychiatry"}, {"key": "508_CR55", "doi-asserted-by": "publisher", "first-page": "135", "DOI": "10.1192/bjp.bp.113.134213", "volume": "205", "author": "WW Fleischhacker", "year": "2014", "unstructured": "Fleischhacker WW, Sanchez R, Perry PP, et al. Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomized, non-inferiority study. Br J Psychiatry. 2014;205:135\u201344.", "journal-title": "Br J Psychiatry"}, {"key": "508_CR56", "doi-asserted-by": "publisher", "first-page": "421", "DOI": "10.1016/j.schres.2014.12.013", "volume": "161", "author": "J Ishigooka", "year": "2015", "unstructured": "Ishigooka J, Nakamura J, Fujii Y, et al. Efficacy and safety of aripiprazole once-monthly in Asian patients with schizophrenia: a multicenter, randomized, double-blind, non-inferiority study versus oral aripiprazole. Schizophr Res. 2015;161:421\u20138.", "journal-title": "Schizophr Res"}, {"key": "508_CR57", "doi-asserted-by": "publisher", "first-page": "2299", "DOI": "10.2147/NDT.S91397", "volume": "11", "author": "K Oya", "year": "2015", "unstructured": "Oya K, Kishi T, Iwata N. Efficacy and tolerability of aripiprazole once monthly for schizophrenia: a systematic review and meta-analysis of randomized controlled trials. Neuropsychiatry Dis Treat. 2015;11:2299\u2013307.", "journal-title": "Neuropsychiatry Dis Treat"}, {"key": "508_CR58", "author": "D Naber", "year": "2017", "unstructured": "Naber D, Baker RA, Eramo A, et al. Long-term effectiveness of aripiprazole once-monthly for schizophrenia is maintained in the QUALIFY extension study. Schizo Res. 2017. \n                    https://doi.org/10.1016/jschres.2017.04.013\n                    \n                  .", "journal-title": "Schizo Res.", "DOI": "10.1016/jschres.2017.04.013", "doi-asserted-by": "publisher"}, {"key": "508_CR59", "doi-asserted-by": "publisher", "first-page": "324", "DOI": "10.4088/JCP.16m11201", "volume": "78", "author": "JR Calabrese", "year": "2017", "unstructured": "Calabrese JR, Sanchez R, Jin N, et al. Efficacy and safety of aripiprazole once-monthly in the maintenance treatment of bipolar I disorder: a double-blind, placebo-controlled, 52-week randomized withdrawal study. J Clin Psychiatr. 2017;78:324\u201331.", "journal-title": "J Clin Psychiatr"}, {"key": "508_CR60", "doi-asserted-by": "publisher", "first-page": "289", "DOI": "10.1097/JCP.0000000000000691", "volume": "37", "author": "ML Hard", "year": "2017", "unstructured": "Hard ML, Mills R, Sadler BM, Turncliff RZ, Citrome L. Aripiprazole lauroxil. Pharmacokinetic profile of this long-acting injectable antipsychotic in persons with schizophrenia. J Clin Psychopharmacol. 2017;37:289\u201395.", "journal-title": "J Clin Psychopharmacol"}, {"key": "508_CR61", "author": "ML Hard", "year": "2017", "unstructured": "Hard ML, Mills RJ, Sadler BM, Wehr AY, Weiden PJ, von Moltke L. Pharmacokinetic profile of a 2-month dose regimen of aripiprazole lauroxil: a phase I study and a population pharmacokinetic model. CNS Drugs. 2017. \n                    https://doi.org/10.1007/s40263-017-0447-7\n                    \n                  .", "journal-title": "CNS Drugs", "DOI": "10.1007/s40263-017-0447-7", "doi-asserted-by": "publisher"}, {"key": "508_CR62", "doi-asserted-by": "publisher", "first-page": "1085", "DOI": "10.4088/JCP.14m09741", "volume": "76", "author": "HY Meltzer", "year": "2015", "unstructured": "Meltzer HY, Risinger R, Nasarallah HA, et al. A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia. J Clin Psychiatry. 2015;76:1085\u201390.", "journal-title": "J Clin Psychiatry"}, {"key": "508_CR63", "author": "SG Potkin", "year": "2017", "unstructured": "Potkin SG, Risinger R, Du Y, et al. Efficacy and safety of aripiprazole lauroxil in schizophrenic patients presenting with severe psychotic symptoms during acute exacerbation. Schizophr Res. 2017. \n                    https://doi.org/10.1016/j.schres.2017.03.003\n                    \n                  .", "journal-title": "Schizophr Res", "DOI": "10.1016/j.schres.2017.03.003", "doi-asserted-by": "publisher"}, {"key": "508_CR64", "doi-asserted-by": "publisher", "first-page": "1519", "DOI": "10.4088/JCP.15m10467", "volume": "77", "author": "HA Nasrallah", "year": "2016", "unstructured": "Nasrallah HA, Newcomer JW, Risinger R, et al. Effect of aripiprazole lauroxil metabolic and endocrine profiles and related safety considerations among patients with acute schizophrenia. J Clin Psychiatry. 2016;77:1519\u201325.", "journal-title": "J Clin Psychiatry"}, {"key": "508_CR65", "first-page": "40", "volume": "9", "author": "LA Raedler", "year": "2016", "unstructured": "Raedler LA. Aripiprazole lauroxil (Aristada): long-acting atypical antipsychotic injection approved for the treatment of patients with schizophrenia. Am Health Drug Benefits. 2016;9:40\u20133.", "journal-title": "Am Health Drug Benefits"}, {"key": "508_CR66", "doi-asserted-by": "publisher", "first-page": "41", "DOI": "10.1007/s40263-014-0216-9", "volume": "29", "author": "D Luedecke", "year": "2015", "unstructured": "Luedecke D, Schottle D, Karow A, Lambert M, Naber D. Post-injection delirium/sedation syndrome in patients treated with olanzapine pamoate: mechanism, incidence, and management. CNS Drugs. 2015;29:41\u20136.", "journal-title": "CNS Drugs"}, {"key": "508_CR67", "author": "HC Detke", "year": "2010", "unstructured": "Detke HC, McDonnell DP, Brunner E, et al. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases. BMC Psychiatr. 2010. \n                    https://doi.org/10.1186/1471-244X-10-43\n                    \n                  .", "journal-title": "BMC Psychiatr", "DOI": "10.1186/1471-244X-10-43", "doi-asserted-by": "publisher"}, {"key": "508_CR68", "doi-asserted-by": "publisher", "first-page": "65", "DOI": "10.1186/s12888-015-0450-9", "volume": "15", "author": "CJ Bushe", "year": "2015", "unstructured": "Bushe CJ, Falk D, Anand E, et al. Olanzapine long-acting injection: a review of first experiences of post-injection delirium/sedation syndrome in routine clinical practice. BMC Psychiatry. 2015;15:65.", "journal-title": "BMC Psychiatry"}, {"key": "508_CR69", "doi-asserted-by": "publisher", "first-page": "2737", "DOI": "10.2147/NDT.S107266", "volume": "12", "author": "E Anand", "year": "2016", "unstructured": "Anand E, Berrgren L, Toth A, Detke HC. Clinical outcomes with olanzapine long-acting injection: impact of the 3-h observation period on patient satisfaction and well-being. Neuropsychiatric Dis Treat. 2016;12:2737\u201343.", "journal-title": "Neuropsychiatric Dis Treat"}, {"key": "508_CR70", "doi-asserted-by": "publisher", "first-page": "1349", "DOI": "10.2147/NDT.S79347", "volume": "11", "author": "E Anand", "year": "2015", "unstructured": "Anand E, Berggren L, Deix C, Toth A, McDonnell DP. A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation. Neuropsychiatry Dis Treat. 2015;11:1349\u201357.", "journal-title": "Neuropsychiatry Dis Treat"}, {"key": "508_CR71", "doi-asserted-by": "publisher", "first-page": "1978", "DOI": "10.1001/jama.2014.4310", "volume": "311", "author": "JP McEvoy", "year": "2014", "unstructured": "McEvoy JP, Byerly M, Hamer RM, et al. Effecitiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia. JAMA. 2014;311:1978\u201386.", "journal-title": "JAMA"}, {"key": "508_CR72", "doi-asserted-by": "publisher", "first-page": "498", "DOI": "10.1016/j.schres.2015.07.007", "volume": "168", "author": "D Naber", "year": "2015", "unstructured": "Naber D, Hansen K, Forray C, et al. Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia. Schizophr Res. 2015;168:498\u2013504.", "journal-title": "Schizophr Res"}, {"key": "508_CR73", "doi-asserted-by": "publisher", "first-page": "3", "DOI": "10.1007/s00213-016-4445-0", "volume": "234", "author": "A Schreiner", "year": "2017", "unstructured": "Schreiner A, Caspi A, Bergmans P, et al. Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: a prospective, open-label, interventional study. Psychopharmacol. 2017;234:3\u201313.", "journal-title": "Psychopharmacol"}, {"key": "508_CR74", "doi-asserted-by": "publisher", "first-page": "59", "DOI": "10.1177/2045125316673012", "volume": "7", "author": "A Schreiner", "year": "2017", "unstructured": "Schreiner A, Bergmans P, Cherubin P, Hargarter L. The effect of long-acting paliperidone palmitate once-monthly on negative and depressive symptoms in patients with schizophrenia switched from previous unsuccessful treatment with oral aripiprazole. Ther Adv Psychopharmacol. 2017;7:59\u201365.", "journal-title": "Ther Adv Psychopharmacol"}, {"key": "508_CR75", "author": "R Dammerman", "year": "2018", "unstructured": "Dammerman R, Kim S, Adera M, Schwarz A. Pharmacokinetics and safety of risperidone subcutaneous implants in stable patients with schizophrenia. Clin Pharmacol Drug Dev. 2018. \n                    https://doi.org/10.1002/cpdd.428\n                    \n                  .", "journal-title": "Clin Pharmacol Drug Dev.", "DOI": "10.1002/cpdd.428", "doi-asserted-by": "publisher"}, {"key": "508_CR76", "doi-asserted-by": "publisher", "first-page": "346", "DOI": "10.1186/s12888-017-1507-8", "volume": "17", "author": "JP Anderson", "year": "2017", "unstructured": "Anderson JP, Icten Z, Alas V, Benson C, Joshi K. Comparison and predictors of treatment adherence and remission among patients with schizophrenia treated with paliperidone palmitate or atypical oral antipsychotics in community behavioral health organizations. BMC Psychiatry. 2017;17:346. \n                    https://doi.org/10.1186/212888-071-1507-8\n                    \n                  .", "journal-title": "BMC Psychiatry"}, {"key": "508_CR77", "doi-asserted-by": "publisher", "first-page": "686", "DOI": "10.1001/jamapsychiatry.2017.1322", "volume": "74", "author": "J Tiihonen", "year": "2017", "unstructured": "Tiihonen J, Mittendorfer-Ruiz E, Majak J, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29,823 patients with schizophrenia. JAMA Psychiatry. 2017;74:686\u201393.", "journal-title": "JAMA Psychiatry"}, {"key": "508_CR78", "first-page": "17", "volume": "22", "author": "JM Meyer", "year": "2017", "unstructured": "Meyer JM. Converting oral to long-acting injectable antipsychotics: a guide for the perplexed. CNS Spectr. 2017;22:17\u201327.", "journal-title": "CNS Spectr"}, {"key": "508_CR79", "doi-asserted-by": "publisher", "first-page": "1029", "DOI": "10.1080/14737175.2017.1371014", "volume": "17", "author": "L Citrome", "year": "2017", "unstructured": "Citrome L. Long-acting injectable antipsychotics update: lengthening the dosing interval and expanding the diagnostic indications. Expert Rev Neurother. 2017;17:1029\u201343.", "journal-title": "Expert Rev Neurother"}], "container-title": ["CNS Drugs"], "language": "en", "link": [{"URL": "http://link.springer.com/article/10.1007/s40263-018-0508-6/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/content/pdf/10.1007/s40263-018-0508-6.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/content/pdf/10.1007/s40263-018-0508-6.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 3, 22]], "date-time": "2019-03-22T01:23:05Z", "timestamp": 1553217785000}, "score": 19.124949, "issued": {"date-parts": [[2018, 3]]}, "references-count": 79, "journal-issue": {"published-print": {"date-parts": [[2018, 3]]}, "issue": "3"}, "alternative-id": ["508"], "URL": "http://dx.doi.org/10.1007/s40263-018-0508-6", "relation": {"cites": []}, "ISSN": ["1172-7047", "1179-1934"], "issn-type": [{"value": "1172-7047", "type": "print"}, {"value": "1179-1934", "type": "electronic"}], "subject": ["Pharmacology (medical)", "Psychiatry and Mental health", "Clinical Neurology"], "assertion": [{"value": "22 March 2018", "order": 1, "name": "first_online", "label": "First Online", "group": {"name": "ArticleHistory", "label": "Article History"}}, {"value": "2 June 2018", "order": 2, "name": "change_date", "label": "Change Date", "group": {"name": "ArticleHistory", "label": "Article History"}}, {"value": "Correction", "order": 3, "name": "change_type", "label": "Change Type", "group": {"name": "ArticleHistory", "label": "Article History"}}, {"value": "1. In Page 244, under General Pharmacokinetic Principles, Column 1\u2014the following sentence should come after reference 21:", "order": 4, "name": "change_details", "label": "Change Details", "group": {"name": "ArticleHistory", "label": "Article History"}}, {"order": 1, "name": "Ethics", "group": {"name": "EthicsHeading", "label": "Compliance with Ethical Standards"}}, {"value": "No funds from any sources were used to assist with the preparation of this review article.", "order": 2, "name": "Ethics", "group": {"name": "EthicsHeading", "label": "Funding"}}, {"value": "Michael W. Jann is on Janssen\u2019s Speaker Bureau. Scott R. Penzak has no conflicts of interest.", "order": 3, "name": "Ethics", "group": {"name": "EthicsHeading", "label": "Conflict of interest"}}]}, {"indexed": {"date-parts": [[2019, 12, 2]], "date-time": "2019-12-02T18:03:13Z", "timestamp": 1575309793307}, "update-to": [{"updated": {"date-parts": [[2018, 6, 2]], "date-time": "2018-06-02T00:00:00Z", "timestamp": 1527897600000}, "DOI": "10.1007/s40263-018-0508-6", "type": "correction", "label": "Correction"}], "reference-count": 0, "publisher": "Springer Science and Business Media LLC", "issue": "6", "license": [{"URL": "http://www.springer.com/tdm", "start": {"date-parts": [[2018, 6, 1]], "date-time": "2018-06-01T00:00:00Z", "timestamp": 1527811200000}, "delay-in-days": 0, "content-version": "tdm"}], "content-domain": {"domain": ["link.springer.com"], "crossmark-restriction": false}, "short-container-title": ["CNS Drugs"], "published-print": {"date-parts": [[2018, 6]]}, "DOI": "10.1007/s40263-018-0531-7", "type": "journal-article", "created": {"date-parts": [[2018, 6, 2]], "date-time": "2018-06-02T00:47:31Z", "timestamp": 1527900451000}, "page": "603-603", "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy", "source": "Crossref", "is-referenced-by-count": 1, "title": ["Correction to: Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents"], "prefix": "10.1007", "volume": "32", "author": [{"given": "Michael W.", "family": "Jann", "sequence": "first", "affiliation": []}, {"given": "Scott R.", "family": "Penzak", "sequence": "additional", "affiliation": []}], "member": "297", "published-online": {"date-parts": [[2018, 6, 2]]}, "container-title": ["CNS Drugs"], "language": "en", "link": [{"URL": "http://link.springer.com/article/10.1007/s40263-018-0531-7/fulltext.html", "content-type": "text/html", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/content/pdf/10.1007/s40263-018-0531-7.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining"}, {"URL": "http://link.springer.com/content/pdf/10.1007/s40263-018-0531-7.pdf", "content-type": "application/pdf", "content-version": "vor", "intended-application": "similarity-checking"}], "deposited": {"date-parts": [[2019, 6, 2]], "date-time": "2019-06-02T05:50:43Z", "timestamp": 1559454643000}, "score": 19.124949, "issued": {"date-parts": [[2018, 6]]}, "references-count": 0, "journal-issue": {"published-print": {"date-parts": [[2018, 6]]}, "issue": "6"}, "alternative-id": ["531"], "URL": "http://dx.doi.org/10.1007/s40263-018-0531-7", "ISSN": ["1172-7047", "1179-1934"], "issn-type": [{"value": "1172-7047", "type": "print"}, {"value": "1179-1934", "type": "electronic"}], "subject": ["Pharmacology (medical)", "Psychiatry and Mental health", "Clinical Neurology"], "assertion": [{"value": "2 June 2018", "order": 1, "name": "first_online", "label": "First Online", "group": {"name": "ArticleHistory", "label": "Article History"}}]}, {"indexed": {"date-parts": [[2019, 11, 23]], "date-time": "2019-11-23T06:52:18Z", "timestamp": 1574491938591}, "reference-count": 5, "publisher": "Wiley", "issue": "4", "license": [{"URL": "http://doi.wiley.com/10.1002/tdm_license_1.1", "start": {"date-parts": [[2015, 9, 1]], "date-time": "2015-09-01T00:00:00Z", "timestamp": 1441065600000}, "delay-in-days": 9284, "content-version": "tdm"}], "content-domain": {"domain": [], "crossmark-restriction": false}, "short-container-title": ["British Journal of Clinical Pharmacology"], "published-print": {"date-parts": [[1990, 4]]}, "DOI": "10.1111/j.1365-2125.1990.tb03670.x", "type": "journal-article", "created": {"date-parts": [[2012, 7, 27]], "date-time": "2012-07-27T00:20:32Z", "timestamp": 1343348432000}, "page": "495-496", "source": "Crossref", "is-referenced-by-count": 2, "title": ["Failure of a nomogram to achieve target aminoglycoside concentrations [letter; comment]"], "prefix": "10.1111", "volume": "29", "author": [{"given": "MW", "family": "Perkins", "sequence": "first", "affiliation": []}], "member": "311", "published-online": {"date-parts": [[2012, 7, 26]]}, "reference": [{"key": "10.1111/j.1365-2125.1990.tb03670.x-BIB1|cit2", "doi-asserted-by": "crossref", "first-page": "643", "DOI": "10.1007/BF00542215", "article-title": "Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients", "volume": "24", "author": "Bauer", "year": "1983", "journal-title": "Eur. J. clin. Pharmac."}, {"key": "10.1111/j.1365-2125.1990.tb03670.x-BIB2|cit3", "doi-asserted-by": "crossref", "first-page": "137", "DOI": "10.1111/j.1365-2125.1989.tb05405.x", "article-title": "Individualised aminoglycoside dosage based on pharmacokinetic analysis is superior to dosage based on physician intuition at achieving target plasma drug concentrations", "volume": "28", "author": "Begg", "year": "1989", "journal-title": "Br. J. clin. Pharmac."}, {"key": "10.1111/j.1365-2125.1990.tb03670.x-BIB3|cit4", "doi-asserted-by": "crossref", "first-page": "31", "DOI": "10.1159/000180580", "article-title": "Prediction of creatinine clearance from serum creatinine", "volume": "16", "author": "Cockcroft", "year": "1976", "journal-title": "Nephron"}, {"key": "10.1111/j.1365-2125.1990.tb03670.x-BIB4|cit5", "doi-asserted-by": "crossref", "first-page": "58", "DOI": "10.1128/AAC.8.1.58", "article-title": "Gentamicin blood levels: a guide to nephrotoxicity", "volume": "8", "author": "Dahlgren", "year": "1975", "journal-title": "Antimicrobial Agents Chemother."}, {"key": "10.1111/j.1365-2125.1990.tb03670.x-BIB5|cit6", "doi-asserted-by": "crossref", "first-page": "183", "DOI": "10.7326/0003-4819-85-2-183", "article-title": "Gentamicin serum concentrations: pharmacokinetic prediction", "volume": "85", "author": "Hull", "year": "1976", "journal-title": "Ann. Intern. Med."}], "container-title": ["British Journal of Clinical Pharmacology"], "language": "en", "link": [{"URL": "https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1365-2125.1990.tb03670.x", "content-type": "unspecified", "content-version": "vor", "intended-application": "text-mining"}], "deposited": {"date-parts": [[2017, 6, 20]], "date-time": "2017-06-20T22:02:56Z", "timestamp": 1497996176000}, "score": 18.885015, "issued": {"date-parts": [[1990, 4]]}, "references-count": 5, "journal-issue": {"published-print": {"date-parts": [[1990, 4]]}, "issue": "4"}, "URL": "http://dx.doi.org/10.1111/j.1365-2125.1990.tb03670.x", "relation": {"cites": []}, "ISSN": ["0306-5251"], "issn-type": [{"value": "0306-5251", "type": "print"}]}], "items-per-page": 20, "query": {"start-index": 0, "search-terms": null}}}